{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The autoreload extension is already loaded. To reload it, use:\n",
      "  %reload_ext autoreload\n"
     ]
    }
   ],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import bert\n",
    "import numpy as np\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import matplotlib.pyplot as plt\n",
    "import spike_queries\n",
    "import spacy\n",
    "from typing import List\n",
    "from collections import defaultdict\n",
    "import tqdm\n",
    "from termcolor import colored\n",
    "from collections import Counter\n",
    "import pandas as pd\n",
    "from pybart.api import Converter\n",
    "from typing import List"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "class color:\n",
    "   PURPLE = '\\033[95m'\n",
    "   CYAN = '\\033[96m'\n",
    "   DARKCYAN = '\\033[36m'\n",
    "   BLUE = '\\033[94m'\n",
    "   GREEN = '\\033[92m'\n",
    "   YELLOW = '\\033[93m'\n",
    "   RED = '\\033[91m'\n",
    "   BOLD = '\\033[1m'\n",
    "   UNDERLINE = '\\033[4m'\n",
    "   END = '\\033[0m'\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def load_results(fname):\n",
    "    \n",
    "    with open(fname, \"r\", encoding = \"utf-8\") as f:\n",
    "        sents = f.readlines()\n",
    "    \n",
    "    sents = [s.strip().split(\"\\t\")[-1] for s in sents]\n",
    "    original, results = sents[0], sents[1:]\n",
    "    return original, results\n",
    "\n",
    "\n",
    "def get_spike_results_arguments_representations(model, spike_results, layers):\n",
    "    \n",
    "    sents = spike_results[\"sentence_text\"].tolist()\n",
    "    arg1_idx_start = spike_results[\"arg1_first_index\"].to_numpy().astype(int)\n",
    "    arg2_idx_start = spike_results[\"arg2_first_index\"].to_numpy().astype(int)\n",
    "    arg1_idx_end = spike_results[\"arg1_last_index\"].to_numpy().astype(int)\n",
    "    arg2_idx_end = spike_results[\"arg2_last_index\"].to_numpy().astype(int)\n",
    "    \n",
    "    arg1_rep = []\n",
    "    arg2_rep = []\n",
    "    \n",
    "    for s, arg1_start, arg2_start, arg1_end, arg2_end in zip(sents, arg1_idx_start, arg2_idx_start, arg1_idx_end, arg2_idx_end):\n",
    "        #idx_to_mask = [arg1_start, arg2_start, arg1_end, arg2_end]\n",
    "        H, _, _, orig2tok = model.encode(s, layers = layers)\n",
    "\n",
    "        h1, h2 = H[orig2tok[arg1_start]:orig2tok[arg1_end] + 1], H[orig2tok[arg2_start]:orig2tok[arg2_end] + 1]\n",
    "        \n",
    "        h1 = np.mean(h1, axis = 0)\n",
    "        h2 = np.mean(h2, axis = 0)\n",
    "        \n",
    "        arg1_rep.append(h1)\n",
    "        arg2_rep.append(h2)\n",
    "        \n",
    "    arg1_mean = np.mean(arg1_rep, axis = 0)\n",
    "    arg2_mean = np.mean(arg2_rep, axis = 0)\n",
    "        \n",
    "    return arg1_mean, arg2_mean\n",
    "    \n",
    "\n",
    "\n",
    "def main(filename, layers = [-1], num = 500):\n",
    "    \n",
    "    \n",
    "    query, results1 = load_results(filename)\n",
    "    results1 = results1[:num]\n",
    "    \n",
    "    spike_results = spike_queries.perform_query(query, dataset_name = \"covid19\", num_results = 100, query_type = \"syntactic\")\n",
    "    spike_results = spike_results[spike_results['sentence_text'].notnull()]\n",
    "    arg1_rep, arg2_rep = get_spike_results_arguments_representations(model, spike_results, layers)\n",
    "        \n",
    "    first, first_ind1, first_ind2 = spike_results[\"sentence_text\"].tolist()[-1], int(spike_results[\"arg1_first_index\"].tolist()[-1]), int(spike_results[\"arg2_first_index\"].tolist()[-1])\n",
    "    \n",
    "    alignments = []\n",
    "    \n",
    "    for s in results1:\n",
    "                    \n",
    "        H, tokenized_text, tok_to_orig_map, orig2tok = model.encode(s, layers = layers)\n",
    "        sims_arg1 = cosine_similarity([arg1_rep], H[1:-2])[0]\n",
    "        sims_arg2 = cosine_similarity([arg2_rep], H[1:-2])[0]\n",
    "        arg1_ind = np.argmax(sims_arg1) + 1\n",
    "        \n",
    "        sims_arg2[np.argmax(sims_arg1)] = -1\n",
    "        arg2_ind = np.argmax(sims_arg2) + 1\n",
    "        #print(arg1_ind, arg2_ind)\n",
    "        if arg1_ind not in tok_to_orig_map or arg2_ind not in tok_to_orig_map:\n",
    "            #print(\"ERROR\")\n",
    "            continue\n",
    "        alignments.append((s, tok_to_orig_map[arg1_ind], tok_to_orig_map[arg2_ind]))\n",
    "            \n",
    "    return query, spike_results, alignments"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "loading configuration file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/config.json from cache at /home/shauli/.cache/torch/transformers/199e28e62d2210c23d63625bd9eecc20cf72a156b29e2a540d4933af4f50bda1.4b6b9f5d813f7395e7ea533039e02deb1723d8fd9d8ba655391a01a69ad6223d\n",
      "Model config BertConfig {\n",
      "  \"attention_probs_dropout_prob\": 0.1,\n",
      "  \"hidden_act\": \"gelu\",\n",
      "  \"hidden_dropout_prob\": 0.1,\n",
      "  \"hidden_size\": 768,\n",
      "  \"initializer_range\": 0.02,\n",
      "  \"intermediate_size\": 3072,\n",
      "  \"layer_norm_eps\": 1e-12,\n",
      "  \"max_position_embeddings\": 512,\n",
      "  \"model_type\": \"bert\",\n",
      "  \"num_attention_heads\": 12,\n",
      "  \"num_hidden_layers\": 12,\n",
      "  \"output_hidden_states\": true,\n",
      "  \"pad_token_id\": 0,\n",
      "  \"type_vocab_size\": 2,\n",
      "  \"vocab_size\": 31090\n",
      "}\n",
      "\n",
      "loading configuration file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/config.json from cache at /home/shauli/.cache/torch/transformers/199e28e62d2210c23d63625bd9eecc20cf72a156b29e2a540d4933af4f50bda1.4b6b9f5d813f7395e7ea533039e02deb1723d8fd9d8ba655391a01a69ad6223d\n",
      "Model config BertConfig {\n",
      "  \"attention_probs_dropout_prob\": 0.1,\n",
      "  \"hidden_act\": \"gelu\",\n",
      "  \"hidden_dropout_prob\": 0.1,\n",
      "  \"hidden_size\": 768,\n",
      "  \"initializer_range\": 0.02,\n",
      "  \"intermediate_size\": 3072,\n",
      "  \"layer_norm_eps\": 1e-12,\n",
      "  \"max_position_embeddings\": 512,\n",
      "  \"model_type\": \"bert\",\n",
      "  \"num_attention_heads\": 12,\n",
      "  \"num_hidden_layers\": 12,\n",
      "  \"pad_token_id\": 0,\n",
      "  \"type_vocab_size\": 2,\n",
      "  \"vocab_size\": 31090\n",
      "}\n",
      "\n",
      "Model name 'allenai/scibert_scivocab_uncased' not found in model shortcut name list (bert-base-uncased, bert-large-uncased, bert-base-cased, bert-large-cased, bert-base-multilingual-uncased, bert-base-multilingual-cased, bert-base-chinese, bert-base-german-cased, bert-large-uncased-whole-word-masking, bert-large-cased-whole-word-masking, bert-large-uncased-whole-word-masking-finetuned-squad, bert-large-cased-whole-word-masking-finetuned-squad, bert-base-cased-finetuned-mrpc, bert-base-german-dbmdz-cased, bert-base-german-dbmdz-uncased, bert-base-finnish-cased-v1, bert-base-finnish-uncased-v1, bert-base-dutch-cased). Assuming 'allenai/scibert_scivocab_uncased' is a path, a model identifier, or url to a directory containing tokenizer files.\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/vocab.txt from cache at /home/shauli/.cache/torch/transformers/e3debd8fbdf40874753724814ee0520f612b577b26c8755bca485103b47cd3bc.60287becc5ab96d85a4bf377eb90feaf3b9c80d3b23e84311dccd3588f56d4fb\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/added_tokens.json from cache at None\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/special_tokens_map.json from cache at None\n",
      "loading file https://s3.amazonaws.com/models.huggingface.co/bert/allenai/scibert_scivocab_uncased/tokenizer_config.json from cache at None\n",
      "loading weights file https://cdn.huggingface.co/allenai/scibert_scivocab_uncased/pytorch_model.bin from cache at /home/shauli/.cache/torch/transformers/54e18c298451d3195ba8359e7a3fa2bc04c70c730c5b6744928278e67940eacb.7587182ea55c40bf7fd0961c1176c31fa22558da2bf20c199874fa5a8ecb4613\n"
     ]
    }
   ],
   "source": [
    "model = bert.BertEncoder(\"cuda\", \"scibert\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Parse"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_results(sentences: List[str]):\n",
    "    \n",
    "    #nlp = spacy.load(\"en_core_sci_sm\")\n",
    "    nlp = spacy.load(\"en_core_sci_lg\")\n",
    "    converter = Converter()\n",
    "    nlp.add_pipe(converter, name=\"BART\")\n",
    "\n",
    "    docs = [spacy.tokens.Doc(vocab=nlp.vocab, words = sentence.split(\" \")) for sentence in sentences]\n",
    "    for name, proc in nlp.pipeline:\n",
    "        for i,doc in enumerate(docs):\n",
    "            docs[i] = proc(doc)\n",
    "    return docs\n",
    "\n",
    "\n",
    "\n",
    "def get_ancestors(tok):\n",
    "    \n",
    "    parents = [tok]\n",
    "    \n",
    "    while tok.head != tok:\n",
    "    \n",
    "        parents.append(tok.head)\n",
    "        tok = tok.head\n",
    "        \n",
    "    \n",
    "    return parents\n",
    "    \n",
    "def get_path_between_tokens(tok1, tok2, doc):\n",
    "    \n",
    "    path1 = get_ancestors(tok1)\n",
    "    path2 = get_ancestors(tok2)\n",
    "    #print(path1, path2)\n",
    "    \n",
    "    lowest_ancestor = None\n",
    "    for tok in path1:\n",
    "        if tok in path2:\n",
    "            lowest_ancestor = tok\n",
    "            break\n",
    "\n",
    "    path1 =  path1[:path1.index(lowest_ancestor)+1]\n",
    "    path2 =  path2[:path2.index(lowest_ancestor)+1]\n",
    "    \n",
    "    linear_path_before = [tok1 if tok1.i < tok2.i else tok2]\n",
    "    linear_path_after = [tok1 if tok1.i > tok2.i else tok2]\n",
    "    linear_path_between =  [t for t in doc if t.i < max(tok1.i, tok2.i) and t.i > min(tok1.i, tok2.i)]\n",
    "    \n",
    "    min_i, max_i = min(tok1.i, lowest_ancestor.i, tok2.i), max(tok1.i, lowest_ancestor.i, tok2.i)\n",
    "    \n",
    "    linear_path = [t.text for t in doc if t.i >= min_i and t.i <= max_i]\n",
    "    linear_path[linear_path.index(tok1.text)] = colored(tok1.text, \"red\")\n",
    "    linear_path[linear_path.index(tok2.text)] = colored(tok2.text, \"blue\")    \n",
    "    linear_path_str = \" \".join(linear_path)\n",
    "    \n",
    "    path = {\"ancestor\": lowest_ancestor, \"path1\": path1, \"path2\": path2, \"tok1\": tok1, \"tok2\": tok2, \"linear_path\": linear_path,\n",
    "           \"linear_path_str\": linear_path_str}\n",
    "    return path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "#from spacy import displacy\n",
    "#displacy.render(doc, style='dep', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "def regularize(path1: List[str], path2: List[str]):\n",
    "\n",
    "    #print(\"path1\", path1)\n",
    "    #print(\"path2\", path2)\n",
    "    path_original = path1.copy() + path2[::-1][1:].copy()\n",
    "\n",
    "    \n",
    "    path1[-1] = color.BOLD + path1[-1] + color.END\n",
    "    path2[0] = colored(path2[0], \"blue\")\n",
    "    path1[0] = colored(path1[0], \"red\")\n",
    "    \n",
    "    path = path1 + path2[::-1][1:]\n",
    "    \n",
    "    \n",
    "\n",
    "    return path, path_original\n",
    "        \n",
    "\n",
    "def get_paths(docs, alignments, path_type = \"lemmas-deps\", parse=\"bart\"):\n",
    "\n",
    "    paths_lemmas = []\n",
    "    paths_deps = []\n",
    "    paths_lemmas_deps = []\n",
    "    paths_lemmas_deps_root = []\n",
    "    paths_pos = []\n",
    "    i = 0\n",
    "    linear_paths = []\n",
    "    \n",
    "    for doc, (sent, idx1, idx2) in zip(docs, alignments):\n",
    "        \n",
    "        tok1, tok2 = doc[idx1], doc[idx2]\n",
    "        \n",
    "        try:\n",
    "            path_dict = get_path_between_tokens(tok1, tok2, doc)\n",
    "        except: continue #TODO: check the \"None\" error.\n",
    "            \n",
    "        linear_paths.append(path_dict[\"linear_path_str\"])\n",
    "    \n",
    "        tok1_2ances = path_dict[\"path1\"]\n",
    "        tok2_2ances = path_dict[\"path2\"]\n",
    "        \n",
    "        \n",
    "        lemmas1 = [tok.lemma_ for tok in tok1_2ances]\n",
    "        lemmas2 = [tok.lemma_ for tok in tok2_2ances]\n",
    "        \n",
    "        if parse == \"pybart\":\n",
    "            deps1 = [tok._.parent_list[0][\"rel\"] for tok in tok1_2ances]\n",
    "            deps2 = [tok._.parent_list[0][\"rel\"] for tok in tok2_2ances]            \n",
    "        else:\n",
    "            deps1 = [tok.dep_ for tok in tok1_2ances]\n",
    "            deps2 = [tok.dep_ for tok in tok2_2ances]\n",
    "        #pos1 = [tok.tag_ for tok in tok1_2ances]\n",
    "        #pos2 = [tok.tag_ for tok in tok2_2ances]\n",
    "        \n",
    "        lemmas, lemmas_original = regularize(lemmas1, lemmas2)\n",
    "        deps, deps_original = regularize(deps1, deps2)\n",
    "        #pos = regularize(pos1, pos2)\n",
    "        \n",
    "        zipped = \"-\".join([lemma+\".\"+dep for lemma, dep in zip(lemmas, deps)])\n",
    "        assert len(lemmas) == len(deps) == len(lemmas_original)\n",
    "        \n",
    "        zipped_only_root = \"-\".join([lemma+\".\"+dep if lemma_orig==path_dict[\"ancestor\"].lemma_ else dep for lemma, dep,lemma_orig in zip(lemmas, deps, lemmas_original)])\n",
    "        paths_lemmas_deps.append(zipped)\n",
    "        paths_lemmas.append(\"-\".join(lemmas))\n",
    "        paths_deps.append(\"-\".join(deps))\n",
    "        paths_lemmas_deps_root.append(zipped_only_root)\n",
    "        #paths_pos.append(\"-\".join(paths_pos))\n",
    "        \n",
    "        i += 1\n",
    "    \n",
    "    paths = None\n",
    "    \n",
    "    if path_type == \"lemmas-deps\":\n",
    "        \n",
    "        paths =  paths_lemmas_deps\n",
    "    \n",
    "    elif path_type == \"lemmas-deps-root\":\n",
    "        \n",
    "        paths = paths_lemmas_deps_root\n",
    "\n",
    "    elif path_type == \"lemmas\":\n",
    "        \n",
    "        paths = paths_lemmas\n",
    "    \n",
    "    elif path_type == \"deps\":\n",
    "        \n",
    "        paths = paths_deps\n",
    "    \n",
    "    elif path_type == \"pos\":\n",
    "        \n",
    "        paths = paths_pos\n",
    "    \n",
    "    else:\n",
    "        \n",
    "        raise Exception(\"Unknown type\")\n",
    "    \n",
    "    return paths, linear_paths"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def sort_by_freq(paths, linear_paths):\n",
    "    \n",
    "    together = zip(paths, linear_paths)\n",
    "    counts = []\n",
    "    \n",
    "    for p, p_lin in zip(paths, linear_paths):\n",
    "        \n",
    "        counts.append(paths.count(p))\n",
    "\n",
    "    paths_linpaths_counts = zip(paths, linear_paths, counts)    \n",
    "    paths_linpaths_counts = sorted(paths_linpaths_counts, key = lambda pair: -pair[-1])\n",
    "    \n",
    "    paths, linear_paths, counts = list(zip(*paths_linpaths_counts))\n",
    "    return paths, linear_paths, counts\n",
    "    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Collect Paths"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "def collect(num_results, path_type, parse_type=\"dep\"):\n",
    "    \n",
    "    fnames = [\"results{}.txt\".format(i) for i in range(1,10)]\n",
    "    k = 0\n",
    "    \n",
    "    for fname in fnames:\n",
    "        query, spike_results, alignments = main(fname, layers = [-1], num = num_results)    \n",
    "        sents = [s for s,ind1,ind2 in alignments]\n",
    "        docs = parse_results(sents)\n",
    "    \n",
    "        paths, linear_paths = get_paths(docs, alignments, path_type, parse_type)\n",
    "        paths, linear_paths, counts = sort_by_freq(paths, linear_paths)\n",
    "    \n",
    "        #df = pd.DataFrame({\"paths\": paths, \"linear_paths\": linear_paths})\n",
    "    \n",
    "        print(color.BOLD + \"QUERY {}:\\n\\t\".format(k) + query + color.END )\n",
    "        print(color.BOLD + \"\\nMOST FREQUENT PATTERNS:\\n\" + color.END)\n",
    "        for i in range(150):\n",
    "        \n",
    "            print(\"PATH: \"+ paths[i] + \"\\tLINEAR: \" + linear_paths[i] +\"\\tCOUNT: \" + str(counts[i]))\n",
    "        \n",
    "        print(\"\\n\\n\")\n",
    "        print(\"=================================================================\")\n",
    "        print(\"=================================================================\")    \n",
    "        \n",
    "        k += 1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: dep labels + lemmas"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans is characterized by extensive pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mmyocarditis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-spectrum.dobj-symptom.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV can cause a spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-result.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-result.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mestablish\u001b[0m.\u001b[1mROOT\u001b[0m-cause.conj-number.dobj-\u001b[34mdisorder\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mestablish\u001b[0m.\u001b[1mROOT\u001b[0m-cause.conj-number.dobj-\u001b[34mdisorder\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-spectrum.dobj-symptom.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-onset.nsubjpass-\u001b[34menteritis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-onset.nsubjpass-\u001b[34menteritis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an important systemic parvoviral \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-spectrum.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-spectrum.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-loss.nmod-\u001b[34mfocal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-loss.nmod-\u001b[34mfocal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mmyocarditis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-manifestation.dobj-\u001b[34mneurologic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-manifestation.dobj-\u001b[34mneurologic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-characterize.conj-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-characterize.conj-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-immunosuppression.dobj-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-encephalitis.dobj-disorder.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause Japanese encephalitis ( JE ) with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-illness.nmod-\u001b[34mfebrile\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbrv\u001b[0m.\u001b[31mnsubj\u001b[0m-infection.nsubj-\u001b[1mcomponent\u001b[0m.\u001b[1mROOT\u001b[0m-pathogenesis.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mBRV\u001b[0m is a lytic infection and destruction of infected mucosal epithelial cells is an important component of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-stage.nmod-infection.nmod-characterize.acl:relcl-fever.nmod-\u001b[34mshock\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m begins with flu-like symptoms and progresses rapidly to the final stages of viral hemorrhagic fever infection , which are characterized by fever , hemorrhage , and hypotensive \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-cause.conj-atrophy.dobj-villi.nmod-result.acl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infects the epithelium of the small intestine , an environment rich in proteases , and causes atrophy of the villi resulting in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-associate.conj-\u001b[34mgastroenteritis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in respiratory tract complications with varying degree of severity and has been associated with \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m.\u001b[31macl\u001b[0m-human.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfected\u001b[0m with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-result.advcl-\u001b[34mseverity\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m increases the susceptibility of the host to a wide range of viral and bacterial respiratory pathogens , resulting in increased \u001b[34mseverity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod\u001b[0m-spread.nmod-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m characterized by a rapid and extensive spread of the \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrepresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod\u001b[0m-ability.nmod-\u001b[1mresult\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34mdamage\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: results from overwhelming cytopathic \u001b[34mdamage\u001b[0m due to the ability of Ebola \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnmod\u001b[0m-infect.acl-human.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m have been reported to develop a severe acute respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJEV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-trigger.advcl-response.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJEV\u001b[0m invades the central nervous system , wherein virus replication triggers a massive \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmcmv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-cause.conj-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMCMV\u001b[0m causes asymptomatic infection in adult immunocompetent mice , but experimental inoculation of neonates has caused lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-viremia.nmod-\u001b[34mto\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m.\u001b[31mnsubj\u001b[0m-pathogen.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-degeneration.dobj-function.nmod-lead.acl:relcl-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m is an important viral pathogen worldwide in the domestic cat ( Felis catus ) , causes a slow progressive degeneration of immune functions that eventually leads to a \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34monset\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-immunosuppression.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreplicate\u001b[0m.\u001b[1mROOT\u001b[0m-lead.conj-infection.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m replicates mainly in porcine alveolar macrophages ( PAMs ) and dendritic cells ( DCs ) and leads to persistent infection , interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-characterize.conj-cascade.nmod-event.nmod-lead.acl-inflammation.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of SARS-CoV causes severe acute respiratory syndrome ( SARS ) , which is an emerging infectious disease and characterized by a cascade of immunological events leading to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmhv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malphavirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34marthritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31malphavirus\u001b[0m infections , such as those involving CHIKV , Ross River virus ( RRV ) , and Sindbis virus ( SINV ) , induce debilitating \u001b[34marthritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-atrophy.nmod-intestine.nmod-result.acl:relcl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is characterized by severe villous atrophy in the small intestine that results in watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mable\u001b[0m.\u001b[1madvcl\u001b[0m-cross.xcomp-stimulate.conj-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m is able to cross the blood-brain barrier and stimulate \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmnv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-replication.nmod-associate.acl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMNV\u001b[0m infection in immunocompromised mice lacking innate immunity factors such as STAT1 or interferon receptors can result in persistent or acute virus replication associated with severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-severe.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in severe and even fatal lung \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-splenomegaly.dobj-\u001b[34msyndrome\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mBIV\u001b[0m induces splenomegaly and lymphademopathy \u001b[34msyndromes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-consequence.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-result.parataxis-disease.nmod-cns.nmod-\u001b[34msepsis\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , such as acute flaccid paralysis , myocarditis , and Reye syndrome , have been reported [ 13 , 18 ] ; HPeV3 infection results in severe diseases of the CNS and neonatal \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjhmv\u001b[0m.\u001b[31mnmod\u001b[0m-strain.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mjHMV\u001b[0m cause a subacute or persistent \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmarv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod\u001b[0m-mouse.nmod-infection.nsubj-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m produces clinical \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mterm\u001b[0m.\u001b[1mROOT\u001b[0m-cause.parataxis-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , also termed epizootic catarrhal \u001b[34menteritis\u001b[0m or ECE , causes mucoid enteritis\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mresult\u001b[0m.\u001b[1madvcl\u001b[0m-symptom.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection usually results in mild \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-model.nsubj-\u001b[1mreveal\u001b[0m.\u001b[1mROOT\u001b[0m-cause.ccomp-bronchiolitis.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have revealed that this lethal pulmonary infection causes a denuding bronchiolitis and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-stage.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-course.nmod-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msg\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: induces \u001b[34mSGs\u001b[0m during the course of \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msystemic\u001b[0m.\u001b[1mROOT\u001b[0m-characterize.dep-hemorrhage.nmod-\u001b[34medema\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds is systemic , characterized by hemorrhage and \u001b[34medema\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-disease.dobj-\u001b[34millness\u001b[0m.\u001b[34macl:relcl\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes Ebola virus disease ( EVD ) , which is an acute systemic \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-mild.nmod-\u001b[34millness\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfluenza\u001b[0m virus infection in humans can lead to mild to severe \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcytolytic\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-\u001b[34matrophy\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infection is cytolytic and causes acute necrosis of the infected enterocytes , leading to marked intestinal villous \u001b[34matrophy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnidovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-inflammation.dobj-tract.nmod-develop.acl:relcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mnidovirus\u001b[0m infection induces an inflammation of the upper respiratory and alimentary tract which can develop into a severe and often fatal proliferative \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-range.nmod-sign.nmod-infection.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with FCoV can result in a diverse range of signs from clinically inapparent infections to a highly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msystemic\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonia.nmod-\u001b[34mdamage\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses from an atypical pneumonia to acute diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-fever.dobj-cough.conj-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m often causes fever , cough , and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvsv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1masymptomatic\u001b[0m.\u001b[1mROOT\u001b[0m-cause.conj-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mVSV\u001b[0m infection of humans is typically either asymptomatic or causes a mild influenza-like \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtrigger\u001b[0m.\u001b[1mROOT\u001b[0m-lesion.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in human , or MERS , commonly manifests as a severe acute respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchikv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfpv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFPV\u001b[0m is responsible of systemic \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-BRDC.nsubjpass-\u001b[1mprecede\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m BRDC \u001b[34mis\u001b[0m often preceded\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1m12\u001b[0m.\u001b[1mROOT\u001b[0m-,.punct-replicate.appos-mucosa.nmod-lead.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , RSV replicates in the respiratory mucosa leading to epithelial \u001b[34mdamage\u001b[0m [ 11 ] and perivascular mononuclear infiltration [ 12\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mjcv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mnmod\u001b[0m-co-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m and S. suis generally induces exacerbated \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1maggravate\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34mcondition\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mcondition\u001b[0m is aggravated by mixed \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjcpyv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-follow.conj-viremia.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m occurs predominately in alveolar macrophages of the lung [ 3 ] , followed by viremia and subsequent interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfilovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mfilovirus\u001b[0m infections \u001b[34mare\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-degree.dobj-manifestation.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes varying degrees of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-seriousness.nsubj-\u001b[1mlie\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nmod-include.acl:relcl-disease.dobj-\u001b[34mencephalitis\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m lies in its complications , which include hand-foot-and-mouth disease , herpangina , aseptic meningitis , poliomyelitis-like paralysis , and fatal \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nmod-\u001b[34millness\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PRRSV leads to reproductive complications , respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfipv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtropic\u001b[0m.\u001b[1mROOT\u001b[0m-result.acl:relcl-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m is macrophage tropic and may cause aberrant cytokine and/or chemokine expression and lymphocyte depletion , which results in a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-disorder.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-condition.dobj-know.acl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by the SARS-CoV-2 causes an inflammatory condition also known as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhcov\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHCoV\u001b[0m infection in immunosuppressed populations can lead to significant lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mveev\u001b[0m.\u001b[31mnmod\u001b[0m-exposure.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mVEEV\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 1\n",
      "PATH: \u001b[31mphev\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-cause.acl-symptom.dobj-\u001b[34mneurological\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPHEV\u001b[0m is a neurovirulent virus that spreads to the central nervous system ( CNS ) via peripheral nerves , where neurite damage and neuronal death are observed , causing \u001b[34mneurological\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjev\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m can develop after \u001b[31mJEV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31miav\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod-manifestation.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIAV\u001b[0m infection range from mild disease to severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpcmv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubjpass-\u001b[1maccompany\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mPCMV\u001b[0m infection \u001b[34mis\u001b[0m typically accompanied\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-depletion.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with the domestic cat ( Felis catus ) strain of FIV ( FIV Fca ) results in CD4 + T-cell depletion and pathogenic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtgev\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-\u001b[34mgastroenteritis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mTGEV\u001b[0m infects the epithelial cells of the small intestine , leading to potentially fatal \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mspread\u001b[0m.\u001b[1mnmod\u001b[0m-symptom.nmod-distress.nmod-\u001b[34mencephalitis\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: spread of the \u001b[31mvirus\u001b[0m in several organs , with symptoms including respiratory distress and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in human \u001b[31minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-lead.conj-\u001b[34mfever\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mROOT\u001b[0m-picture.nmod-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mROOT\u001b[0m-picture.nmod-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdyspnea\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m.\u001b[31mconj\u001b[0m-suckle.nmod-growth.nmod-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m.\u001b[31mconj\u001b[0m-suckle.nmod-growth.nmod-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-lead.conj-\u001b[34mfever\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung , and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdyspnea\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mconj\u001b[0m-young.nsubj-have.aux-\u001b[1mprofuse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mconj\u001b[0m-young.nsubj-have.aux-\u001b[1mprofuse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpeople\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-feature.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpeople\u001b[0m commonly manifest features of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mROOT\u001b[0m-encephalopathy.dobj-\u001b[34mencephalitis\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m suffering from severe DENV infection often exhibit encephalopathy and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with signs from FIV often \u001b[34mhave\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34menteric\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-illness.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-stage.nsubj-\u001b[1minclude\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbleeding\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1masymptomatic\u001b[0m.\u001b[1mROOT\u001b[0m-occur.advcl-sign.nsubj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic , although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-headache.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdeteriorate\u001b[0m.\u001b[1mROOT\u001b[0m-present.conj-\u001b[34msymptom\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with EVD rapidly deteriorate and commonly present with gastrointestinal \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-course.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-manifest.conj-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m are primarily infected subclinically , but gastrointestinal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmarmoset\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-onset.dobj-\u001b[34msudden\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , VEEV infection causes a \u001b[34msudden\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-subset.nsubj-progress.conj-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is associated with fever and liver damage , but a subset of \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-worsen.conj-symptom.nsubj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by SARS-CoV typically has an insidious onset , and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuffer\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-inflammation.nmod-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m infected with SARS suffer fever , cough , muscle aches , and shortness of breath and often progress to severe \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mleptospirosis\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mHuman\u001b[0m \u001b[34mleptospirosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-symptom.dobj-as.prep-vomiting.pobj-\u001b[34mdiarrhea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mPigs\u001b[0m that are infected with TGEV usually present symptoms such as vomiting , dehydration , and severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-occur.conj-result.advcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrats\u001b[0m are especially susceptible to SDA , and the infection can occur in the lower respiratory tract , resulting in \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbecome\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mill\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m typically become acutely \u001b[34mill\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-fever.conj-\u001b[34mdiarrhoea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , adenovirus infections often manifest as upper respiratory tract infections , pharyngoconjunctival fever , or \u001b[34mdiarrhoea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-characterize.conj-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually leads to the development of CHIKF and \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-after.prep-onset.pobj-of.prep-\u001b[34mrash\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m develops insidiously , usually a few days after the onset of \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-occur.parataxis-symptom.nsubj-\u001b[34mrash\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m manifests as fever , headache , weakness , and myalgias/ arthralgias ; gastrointestinal symptoms and a maculopapular \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-nonlethal.dobj-incapacitate.dep-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes nonlethal , incapacitating \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-rvf.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-to.prep-\u001b[34mfever\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually begins with a nonspecific influenza-like acute \u001b[34mfever\u001b[0m , but can progress to serious hemorrhagic fever\tCOUNT: 1\n",
      "PATH: \u001b[31mleptospirosis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-call.ccomp-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m , also called Pretibial fever or Fort Bragg fever , \u001b[34mhas\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34monset\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdog\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mparataxis\u001b[0m-\u001b[34mparalysis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m exhibit pharyngeal \u001b[34mparalysis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-plague.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m \u001b[34mis\u001b[0m usually characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mlesion\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnmod\u001b[0m-%.nmod-\u001b[1mappear\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mFever\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mFever\u001b[0m , absolute lymphopenia , inappetence , jaundice , and abdominal effusion appear 2 - 3 weeks after infection in around 80 % of \u001b[31mcats\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod\u001b[0m-%.nsubj-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m show acute \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-sign.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mself-limiting\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mhepatitis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , infection is usually self-limiting , but a small percent of cases ( 1 - 2 % ) can progress to severe \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnsubjpass\u001b[0m-infect.advcl-\u001b[1mreach\u001b[0m.\u001b[1mROOT\u001b[0m-%.dobj-range.conj-sign.nsubj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m are infected by the virus , mortality can reach up to 50 % of affected horses , and \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1masymptomatic\u001b[0m.\u001b[1mROOT\u001b[0m-observe.advcl-sign.nsubjpass-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-severity.nsubj-range.ccomp-\u001b[1minclude\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m severities range from asymptomatic infection to fatal HF ( Fisher-Hoch et al. , 1995 ) and commonly resulting from other viral infections , nonspecific \u001b[34msymptoms\u001b[0m beginning several days after infection include\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrestricted\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-onset.nmod-sign.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is generally restricted to the alimentary tract , leading to the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-illness.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcalf\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-BRDC.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-fever.nmod-lesion.conj-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m is characterized by fever , dyspnea , inflammatory and necrotizing \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod-picture.nsubj-\u001b[1mdisease\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection of the respiratory tract is mild self-limiting upper respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-associate.conj-\u001b[34mfever\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m infection begins in the upper respiratory tract with nasal congestion and pharyngitis and is associated with \u001b[34mfever\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1madvcl\u001b[0m-onset.dobj-of.prep-fever.pobj-chill.conj-develop.conj-tachypnea.dobj-\u001b[34mdyspnea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience the abrupt onset of high fever , chills , and rapidly developing tachypnea and \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-sign.dobj-anemia.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with acute leukemia usually show signs of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnmod\u001b[0m-infection.nsubj-\u001b[1myield\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-onset.dobj-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with E coli may develop an acute onset of watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-anemia.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m commonly develop anemia and secondary infections , especially bacterial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mROOT\u001b[0m-presentation.nmod-failure.nmod-\u001b[34mshock\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant presentation with progressive respiratory failure and \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod\u001b[0m-percentage.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-asymptomatic.advcl-have.conj-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m , a small percentage of affected \u001b[31mindividuals\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhepatitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnmod\u001b[0m-%.nmod-occur.parataxis-\u001b[1minvolve\u001b[0m.\u001b[1mROOT\u001b[0m-outcome.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m usually involves mild upper respiratory tract infections ; however , more severe conditions , such as pneumonia and bronchiolitis occur in 25 - 40 % of \u001b[31mchildren\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-symptom.nsubj-\u001b[1mmild\u001b[0m.\u001b[1mROOT\u001b[0m-include.conj-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m are usually mild and include febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madult\u001b[0m.\u001b[31mnmod\u001b[0m-case.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-in.prep-\u001b[34mdyspnea\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m usually result in \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-progress.relcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: period of 2 - 14 days \u001b[31mpatients\u001b[0m initially present with influenza-like symptoms , fever , and cough that can progress to atypic \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-apathy.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m show \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-fatigue.npadvmod-lead.acl:relcl-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses quickly to fever , intense fatigue , diarrhea , anorexia , abdominal pain , hiccups , myalgia , vomiting , confusion , and conjunctivitis ( 14 ) which \u001b[34mmay\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdamage\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m who die within 10 days of the onset of symptoms show diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-resemble.conj-\u001b[34mdengue\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m presents with high fever , headache , myalgias , and arthralgias , and can resemble \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m.\u001b[31macl\u001b[0m-\u001b[1mmouse\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m Signs Mice \u001b[31minfected\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthese\u001b[0m.\u001b[31mdet\u001b[0m-symptom.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-infection.nmod-\u001b[34millness\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mThese\u001b[0m symptoms generally develop 3 days to 6 weeks following an upper respiratory infection or diarrheal type \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1millness\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpertussis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-symptom.nmod-develop.acl:relcl-paroxysmal.nsubj-\u001b[34mcough\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mPertussis\u001b[0m usually presents with nonspecific upper respiratory tract infection symptoms for 1 to 2 weeks ( catarrhal stage ) , after which the paroxysmal and sometimes uncontrollable \u001b[34mcough\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-uri.dobj-\u001b[34macute\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m typically cause \u001b[34macute\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-pneumonia.nmod-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-pneumonia.nmod-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-result.conj-failure.nmod-\u001b[34mcardiac\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-result.conj-failure.nmod-\u001b[34mcardiac\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-syndrome.nmod-\u001b[34mand\u001b[0m.\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-syndrome.nmod-\u001b[34mand\u001b[0m.\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-infection.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops rapidly and eventually progresses after 2 to 4 days into \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-infection.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-edema.dobj-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-edema.dobj-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nsubj-involvement.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nsubj-involvement.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-response.conj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-response.conj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-form.dobj-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-suffer.conj-complication.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-form.dobj-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-suffer.conj-complication.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-have.advcl-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-\u001b[34mdeath\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-have.advcl-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-\u001b[34mdeath\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdevelop\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdevelop\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-syndrome.nmod-failure.conj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-syndrome.nmod-failure.conj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-lymphadenopathy.conj-\u001b[34mgeneralize\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-lymphadenopathy.conj-\u001b[34mgeneralize\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mform\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mthis\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mform\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mthis\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-onset.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-onset.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-plague.dobj-pneumonic.amod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-plague.dobj-pneumonic.amod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonia.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonia.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-state.pobj-\u001b[34mtoxic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-state.pobj-\u001b[34mtoxic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-asymptomatic.advcl-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-symptom.dobj-\u001b[34mserious\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-asymptomatic.advcl-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-symptom.dobj-\u001b[34mserious\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-presentation.nmod-include.acl:relcl-pharyngitis.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-presentation.nmod-include.acl:relcl-pharyngitis.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-to.prep-dyspnea.pobj-stridor.conj-cyanosis.conj-shock.conj-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-lead.advcl-to.prep-dyspnea.pobj-stridor.conj-cyanosis.conj-shock.conj-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-infection.nmod-bronchiolitis.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-infection.nmod-bronchiolitis.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-some.nsubj-\u001b[1msevere\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-some.nsubj-\u001b[1msevere\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mshock\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m-have.conj-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m-have.conj-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m.\u001b[31mcompound\u001b[0m-decompensation.nsubj-\u001b[1mcoincide\u001b[0m.\u001b[1mROOT\u001b[0m-development.nmod-syndrome.nmod-difficult.acl:relcl-differentiate.xcomp-infection.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m.\u001b[31mcompound\u001b[0m-decompensation.nsubj-\u001b[1mcoincide\u001b[0m.\u001b[1mROOT\u001b[0m-development.nmod-syndrome.nmod-difficult.acl:relcl-differentiate.xcomp-infection.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-spectrum.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mROOT\u001b[0m-infection.nmod-disease.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-spectrum.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mROOT\u001b[0m-infection.nmod-disease.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-associate.conj-damage.nmod-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-associate.conj-damage.nmod-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mshock\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-course.nsubj-\u001b[1mlast\u001b[0m.\u001b[1mROOT\u001b[0m-result.conj-in.prep-\u001b[34mcoma\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-course.nsubj-\u001b[1mlast\u001b[0m.\u001b[1mROOT\u001b[0m-result.conj-in.prep-\u001b[34mcoma\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-onset.pobj-after.prep-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , dyspnea and/or hypoxemia usually occur one week after the onset of the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-mild.advcl-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-presentation.pobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is often mild with cold-like symptoms , it can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1moccur\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-progression.nsubj-\u001b[34mrapid\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrapid\u001b[0m progression of lung consolidation \u001b[31moccurs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mself-limiting\u001b[0m.\u001b[1mROOT\u001b[0m-develop.conj-symptom.nsubj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be self-limiting in few days , but in some cases the \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-patient.nmod-\u001b[34mcritical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31msymptom\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-form.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonia.dobj-associate.acl-bacteremia.nmod-failure.conj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , pneumonia , associated with bacteremia and \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mmild\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-case.nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-opacity.nmod-failure.conj-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m have a rapid and relentless fatal course , with generalized alveolar and interstitial opacities , development of the adult respiratory distress syndrome ( ARDS ) , and \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-anemia.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34m-PRON-\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mit\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcondition\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31mconditions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbecome\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m becomes relentlessly \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-mild.advcl-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-manifestation.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is mild in most of the affected individuals , it may cause \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mips\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-dysfunction.nmod-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m.\u001b[31mdet\u001b[0m-infection.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-croup.nmod-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m infection usually begins as a \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-\u001b[34msevere\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m , and potentially fatal , systemic \u001b[31mdisease\u001b[0m may develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-associate.advcl-\u001b[1mfollow\u001b[0m.\u001b[1mROOT\u001b[0m-infection.nmod-bronchitis.nmod-abscess.conj-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , this may be followed by persistent , chronic infection , including chronic bronchitis , bronchiectasis , and \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogressive\u001b[0m.\u001b[1mROOT\u001b[0m-development.nmod-opacity.nmod-\u001b[34mbilateral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m can be rapidly progressive with the development of multifocal \u001b[34mbilateral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mcompound\u001b[0m-onset.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-failure.dobj-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m onset can cause \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-progress.conj-\u001b[34mrespiratory\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME can develop aseptic meningitis and meningoencephalitis or progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-development.nmod-encephalitis.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-pain.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m develop , with high fever , \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-form.nmod-\u001b[1mprogression\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mrapid\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , in the absence of appropriate treatment , there may be \u001b[34mrapid\u001b[0m progression\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-damage.nmod-\u001b[34malveolar\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-phase.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can rapidly progress to the hemorrhagic phase of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-bronchiectasis.nmod-failure.conj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-occurrence.nmod-pneumonia.nmod-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may progress rapidly , with occurrence of \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-form.dobj-pneumonia.nmod-result.acl:relcl-failure.nmod-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m who suffer from this illness may experience a clinical course ranging from being asymptomatic to having a minor illness , and in a significant minority a severe form of viral pneumonia , which can result in \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-percentage.conj-patient.nmod-\u001b[1mcomplicate\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonia.nmod-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , it can be complicated by \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmild\u001b[0m.\u001b[1mROOT\u001b[0m-progress.parataxis-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is mild in most people ; in some ( usually the elderly and those with comorbidities ) , it may progress to \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mshock\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can rapidly progress to \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m progress\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod\u001b[0m-subject.conj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to bacterial , fungal , viral , and parasitic \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 4\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-lower.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-lower.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-lower.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mconj\u001b[0m-dentition.nmod-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mconj\u001b[0m-dentition.nmod-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mconj\u001b[0m-dentition.nmod-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-bacterial.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly susceptible to bacterial and candidal \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-cause.acl-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by encapsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-severity.dobj-increase.acl:relcl-depletion.nmod-\u001b[1mrelated\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are more heavily immunosuppressed and who are suffering from other immunologic and infectious complications of transplant are at higher risk for \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1macl\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m upon primary HRSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mdep\u001b[0m-form.dobj-\u001b[34maspergillosis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mdep\u001b[0m-form.dobj-\u001b[34maspergillosis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-cause.acl-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by capsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-be.cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at risk of serious \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-bacterial.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m on high dose corticosteroids and mechanical ventilation are particularly susceptible to superimposed bacterial and opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-severity.dobj-increase.acl:relcl-depletion.nmod-\u001b[1mrelated\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1macl\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m by \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with GI bleeding are at risk of developing bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-be.cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at the risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.conj-reservoir.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-antibiotic.nmod-use.nsubj-\u001b[1mpromote\u001b[0m.\u001b[1mROOT\u001b[0m-emergence.dobj-colonization.nmod-\u001b[34minfection\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-antibiotic.nmod-use.nsubj-\u001b[1mpromote\u001b[0m.\u001b[1mROOT\u001b[0m-emergence.dobj-colonization.nmod-\u001b[34minfection\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mmake\u001b[0m.\u001b[1mROOT\u001b[0m-vulnerable.ccomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mmake\u001b[0m.\u001b[1mROOT\u001b[0m-vulnerable.ccomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.conj-reservoir.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mards\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-trigger.acl-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m triggered by viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mnmod\u001b[0m-individual.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34morganism\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdiabetes\u001b[0m.\u001b[31mnmod\u001b[0m-individual.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-receive.csubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m receiving immunomodulatory or immunosuppressive therapies due to malignancy , transplantation , or autoimmune disease are more susceptible to viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-\u001b[34mprimary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprimary\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-prone.conj-superinfection.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for gram-negative and anaerobic polymicrobial aspiration pneumonia , and on the other hand are more prone to bacterial superinfections following influenza \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubjpass-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-risk.xcomp-virus.nmod-\u001b[34minfluenza\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are known to be at an increased risk for community-acquired respiratory viruses , such as \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maml\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nmod-\u001b[1mlow\u001b[0m.\u001b[1madvcl\u001b[0m-incidence.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is low among patients with \u001b[31mAML\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhowever\u001b[0m.\u001b[31madvmod\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHowever\u001b[0m , neonates , older individuals , and those with immune deficiencies are prone to more frequent and more serious CNS viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-result.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m as a result of HPIV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-therapy.conj-predispose.acl:relcl-risk.nmod-contract.acl-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m have immune dysfunction and are often on glucocorticoid and immunosuppressant therapy , which in turn predispose them to an increased risk of contracting SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-risk.conj-of.prep-develop.pcomp-complication.dobj-as.prep-\u001b[34mpneumonia\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild to moderate symptoms or are even asymptomatic , older patients or those with existing chronic diseases are at greater risk of developing serious complications such as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcf\u001b[0m.\u001b[31mappos\u001b[0m-fibrosis.nmod-those.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-prone.acomp-develop.xcomp-pneumonia.dobj-cause.acl-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m ) , chronic obstructive pulmonary disease ( COPD ) , and on mechanical ventilation are particularly prone to develop pneumonia caused by PA \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mimmunosuppressed\u001b[0m.\u001b[1mROOT\u001b[0m-susceptible.conj-\u001b[34minfluenza\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m are immunosuppressed , and therefore , are more susceptible to \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mfungal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-extension.acl:relcl-lung.nmod-\u001b[34msuperinfection\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , which may be due to viral extension to the lungs or bacterial \u001b[34msuperinfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-development.nmod-risk.nmod-lead.conj-\u001b[1mprolonged\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m in patients with hematological malignancy ( particularly after HSCT ) are more prolonged , lasting weeks and even months , and lead to an increased risk of respiratory compromise due to the development of viral or secondary bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-co-infecte.xcomp-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m are more likely to be co-infected with \u001b[34mbacteria\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuffer\u001b[0m.\u001b[1mROOT\u001b[0m-be.advcl-coinfection.nsubj-sa.nmod-\u001b[34mAspergillus\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with NTM suffer from a more rapid decline in pulmonary function than control patients without NTM although coinfections with SA and \u001b[34mAspergillus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-incidence.nmod-from.prep-\u001b[34mpneumonia\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m that are immunosuppressed such as those that are severely malnourished or HIV-infected are susceptible not only to a higher incidence and mortality from \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-risk.dobj-of.prep-develop.pcomp-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are immunocompromised , as a result of disease or therapeutic interventions , have the greatest risk of developing a fatal \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mckd\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nmod-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-susceptibility.nmod-bacterial.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mCKD\u001b[0m , impairment of the immune system could result in greater susceptibility to bacterial and viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-pneumonitis.nmod-\u001b[34mcmv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-develop.acl-\u001b[34mhepatitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at higher risk for developing fulminant acute \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , common respiratory viruses may cause severe \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpathogen\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m with congenital or acquired immunodeficiencies are more susceptible to viral \u001b[34mpathogens\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcirrhosis\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-have.advcl-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m have both complement and B-cell defects , they are at increased risk for \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcirrhosis\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mimmunocompromise\u001b[0m.\u001b[1mROOT\u001b[0m-variety.conj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are immunocompromised and have increased susceptibility to develop spontaneous bacterial \u001b[34minfections\u001b[0m , hospital-acquired infections , and a variety of infections\tCOUNT: 1\n",
      "PATH: \u001b[31mdiarrhea\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[34mdevelop\u001b[0m life-threatening \u001b[31mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are at an increased risk for these \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-high.conj-\u001b[1mpredispose\u001b[0m.\u001b[1mROOT\u001b[0m-patient.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: predisposes the patient to other rarer CNS \u001b[34minfections\u001b[0m , such as CMV , and the incidence of common CNS infections is higher in HIV-infected \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with compromised immune systems are especially susceptible to severe complications of adenovirus \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at increased risk for bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-factor.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies who are undergoing aggressive chemotherapy and treatment with corticosteroids are at increased risk of HSV , as impairment of cellular immunity is a risk factor for HSV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minflammation\u001b[0m.\u001b[31mnmod\u001b[0m-presence.nsubj-\u001b[1mcontribute\u001b[0m.\u001b[1mROOT\u001b[0m-susceptible.conj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minflammation\u001b[0m may contribute to portal hypertension and the development of acute-on-chronic liver failure , and cirrhotic patients are more susceptible to bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdermatitis\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-bacterial.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m are highly susceptible to cutaneous bacterial , viral , and fungal \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mcompound\u001b[0m-outcome.nsubj-severe.conj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: susceptible to such \u001b[34minfections\u001b[0m , and the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mpobj\u001b[0m-with.prep-child.nsubj-be.cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at extremely high risk for disseminated bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m prone to \u001b[31minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mlri\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with immunocompromise or extremes of age are at higher risk for more severe \u001b[34mLRI\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-influenza.nmod-\u001b[34minfection\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-influenza.nmod-\u001b[34minfection\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-management.nmod-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-virus.nmod-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-be.advcl-prove.conj-effective.xcomp-occur.advcl-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-be.advcl-prove.conj-effective.xcomp-occur.advcl-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mconj\u001b[0m-cidofovir.nmod-\u001b[1magent\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mconj\u001b[0m-cidofovir.nmod-\u001b[1magent\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-virus.nmod-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mcase\u001b[0m-therapy.nmod-efficacy.conj-effect.nmod-\u001b[1mcompromise\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nsubjpass-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-management.nmod-case.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-sufficient.ccomp-\u001b[1mthink\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-sufficient.ccomp-\u001b[1mthink\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mcase\u001b[0m-therapy.nmod-efficacy.conj-effect.nmod-\u001b[1mcompromise\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nsubjpass-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-available.amod-practice.nmod-treatment.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-form.nmod-\u001b[34mttp\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-form.nmod-\u001b[34mttp\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-induce.conj-rejection.dobj-\u001b[34morgan\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-induce.conj-rejection.dobj-\u001b[34morgan\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-available.amod-practice.nmod-treatment.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-agent.nsubj-patient.nmod-active.nmod-\u001b[34mtuberculosis\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msufficient\u001b[0m.\u001b[1macl:relcl\u001b[0m-suppress.advcl-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1museful\u001b[0m.\u001b[1mROOT\u001b[0m-treat.advcl-infection.dobj-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-sars-cov-2.nmod-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-fail.conj-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-recommend.ccomp-\u001b[1mdelay\u001b[0m.\u001b[1mROOT\u001b[0m-clearance.dobj-\u001b[34mvirus\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mavailable\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlicense\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-infection.nmod-\u001b[34mcmv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-Most.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-use.conj-progression.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-infection.nmod-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-ineffective.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-low.acomp-in.prep-\u001b[34mchild\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-suppression.dobj-\u001b[34mhost\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minterferon\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mnsubj\u001b[0m-treat.acl-\u001b[34mdengue\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mconj\u001b[0m-trial.nmod-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-consider.conj-be.xcomp-drug.attr-of.prep-choice.pobj-for.prep-\u001b[34minfluenza\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maciclovir\u001b[0m.\u001b[31mcompound\u001b[0m-monotherapy.nmod-efficacy.nsubjpass-\u001b[1mhamper\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1madvcl\u001b[0m-efficacy.dobj-prevent.acl-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfam\u001b[0m.\u001b[31mnsubj\u001b[0m-therapy.advcl-\u001b[1margue\u001b[0m.\u001b[1mROOT\u001b[0m-use.advcl-prophylaxis.nmod-\u001b[34msurvival\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-available.advcl-infection.nmod-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-response.nmod-therapy.nmod-suppression.nmod-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-demonstrate.advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nsubj-\u001b[34mcchf\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiologic\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubj-\u001b[1mprovide\u001b[0m.\u001b[1madvcl\u001b[0m-option.dobj-\u001b[34mUC\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mappos\u001b[0m-therapy.nsubjpass-use.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-vaccine.nsubj-prevent.acl-\u001b[34mrsv\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-resistance.nmod-association.appos-shedding.nmod-\u001b[34mvirus\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mzanamivir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-be.ccomp-benefit.attr-prove.acl-\u001b[34mtreatment\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mtherapy\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mspecific\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-choice.attr-patient.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcirrhosis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-effective.advcl-c.nmod-\u001b[34mhepatitis\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mcidofovir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mremain\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.attr-death.nmod-report.acl-secondary.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-efficacy.dobj-pneumonia.nmod-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mcompound\u001b[0m-toxicity.nmod-associate.conj-\u001b[1mcomplicated\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nsubj-recipient.nmod-develop.acl:relcl-cre.dobj-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mnmod\u001b[0m-treatment.nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34mkd\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mad\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mchallenging\u001b[0m.\u001b[1mROOT\u001b[0m-alleviate.advcl-symptom.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod\u001b[0m-interaction.nmod-\u001b[1mpose\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mtreatment\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubj-\u001b[1mcontroversial\u001b[0m.\u001b[1mROOT\u001b[0m-impact.nmod-response.nmod-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-switch.nsubjpass-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-worsen.conj-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhaart\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-make.xcomp-timing.dobj-controversial.amod-patient.nmod-\u001b[34msepsis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-absence.conj-intervention.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malthough\u001b[0m.\u001b[31mmark\u001b[0m-\u001b[1madopt\u001b[0m.\u001b[1madvcl\u001b[0m-treatment.nmod-\u001b[34msars\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod\u001b[0m-use.dobj-need.advcl-\u001b[1mrespond\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1madvcl\u001b[0m-treatment.nmod-infection.nmod-\u001b[34mhrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minhibit\u001b[0m.\u001b[1mROOT\u001b[0m-replication.dobj-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-drug.nmod-benefit.nsubjpass-\u001b[1mestablish\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-\u001b[34msars\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubj-be.cop-\u001b[1mconvenient\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod\u001b[0m-use.dobj-need.advcl-\u001b[1mrespond\u001b[0m.\u001b[1mROOT\u001b[0m-proportion.nsubj-involvement.nmod-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvzig\u001b[0m.\u001b[31mnsubj\u001b[0m-efficient.advcl-\u001b[1mbeneficial\u001b[0m.\u001b[1mROOT\u001b[0m-therapy.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod\u001b[0m-class.nmod-efficacy.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-development.nmod-resistance.nmod-\u001b[34mantiviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mCRS\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mefficacious\u001b[0m.\u001b[1madvcl\u001b[0m-reduce.conj-level.dobj-patient.nmod-infection.nmod-\u001b[34mhbv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod\u001b[0m-profile.nsubj-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-use.dobj-treat.acl-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnmod\u001b[0m-conjunction.nmod-\u001b[1mtoxicity\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-mainstay.nsubj-\u001b[1mcontroversial\u001b[0m.\u001b[1mROOT\u001b[0m-use.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-treatment.nmod-\u001b[34mvhf\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mcompound\u001b[0m-treatment.nmod-initiation.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mkd\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod\u001b[0m-therapy.nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-control.xcomp-\u001b[34mvasculitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mefficacy\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mtreatment\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-that.dobj-effective.amod-control.advcl-activity.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mcompound\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-trial.conj-lopinavir/ritonavir.nmod-medication.appos-\u001b[34mhiv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcombination\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nsubj-patient.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mdep\u001b[0m-effect.nsubjpass-\u001b[1mcontraindicate\u001b[0m.\u001b[1mROOT\u001b[0m-patient.nmod-\u001b[34mmyocarditis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mconj\u001b[0m-bronchodilator.dobj-include.conj-\u001b[1mbenefit\u001b[0m.\u001b[1mROOT\u001b[0m-plan.nsubj-\u001b[34mrsv\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-treat.acl-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnmod\u001b[0m-refractory.xcomp-\u001b[1mremain\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod\u001b[0m-therapy.nsubjpass-use.advcl-\u001b[1mrefractory\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mRibavirin\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-option.appos-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maminoglycoside\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mmonotherapy\u001b[0m.\u001b[1mnsubjpass\u001b[0m-treatment.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhydroxychloroquine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mworsen\u001b[0m.\u001b[1mccomp\u001b[0m-covid-19.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mbenefit\u001b[0m.\u001b[1mccomp\u001b[0m-patient.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrituximab\u001b[0m.\u001b[31mnmod\u001b[0m-experience.nsubj-encourage.advcl-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-become.conj-\u001b[1mpersist\u001b[0m.\u001b[1mROOT\u001b[0m-success.nsubj-\u001b[34mtreatment\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJakinibs\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1madvcl\u001b[0m-efficacy.dobj-treatment.nmod-condition.nmod-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdaptomycin\u001b[0m.\u001b[31mconj\u001b[0m-vancomycin.nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1mnsubjpass\u001b[0m-bacteremia.nmod-\u001b[34mmrsa\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-agent.nmod-\u001b[1msee\u001b[0m.\u001b[1mROOT\u001b[0m-occur.advcl-result.nmod-response.nmod-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-treat.pcomp-covid-19.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcart\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mtolerate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not tolerate \u001b[31mcART\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-remain.advcl-effect.nsubj-outcome.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is still limited because beneficial effects on \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-mers-cov.nmod-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1msuggest\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not suggested to systemically use in SARS-CoV-2 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1madvcl\u001b[0m-treat.xcomp-covid-19.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: using HIV antiretroviral \u001b[31mtherapy\u001b[0m to treat \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34m[\u001b[0m.\u001b[34mpunct\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m or second line foscarnet and cidofovir can result in substantial hematotoxicity and nephrotoxicity \u001b[34m[\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m.\u001b[31mnmod\u001b[0m-dose.nmod-\u001b[1memerge\u001b[0m.\u001b[1mccomp\u001b[0m-resistance.nsubj-\u001b[34mantiviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1maddition\u001b[0m.\u001b[1mnsubj\u001b[0m-treat.acl-mas.dobj-associate.acl-\u001b[34msjia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: addition to \u001b[31mcorticosteroids\u001b[0m and CsA in treating MAS associated with \u001b[34msJIA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1madvance\u001b[0m.\u001b[1madvcl\u001b[0m-show.conj-result.dobj-decrease.acl-severity.dobj-\u001b[34msymptom\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been advanced to clinical trials and shown modest results in decreasing either \u001b[34msymptom\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-rapid.advcl-kinetic.nsubj-\u001b[34mcmv\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m may not be completely effective in \u001b[34mCMV\u001b[0m D+/R liver transplant recipients because the replication kinetics of CMV\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuccessful\u001b[0m.\u001b[1mROOT\u001b[0m-patient.nmod-\u001b[34mms\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34muri\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantibiotic\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1moverprescribe\u001b[0m.\u001b[1mROOT\u001b[0m-difficulty.nmod-distinguish.acl-etiology.dobj-\u001b[34mcap\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mCAP\u001b[0m , especially in young children , \u001b[31mantibiotics\u001b[0m often are overprescribed\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-injury.nmod-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-effective.conj-subset.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod\u001b[0m-efficacy.nsubjpass-establish.parataxis-\u001b[1mtreat\u001b[0m.\u001b[1mROOT\u001b[0m-infection.nsubjpass-\u001b[34minfluenza\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mInfluenza\u001b[0m infections have been successfully treated with neuraminidase inhibitors ( oseltamivir or zanamivir ) ; however , the efficacy of these \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-treatment.nmod-infection.nmod-\u001b[34mfilovirus\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1minduction\u001b[0m.\u001b[1mnsubj\u001b[0m-immunosuppression.nmod-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: induction \u001b[34mof\u001b[0m immunosuppression by \u001b[31msteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-make.ccomp-treatment.dobj-crucial.amod-management.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m options are still limited and vaccines are often not available , which makes supportive treatment crucial in the clinical management of these often lifethreatening \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-prove.advcl-\u001b[1mrecommend\u001b[0m.\u001b[1mpcomp\u001b[0m-patient.nmod-\u001b[34mra\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: recommending allo-HSCT to \u001b[34mRA\u001b[0m patients unless all other standard \u001b[31mtreatments\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msteroid\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mmers\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-treat.xcomp-itp.dobj-associate.acl-\u001b[34mcvid\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are used to treat ITP associated with \u001b[34mCVID\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexpensive\u001b[0m.\u001b[1mROOT\u001b[0m-use.advcl-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m is expensive and may not provide additional benefit compared to the use of oral antiviral agents alone , especially in low-risk \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mcompound\u001b[0m-use.nmod-rationale.nsubj-be.advcl-\u001b[1mconduct\u001b[0m.\u001b[1mROOT\u001b[0m-remain.conj-use.advcl-treatment.nmod-tss.nmod-\u001b[34mstss\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m use in these syndromes based in theory , several lines of laboratory investigation , and retrospective clinical series , no definitive clinical trial has been conducted and there remains clinical equipoise as to whether IVIG should be used in the treatment of TSS and \u001b[34mSTSS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mtreatment\u001b[0m of PYR has been associated\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m.\u001b[31mnmod\u001b[0m-therapy.nsubj-\u001b[1mineffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mconj\u001b[0m-enough.advmod-genotype.nmod-\u001b[34mhcv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not effective enough for some \u001b[34mHCV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtocilizumab\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mappear\u001b[0m.\u001b[1mROOT\u001b[0m-effective.xcomp-\u001b[34micans\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mTocilizumab\u001b[0m appears to be not as effective for \u001b[34mICANS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-treatment.nsubjpass-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-option.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m treatment is not routinely recommended as a therapeutic option for COVID-19 \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-administer.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nmod-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mROOT\u001b[0m-need.conj-\u001b[34mresponse\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapy in immunosuppressed hosts depends on clinical and radiological resolution , the degree and duration of immunosuppression , and therefore maintenance therapy is sometimes needed after the initial \u001b[34mresponse\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmpa\u001b[0m.\u001b[31mnmod\u001b[0m-discontinuation.nsubjpass-\u001b[1mpropose\u001b[0m.\u001b[1mROOT\u001b[0m-case.nmod-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpneumonia\u001b[0m , discontinuation of \u001b[31mMPA\u001b[0m has also been proposed\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod\u001b[0m-utility.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the clinical utility of \u001b[31mribavirin\u001b[0m may be limited\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-therapeutic.ccomp-think.xcomp-\u001b[1mdrive\u001b[0m.\u001b[1mROOT\u001b[0m-development.nsubj-use.acl-stage.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m drives us to think that \u001b[31mRibavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mpreferred\u001b[0m.\u001b[1madvcl\u001b[0m-h.nmod-onset.nmod-symptom.nmod-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m are usually preferred within 48 h of the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-rate.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m not recommended due to low treatment response rates in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m.\u001b[31mnmod\u001b[0m-addition.nsubj-\u001b[1mprovide\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34msetting\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mavailable\u001b[0m.\u001b[1mROOT\u001b[0m-hpev.nmod-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not available for HPeV or enterovirus \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubj-\u001b[1minadequate\u001b[0m.\u001b[1mROOT\u001b[0m-due.prep-to.prep-window.pobj-\u001b[34madministration\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34madministration\u001b[0m window , current \u001b[31mantiviral\u001b[0m therapies are often inadequate\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1madvcl\u001b[0m-help.xcomp-control.xcomp-response.dobj-associate.acl-\u001b[34mfip\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are needed to help control the immune response associated with clinical \u001b[34mFIP\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdrug\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is a controversial \u001b[34mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m.\u001b[31mnsubjpass\u001b[0m-approve.advcl-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , although type I \u001b[31mIFNs\u001b[0m have been approved for diverse indications including genital warts , viral hepatitis , hairy cell leukemia and chronic myelogenous leukemia , their use in the clinic is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtegobuvir\u001b[0m.\u001b[31mnmod\u001b[0m-use.nsubj-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-offer.advcl-\u001b[34mactivity\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtegobuvir\u001b[0m is limited in that advanced DAAs offer pan-genotypic \u001b[34mactivity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mtreatable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are treatable with \u001b[31mIFN\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maspirin\u001b[0m.\u001b[31mnmod\u001b[0m-nsaid.nsubj-effective.advcl-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-achieve.parataxis-%.nsubj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31maspirin\u001b[0m , have been effective in systemic JIA , they are rarely effective in AoSD ; only 20 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mgc\u001b[0m.\u001b[31mnmod\u001b[0m-dose.nmod-treatment.nmod-\u001b[1mdemonstrate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: demonstrate persistent tissue \u001b[34minflammation\u001b[0m despite treatment with high doses of \u001b[31mGC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnmod\u001b[0m-need.conj-those.nmod-effect.nmod-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m associated with potentially serious side effects , including those requiring ICU-level resources and need for high-dose \u001b[31mglucocorticoids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m for COVID-19 \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mimpaired\u001b[0m.\u001b[1madvcl\u001b[0m-reconstitution.nmod-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m as cidofovir ( ADV ) and Rituximab ( EBV ) , their effi ciency is impaired in absence of specifi c \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mresistance\u001b[0m.\u001b[1mnmod\u001b[0m-h5n1.nmod-strain.conj-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31moseltamivir\u001b[0m resistance in HPAI H5N1 as well as in seasonal human \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a known complication among critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of APSCT in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-morbidity.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-morbidity.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-morbidity.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an important cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a frequent infectious complication in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication for \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-patient.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-patient.nmod-\u001b[34mdisease\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-associate.acl-mortality.nmod-cause.nmod-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod\u001b[0m-associate.acl-mortality.nmod-cause.nmod-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mchild\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mchild\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m.\u001b[31mamod\u001b[0m-superinfection.nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m.\u001b[31mamod\u001b[0m-superinfection.nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-covid-19.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproblem\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproblem\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with ARDS , superinfection is frequently associated with septic \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-covid-19.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , superinfection is often associated with \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m.\u001b[31mdobj\u001b[0m-develop.advcl-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-be.cop-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m.\u001b[31mdobj\u001b[0m-develop.advcl-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-be.cop-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-arise.acl:relcl-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-arise.acl:relcl-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mcop\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfinding\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfinding\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m necrotizing CA-MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m.\u001b[31mconj\u001b[0m-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-among.prep-cause.pobj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m.\u001b[31mconj\u001b[0m-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-among.prep-cause.pobj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mfeature\u001b[0m.\u001b[1mROOT\u001b[0m-covid-19.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mfeature\u001b[0m.\u001b[1mROOT\u001b[0m-covid-19.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m and renal injury are common in severe or critical COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-%.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m following primary influenza virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 2\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m after or during an RSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mROOT\u001b[0m-morbidity.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mROOT\u001b[0m-morbidity.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in infected \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mROOT\u001b[0m-form.nmod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a possible manifestation in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhypoxia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-manifestation.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-related.acl:relcl-aspiration.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common and severe complication that is related to aspiration in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbarotrauma\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m one\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumothorax\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-covid-19.nmod-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most frequent and serious complication \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod\u001b[0m-patient.nmod-develop.acl-syndrome.nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-cause.nsubj-patient.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mconj\u001b[0m-ards.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-complication.attr-lead.relcl-death.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m are common complications that can lead to death in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mevident\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mih\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfusion\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m.\u001b[31mappos\u001b[0m-coagulation.conj-failure.nsubjpass-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m ) are also frequently observed during COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m.\u001b[31mappos\u001b[0m-syndrome.nsubj-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-complication.nmod-develop.acl-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m ) is one of the commonest complications developing in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m is a severe complication in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmortality\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-patient.nmod-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmortality\u001b[0m in patients with COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mconsequence\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m a common consequence\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muncommon\u001b[0m.\u001b[1mROOT\u001b[0m-lethal.conj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m is very uncommon but can be lethal in immunocompetent \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minflammation\u001b[0m.\u001b[31mnmod\u001b[0m-onset.nmod-characterize.acl-failure.nmod-type.acl:relcl-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-cause.nsubj-mortality.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minflammation\u001b[0m in the lungs , is the leading cause of mortality of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-proportion.nsubj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 may develop \u001b[31mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-covid-19.nmod-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-presentation.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a common presentation in COVID-19 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mROOT\u001b[0m-indicate.conj-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m is a possible manifestation of COVID-19 , and its occurrence usually indicates a severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m can be the primary presenting manifestation of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msyndrome\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-occur.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m ( DSS ) is more likely to occur after a second DENV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdamage\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfeature\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdamage\u001b[0m is a common feature in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mcase\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31msevere\u001b[0m \u001b[34mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-one.attr-of.prep-complication.pobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is one of the complications or preexisting conditions of MERS-CoV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-report.conj-%.nmod-\u001b[34mpatient\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m has been reported as the most common cardiac manifestation of COVID -19 and is reported in 8 -12 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-week.nmod-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-week.nmod-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-week.nmod-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-week.npadvmod-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-week.npadvmod-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-day.pobj-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mattr\u001b[0m-be.acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mattr\u001b[0m-be.acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mROOT\u001b[0m-value.nsubj-\u001b[34mthese\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mROOT\u001b[0m-value.nsubj-\u001b[34mthese\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m.\u001b[31mdobj\u001b[0m-make.acl-order.pobj-in.prep-\u001b[1mfall\u001b[0m.\u001b[1mROOT\u001b[0m-under.prep-hour.pobj-8.nummod-\u001b[34m12\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m.\u001b[31mdobj\u001b[0m-make.acl-order.pobj-in.prep-\u001b[1mfall\u001b[0m.\u001b[1mROOT\u001b[0m-under.prep-hour.pobj-8.nummod-\u001b[34m12\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-day.nmod-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m9\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-wait.parataxis-day.nsubjpass-\u001b[34m62\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-in.prep-order.pobj-have.acl-after.prep-day.pobj-\u001b[34m60\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-in.prep-order.pobj-have.acl-after.prep-day.pobj-\u001b[34m60\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m9\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mincubation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-be.xcomp-day.npadvmod-2.nummod-\u001b[34m10\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-wait.parataxis-day.nsubjpass-\u001b[34m62\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-day.nmod-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mincubation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-be.xcomp-day.npadvmod-2.nummod-\u001b[34m10\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-day.pobj-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m.\u001b[31mnmod\u001b[0m-mg.nmod-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-for.prep-day.pobj-\u001b[34mten\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m.\u001b[31mnmod\u001b[0m-mg.nmod-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-for.prep-day.pobj-\u001b[34mten\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m.\u001b[31mcompound\u001b[0m-level.nsubj-reach.advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-after.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m.\u001b[31mcompound\u001b[0m-level.nsubj-reach.advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-after.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m.\u001b[31mpobj\u001b[0m-to.prep-delay.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-maximum.nmod-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m.\u001b[31mpobj\u001b[0m-to.prep-delay.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-maximum.nmod-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mconj\u001b[0m-bip.pobj-between.prep-transport.relcl-distance.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mconj\u001b[0m-bip.pobj-between.prep-transport.relcl-distance.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-take.conj-=.parataxis-day.dobj-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-take.conj-=.parataxis-day.dobj-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.pobj-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-\u001b[1mday\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m22\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-implement.xcomp-\u001b[34mwithin\u001b[0m.\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m from symptom onset needs to be implemented \u001b[34mwithin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-after.prep-week.npadvmod-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-period.attr-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.nsubj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days should be the period of \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-week.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-last.ccomp-be.conj-\u001b[1mvary\u001b[0m.\u001b[1mROOT\u001b[0m-day.nmod-7.nummod-\u001b[34m14\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: varies between 7 and \u001b[34m14\u001b[0m days for moderate cases according to [ 3 ] , and this is why \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-of.prep-day.pobj-\u001b[34m15\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-base.prep-day.npadvmod-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexceed\u001b[0m.\u001b[1mROOT\u001b[0m-hour.npadvmod-\u001b[34m24\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-minimum.attr-of.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m duration depends on national regulations but should be a minimum of \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubjpass\u001b[0m-of.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of 60 to \u001b[34m90\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-less.acomp-than.prep-week.pobj-\u001b[34mseveral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period , which starts when the most recently received animals are placed into a quarantine , should not be less than \u001b[34mseveral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-officer.nsubj-detain.ccomp-mean.advcl-\u001b[1mdescribe\u001b[0m.\u001b[1mROOT\u001b[0m-day.nmod-\u001b[34m20\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: described as \u001b[34m20\u001b[0m days , meaning a \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-buffer.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-d.nsubj-\u001b[34m15\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m buffer in January is around \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mpobj\u001b[0m\u001b[0m-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2.73 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-\u001b[1mbe\u001b[0m.\u001b[1mxcomp\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: be in \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mROOT\u001b[0m-on.prep-period.pobj-be.relcl-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m depends on the incubation period of COVID-19 , which is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mrecommend\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantining\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-day.pobj-\u001b[34m70\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrelax\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mday\u001b[0m.\u001b[34mnpadvmod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed only after 27 , 26 and 53 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mexposure\u001b[0m.\u001b[31mcompound\u001b[0m-time.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-minute.attr-\u001b[34m1\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mself-quarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-cut-off.attr-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-day.npadvmod-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days is the chosen cut-off for \u001b[31mself-quarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mprep\u001b[0m-isolation.nsubj-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-impose.xcomp-within.prep-day.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mof\u001b[0m persons exposed to the virus needs to be imposed within \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34moptimal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34moptimal\u001b[0m \u001b[31mtime\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mlatent\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34mfour\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-recommendation.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-with.prep-time.pobj-of.prep-day.pobj-\u001b[34m5\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m5\u001b[0m days on average , 15 initial recommendations for \u001b[31mquarantine\u001b[0m of exposed health care workers were\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mshorten\u001b[0m.\u001b[1mROOT\u001b[0m-to.prep-day.pobj-\u001b[34m6\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-mandatory.acomp-for.prep-day.pobj-\u001b[34m17\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m with respiratory isolation is also mandatory for \u001b[34m17\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrelaxed\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed for the young , adults and elderly after 13 , 11 and 47 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-diagnose.advcl-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m-day.nsubjpass-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is diagnosed at sentinel medical institutions , at least \u001b[34m10\u001b[0m days are required\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mcompound\u001b[0m-spreading.dobj-prevent.advcl-\u001b[1mgo\u001b[0m.\u001b[1mROOT\u001b[0m-into.prep-isolation.pobj-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m spreading , any individual who may have been exposed should go into isolation for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mincrease\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-day.pobj-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-rule.conj-control.pobj-to.prep-accord.prep-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-within.prep-\u001b[34m4\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m rules at airports , the time taken between specimen collection and the reporting of results was within \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlast\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-week.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mtake\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mweek\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should take at least 4 - 6 \u001b[34mweeks\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mborehole\u001b[0m.\u001b[31mconj\u001b[0m-%.pobj-to.prep-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-latrine.nsubjpass-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m latrines should be increased to 16.1 % and \u001b[31mboreholes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccine\u001b[0m.\u001b[31mcompound\u001b[0m-availability.nsubj-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-within.prep-day.pobj-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod\u001b[0m-onset.nmod-\u001b[1moccur\u001b[0m.\u001b[1madvcl\u001b[0m-day.nmod-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: occur within \u001b[34m8\u001b[0m days following the onset of symptoms in the last resident \u001b[31mcase\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mccomp\u001b[0m\u001b[0m-for.prep-minimum.pobj-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for a minimum of \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-be.ccomp-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-be.xcomp-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be of sufficient length to allow risk periods for respiratory and digestive diseases to pass ; this has generally been recommended to be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mxcomp\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-confinement.nsubjpass-of.prep-day.pobj-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days has generally been recommended to \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcontrol\u001b[0m.\u001b[31mnmod\u001b[0m-view.pobj-from.prep-treat.ccomp-show.advcl-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-pair.nsubjpass-\u001b[34m20\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m20\u001b[0m pairs of gloves/doctor ( high risk)/day will be required because 1 SARS report showed that 1 doctor can treat 5 to 10 patients per day from the view of infection \u001b[31mcontrol\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31misolation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-extend.xcomp-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31misolation\u001b[0m periods may need to be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod\u001b[0m-case.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-be.ccomp-week.nsubj-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have been officially reported for a few days , at least \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mdobj\u001b[0m-detect.xcomp-\u001b[1mtake\u001b[0m.\u001b[1mROOT\u001b[0m-average.nsubjpass-of.prep-day.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m3\u001b[0m days was taken to detect imported \u001b[31mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m.\u001b[31mdet\u001b[0m-period.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mROOT\u001b[0m-day.nmod-\u001b[34m50\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m period is reduced to \u001b[34m50\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mdobj\u001b[0m-start.advcl-\u001b[1mwait\u001b[0m.\u001b[1madvcl\u001b[0m-day.dobj-10.nummod-\u001b[34m20\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: waiting 10 or \u001b[34m20\u001b[0m days , respectively , to start the \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mduration\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnpadvmod\u001b[0m-minimum.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-month.attr-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m necessary to complete reference virus development and safety testing is \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mxcomp\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-have.advcl-period.dobj-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , the individuals are to be \u001b[31mquarantined\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mlong\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mLonger\u001b[0m \u001b[31mquarantine\u001b[0m periods\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-day.compound-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-individual.nmod-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for \u001b[34msymptomatic\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubjpass-\u001b[1mbase\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mis\u001b[0m based\tCOUNT: 1\n",
      "PATH: \u001b[31mclose\u001b[0m.\u001b[31mamod\u001b[0m-contact.dobj-identify.xcomp-sufficient.oprd-\u001b[1mconsider\u001b[0m.\u001b[1mROOT\u001b[0m-period.nsubjpass-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 7-day period is considered sufficient to identify \u001b[31mclose\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mpobj\u001b[0m-between.prep-interval.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mvaccinations\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthe\u001b[0m.\u001b[31mdet\u001b[0m-lockdown.nsubjpass-\u001b[1mdelay\u001b[0m.\u001b[1mconj\u001b[0m-by.agent-day.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mthe\u001b[0m lockdown should not be delayed by more than \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-determine.xcomp-important.acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m11\u001b[0m days , which is important to determine the appropriate duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mdobj\u001b[0m-enter.pcomp-before.prep-\u001b[1mspend\u001b[0m.\u001b[1mxcomp\u001b[0m-minimum.dobj-of.prep-day.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: spend a minimum of \u001b[34m2\u001b[0m days in Cte d'Ivoire before entering \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-for.prep-day.pobj-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m for contacts should at least be for \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-infect.conj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-infect.conj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-infect.conj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mairway\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mtract\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mtract\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-allow.acl:relcl-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-allow.acl:relcl-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-enter.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mROOT\u001b[0m-infect.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mROOT\u001b[0m-infect.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mairway\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-evidence.attr-associate.acl-surface-exposed.advcl-mediate.conj-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-evidence.attr-associate.acl-surface-exposed.advcl-mediate.conj-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mentry\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: entry of \u001b[31mSARS-CoV-2\u001b[0m into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-enter.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters human target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE2 ) as a viral receptor to enter the target \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-potential.dobj-replicate.acl-\u001b[34mcardiomyocyte\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-potential.dobj-replicate.acl-\u001b[34mcardiomyocyte\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use host receptor angiotensin-converting enzyme 2 ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-infect.advcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes COVID-19 by infecting host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-tract.dobj-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mentry\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: entry into target \u001b[34mcells\u001b[0m by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubj-dominate.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubj-dominate.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-tract.dobj-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-infect.advcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes respiratory symptoms by infecting alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.dobj-\u001b[1mtarget\u001b[0m.\u001b[1mROOT\u001b[0m-infect.conj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: targets human angiotensin-converting enzyme \u001b[31m2\u001b[0m ( hACE2 ) and infects intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-ace2.dobj-\u001b[34mcell\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msara-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-type.dobj-\u001b[34mcell\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.conj-protein.nmod-interaction.dobj-involve.acl-mechanism.nmod-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: enters host \u001b[34mcells\u001b[0m by a mechanism involving the interaction between its spike ( S ) protein and human angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-enter.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) , which enters the \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexploit\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-invade.acl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to invade \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-target.nsubj-mucosa.nsubj-\u001b[1mact\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-entry.conj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is the upper respiratory mucosa , and angiotensin-converting enzyme 2 ( ACE2 ) acts as a functional receptor for the viral spikes and eventually viral entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.nmod-bind.acl:relcl-protein.nmod-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: infects \u001b[34mcells\u001b[0m through the S protein , which binds to cell surface receptor-angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-bind.advcl-replicate.conj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly invades alveolar epithelial \u001b[34mcells\u001b[0m by binding to the ACE-2 receptor and then replicates within cells\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mROOT\u001b[0m-pathogen.oprd-gain.acl:relcl-access.dobj-to.prep-\u001b[34mbody\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is considered a lower respiratory tract pathogen that gains access to the \u001b[34mbody\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-pathogenesis.nsubj-\u001b[1minvolve\u001b[0m.\u001b[1mROOT\u001b[0m-binding.dobj-\u001b[34mhost\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m involves the binding of its spike protein to angiotensin converting enzyme-2 ( ACE2 ) in the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mparataxis\u001b[0m-attack.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also needs ACE2 to attack human alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-receptor.nmod-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: binds to angiotensin-converting enzyme \u001b[31m2\u001b[0m receptors ( ACE2r ) to invade human lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov-1.nsubj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use angiotensin-converting enzyme 2 ( ACE2 ) as receptor to infect ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mamod\u001b[0m-injury.nmod-pathology.nsubjpass-elucidate.advcl-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-that.dep-replicate.dep-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m lung injury has not yet been elucidated , it has been estimated from MERS and SARS that the virus replicates in alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-protein.nmod-\u001b[34m-PRON-\u001b[0m.\u001b[34mnmod:poss\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the angiotensin converting enzyme 2 receptor ( ACE2 ) by \u001b[34mits\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.dobj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-infect.advcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the cellular receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mentry\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mhost\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m gains entry into the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mbelieve\u001b[0m.\u001b[1mROOT\u001b[0m-invade.xcomp-\u001b[34mhost\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is believed to invade the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-protein.nmod-express.acl:relcl-cell.nmod-\u001b[34mendothelial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to ACE2 protein that is abundantly expressed in \u001b[34mendothelial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-generate.conj-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the ACE2 protein as a virus receptor [ 4 ] and can generate \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod\u001b[0m-bind.advcl-increase.conj-lead.conj-\u001b[1mreach\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: reaches the \u001b[34mcell\u001b[0m through angiotensin-converting enzyme ( ACE ) receptors and leads to severe pneumonia and thus increased mortality rates during infection by binding to human \u001b[31mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus binds to angiotensin converting enzyme 2 ( ACE2 ) receptors in the respiratory tracts of infected patients to enter host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-facilitate.xcomp-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( ACE2 ) as the key receptor to facilitate its entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( ACE2 ) on pulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.nmod-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: enters lung \u001b[34mcells\u001b[0m through angiotensinconverting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mpneumocyte\u001b[0m.\u001b[1mdobj\u001b[0m-epithelium.nmod-\u001b[34malveolar\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m pneumocytes in the \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-protein.nmod-allow.acl-act.ccomp-express.conj-surface.nmod-type.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is characterized by a spike protein allowing viral binding to the angiotensin-converting enzyme (ACE)-2 , which acts as a viral receptor and is expressed on the surface of several pulmonary and extra-pulmonary \u001b[34mcell\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m both enter \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-target.nmod-use.acl-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to its target using the angiotensin-converting enzyme 2 ( ACE2 ) receptor on human \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-strain.nsubj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-furin.dobj-express.acl-\u001b[34mlung\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m strain , uniquely uses furin expressed highly in the \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( ACE2 ) receptor on the host \u001b[34mcell\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-capacity.dobj-allow.acl:relcl-produce.xcomp-\u001b[34mtissue\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m has the capacity to escape innate immune responses , which allows the pathogen to produce large copy numbers in primarily infected \u001b[34mtissues\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mattach\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-present.acl:relcl-surface.nmod-cell.nmod-epithelium.nmod-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m attaches to the angiotensin-converting enzyme 2 ( ACE 2 ) receptor which is usually present on the surface of alveolar cells of the \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds with the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.nmod-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-bind.advcl-domain.nmod-enzyme.nmod-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-bind.advcl-domain.nmod-enzyme.nmod-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcell\u001b[0m \u001b[31mACE2\u001b[0m receptors\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nmod-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nmod-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-identify.advcl-\u001b[1msurprising\u001b[0m.\u001b[1mROOT\u001b[0m-adapt.ccomp-bind.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-identify.advcl-\u001b[1msurprising\u001b[0m.\u001b[1mROOT\u001b[0m-adapt.ccomp-bind.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-receptor.xcomp-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-receptor.xcomp-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod\u001b[0m-invade.conj-\u001b[1mbelong\u001b[0m.\u001b[1mROOT\u001b[0m-covid-19.nsubj-\u001b[34mboth\u001b[0m.\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod\u001b[0m-invade.conj-\u001b[1mbelong\u001b[0m.\u001b[1mROOT\u001b[0m-covid-19.nsubj-\u001b[34mboth\u001b[0m.\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-protein.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-protein.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mROOT\u001b[0m-with.prep-protein.pobj-use.acl:relcl-gain.conj-membrane.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mROOT\u001b[0m-with.prep-protein.pobj-use.acl:relcl-gain.conj-membrane.nmod-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-protein.nmod-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-enter.xcomp-protein.nmod-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-entry.nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-\u001b[34mreceptor\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-protein.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-evidence.attr-associate.acl-bind.advcl-receptor.nmod-\u001b[34menzyme-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-be.conj-evidence.attr-associate.acl-bind.advcl-receptor.nmod-\u001b[34menzyme-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mprotein\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mace2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mhuman\u001b[0m \u001b[31mace2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-entry.nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-\u001b[34mreceptor\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mamod\u001b[0m-glycoprotein.nmod-receptor.nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-mean.nmod-binding.nmod-receptor(s.nmod-\u001b[34mcellular\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-mean.nmod-binding.nmod-receptor(s.nmod-\u001b[34mcellular\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nmod-entry.nmod-receptor.nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for 25 entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhomologous\u001b[0m.\u001b[1mccomp\u001b[0m-infect.conj-binding.nmod-\u001b[34mace2\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhomologous\u001b[0m.\u001b[1mccomp\u001b[0m-infect.conj-binding.nmod-\u001b[34mace2\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mcell\u001b[0m receptor\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-receptor.conj-\u001b[1mconverting\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-receptor.conj-\u001b[1mconverting\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSars-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mace2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mhuman\u001b[0m \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mamod\u001b[0m-glycoprotein.nmod-receptor.nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mhace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.dobj-\u001b[34mhace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nmod-entry.nmod-receptor.nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-coronavirus.nmod-\u001b[1mreceptor\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m is also a functional receptor for the new \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-coronavirus.nmod-\u001b[1mreceptor\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m is also a functional receptor for the new \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-receptor.nmod-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can bind to human angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-receptor.nmod-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mprotein\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-protein.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m directly interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-hijack.acl-\u001b[1mreceptor\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme.nsubj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is a functional receptor hijacked by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mace-2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus likely uses \u001b[34mACE-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.parataxis-\u001b[34mbe\u001b[0m.\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial cells by attaching to angiotensin converting enzyme-2 ( ACE-2 ) via S-protein ; ACE-2 \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod\u001b[0m-point.dobj-\u001b[1mprovide\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m provides the cell membrane receptor entry point for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mccomp\u001b[0m-receptor.dobj-enzyme.acl:relcl-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the same receptor of SARS-CoV , which is angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mconj\u001b[0m-sars-cov.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-interaction.nmod-\u001b[34mace2\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial cells through the interaction of spike protein with human \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mseem\u001b[0m.\u001b[1mROOT\u001b[0m-use.xcomp-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m seems to use the same cell entry receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexploit\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-\u001b[34mace-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits the \u001b[34mACE-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-enzyme-2.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1mutilize\u001b[0m.\u001b[1mROOT\u001b[0m-receptor.dobj-enzyme.compound-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus utilizes Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"lemmas-deps\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: dep labels + lemmas (PyBART)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod:agent\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans is characterized by extensive pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod:agent\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mnmod:agent\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mmyocarditis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-spectrum.dobj-symptom.nmod:of-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV can cause a spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-result.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-result.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mestablish\u001b[0m.\u001b[1mroot\u001b[0m-cause.conj:and-number.mwe-\u001b[34mdisorder\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mestablish\u001b[0m.\u001b[1mroot\u001b[0m-cause.conj:and-number.mwe-\u001b[34mdisorder\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-spectrum.dobj-symptom.nmod:of-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-onset.nsubjpass-\u001b[34menteritis\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-onset.nsubjpass-\u001b[34menteritis\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an important systemic parvoviral \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-spectrum.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-spectrum.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-loss.nmod:in-\u001b[34mfocal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-loss.nmod:in-\u001b[34mfocal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mmyocarditis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-manifestation.dobj-\u001b[34mneurologic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-manifestation.dobj-\u001b[34mneurologic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-characterize.conj:and-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-characterize.conj:and-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-immunosuppression.dobj-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-encephalitis.dobj-disorder.nmod:with-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause Japanese encephalitis ( JE ) with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-illness.nmod:in-\u001b[34mfebrile\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbrv\u001b[0m.\u001b[31mnsubj\u001b[0m-infection.xcomp-\u001b[1mcomponent\u001b[0m.\u001b[1mxcomp\u001b[0m-pathogenesis.nmod:of-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mBRV\u001b[0m is a lytic infection and destruction of infected mucosal epithelial cells is an important component of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-stage.nmod:to-infection.nmod:of-characterize.acl:relcl-fever.nmod:agent-\u001b[34mshock\u001b[0m.\u001b[34mnmod:agent\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m begins with flu-like symptoms and progresses rapidly to the final stages of viral hemorrhagic fever infection , which are characterized by fever , hemorrhage , and hypotensive \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-cause.conj:and-atrophy.dobj-villi.nmod:of-result.acl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infects the epithelium of the small intestine , an environment rich in proteases , and causes atrophy of the villi resulting in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-associate.conj:and-\u001b[34mgastroenteritis\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in respiratory tract complications with varying degree of severity and has been associated with \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m.\u001b[31macl\u001b[0m-human.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfected\u001b[0m with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-result.advcl-\u001b[34mseverity\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m increases the susceptibility of the host to a wide range of viral and bacterial respiratory pathogens , resulting in increased \u001b[34mseverity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod:of\u001b[0m-spread.nmod:agent-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m characterized by a rapid and extensive spread of the \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrepresent\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod:of\u001b[0m-ability.nmod:due_to-\u001b[1mresult\u001b[0m.\u001b[1mconj:but\u001b[0m-\u001b[34mdamage\u001b[0m.\u001b[34mnmod:from\u001b[0m\tLINEAR: results from overwhelming cytopathic \u001b[34mdamage\u001b[0m due to the ability of Ebola \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnmod:with\u001b[0m-infect.acl-human.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-develop.xcomp-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m have been reported to develop a severe acute respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJEV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-trigger.advcl-response.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJEV\u001b[0m invades the central nervous system , wherein virus replication triggers a massive \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmcmv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-cause.conj:but-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMCMV\u001b[0m causes asymptomatic infection in adult immunocompetent mice , but experimental inoculation of neonates has caused lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-viremia.nmod:to-\u001b[34mto\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m.\u001b[31mnsubj\u001b[0m-pathogen.xcomp-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-degeneration.dobj-function.nmod:of-lead.acl:relcl-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m is an important viral pathogen worldwide in the domestic cat ( Felis catus ) , causes a slow progressive degeneration of immune functions that eventually leads to a \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34monset\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-immunosuppression.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreplicate\u001b[0m.\u001b[1mroot\u001b[0m-lead.conj:and-infection.nmod:to-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m replicates mainly in porcine alveolar macrophages ( PAMs ) and dendritic cells ( DCs ) and leads to persistent infection , interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-characterize.conj-cascade.nmod:by-event.nmod:of-lead.acl-inflammation.nmod:to-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of SARS-CoV causes severe acute respiratory syndrome ( SARS ) , which is an emerging infectious disease and characterized by a cascade of immunological events leading to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmhv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malphavirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34marthritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31malphavirus\u001b[0m infections , such as those involving CHIKV , Ross River virus ( RRV ) , and Sindbis virus ( SINV ) , induce debilitating \u001b[34marthritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-atrophy.nmod:agent-intestine.nmod:in-result.acl:relcl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is characterized by severe villous atrophy in the small intestine that results in watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mable\u001b[0m.\u001b[1mamod\u001b[0m-cross.xcomp-stimulate.xcomp-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m is able to cross the blood-brain barrier and stimulate \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmnv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-replication.nmod:in-associate.acl-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mMNV\u001b[0m infection in immunocompromised mice lacking innate immunity factors such as STAT1 or interferon receptors can result in persistent or acute virus replication associated with severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-severe.nmod:in-\u001b[34mdisease\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in severe and even fatal lung \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-splenomegaly.dobj-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBIV\u001b[0m induces splenomegaly and lymphademopathy \u001b[34msyndromes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-consequence.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-result.parataxis-disease.nmod:in-cns.nmod:of-\u001b[34msepsis\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , such as acute flaccid paralysis , myocarditis , and Reye syndrome , have been reported [ 13 , 18 ] ; HPeV3 infection results in severe diseases of the CNS and neonatal \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjhmv\u001b[0m.\u001b[31mnmod:of\u001b[0m-strain.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mjHMV\u001b[0m cause a subacute or persistent \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmarv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod:with\u001b[0m-mouse.nmod:of-infection.nsubj-\u001b[1mproduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m produces clinical \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mterm\u001b[0m.\u001b[1mroot\u001b[0m-cause.parataxis-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , also termed epizootic catarrhal \u001b[34menteritis\u001b[0m or ECE , causes mucoid enteritis\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mresult\u001b[0m.\u001b[1madvcl:while\u001b[0m-symptom.nmod:in-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection usually results in mild \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-model.nsubj-\u001b[1mreveal\u001b[0m.\u001b[1mroot\u001b[0m-cause.ccomp-bronchiolitis.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have revealed that this lethal pulmonary infection causes a denuding bronchiolitis and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-stage.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-course.nmod:during-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msg\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: induces \u001b[34mSGs\u001b[0m during the course of \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msystemic\u001b[0m.\u001b[1mamod\u001b[0m-characterize.dep-hemorrhage.nmod:by-\u001b[34medema\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds is systemic , characterized by hemorrhage and \u001b[34medema\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-disease.dobj-\u001b[34millness\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes Ebola virus disease ( EVD ) , which is an acute systemic \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-mild.nmod:to-\u001b[34millness\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mInfluenza\u001b[0m virus infection in humans can lead to mild to severe \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mcytolytic\u001b[0m.\u001b[1mamod\u001b[0m-lead.advcl-\u001b[34matrophy\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infection is cytolytic and causes acute necrosis of the infected enterocytes , leading to marked intestinal villous \u001b[34matrophy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnidovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-inflammation.dobj-tract.nmod:of-develop.acl:relcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mnidovirus\u001b[0m infection induces an inflammation of the upper respiratory and alimentary tract which can develop into a severe and often fatal proliferative \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-range.nmod:in-sign.nmod:of-infection.nmod:from-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with FCoV can result in a diverse range of signs from clinically inapparent infections to a highly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msystemic\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-pneumonia.nmod:from-\u001b[34mdamage\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses from an atypical pneumonia to acute diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-fever.dobj-cough.conj-\u001b[34mpneumonia\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m often causes fever , cough , and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvsv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1masymptomatic\u001b[0m.\u001b[1mamod\u001b[0m-cause.conj:or-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mVSV\u001b[0m infection of humans is typically either asymptomatic or causes a mild influenza-like \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menteritis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtrigger\u001b[0m.\u001b[1mroot\u001b[0m-lesion.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in human , or MERS , commonly manifests as a severe acute respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchikv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfpv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mFPV\u001b[0m is responsible of systemic \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-BRDC.nsubjpass-\u001b[1mprecede\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m BRDC \u001b[34mis\u001b[0m often preceded\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:following\u001b[0m-\u001b[1m12\u001b[0m.\u001b[1mroot\u001b[0m-,.punct-replicate.appos-mucosa.nmod:in-lead.acl-\u001b[34mdamage\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , RSV replicates in the respiratory mucosa leading to epithelial \u001b[34mdamage\u001b[0m [ 11 ] and perivascular mononuclear infiltration [ 12\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mjcv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m.\u001b[31mnmod:with\u001b[0m-co-infection.nsubj-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m and S. suis generally induces exacerbated \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:agent\u001b[0m-\u001b[1maggravate\u001b[0m.\u001b[1mconj:and\u001b[0m-\u001b[34mcondition\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mcondition\u001b[0m is aggravated by mixed \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjcpyv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-follow.conj-viremia.nmod:by-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m occurs predominately in alveolar macrophages of the lung [ 3 ] , followed by viremia and subsequent interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfilovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mfilovirus\u001b[0m infections \u001b[34mare\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-degree.dobj-manifestation.nmod:of-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes varying degrees of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-seriousness.nsubj-\u001b[1mlie\u001b[0m.\u001b[1mroot\u001b[0m-complication.nmod:in-include.acl:relcl-disease.dobj-\u001b[34mencephalitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m lies in its complications , which include hand-foot-and-mouth disease , herpangina , aseptic meningitis , poliomyelitis-like paralysis , and fatal \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-complication.nmod:to-\u001b[34millness\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PRRSV leads to reproductive complications , respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfipv\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtropic\u001b[0m.\u001b[1mamod\u001b[0m-result.acl:relcl-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m is macrophage tropic and may cause aberrant cytokine and/or chemokine expression and lymphocyte depletion , which results in a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-disorder.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-condition.dobj-know.acl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by the SARS-CoV-2 causes an inflammatory condition also known as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhcov\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mHCoV\u001b[0m infection in immunosuppressed populations can lead to significant lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mveev\u001b[0m.\u001b[31mnmod:to\u001b[0m-exposure.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mVEEV\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 1\n",
      "PATH: \u001b[31mphev\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mxcomp\u001b[0m-cause.acl-symptom.dobj-\u001b[34mneurological\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPHEV\u001b[0m is a neurovirulent virus that spreads to the central nervous system ( CNS ) via peripheral nerves , where neurite damage and neuronal death are observed , causing \u001b[34mneurological\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjev\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod:after-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m can develop after \u001b[31mJEV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31miav\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod:of-manifestation.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mIAV\u001b[0m infection range from mild disease to severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpcmv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubjpass-\u001b[1maccompany\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mPCMV\u001b[0m infection \u001b[34mis\u001b[0m typically accompanied\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-depletion.nmod:in-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with the domestic cat ( Felis catus ) strain of FIV ( FIV Fca ) results in CD4 + T-cell depletion and pathogenic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtgev\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-lead.advcl-\u001b[34mgastroenteritis\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mTGEV\u001b[0m infects the epithelial cells of the small intestine , leading to potentially fatal \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mspread\u001b[0m.\u001b[1mnmod:agent\u001b[0m-symptom.nmod:with-distress.nmod:including-\u001b[34mencephalitis\u001b[0m.\u001b[34mnmod:including\u001b[0m\tLINEAR: spread of the \u001b[31mvirus\u001b[0m in several organs , with symptoms including respiratory distress and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mfever\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-lead.conj:and-\u001b[34mfever\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mroot\u001b[0m-picture.nmod:to-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mroot\u001b[0m-picture.nmod:to-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdyspnea\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m.\u001b[31mnmod:in\u001b[0m-suckle.nmod:in-growth.nmod:agent-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m.\u001b[31mnmod:in\u001b[0m-suckle.nmod:in-growth.nmod:agent-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj:and\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj:and\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-lead.conj:and-\u001b[34mfever\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung , and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1msevere\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdyspnea\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-young.nsubj-have.aux-\u001b[1mprofuse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-young.nsubj-have.aux-\u001b[1mprofuse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpeople\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-feature.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpeople\u001b[0m commonly manifest features of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mroot\u001b[0m-encephalopathy.dobj-\u001b[34mencephalitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m suffering from severe DENV infection often exhibit encephalopathy and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with signs from FIV often \u001b[34mhave\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34menteric\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-illness.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-stage.nsubj-\u001b[1minclude\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbleeding\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1masymptomatic\u001b[0m.\u001b[1mamod\u001b[0m-occur.advcl:although-sign.nsubj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic , although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-headache.nmod:with-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdeteriorate\u001b[0m.\u001b[1mroot\u001b[0m-present.conj:and-\u001b[34msymptom\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with EVD rapidly deteriorate and commonly present with gastrointestinal \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-course.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-manifest.conj:but-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m are primarily infected subclinically , but gastrointestinal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmarmoset\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-onset.dobj-\u001b[34msudden\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , VEEV infection causes a \u001b[34msudden\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:of\u001b[0m-subset.nsubj-progress.conj:but-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is associated with fever and liver damage , but a subset of \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-worsen.conj:and-symptom.nsubj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by SARS-CoV typically has an insidious onset , and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuffer\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj-inflammation.nmod:to-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m infected with SARS suffer fever , cough , muscle aches , and shortness of breath and often progress to severe \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mleptospirosis\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mHuman\u001b[0m \u001b[34mleptospirosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-symptom.dobj-as.prep-vomiting.pobj-\u001b[34mdiarrhea\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mPigs\u001b[0m that are infected with TGEV usually present symptoms such as vomiting , dehydration , and severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-occur.conj:and-result.advcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mrats\u001b[0m are especially susceptible to SDA , and the infection can occur in the lower respiratory tract , resulting in \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbecome\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mill\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m typically become acutely \u001b[34mill\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-fever.conj-\u001b[34mdiarrhoea\u001b[0m.\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , adenovirus infections often manifest as upper respiratory tract infections , pharyngoconjunctival fever , or \u001b[34mdiarrhoea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-characterize.conj:and-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually leads to the development of CHIKF and \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-after.prep-onset.pobj-of.prep-\u001b[34mrash\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m develops insidiously , usually a few days after the onset of \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-occur.parataxis-symptom.nsubj-\u001b[34mrash\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m manifests as fever , headache , weakness , and myalgias/ arthralgias ; gastrointestinal symptoms and a maculopapular \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-infection.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-nonlethal.dobj-incapacitate.dep-\u001b[34msymptom\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes nonlethal , incapacitating \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-rvf.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:but-to.prep-\u001b[34mfever\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually begins with a nonspecific influenza-like acute \u001b[34mfever\u001b[0m , but can progress to serious hemorrhagic fever\tCOUNT: 1\n",
      "PATH: \u001b[31mleptospirosis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-call.ccomp-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m , also called Pretibial fever or Fort Bragg fever , \u001b[34mhas\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34monset\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdog\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mparataxis\u001b[0m-\u001b[34mparalysis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m exhibit pharyngeal \u001b[34mparalysis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-plague.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m \u001b[34mis\u001b[0m usually characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mlesion\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnmod:of\u001b[0m-%.nmod:in-\u001b[1mappear\u001b[0m.\u001b[1mev\u001b[0m-\u001b[34mFever\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mFever\u001b[0m , absolute lymphopenia , inappetence , jaundice , and abdominal effusion appear 2 - 3 weeks after infection in around 80 % of \u001b[31mcats\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod:of\u001b[0m-%.nsubj-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m show acute \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-sign.nmod:in-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mself-limiting\u001b[0m.\u001b[1mamod\u001b[0m-progress.conj:but-\u001b[34mhepatitis\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , infection is usually self-limiting , but a small percent of cases ( 1 - 2 % ) can progress to severe \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnsubjpass\u001b[0m-infect.advcl-\u001b[1mreach\u001b[0m.\u001b[1mroot\u001b[0m-%.dobj-range.dobj-sign.nsubj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m are infected by the virus , mortality can reach up to 50 % of affected horses , and \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1masymptomatic\u001b[0m.\u001b[1mamod\u001b[0m-observe.advcl:although-sign.nsubjpass-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-severity.nsubj-range.ccomp-\u001b[1minclude\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msymptom\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m severities range from asymptomatic infection to fatal HF ( Fisher-Hoch et al. , 1995 ) and commonly resulting from other viral infections , nonspecific \u001b[34msymptoms\u001b[0m beginning several days after infection include\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrestricted\u001b[0m.\u001b[1mamod\u001b[0m-lead.advcl-onset.nmod:to-sign.nmod:of-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is generally restricted to the alimentary tract , leading to the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-illness.dobj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcalf\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-BRDC.nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-fever.nmod:agent-lesion.conj-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m is characterized by fever , dyspnea , inflammatory and necrotizing \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nmod:after-picture.nsubj-\u001b[1mdisease\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection of the respiratory tract is mild self-limiting upper respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-infection.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-associate.conj:and-\u001b[34mfever\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m infection begins in the upper respiratory tract with nasal congestion and pharyngitis and is associated with \u001b[34mfever\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1madvcl\u001b[0m-onset.dobj-of.prep-fever.pobj-chill.conj-develop.conj-tachypnea.dobj-\u001b[34mdyspnea\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience the abrupt onset of high fever , chills , and rapidly developing tachypnea and \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-sign.dobj-anemia.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with acute leukemia usually show signs of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m.\u001b[31mnmod:in\u001b[0m-infection.nsubj-\u001b[1myield\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msyndrome\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-onset.dobj-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with E coli may develop an acute onset of watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-anemia.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m commonly develop anemia and secondary infections , especially bacterial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-manifestation.nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mroot\u001b[0m-presentation.nmod:to-failure.nmod:with-\u001b[34mshock\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant presentation with progressive respiratory failure and \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnmod:of\u001b[0m-percentage.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-asymptomatic.amod-have.advcl:although-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m , a small percentage of affected \u001b[31mindividuals\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhepatitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnmod:of\u001b[0m-%.nmod:in-occur.parataxis-\u001b[1minvolve\u001b[0m.\u001b[1mroot\u001b[0m-outcome.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m usually involves mild upper respiratory tract infections ; however , more severe conditions , such as pneumonia and bronchiolitis occur in 25 - 40 % of \u001b[31mchildren\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-symptom.nsubj-\u001b[1mmild\u001b[0m.\u001b[1mamod\u001b[0m-include.conj:and-\u001b[34millness\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m are usually mild and include febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madult\u001b[0m.\u001b[31mnmod:in\u001b[0m-case.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-in.prep-\u001b[34mdyspnea\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m usually result in \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-progress.relcl-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: period of 2 - 14 days \u001b[31mpatients\u001b[0m initially present with influenza-like symptoms , fever , and cough that can progress to atypic \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31manimal\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-apathy.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m show \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-fatigue.npadvmod-lead.acl:relcl-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses quickly to fever , intense fatigue , diarrhea , anorexia , abdominal pain , hiccups , myalgia , vomiting , confusion , and conjunctivitis ( 14 ) which \u001b[34mmay\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdamage\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m who die within 10 days of the onset of symptoms show diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-resemble.conj:and-\u001b[34mdengue\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m presents with high fever , headache , myalgias , and arthralgias , and can resemble \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m.\u001b[31macl\u001b[0m-\u001b[1mmouse\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m Signs Mice \u001b[31minfected\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthese\u001b[0m.\u001b[31mdet\u001b[0m-symptom.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-infection.nmod:following-\u001b[34millness\u001b[0m.\u001b[34mnmod:following\u001b[0m\tLINEAR: \u001b[31mThese\u001b[0m symptoms generally develop 3 days to 6 weeks following an upper respiratory infection or diarrheal type \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1millness\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpertussis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-symptom.nmod:with-develop.acl:relcl-paroxysmal.nsubj-\u001b[34mcough\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mPertussis\u001b[0m usually presents with nonspecific upper respiratory tract infection symptoms for 1 to 2 weeks ( catarrhal stage ) , after which the paroxysmal and sometimes uncontrollable \u001b[34mcough\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-uri.dobj-\u001b[34macute\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m typically cause \u001b[34macute\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mroot\u001b[0m-follow.conj-\u001b[34mpharyngitis\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt onset of malaise , fatigue , fever , and headache , followed closely by \u001b[34mpharyngitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdog\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34miha\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with peracute \u001b[34mIHA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcourse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdiarrhea\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually courses as a self-limited \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-failure.nmod:to-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-failure.nmod:to-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj:and\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mconj:and\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-pneumonia.nmod:to-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-pneumonia.nmod:to-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-result.conj:but-failure.nmod:in-\u001b[34mcardiac\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-result.conj:but-failure.nmod:in-\u001b[34mcardiac\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-syndrome.nmod:to-\u001b[34mand\u001b[0m.\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-syndrome.nmod:to-\u001b[34mand\u001b[0m.\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-infection.nmod:with-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-infection.nmod:with-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-edema.dobj-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-edema.dobj-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-complication.nsubj-involvement.nmod:of-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-complication.nsubj-involvement.nmod:of-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-response.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-response.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-form.dobj-\u001b[1mexperience\u001b[0m.\u001b[1mroot\u001b[0m-suffer.conj:but-complication.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-form.dobj-\u001b[1mexperience\u001b[0m.\u001b[1mroot\u001b[0m-suffer.conj:but-complication.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-have.advcl:although-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-lead.advcl-\u001b[34mdeath\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-have.advcl:although-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-lead.advcl-\u001b[34mdeath\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdevelop\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdevelop\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-syndrome.nmod:in-failure.nmod:in-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-syndrome.nmod:in-failure.nmod:in-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-lymphadenopathy.conj-\u001b[34mgeneralize\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-lymphadenopathy.conj-\u001b[34mgeneralize\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mform\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mthis\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mform\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mthis\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-onset.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-onset.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-plague.dobj-pneumonic.amod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-plague.dobj-pneumonic.amod-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-pneumonia.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-pneumonia.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-state.pobj-\u001b[34mtoxic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-state.pobj-\u001b[34mtoxic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-asymptomatic.amod-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-symptom.dobj-\u001b[34mserious\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-asymptomatic.amod-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-symptom.dobj-\u001b[34mserious\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-presentation.nmod:with-include.acl:relcl-pharyngitis.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-presentation.nmod:with-include.acl:relcl-pharyngitis.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-lead.advcl-to.prep-dyspnea.pobj-stridor.conj-cyanosis.conj-shock.conj-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-lead.advcl-to.prep-dyspnea.pobj-stridor.conj-cyanosis.conj-shock.conj-\u001b[34mseptic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:but-infection.nmod:to-bronchiolitis.nmod:as-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:but-infection.nmod:to-bronchiolitis.nmod:as-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-some.det:qmod-\u001b[1msevere\u001b[0m.\u001b[1mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-some.det:qmod-\u001b[1msevere\u001b[0m.\u001b[1mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mshock\u001b[0m.\u001b[1mnmod:to\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mroot\u001b[0m-have.conj:and-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mroot\u001b[0m-have.conj:and-sign.dobj-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m.\u001b[31mcompound\u001b[0m-decompensation.nsubj-\u001b[1mcoincide\u001b[0m.\u001b[1mroot\u001b[0m-development.nmod:with-syndrome.nmod:of-difficult.xcomp-differentiate.xcomp-infection.nmod:from-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m.\u001b[31mcompound\u001b[0m-decompensation.nsubj-\u001b[1mcoincide\u001b[0m.\u001b[1mroot\u001b[0m-development.nmod:with-syndrome.nmod:of-difficult.xcomp-differentiate.xcomp-infection.nmod:from-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-spectrum.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mroot\u001b[0m-infection.nmod:from-disease.nmod:to-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-spectrum.nsubj-\u001b[1mrange\u001b[0m.\u001b[1mroot\u001b[0m-infection.nmod:from-disease.nmod:to-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-associate.conj:and-damage.nmod:with-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mroot\u001b[0m-associate.conj:and-damage.nmod:with-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mshock\u001b[0m.\u001b[1mnmod:to\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-course.nsubj-\u001b[1mlast\u001b[0m.\u001b[1mroot\u001b[0m-result.conj:and-in.prep-\u001b[34mcoma\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m.\u001b[31mamod\u001b[0m-course.nsubj-\u001b[1mlast\u001b[0m.\u001b[1mroot\u001b[0m-result.conj:and-in.prep-\u001b[34mcoma\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:of\u001b[0m-onset.pobj-after.prep-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , dyspnea and/or hypoxemia usually occur one week after the onset of the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-mild.amod-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-presentation.pobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is often mild with cold-like symptoms , it can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1moccur\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-progression.nsubj-\u001b[34mrapid\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrapid\u001b[0m progression of lung consolidation \u001b[31moccurs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mself-limiting\u001b[0m.\u001b[1mamod\u001b[0m-develop.conj:but-symptom.nsubj-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be self-limiting in few days , but in some cases the \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-patient.nmod:in-\u001b[34mcritical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31msymptom\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-form.nmod:to-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-pneumonia.dobj-associate.acl-bacteremia.nmod:with-failure.nmod:with-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , pneumonia , associated with bacteremia and \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mmild\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-failure.nmod:into-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:of\u001b[0m-case.nsubj-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-opacity.nmod:with-failure.nmod:with-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m have a rapid and relentless fatal course , with generalized alveolar and interstitial opacities , development of the adult respiratory distress syndrome ( ARDS ) , and \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-anemia.nmod:to-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34m-PRON-\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mit\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcondition\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31mconditions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbecome\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mprogressive\u001b[0m.\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m becomes relentlessly \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-mild.amod-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-manifestation.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is mild in most of the affected individuals , it may cause \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mips\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-dysfunction.nmod:to-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m.\u001b[31mdet\u001b[0m-infection.nsubj-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-croup.nmod:as-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m infection usually begins as a \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-%.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m , and potentially fatal , systemic \u001b[31mdisease\u001b[0m may develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:with\u001b[0m-associate.advcl:although-\u001b[1mfollow\u001b[0m.\u001b[1mroot\u001b[0m-infection.nmod:agent-bronchitis.nmod:including-abscess.nmod:including-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , this may be followed by persistent , chronic infection , including chronic bronchitis , bronchiectasis , and \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogressive\u001b[0m.\u001b[1mamod\u001b[0m-development.nmod:with-opacity.nmod:of-\u001b[34mbilateral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m can be rapidly progressive with the development of multifocal \u001b[34mbilateral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mcompound\u001b[0m-onset.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-failure.dobj-\u001b[34mprogressive\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m onset can cause \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:or-\u001b[34mrespiratory\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME can develop aseptic meningitis and meningoencephalitis or progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-development.nmod:toward-encephalitis.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmay\u001b[0m.\u001b[31maux\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-pain.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m develop , with high fever , \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:of\u001b[0m-form.nmod:unlike-\u001b[1mprogression\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mrapid\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , in the absence of appropriate treatment , there may be \u001b[34mrapid\u001b[0m progression\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-damage.nmod:in-\u001b[34malveolar\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-phase.nmod:to-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can rapidly progress to the hemorrhagic phase of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-bronchiectasis.nmod:to-failure.nmod:to-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcondition\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-occurrence.nmod:with-pneumonia.nmod:of-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may progress rapidly , with occurrence of \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-failure.nmod:to-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mroot\u001b[0m-form.dobj-pneumonia.nmod:of-result.acl:relcl-failure.nmod:in-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m who suffer from this illness may experience a clinical course ranging from being asymptomatic to having a minor illness , and in a significant minority a severe form of viral pneumonia , which can result in \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:of\u001b[0m-percentage.nmod:in-patient.nmod:in-\u001b[1mcomplicate\u001b[0m.\u001b[1mroot\u001b[0m-pneumonia.nmod:agent-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , it can be complicated by \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmild\u001b[0m.\u001b[1mamod\u001b[0m-progress.parataxis-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is mild in most people ; in some ( usually the elderly and those with comorbidities ) , it may progress to \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mshock\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can rapidly progress to \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m progress\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mroot\u001b[0m-injury.nmod:to-\u001b[34macute\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:after\u001b[0m-day.nmod-\u001b[1mbegin\u001b[0m.\u001b[1mroot\u001b[0m-progress.conj:and-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: begin 3 - 6 days after \u001b[31minfection\u001b[0m and include fever , chills , headache , and myalgia and \u001b[34mmay\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-infection.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , of any age , may develop \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m.\u001b[31mnmod:with\u001b[0m-subject.dobj-exacerbation.dobj-trigger.xcomp-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with compromised immune systems are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-lower.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-lower.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-lower.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod:of-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod:of-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nmod:of-status.nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-risk.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-dentition.nmod:with-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-dentition.nmod:with-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-dentition.nmod:with-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-bacterial.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly susceptible to bacterial and candidal \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-cause.acl-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by encapsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-severity.dobj-increase.acl:relcl-depletion.nmod:to-\u001b[1mrelated\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34msepsis\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mdep\u001b[0m-form.dobj-\u001b[34maspergillosis\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mdep\u001b[0m-form.dobj-\u001b[34maspergillosis\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-cause.acl-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by capsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-bacterial.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m on high dose corticosteroids and mechanical ventilation are particularly susceptible to superimposed bacterial and opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-severity.dobj-increase.acl:relcl-depletion.nmod:to-\u001b[1mrelated\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:to\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:to\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.xcomp-reservoir.xcomp-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-antibiotic.nmod:of-use.nsubj-\u001b[1mpromote\u001b[0m.\u001b[1mroot\u001b[0m-emergence.dobj-colonization.nmod:of-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-antibiotic.nmod:of-use.nsubj-\u001b[1mpromote\u001b[0m.\u001b[1mroot\u001b[0m-emergence.dobj-colonization.nmod:of-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mmake\u001b[0m.\u001b[1mroot\u001b[0m-vulnerable.ccomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-be.cop-\u001b[1mmake\u001b[0m.\u001b[1mroot\u001b[0m-vulnerable.ccomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.xcomp-reservoir.xcomp-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-develop.xcomp-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mards\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-trigger.acl-\u001b[34minfection\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m triggered by viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mnmod:with\u001b[0m-individual.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34morganism\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdiabetes\u001b[0m.\u001b[31mnmod:with\u001b[0m-individual.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-receive.csubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m receiving immunomodulatory or immunosuppressive therapies due to malignancy , transplantation , or autoimmune disease are more susceptible to viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-\u001b[34mprimary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprimary\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-prone.xcomp-superinfection.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mnmod:following\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for gram-negative and anaerobic polymicrobial aspiration pneumonia , and on the other hand are more prone to bacterial superinfections following influenza \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubjpass-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-risk.nmod:@-virus.nmod:for-\u001b[34minfluenza\u001b[0m.\u001b[34mnmod:such_as\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are known to be at an increased risk for community-acquired respiratory viruses , such as \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maml\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nmod:among-\u001b[1mlow\u001b[0m.\u001b[1mamod\u001b[0m-incidence.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is low among patients with \u001b[31mAML\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhowever\u001b[0m.\u001b[31madvmod\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mHowever\u001b[0m , neonates , older individuals , and those with immune deficiencies are prone to more frequent and more serious CNS viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-result.nmod:as-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m as a result of HPIV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-therapy.nmod:on-predispose.acl:relcl-risk.nmod:to-contract.acl:of-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m have immune dysfunction and are often on glucocorticoid and immunosuppressant therapy , which in turn predispose them to an increased risk of contracting SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-risk.nmod:@-of.prep-develop.pcomp-complication.dobj-as.prep-\u001b[34mpneumonia\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild to moderate symptoms or are even asymptomatic , older patients or those with existing chronic diseases are at greater risk of developing serious complications such as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcf\u001b[0m.\u001b[31mappos\u001b[0m-fibrosis.nmod:with-those.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-prone.acomp-develop.xcomp-pneumonia.dobj-cause.acl-\u001b[34minfection\u001b[0m.\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m ) , chronic obstructive pulmonary disease ( COPD ) , and on mechanical ventilation are particularly prone to develop pneumonia caused by PA \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mimmunosuppressed\u001b[0m.\u001b[1mroot\u001b[0m-susceptible.xcomp-\u001b[34minfluenza\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m are immunosuppressed , and therefore , are more susceptible to \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mfungal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-extension.nmod:due-lung.nmod:to-\u001b[34msuperinfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , which may be due to viral extension to the lungs or bacterial \u001b[34msuperinfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:of\u001b[0m-development.nmod:due_to-risk.nmod:to-lead.conj:and-\u001b[1mprolonged\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m in patients with hematological malignancy ( particularly after HSCT ) are more prolonged , lasting weeks and even months , and lead to an increased risk of respiratory compromise due to the development of viral or secondary bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-co-infecte.xcomp-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m are more likely to be co-infected with \u001b[34mbacteria\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuffer\u001b[0m.\u001b[1mroot\u001b[0m-be.ev-coinfection.nsubj-sa.nmod:with-\u001b[34mAspergillus\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with NTM suffer from a more rapid decline in pulmonary function than control patients without NTM although coinfections with SA and \u001b[34mAspergillus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-incidence.nmod:to-from.prep-\u001b[34mpneumonia\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m that are immunosuppressed such as those that are severely malnourished or HIV-infected are susceptible not only to a higher incidence and mortality from \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-risk.dobj-of.prep-develop.pcomp-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are immunocompromised , as a result of disease or therapeutic interventions , have the greatest risk of developing a fatal \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mckd\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nmod:in-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-susceptibility.nmod:in-bacterial.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mCKD\u001b[0m , impairment of the immune system could result in greater susceptibility to bacterial and viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-pneumonitis.nmod:for-\u001b[34mcmv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-develop.acl:for-\u001b[34mhepatitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at higher risk for developing fulminant acute \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , common respiratory viruses may cause severe \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpathogen\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m with congenital or acquired immunodeficiencies are more susceptible to viral \u001b[34mpathogens\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcirrhosis\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-have.advcl:as-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m have both complement and B-cell defects , they are at increased risk for \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcirrhosis\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mimmunocompromise\u001b[0m.\u001b[1mroot\u001b[0m-variety.mwe-\u001b[34minfection\u001b[0m.\u001b[34mconj:and\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are immunocompromised and have increased susceptibility to develop spontaneous bacterial \u001b[34minfections\u001b[0m , hospital-acquired infections , and a variety of infections\tCOUNT: 1\n",
      "PATH: \u001b[31mdiarrhea\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[34mdevelop\u001b[0m life-threatening \u001b[31mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m.\u001b[31mcompound\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are at an increased risk for these \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:in\u001b[0m-high.amod-\u001b[1mpredispose\u001b[0m.\u001b[1mroot\u001b[0m-patient.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: predisposes the patient to other rarer CNS \u001b[34minfections\u001b[0m , such as CMV , and the incidence of common CNS infections is higher in HIV-infected \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-complication.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with compromised immune systems are especially susceptible to severe complications of adenovirus \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at increased risk for bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-factor.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies who are undergoing aggressive chemotherapy and treatment with corticosteroids are at increased risk of HSV , as impairment of cellular immunity is a risk factor for HSV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minflammation\u001b[0m.\u001b[31mnmod:of\u001b[0m-presence.nsubj-\u001b[1mcontribute\u001b[0m.\u001b[1mroot\u001b[0m-susceptible.amod-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31minflammation\u001b[0m may contribute to portal hypertension and the development of acute-on-chronic liver failure , and cirrhotic patients are more susceptible to bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdermatitis\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-bacterial.nmod:to-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m are highly susceptible to cutaneous bacterial , viral , and fungal \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mcompound\u001b[0m-outcome.nsubj-severe.amod-\u001b[1msusceptible\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: susceptible to such \u001b[34minfections\u001b[0m , and the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m.\u001b[31mpobj\u001b[0m-with.prep-child.nsubj-be.ev-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at extremely high risk for disseminated bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:to\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m prone to \u001b[31minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34mlri\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with immunocompromise or extremes of age are at higher risk for more severe \u001b[34mLRI\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-have.xcomp-injury.dobj-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m severely affected by COVID-19 are more likely to have acute kidney injury as well as secondary \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcirrhosis\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-have.xcomp-progression.dobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , such as posttransplant and lymphopenic patients , are more likely to have progression of the \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mobesity\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-cause.attr-aggravate.relcl-severity.dobj-disease.nmod:of-\u001b[34mrespiratory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mObesity\u001b[0m is a common cause to aggravate the severity of \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtumor\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nsubjpass-\u001b[1mimmunocompromise\u001b[0m.\u001b[1mroot\u001b[0m-regimen.nmod:to-impair.acl:relcl-make.acl:relcl-susceptible.ccomp-develop.advcl:to-\u001b[34mTB\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtumors\u001b[0m are immunocompromised due to the local or systemic effects of the disease itself , as well as to the treatment regimens , which can impair the immune system and make these patients particularly susceptible to developing \u001b[34mTB\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:of\u001b[0m-group.nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-of.prep-develop.pcomp-illness.dobj-result.acl-\u001b[34minfection\u001b[0m.\u001b[34mnmod:from\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk of developing serious illness resulting from the lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcmv\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-have.acl:relcl-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCMV\u001b[0m that have subsequent bacterial \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:in\u001b[0m-result.acl-\u001b[1minfection\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m resulting in severe \u001b[31mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-due.prep-\u001b[34mbacteria\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: develop \u001b[31mpneumonia\u001b[0m due to debilitation and colonization of the upper airway with pathogenic \u001b[34mbacteria\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpregnancy\u001b[0m.\u001b[31mnmod:of\u001b[0m-stage.nmod-virus.nmod:by-infect.acl-woman.nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpregnancy\u001b[0m are susceptible to \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-development.nmod:for-risk.nmod:@-\u001b[1mimmunosuppressed\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m undergoing radiation and/or chemotherapy are frequently immunosuppressed and are at exquisite risk for the development of \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-influenza.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-influenza.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-management.nmod:for-case.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-virus.nmod:against-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-be.advcl:because-prove.advcl:because-effective.xcomp-occur.advcl:once-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-be.advcl:because-prove.advcl:because-effective.xcomp-occur.advcl:once-\u001b[34mdisease\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:such_as\u001b[0m-cidofovir.nmod:such_as-\u001b[1magent\u001b[0m.\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:such_as\u001b[0m-cidofovir.nmod:such_as-\u001b[1magent\u001b[0m.\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-virus.nmod:against-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mcase\u001b[0m-therapy.nmod:of-efficacy.nmod:agent-effect.nmod:agent-\u001b[1mcompromise\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nsubjpass-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-management.nmod:for-case.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-sufficient.amod-\u001b[1mthink\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-sufficient.amod-\u001b[1mthink\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mcase\u001b[0m-therapy.nmod:of-efficacy.nmod:agent-effect.nmod:agent-\u001b[1mcompromise\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nsubjpass-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-available.amod-practice.nmod:in-treatment.nmod:for-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-%.nmod:in-form.nmod:of-\u001b[34mttp\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-therapy.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-%.nmod:in-form.nmod:of-\u001b[34mttp\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-induce.conj:and-rejection.dobj-\u001b[34morgan\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-induce.conj:and-rejection.dobj-\u001b[34morgan\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-available.amod-practice.nmod:in-treatment.nmod:for-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-agent.nsubj-patient.nmod:in-active.nmod:with-\u001b[34mtuberculosis\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msufficient\u001b[0m.\u001b[1mamod\u001b[0m-suppress.advcl:for-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1museful\u001b[0m.\u001b[1mamod\u001b[0m-treat.advcl:for-infection.dobj-\u001b[34msars\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nmod:in-sars-cov-2.nmod:of-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-fail.conj:and-\u001b[1mdie\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-treatment.nmod:for-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-recommend.ccomp-\u001b[1mdelay\u001b[0m.\u001b[1mroot\u001b[0m-clearance.dobj-\u001b[34mvirus\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mavailable\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlicense\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nmod:for-infection.nmod:of-\u001b[34mcmv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-Most.nsubj-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-use.conj:and-progression.nmod:due_to-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-infection.nmod:of-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-ineffective.amod-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-low.acomp-in.prep-\u001b[34mchild\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubj-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-suppression.dobj-\u001b[34mhost\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minterferon\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mnsubj\u001b[0m-treat.acl:to-\u001b[34mdengue\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:in\u001b[0m-trial.nmod:in-\u001b[1mobserve\u001b[0m.\u001b[1mroot\u001b[0m-consider.conj-be.xcomp-drug.attr-of.prep-choice.pobj-for.prep-\u001b[34minfluenza\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maciclovir\u001b[0m.\u001b[31mcompound\u001b[0m-monotherapy.nmod:of-efficacy.nsubjpass-\u001b[1mhamper\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mencephalitis\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1madvcl:although\u001b[0m-efficacy.dobj-prevent.acl:for-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfam\u001b[0m.\u001b[31mnsubj\u001b[0m-therapy.xcomp-\u001b[1margue\u001b[0m.\u001b[1mroot\u001b[0m-use.advcl:against-prophylaxis.nmod:as-\u001b[34msurvival\u001b[0m.\u001b[34mnmod:due_to\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-available.amod-infection.nmod:for-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-response.nmod:agent-therapy.nmod:to-suppression.nmod:of-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-demonstrate.advcl:though-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nsubj-\u001b[34mcchf\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiologic\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubj-\u001b[1mprovide\u001b[0m.\u001b[1madvcl:although\u001b[0m-option.dobj-\u001b[34mUC\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mappos\u001b[0m-therapy.nsubjpass-use.conj:and-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-vaccine.nsubj-prevent.acl:to-\u001b[34mrsv\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-resistance.nmod:because_of-association.appos-shedding.nmod:with-\u001b[34mvirus\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mzanamivir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-be.ccomp-benefit.attr-prove.acl-\u001b[34mtreatment\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mtherapy\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mspecific\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-choice.attr-patient.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcirrhosis\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mroot\u001b[0m-effective.amod-c.nmod:for-\u001b[34mhepatitis\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mcidofovir\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mremain\u001b[0m.\u001b[1mroot\u001b[0m-treatment.attr-death.nmod:with-report.acl-secondary.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-efficacy.dobj-pneumonia.nmod:in-\u001b[34mbacterial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mcompound\u001b[0m-toxicity.nmod:with-associate.conj:and-\u001b[1mcomplicated\u001b[0m.\u001b[1mamod\u001b[0m-treatment.nsubj-recipient.nmod:of-develop.acl:relcl-cre.dobj-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mnmod:with\u001b[0m-treatment.nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mkd\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mad\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mchallenging\u001b[0m.\u001b[1mamod\u001b[0m-alleviate.advcl:as-symptom.dobj-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod:between\u001b[0m-interaction.nmod:because_of-\u001b[1mpose\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mtreatment\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubj-\u001b[1mcontroversial\u001b[0m.\u001b[1mamod\u001b[0m-impact.nmod:due_to-response.nmod:on-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:to\u001b[0m-switch.nsubjpass-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-worsen.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhaart\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-make.xcomp-timing.dobj-controversial.amod-patient.nmod:in-\u001b[34msepsis\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-absence.conj:and-intervention.nmod:of-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malthough\u001b[0m.\u001b[31mmark\u001b[0m-\u001b[1madopt\u001b[0m.\u001b[1madvcl:although\u001b[0m-treatment.nmod:for-\u001b[34msars\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.dobj-need.advcl-\u001b[1mrespond\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1madvcl:although\u001b[0m-treatment.nmod:for-infection.nmod:of-\u001b[34mhrsv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minhibit\u001b[0m.\u001b[1mroot\u001b[0m-replication.dobj-\u001b[34mviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-drug.nmod:of-benefit.nsubjpass-\u001b[1mestablish\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nmod:for-\u001b[34msars\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubj-be.ev-\u001b[1mconvenient\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.dobj-need.advcl-\u001b[1mrespond\u001b[0m.\u001b[1mroot\u001b[0m-proportion.nsubj-involvement.nmod:including-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvzig\u001b[0m.\u001b[31mnsubj\u001b[0m-efficient.amod-\u001b[1mbeneficial\u001b[0m.\u001b[1mamod\u001b[0m-therapy.nmod:for-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod:of\u001b[0m-class.nmod:for-efficacy.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-development.nmod:due_to-resistance.nmod:of-\u001b[34mantiviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mCRS\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mefficacious\u001b[0m.\u001b[1mamod\u001b[0m-reduce.advcl:although-level.dobj-patient.nmod:in-infection.nmod:with-\u001b[34mhbv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:of\u001b[0m-profile.nsubj-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-use.dobj-treat.acl:to-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnmod:with\u001b[0m-conjunction.nmod:in-\u001b[1mtoxicity\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mpulmonary\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubj\u001b[0m-mainstay.xcomp-\u001b[1mcontroversial\u001b[0m.\u001b[1mamod\u001b[0m-use.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:during\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-treatment.nmod:for-\u001b[34mvhf\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mcompound\u001b[0m-treatment.nmod:of-initiation.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mkd\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod:with\u001b[0m-therapy.nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-control.xcomp-\u001b[34mvasculitis\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mefficacy\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mtreatment\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-that.dobj-effective.amod-control.advcl:in-activity.dobj-\u001b[34mdisease\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mcompound\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mamod\u001b[0m-trial.xcomp-lopinavir/ritonavir.nmod:of-medication.appos-\u001b[34mhiv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mcombination\u001b[0m.\u001b[1mxcomp\u001b[0m-treatment.nsubj-patient.nmod:for-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mdep\u001b[0m-effect.nsubjpass-\u001b[1mcontraindicate\u001b[0m.\u001b[1mroot\u001b[0m-patient.nmod:in-\u001b[34mmyocarditis\u001b[0m.\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mdobj\u001b[0m-bronchodilator.dobj-include.conj:and-\u001b[1mbenefit\u001b[0m.\u001b[1mnmod:of\u001b[0m-plan.nsubj-\u001b[34mrsv\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-treat.acl:to-\u001b[34minfection\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnmod:to\u001b[0m-refractory.xcomp-\u001b[1mremain\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod:such_as\u001b[0m-therapy.nsubjpass-use.advcl:although-\u001b[1mrefractory\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mRibavirin\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-option.appos-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maminoglycoside\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mmonotherapy\u001b[0m.\u001b[1mnsubjpass\u001b[0m-treatment.nmod:for-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhydroxychloroquine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mworsen\u001b[0m.\u001b[1mccomp\u001b[0m-covid-19.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:from\u001b[0m-\u001b[1mbenefit\u001b[0m.\u001b[1mccomp\u001b[0m-patient.nsubj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrituximab\u001b[0m.\u001b[31mnmod:with\u001b[0m-experience.nsubj-encourage.advcl:although-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-%.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubj\u001b[0m-become.conj:and-\u001b[1mpersist\u001b[0m.\u001b[1mroot\u001b[0m-success.nsubj-\u001b[34mtreatment\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJakinibs\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1madvcl:whereas\u001b[0m-efficacy.dobj-treatment.nmod:in-condition.nmod:of-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdaptomycin\u001b[0m.\u001b[31mnsubj\u001b[0m-vancomycin.nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1mxcomp\u001b[0m-bacteremia.nmod:for-\u001b[34mmrsa\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:such_as\u001b[0m-agent.nmod:with-\u001b[1msee\u001b[0m.\u001b[1mroot\u001b[0m-occur.advcl:because-result.nmod:as-response.nmod:of-\u001b[34minflammatory\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-treat.pcomp-covid-19.dobj-\u001b[34mpneumonia\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcart\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mtolerate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not tolerate \u001b[31mcART\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-remain.advcl:because-effect.nsubj-outcome.nmod:on-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is still limited because beneficial effects on \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-treatment.nmod:for-mers-cov.nmod:of-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1msuggest\u001b[0m.\u001b[1mroot\u001b[0m-use.xcomp-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not suggested to systemically use in SARS-CoV-2 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1madvcl:in\u001b[0m-treat.xcomp-covid-19.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: using HIV antiretroviral \u001b[31mtherapy\u001b[0m to treat \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubj-\u001b[1mresult\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34m[\u001b[0m.\u001b[34mpunct\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m or second line foscarnet and cidofovir can result in substantial hematotoxicity and nephrotoxicity \u001b[34m[\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m.\u001b[31mnmod:of\u001b[0m-dose.nmod:with-\u001b[1memerge\u001b[0m.\u001b[1mccomp\u001b[0m-resistance.nsubj-\u001b[34mantiviral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mnmod:to\u001b[0m-\u001b[1maddition\u001b[0m.\u001b[1mxcomp\u001b[0m-treat.acl:in-mas.dobj-associate.acl-\u001b[34msjia\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: addition to \u001b[31mcorticosteroids\u001b[0m and CsA in treating MAS associated with \u001b[34msJIA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1madvance\u001b[0m.\u001b[1madvcl:although\u001b[0m-show.advcl:although-result.dobj-decrease.acl:in-severity.dobj-\u001b[34msymptom\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been advanced to clinical trials and shown modest results in decreasing either \u001b[34msymptom\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-rapid.amod-kinetic.nsubj-\u001b[34mcmv\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m may not be completely effective in \u001b[34mCMV\u001b[0m D+/R liver transplant recipients because the replication kinetics of CMV\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1msuccessful\u001b[0m.\u001b[1mamod\u001b[0m-patient.nmod:in-\u001b[34mms\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mindicate\u001b[0m.\u001b[1madvcl:whether\u001b[0m-\u001b[34muri\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantibiotic\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1moverprescribe\u001b[0m.\u001b[1mroot\u001b[0m-difficulty.nmod:due-distinguish.acl:in-etiology.dobj-\u001b[34mcap\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34mCAP\u001b[0m , especially in young children , \u001b[31mantibiotics\u001b[0m often are overprescribed\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-treatment.nmod:in-injury.nmod:of-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-effective.xcomp-subset.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod:of\u001b[0m-efficacy.nsubjpass-establish.parataxis-\u001b[1mtreat\u001b[0m.\u001b[1mroot\u001b[0m-infection.nsubjpass-\u001b[34minfluenza\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mInfluenza\u001b[0m infections have been successfully treated with neuraminidase inhibitors ( oseltamivir or zanamivir ) ; however , the efficacy of these \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-treatment.nmod:in-infection.nmod:of-\u001b[34mfilovirus\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m.\u001b[31mnmod:by\u001b[0m-\u001b[1minduction\u001b[0m.\u001b[1mnsubj\u001b[0m-immunosuppression.nmod:of-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: induction \u001b[34mof\u001b[0m immunosuppression by \u001b[31msteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-option.nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mroot\u001b[0m-make.ccomp-treatment.dobj-crucial.amod-management.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m options are still limited and vaccines are often not available , which makes supportive treatment crucial in the clinical management of these often lifethreatening \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-prove.advcl:unless-\u001b[1mrecommend\u001b[0m.\u001b[1mpcomp\u001b[0m-patient.nmod:to-\u001b[34mra\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: recommending allo-HSCT to \u001b[34mRA\u001b[0m patients unless all other standard \u001b[31mtreatments\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msteroid\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mmers\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-treat.xcomp-itp.dobj-associate.acl-\u001b[34mcvid\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are used to treat ITP associated with \u001b[34mCVID\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexpensive\u001b[0m.\u001b[1mamod\u001b[0m-use.advcl:compared_to-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m is expensive and may not provide additional benefit compared to the use of oral antiviral agents alone , especially in low-risk \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m.\u001b[31mcompound\u001b[0m-use.nmod:for-rationale.nsubj-be.advcl:although-\u001b[1mconduct\u001b[0m.\u001b[1mroot\u001b[0m-remain.conj:and-use.advcl:as-treatment.nmod:in-tss.nmod:of-\u001b[34mstss\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m use in these syndromes based in theory , several lines of laboratory investigation , and retrospective clinical series , no definitive clinical trial has been conducted and there remains clinical equipoise as to whether IVIG should be used in the treatment of TSS and \u001b[34mSTSS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mtreatment\u001b[0m of PYR has been associated\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m.\u001b[31mnmod:with\u001b[0m-therapy.nsubj-\u001b[1mineffective\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-enough.case-genotype.nmod:enough_for-\u001b[34mhcv\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not effective enough for some \u001b[34mHCV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtocilizumab\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mappear\u001b[0m.\u001b[1mev\u001b[0m-effective.xcomp-\u001b[34micans\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mTocilizumab\u001b[0m appears to be not as effective for \u001b[34mICANS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m.\u001b[31mcompound\u001b[0m-treatment.nsubjpass-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-option.nmod:as-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m treatment is not routinely recommended as a therapeutic option for COVID-19 \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-administer.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:during\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nmod:of-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mroot\u001b[0m-need.conj:and-\u001b[34mresponse\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapy in immunosuppressed hosts depends on clinical and radiological resolution , the degree and duration of immunosuppression , and therefore maintenance therapy is sometimes needed after the initial \u001b[34mresponse\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmpa\u001b[0m.\u001b[31mnmod:of\u001b[0m-discontinuation.nsubjpass-\u001b[1mpropose\u001b[0m.\u001b[1mroot\u001b[0m-case.nmod:in-\u001b[34mpneumonia\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34mpneumonia\u001b[0m , discontinuation of \u001b[31mMPA\u001b[0m has also been proposed\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnmod:of\u001b[0m-utility.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the clinical utility of \u001b[31mribavirin\u001b[0m may be limited\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-therapeutic.xcomp-think.xcomp-\u001b[1mdrive\u001b[0m.\u001b[1mroot\u001b[0m-development.nsubj-use.acl-stage.nmod:in-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m drives us to think that \u001b[31mRibavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mpreferred\u001b[0m.\u001b[1madvcl:although\u001b[0m-h.nmod:within-onset.nmod:of-symptom.nmod:of-\u001b[34mclinical\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m are usually preferred within 48 h of the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-rate.nmod:due-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m not recommended due to low treatment response rates in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m.\u001b[31mnmod:of\u001b[0m-addition.nsubj-\u001b[1mprovide\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34msetting\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mavailable\u001b[0m.\u001b[1mamod\u001b[0m-hpev.nmod:for-\u001b[34minfection\u001b[0m.\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not available for HPeV or enterovirus \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m.\u001b[31mamod\u001b[0m-therapy.nsubj-\u001b[1minadequate\u001b[0m.\u001b[1mamod\u001b[0m-due.prep-to.prep-window.pobj-\u001b[34madministration\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34madministration\u001b[0m window , current \u001b[31mantiviral\u001b[0m therapies are often inadequate\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1madvcl:although\u001b[0m-help.xcomp-control.xcomp-response.dobj-associate.acl-\u001b[34mfip\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are needed to help control the immune response associated with clinical \u001b[34mFIP\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdrug\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is a controversial \u001b[34mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m.\u001b[31mnsubjpass\u001b[0m-approve.advcl:although-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhowever\u001b[0m.\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , although type I \u001b[31mIFNs\u001b[0m have been approved for diverse indications including genital warts , viral hepatitis , hairy cell leukemia and chronic myelogenous leukemia , their use in the clinic is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtegobuvir\u001b[0m.\u001b[31mnmod:of\u001b[0m-use.nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mroot\u001b[0m-offer.advcl:in-\u001b[34mactivity\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtegobuvir\u001b[0m is limited in that advanced DAAs offer pan-genotypic \u001b[34mactivity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mtreatable\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are treatable with \u001b[31mIFN\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maspirin\u001b[0m.\u001b[31mnmod:including\u001b[0m-nsaid.nsubj-effective.amod-\u001b[1meffective\u001b[0m.\u001b[1mamod\u001b[0m-achieve.parataxis-%.nsubj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31maspirin\u001b[0m , have been effective in systemic JIA , they are rarely effective in AoSD ; only 20 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mgc\u001b[0m.\u001b[31mnmod:of\u001b[0m-dose.nmod:with-treatment.nmod:despite-\u001b[1mdemonstrate\u001b[0m.\u001b[1madvcl:because\u001b[0m-\u001b[34minflammation\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: demonstrate persistent tissue \u001b[34minflammation\u001b[0m despite treatment with high doses of \u001b[31mGC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m.\u001b[31mnmod:for\u001b[0m-need.nmod:including-those.nmod:including-effect.nmod:with-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m associated with potentially serious side effects , including those requiring ICU-level resources and need for high-dose \u001b[31mglucocorticoids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m.\u001b[31mnmod:for\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnmod:for\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m for COVID-19 \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m.\u001b[31mnmod\u001b[0m-\u001b[1mimpaired\u001b[0m.\u001b[1mamod\u001b[0m-reconstitution.nmod:in-\u001b[34mimmune\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m as cidofovir ( ADV ) and Rituximab ( EBV ) , their effi ciency is impaired in absence of specifi c \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mresistance\u001b[0m.\u001b[1mnmod:of\u001b[0m-h5n1.nmod:in-strain.nmod:in-\u001b[34minfluenza\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31moseltamivir\u001b[0m resistance in HPAI H5N1 as well as in seasonal human \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:among\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of APSCT in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-morbidity.nmod:of-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-morbidity.nmod:of-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:among\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-condition.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:among\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-morbidity.nmod:of-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an important cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-patient.nmod:among-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-patient.nmod:among-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-associate.acl-mortality.nmod:of-cause.xcomp-\u001b[1mone\u001b[0m.\u001b[1mdet:qmod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnmod:with\u001b[0m-associate.acl-mortality.nmod:of-cause.xcomp-\u001b[1mone\u001b[0m.\u001b[1mdet:qmod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mchild\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mchild\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m.\u001b[31mamod\u001b[0m-superinfection.nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m.\u001b[31mamod\u001b[0m-superinfection.nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mobserve\u001b[0m.\u001b[1mroot\u001b[0m-%.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-covid-19.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproblem\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mproblem\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with ARDS , superinfection is frequently associated with septic \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-covid-19.nsubj-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcan\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mnmod:with\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , superinfection is often associated with \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m.\u001b[31mdobj\u001b[0m-develop.advcl:for-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-be.ev-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m.\u001b[31mdobj\u001b[0m-develop.advcl:for-\u001b[1mrisk\u001b[0m.\u001b[1mnmod:@\u001b[0m-be.ev-\u001b[34mpatient\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-arise.acl:relcl-\u001b[34minfection\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-arise.acl:relcl-\u001b[34minfection\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a serious lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mnmod:among\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mev\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mnmod:among\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfinding\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfinding\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m necrotizing CA-MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m.\u001b[31mnsubj\u001b[0m-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-among.prep-cause.pobj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m.\u001b[31mnsubj\u001b[0m-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-among.prep-cause.pobj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.ev-\u001b[1mfeature\u001b[0m.\u001b[1mxcomp\u001b[0m-covid-19.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.ev-\u001b[1mfeature\u001b[0m.\u001b[1mxcomp\u001b[0m-covid-19.nmod:of-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mobserve\u001b[0m.\u001b[1mroot\u001b[0m-%.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 2\n",
      "PATH: \u001b[31mrsv\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mamod\u001b[0m-morbidity.nmod:for-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mresponsible\u001b[0m.\u001b[1mamod\u001b[0m-morbidity.nmod:for-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:among\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:among\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mxcomp\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an uncommon but serious \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mxcomp\u001b[0m-form.nmod:in-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a possible manifestation in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhypoxia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-manifestation.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.ev-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-related.xcomp-aspiration.nmod:to-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common and severe complication that is related to aspiration in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbarotrauma\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mone\u001b[0m.\u001b[1mdet:qmod\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m one\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumothorax\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mmay\u001b[0m.\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-covid-19.nmod:of-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most frequent and serious complication \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnmod:with\u001b[0m-patient.nmod:in-develop.acl-syndrome.nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mroot\u001b[0m-be.conj:and-cause.nsubj-patient.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mnsubj\u001b[0m-ards.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-complication.attr-lead.relcl-death.nmod:to-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m are common complications that can lead to death in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mevident\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mih\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfusion\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m.\u001b[31mappos\u001b[0m-coagulation.nsubjpass-failure.nsubjpass-\u001b[1mobserve\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:during\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m ) are also frequently observed during COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m.\u001b[31mappos\u001b[0m-syndrome.nsubj-\u001b[1mone\u001b[0m.\u001b[1mdet:qmod\u001b[0m-complication.xcomp-develop.acl-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m ) is one of the commonest complications developing in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m.\u001b[31mnsubj\u001b[0m-be.ev-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m is a severe complication in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmortality\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-patient.nmod:in-\u001b[34minfection\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mmortality\u001b[0m in patients with COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mconsequence\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m a common consequence\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muncommon\u001b[0m.\u001b[1mamod\u001b[0m-lethal.xcomp-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m is very uncommon but can be lethal in immunocompetent \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minflammation\u001b[0m.\u001b[31mnmod:of\u001b[0m-onset.nmod:by-characterize.acl-failure.xcomp-type.mwe-syndrome.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-cause.nsubj-mortality.nmod:of-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minflammation\u001b[0m in the lungs , is the leading cause of mortality of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-proportion.nsubj-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 may develop \u001b[31mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-covid-19.nmod:of-\u001b[34mof\u001b[0m.\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-presentation.attr-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a common presentation in COVID-19 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mxcomp\u001b[0m-indicate.conj:and-\u001b[34mdisease\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m is a possible manifestation of COVID-19 , and its occurrence usually indicates a severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfailure\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m can be the primary presenting manifestation of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msyndrome\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mamod\u001b[0m-occur.xcomp-\u001b[34minfection\u001b[0m.\u001b[34mnmod:after\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m ( DSS ) is more likely to occur after a second DENV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdamage\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mfeature\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdamage\u001b[0m is a common feature in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mcase\u001b[0m.\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[31msevere\u001b[0m \u001b[34mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-one.attr-of.prep-complication.pobj-\u001b[34minfection\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is one of the complications or preexisting conditions of MERS-CoV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-report.conj:and-%.nmod:in-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m has been reported as the most common cardiac manifestation of COVID -19 and is reported in 8 -12 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minflammatory\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a severe \u001b[31minflammatory\u001b[0m complication\tCOUNT: 1\n",
      "PATH: \u001b[31mthrombotic\u001b[0m.\u001b[31mamod\u001b[0m-coagulopathy.nsubj-\u001b[1mcommon\u001b[0m.\u001b[1mamod\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mThrombotic\u001b[0m coagulopathy is common in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maki\u001b[0m.\u001b[31mappos\u001b[0m-injury.nsubj-\u001b[1mmanifestation\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m ) can be a manifestation of COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-associate.acl-\u001b[34mdisease\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m associated with COVID-19 \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31membolism\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mpresentation\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31membolism\u001b[0m is an uncharacteristic presentation in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31marrhythmia\u001b[0m.\u001b[31mnsubj\u001b[0m-be.ev-\u001b[1mmanifestation\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mpatient\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31marrhythmias\u001b[0m are a common manifestation in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mcompound\u001b[0m-protocol.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-administration.attr-\u001b[34msingle\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mroot\u001b[0m-week.nmod:for-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mroot\u001b[0m-week.nmod:for-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mroot\u001b[0m-week.nmod:for-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj:and-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj:and-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m.\u001b[31mamod\u001b[0m-period.nsubj-be.conj:and-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m12\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-week.npadvmod-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-week.npadvmod-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-day.pobj-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mattr\u001b[0m-be.acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod:for\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mattr\u001b[0m-be.acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod:for\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mroot\u001b[0m-value.nsubj-\u001b[34mthese\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mroot\u001b[0m-value.nsubj-\u001b[34mthese\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj:and\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj:and\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m.\u001b[31mdobj\u001b[0m-make.acl-order.pobj-in.prep-\u001b[1mfall\u001b[0m.\u001b[1mroot\u001b[0m-under.prep-hour.pobj-8.nummod-\u001b[34m12\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m.\u001b[31mdobj\u001b[0m-make.acl-order.pobj-in.prep-\u001b[1mfall\u001b[0m.\u001b[1mroot\u001b[0m-under.prep-hour.pobj-8.nummod-\u001b[34m12\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-day.nmod:for-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m9\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-wait.parataxis-day.nsubjpass-\u001b[34m62\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-in.prep-order.pobj-have.acl-after.prep-day.pobj-\u001b[34m60\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-in.prep-order.pobj-have.acl-after.prep-day.pobj-\u001b[34m60\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m9\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mincubation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mroot\u001b[0m-be.xcomp-day.npadvmod-2.nummod-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-wait.parataxis-day.nsubjpass-\u001b[34m62\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-day.nmod:for-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mincubation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mroot\u001b[0m-be.xcomp-day.npadvmod-2.nummod-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m.\u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-day.pobj-\u001b[34m21\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m.\u001b[31mnmod:of\u001b[0m-mg.nmod:of-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-for.prep-day.pobj-\u001b[34mten\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m.\u001b[31mnmod:of\u001b[0m-mg.nmod:of-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-for.prep-day.pobj-\u001b[34mten\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m.\u001b[31mcompound\u001b[0m-level.nsubj-reach.advcl-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-after.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m.\u001b[31mcompound\u001b[0m-level.nsubj-reach.advcl-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-after.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m.\u001b[31mpobj\u001b[0m-to.prep-delay.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mroot\u001b[0m-maximum.nmod:@-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m.\u001b[31mpobj\u001b[0m-to.prep-delay.nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mroot\u001b[0m-maximum.nmod:@-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-bip.pobj-between.prep-transport.relcl-distance.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-bip.pobj-between.prep-transport.relcl-distance.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-take.conj:and-=.amod-day.dobj-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mroot\u001b[0m-take.conj:and-=.amod-day.dobj-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.pobj-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-\u001b[1mday\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m22\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-implement.xcomp-\u001b[34mwithin\u001b[0m.\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m from symptom onset needs to be implemented \u001b[34mwithin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-after.prep-week.npadvmod-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-period.attr-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.nsubj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days should be the period of \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-week.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-last.conj:and-be.ev-\u001b[1mvary\u001b[0m.\u001b[1mroot\u001b[0m-day.nmod:between-7.nummod-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: varies between 7 and \u001b[34m14\u001b[0m days for moderate cases according to [ 3 ] , and this is why \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m4\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-of.prep-day.pobj-\u001b[34m15\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-base.prep-day.npadvmod-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexceed\u001b[0m.\u001b[1mroot\u001b[0m-hour.npadvmod-\u001b[34m24\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mroot\u001b[0m-be.conj:but-minimum.attr-of.prep-day.pobj-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m duration depends on national regulations but should be a minimum of \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubjpass\u001b[0m-of.prep-day.pobj-\u001b[34m90\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of 60 to \u001b[34m90\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-less.acomp-than.prep-week.pobj-\u001b[34mseveral\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period , which starts when the most recently received animals are placed into a quarantine , should not be less than \u001b[34mseveral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-officer.nsubj-detain.ccomp-mean.advcl-\u001b[1mdescribe\u001b[0m.\u001b[1mroot\u001b[0m-day.nmod:as-\u001b[34m20\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: described as \u001b[34m20\u001b[0m days , meaning a \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-buffer.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-d.nsubj-\u001b[34m15\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m buffer in January is around \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mpobj\u001b[0m\u001b[0m-of.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2.73 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-in.prep-\u001b[1mbe\u001b[0m.\u001b[1mxcomp\u001b[0m-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: be in \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mroot\u001b[0m-on.prep-period.pobj-be.relcl-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m depends on the incubation period of COVID-19 , which is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mrecommend\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantining\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-day.pobj-\u001b[34m70\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrelax\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mday\u001b[0m.\u001b[34mnpadvmod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed only after 27 , 26 and 53 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mexposure\u001b[0m.\u001b[31mcompound\u001b[0m-time.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-minute.attr-\u001b[34m1\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mself-quarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-cut-off.attr-\u001b[1mbe\u001b[0m.\u001b[1mconj:and\u001b[0m-day.npadvmod-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days is the chosen cut-off for \u001b[31mself-quarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mof\u001b[0m.\u001b[31mprep\u001b[0m-isolation.nsubj-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-impose.xcomp-within.prep-day.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mof\u001b[0m persons exposed to the virus needs to be imposed within \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34moptimal\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34moptimal\u001b[0m \u001b[31mtime\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mlatent\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-of.prep-day.pobj-\u001b[34mfour\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-recommendation.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-with.prep-time.pobj-of.prep-day.pobj-\u001b[34m5\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m5\u001b[0m days on average , 15 initial recommendations for \u001b[31mquarantine\u001b[0m of exposed health care workers were\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubjpass-\u001b[1mshorten\u001b[0m.\u001b[1mroot\u001b[0m-to.prep-day.pobj-\u001b[34m6\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-mandatory.acomp-for.prep-day.pobj-\u001b[34m17\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m with respiratory isolation is also mandatory for \u001b[34m17\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mrelaxed\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-\u001b[34mday\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed for the young , adults and elderly after 13 , 11 and 47 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m.\u001b[31mnsubjpass\u001b[0m-diagnose.advcl:after-\u001b[1mrequire\u001b[0m.\u001b[1mroot\u001b[0m-day.nsubjpass-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is diagnosed at sentinel medical institutions , at least \u001b[34m10\u001b[0m days are required\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m.\u001b[31mcompound\u001b[0m-spreading.dobj-prevent.advcl:to-\u001b[1mgo\u001b[0m.\u001b[1mroot\u001b[0m-into.prep-isolation.pobj-for.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m spreading , any individual who may have been exposed should go into isolation for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.dobj-\u001b[1mincrease\u001b[0m.\u001b[1mxcomp\u001b[0m-to.prep-day.pobj-\u001b[34m22\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-rule.pobj-control.pobj-to.prep-accord.prep-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-within.prep-\u001b[34m4\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m rules at airports , the time taken between specimen collection and the reporting of results was within \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mlast\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-week.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mtake\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mweek\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should take at least 4 - 6 \u001b[34mweeks\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mborehole\u001b[0m.\u001b[31mpobj\u001b[0m-%.pobj-to.prep-\u001b[1mincrease\u001b[0m.\u001b[1mroot\u001b[0m-latrine.nsubjpass-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m latrines should be increased to 16.1 % and \u001b[31mboreholes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccine\u001b[0m.\u001b[31mcompound\u001b[0m-availability.nsubj-\u001b[1moccur\u001b[0m.\u001b[1mroot\u001b[0m-within.prep-day.pobj-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mnmod:in\u001b[0m-onset.nmod:following-\u001b[1moccur\u001b[0m.\u001b[1madvcl:if\u001b[0m-day.nmod:within-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: occur within \u001b[34m8\u001b[0m days following the onset of symptoms in the last resident \u001b[31mcase\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mccomp\u001b[0m\u001b[0m-for.prep-minimum.pobj-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for a minimum of \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.nsubj-be.ccomp-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-be.xcomp-day.attr-\u001b[34m30\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be of sufficient length to allow risk periods for respiratory and digestive diseases to pass ; this has generally been recommended to be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mxcomp\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mroot\u001b[0m-confinement.nsubjpass-of.prep-day.pobj-\u001b[34m10\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days has generally been recommended to \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcontrol\u001b[0m.\u001b[31mnmod:of\u001b[0m-view.pobj-from.prep-treat.ccomp-show.advcl:because-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-pair.det:qmod-\u001b[34m20\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m20\u001b[0m pairs of gloves/doctor ( high risk)/day will be required because 1 SARS report showed that 1 doctor can treat 5 to 10 patients per day from the view of infection \u001b[31mcontrol\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31misolation\u001b[0m.\u001b[31mcompound\u001b[0m-period.nsubj-\u001b[1mneed\u001b[0m.\u001b[1mroot\u001b[0m-extend.xcomp-to.prep-week.pobj-\u001b[34mthree\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31misolation\u001b[0m periods may need to be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m.\u001b[31mnmod:of\u001b[0m-case.nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-be.ccomp-week.nsubj-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have been officially reported for a few days , at least \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m.\u001b[31mdobj\u001b[0m-detect.xcomp-\u001b[1mtake\u001b[0m.\u001b[1mroot\u001b[0m-average.nsubjpass-of.prep-day.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m3\u001b[0m days was taken to detect imported \u001b[31mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m.\u001b[31mdet\u001b[0m-period.nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mroot\u001b[0m-day.nmod:to-\u001b[34m50\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m period is reduced to \u001b[34m50\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mdobj\u001b[0m-start.advcl-\u001b[1mwait\u001b[0m.\u001b[1madvcl\u001b[0m-day.dobj-10.nummod-\u001b[34m20\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: waiting 10 or \u001b[34m20\u001b[0m days , respectively , to start the \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-for.prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mduration\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m.\u001b[31mnpadvmod\u001b[0m-minimum.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-month.attr-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m necessary to complete reference virus development and safety testing is \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mroot\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mev\u001b[0m-have.advcl:as-period.dobj-of.prep-day.pobj-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , the individuals are to be \u001b[31mquarantined\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mlong\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mLonger\u001b[0m \u001b[31mquarantine\u001b[0m periods\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-day.compound-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-individual.nmod:for-\u001b[34msymptomatic\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for \u001b[34msymptomatic\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-length.nsubjpass-\u001b[1mbase\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mbe\u001b[0m.\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mis\u001b[0m based\tCOUNT: 1\n",
      "PATH: \u001b[31mclose\u001b[0m.\u001b[31mamod\u001b[0m-contact.dobj-identify.xcomp-sufficient.oprd-\u001b[1mconsider\u001b[0m.\u001b[1mroot\u001b[0m-period.nsubjpass-\u001b[34ma\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 7-day period is considered sufficient to identify \u001b[31mclose\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccination\u001b[0m.\u001b[31mpobj\u001b[0m-between.prep-interval.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mvaccinations\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthe\u001b[0m.\u001b[31mdet\u001b[0m-lockdown.nsubjpass-\u001b[1mdelay\u001b[0m.\u001b[1mconj:and\u001b[0m-by.agent-day.pobj-\u001b[34m3\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mthe\u001b[0m lockdown should not be delayed by more than \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-duration.dobj-determine.xcomp-important.xcomp-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34m11\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m11\u001b[0m days , which is important to determine the appropriate duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mdobj\u001b[0m-enter.pcomp-before.prep-\u001b[1mspend\u001b[0m.\u001b[1mxcomp\u001b[0m-minimum.dobj-of.prep-day.pobj-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: spend a minimum of \u001b[34m2\u001b[0m days in Cte d'Ivoire before entering \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mroot\u001b[0m-for.prep-day.pobj-\u001b[34m8\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m for contacts should at least be for \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m.\u001b[31mpobj\u001b[0m-of.prep-period.nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj:and\u001b[0m-day.attr-\u001b[34m14\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-coronavirus.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-infect.conj:and-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.xcomp-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.xcomp-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-protein.xcomp-\u001b[1mreport\u001b[0m.\u001b[1mroot\u001b[0m-form.xcomp-channel.dobj-associate.acl:relcl-\u001b[34mpathogenesis\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod:agent\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-infect.conj:and-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-infect.conj:and-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mhuman\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod:agent\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod:agent\u001b[0m-invade.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mairway\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mtract\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mtract\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-allow.acl:relcl-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-allow.acl:relcl-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mxcomp\u001b[0m-infect.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mxcomp\u001b[0m-infect.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mairway\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mxcomp\u001b[0m-be.conj:and-evidence.attr-associate.acl:that-surface-exposed.amod-mediate.advcl:as-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mxcomp\u001b[0m-be.conj:and-evidence.attr-associate.acl:that-surface-exposed.amod-mediate.advcl:as-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE2 ) as a viral receptor to enter the target \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-potential.dobj-replicate.acl:to-\u001b[34mcardiomyocyte\u001b[0m.\u001b[34mnmod:within\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-potential.dobj-replicate.acl:to-\u001b[34mcardiomyocyte\u001b[0m.\u001b[34mnmod:within\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use host receptor angiotensin-converting enzyme 2 ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-infect.advcl:by-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes COVID-19 by infecting host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-tract.dobj-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mxcomp\u001b[0m-enzyme.nsubj-dominate.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mxcomp\u001b[0m-enzyme.nsubj-dominate.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-tract.dobj-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mroot\u001b[0m-infect.advcl:by-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes respiratory symptoms by infecting alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.dobj-\u001b[1mtarget\u001b[0m.\u001b[1mroot\u001b[0m-infect.conj:and-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: targets human angiotensin-converting enzyme \u001b[31m2\u001b[0m ( hACE2 ) and infects intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-ace2.dobj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msara-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-type.dobj-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.nmod:between-protein.nmod:between-interaction.dobj-involve.acl-mechanism.nmod:by-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: enters host \u001b[34mcells\u001b[0m by a mechanism involving the interaction between its spike ( S ) protein and human angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod:agent\u001b[0m-enter.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) , which enters the \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexploit\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-invade.acl:to-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to invade \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-target.nsubj-mucosa.xcomp-\u001b[1mact\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-entry.nmod:as-\u001b[34mcell\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is the upper respiratory mucosa , and angiotensin-converting enzyme 2 ( ACE2 ) acts as a functional receptor for the viral spikes and eventually viral entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.nmod:to-bind.acl:relcl-protein.nmod:through-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: infects \u001b[34mcells\u001b[0m through the S protein , which binds to cell surface receptor-angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mroot\u001b[0m-bind.advcl:by-replicate.advcl:by-\u001b[34mcell\u001b[0m.\u001b[34mnmod:within\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly invades alveolar epithelial \u001b[34mcells\u001b[0m by binding to the ACE-2 receptor and then replicates within cells\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mroot\u001b[0m-pathogen.oprd-gain.acl:relcl-access.dobj-to.prep-\u001b[34mbody\u001b[0m.\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is considered a lower respiratory tract pathogen that gains access to the \u001b[34mbody\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-pathogenesis.nsubj-\u001b[1minvolve\u001b[0m.\u001b[1mroot\u001b[0m-binding.dobj-\u001b[34mhost\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m involves the binding of its spike protein to angiotensin converting enzyme-2 ( ACE2 ) in the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mparataxis\u001b[0m-attack.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also needs ACE2 to attack human alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-receptor.nmod:to-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-invade.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: binds to angiotensin-converting enzyme \u001b[31m2\u001b[0m receptors ( ACE2r ) to invade human lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov-1.nsubj-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-infect.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use angiotensin-converting enzyme 2 ( ACE2 ) as receptor to infect ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mamod\u001b[0m-injury.nmod:of-pathology.nsubjpass-elucidate.advcl:although-\u001b[1mestimate\u001b[0m.\u001b[1mroot\u001b[0m-that.dep-replicate.dep-\u001b[34mcell\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m lung injury has not yet been elucidated , it has been estimated from MERS and SARS that the virus replicates in alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-protein.nmod:by-\u001b[34m-PRON-\u001b[0m.\u001b[34mnmod:poss\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the angiotensin converting enzyme 2 receptor ( ACE2 ) by \u001b[34mits\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.dobj-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-infect.advcl:to-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the cellular receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mentry\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mhost\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m gains entry into the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mbelieve\u001b[0m.\u001b[1mroot\u001b[0m-invade.xcomp-\u001b[34mhost\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is believed to invade the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-protein.nmod:to-express.acl:relcl-cell.nmod:in-\u001b[34mendothelial\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to ACE2 protein that is abundantly expressed in \u001b[34mendothelial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod:by\u001b[0m\u001b[0m-enter.acl:relcl-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-generate.conj:and-disease.dobj-\u001b[34msevere\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the ACE2 protein as a virus receptor [ 4 ] and can generate \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod:to\u001b[0m-bind.advcl:by-increase.conj:and-lead.conj:and-\u001b[1mreach\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: reaches the \u001b[34mcell\u001b[0m through angiotensin-converting enzyme ( ACE ) receptors and leads to severe pneumonia and thus increased mortality rates during infection by binding to human \u001b[31mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus binds to angiotensin converting enzyme 2 ( ACE2 ) receptors in the respiratory tracts of infected patients to enter host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-facilitate.xcomp-entry.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( ACE2 ) as the key receptor to facilitate its entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( ACE2 ) on pulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.nmod:through-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: enters lung \u001b[34mcells\u001b[0m through angiotensinconverting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mpneumocyte\u001b[0m.\u001b[1mdobj\u001b[0m-epithelium.nmod:in-\u001b[34malveolar\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m pneumocytes in the \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mroot\u001b[0m-protein.nmod:agent-allow.acl-act.ccomp-express.ccomp-surface.nmod:on-type.nmod:of-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is characterized by a spike protein allowing viral binding to the angiotensin-converting enzyme (ACE)-2 , which acts as a viral receptor and is expressed on the surface of several pulmonary and extra-pulmonary \u001b[34mcell\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m both enter \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-target.nmod:to-use.acl-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to its target using the angiotensin-converting enzyme 2 ( ACE2 ) receptor on human \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-strain.nsubj-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-furin.dobj-express.acl-\u001b[34mlung\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m strain , uniquely uses furin expressed highly in the \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mnmod:on\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( ACE2 ) receptor on the host \u001b[34mcell\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mroot\u001b[0m-capacity.dobj-allow.acl:relcl-produce.xcomp-\u001b[34mtissue\u001b[0m.\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m has the capacity to escape innate immune responses , which allows the pathogen to produce large copy numbers in primarily infected \u001b[34mtissues\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mattach\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-present.xcomp-surface.nmod:on-cell.nmod:of-epithelium.nmod:of-\u001b[34mlung\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m attaches to the angiotensin-converting enzyme 2 ( ACE 2 ) receptor which is usually present on the surface of alveolar cells of the \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-infect.acl:to-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to infect \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-entry.nmod:for-\u001b[34mcell\u001b[0m.\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor for entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmers-cov\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mcell\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m.\u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-bind.advcl:by-domain.nmod:to-enzyme.nmod:of-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-use.xcomp-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-use.xcomp-receptor.dobj-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-bind.advcl:by-domain.nmod:to-enzyme.nmod:of-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nmod:with-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nmod:with-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod:to\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-identify.advcl:since-\u001b[1msurprising\u001b[0m.\u001b[1mamod\u001b[0m-adapt.ccomp-bind.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-identify.advcl:since-\u001b[1msurprising\u001b[0m.\u001b[1mamod\u001b[0m-adapt.ccomp-bind.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:for\u001b[0m-receptor.xcomp-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:for\u001b[0m-receptor.xcomp-\u001b[1mshow\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod:through\u001b[0m-invade.conj:and-\u001b[1mbelong\u001b[0m.\u001b[1mroot\u001b[0m-covid-19.nsubj-\u001b[34mboth\u001b[0m.\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod:through\u001b[0m-invade.conj:and-\u001b[1mbelong\u001b[0m.\u001b[1mroot\u001b[0m-covid-19.nsubj-\u001b[34mboth\u001b[0m.\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-protein.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-protein.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod:to\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mroot\u001b[0m-with.prep-protein.pobj-use.acl:relcl-gain.acl:relcl-membrane.nmod:through-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mroot\u001b[0m-with.prep-protein.pobj-use.acl:relcl-gain.acl:relcl-membrane.nmod:through-\u001b[34mcell\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-protein.nmod:via-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mroot\u001b[0m-enter.xcomp-protein.nmod:via-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-entry.nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-use.xcomp-\u001b[34mreceptor\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-protein.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mxcomp\u001b[0m-be.conj:and-evidence.attr-associate.acl:that-bind.advcl:by-receptor.nmod:to-\u001b[34menzyme-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mxcomp\u001b[0m-be.conj:and-evidence.attr-associate.acl:that-bind.advcl:by-receptor.nmod:to-\u001b[34menzyme-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mprotein\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-entry.nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-use.xcomp-\u001b[34mreceptor\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mamod\u001b[0m-glycoprotein.nmod:for-receptor.nmod:as-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-mean.nmod:by-binding.nmod:of-receptor(s.nmod:of-\u001b[34mcellular\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-mean.nmod:by-binding.nmod:of-receptor(s.nmod:of-\u001b[34mcellular\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-sars-cov.nmod:of-entry.nmod:for-receptor.nmod:as-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for 25 entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhomologous\u001b[0m.\u001b[1mamod\u001b[0m-infect.ccomp-binding.nmod:through-\u001b[34mace2\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mhomologous\u001b[0m.\u001b[1mamod\u001b[0m-infect.ccomp-binding.nmod:through-\u001b[34mace2\u001b[0m.\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:by\u001b[0m-receptor.xcomp-\u001b[1mconverting\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:by\u001b[0m-receptor.xcomp-\u001b[1mconverting\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSars-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m.\u001b[31mamod\u001b[0m-glycoprotein.nmod:for-receptor.nmod:as-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34menzyme\u001b[0m.\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mhace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mhace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-sars-cov.nmod:of-entry.nmod:for-receptor.nmod:as-\u001b[1midentify\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.nsubjpass-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-coronavirus.nmod:for-\u001b[1mreceptor\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m is also a functional receptor for the new \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-coronavirus.nmod:for-\u001b[1mreceptor\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m is also a functional receptor for the new \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m.\u001b[31mappos\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34m2\u001b[0m.\u001b[34mnummod\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mcompound\u001b[0m-\u001b[1mprotein\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-protein.nsubj-\u001b[1minteract\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m directly interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:by\u001b[0m-hijack.acl-\u001b[1mreceptor\u001b[0m.\u001b[1mxcomp\u001b[0m-enzyme.nsubj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is a functional receptor hijacked by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-\u001b[34mace-2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus likely uses \u001b[34mACE-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mroot\u001b[0m-receptor.xcomp-\u001b[34mbe\u001b[0m.\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial cells by attaching to angiotensin converting enzyme-2 ( ACE-2 ) via S-protein ; ACE-2 \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:for\u001b[0m-point.dobj-\u001b[1mprovide\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mace2\u001b[0m.\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m provides the cell membrane receptor entry point for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mccomp\u001b[0m-receptor.dobj-enzyme.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the same receptor of SARS-CoV , which is angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1minfect\u001b[0m.\u001b[1mroot\u001b[0m-interaction.nmod:through-\u001b[34mace2\u001b[0m.\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial cells through the interaction of spike protein with human \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mseem\u001b[0m.\u001b[1mev\u001b[0m-use.root-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m seems to use the same cell entry receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexploit\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-\u001b[34mace-2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits the \u001b[34mACE-2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mroot\u001b[0m-enzyme-2.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mcompound\u001b[0m-virus.nsubj-\u001b[1mutilize\u001b[0m.\u001b[1mroot\u001b[0m-receptor.dobj-enzyme.compound-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus utilizes Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod:to\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mleverage\u001b[0m.\u001b[1mccomp\u001b[0m-receptor.dobj-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also leverages the \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mace2\u001b[0m.\u001b[31mnmod:in\u001b[0m-enter.conj-\u001b[1mundergo\u001b[0m.\u001b[1mroot\u001b[0m-motif.nsubj-\u001b[34mthe\u001b[0m.\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m receptor-binding motif of 2019-nCoV has undergone modification SARS-CoV and 2019-nCoV enter the cell in the same waythrough binding \u001b[31mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubjpass\u001b[0m-\u001b[1mbelieve\u001b[0m.\u001b[1mroot\u001b[0m-invade.xcomp-\u001b[34mace2\u001b[0m.\u001b[34mnmod:through\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is believed to invade the host through the cell entry receptor \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1mexploit\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-sars-cov.nsubj-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m bind to the \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-enzyme.dobj-\u001b[34mhost\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mroot\u001b[0m-enzyme.dobj-\u001b[34mace2\u001b[0m.\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m.\u001b[31mnmod:of\u001b[0m-protein.nmod:in-domain.nsubj-\u001b[1mbind\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:to-\u001b[34mace2\u001b[0m.\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to human \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m.\u001b[31mnummod\u001b[0m-enzyme.dobj-\u001b[1muse\u001b[0m.\u001b[1mroot\u001b[0m-receptor.nmod:as-\u001b[34mcellular\u001b[0m.\u001b[34mamod\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the \u001b[34mcellular\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthat\u001b[0m.\u001b[31mmark\u001b[0m-\u001b[1mshare\u001b[0m.\u001b[1mccomp\u001b[0m-engage.ccomp-\u001b[34mace2\u001b[0m.\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mthat\u001b[0m SARS-2-S shares 76 % amino acid identity with SARS-S , and both engage \u001b[34mACE2\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"lemmas-deps\", parse_type=\"pybart\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: lemmas along dep path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans can cause a wide range of clinical manifestations , from mild febrile \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans is characterized by extensive pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34mInfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV can cause a spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-result-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-result-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m-\u001b[1mestablish\u001b[0m-cause-number-\u001b[34mdisorder\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m-\u001b[1mestablish\u001b[0m-cause-number-\u001b[34mdisorder\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-onset-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-onset-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an important systemic parvoviral \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections \u001b[34mare\u001b[0m characterized\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-loss-\u001b[34mfocal\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-loss-\u001b[34mfocal\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-manifestation-\u001b[34mneurologic\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-manifestation-\u001b[34mneurologic\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-immunosuppression-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-encephalitis-disorder-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause Japanese encephalitis ( JE ) with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-illness-\u001b[34mfebrile\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbrv\u001b[0m-infection-\u001b[1mcomponent\u001b[0m-pathogenesis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mBRV\u001b[0m is a lytic infection and destruction of infected mucosal epithelial cells is an important component of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mbegin\u001b[0m-progress-stage-infection-characterize-fever-\u001b[34mshock\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m begins with flu-like symptoms and progresses rapidly to the final stages of viral hemorrhagic fever infection , which are characterized by fever , hemorrhage , and hypotensive \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m-\u001b[1minfect\u001b[0m-cause-atrophy-villi-result-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infects the epithelium of the small intestine , an environment rich in proteases , and causes atrophy of the villi resulting in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-associate-\u001b[34mgastroenteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in respiratory tract complications with varying degree of severity and has been associated with \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m-human-\u001b[1mdevelop\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31minfected\u001b[0m with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-\u001b[1mincrease\u001b[0m-result-\u001b[34mseverity\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m increases the susceptibility of the host to a wide range of viral and bacterial respiratory pathogens , resulting in increased \u001b[34mseverity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-spread-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m characterized by a rapid and extensive spread of the \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrepresent\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-ability-\u001b[1mresult\u001b[0m-\u001b[34mdamage\u001b[0m\tLINEAR: results from overwhelming cytopathic \u001b[34mdamage\u001b[0m due to the ability of Ebola \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-infect-human-\u001b[1mreport\u001b[0m-develop-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m have been reported to develop a severe acute respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJEV\u001b[0m-\u001b[1minvade\u001b[0m-trigger-response-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mJEV\u001b[0m invades the central nervous system , wherein virus replication triggers a massive \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmcmv\u001b[0m-\u001b[1mcause\u001b[0m-cause-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mMCMV\u001b[0m causes asymptomatic infection in adult immunocompetent mice , but experimental inoculation of neonates has caused lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-viremia-\u001b[34mto\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m-pathogen-\u001b[1mcause\u001b[0m-degeneration-function-lead-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m is an important viral pathogen worldwide in the domestic cat ( Felis catus ) , causes a slow progressive degeneration of immune functions that eventually leads to a \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34monset\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-immunosuppression-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-\u001b[1mreplicate\u001b[0m-lead-infection-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m replicates mainly in porcine alveolar macrophages ( PAMs ) and dendritic cells ( DCs ) and leads to persistent infection , interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-characterize-cascade-event-lead-inflammation-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of SARS-CoV causes severe acute respiratory syndrome ( SARS ) , which is an emerging infectious disease and characterized by a cascade of immunological events leading to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmhv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malphavirus\u001b[0m-infection-\u001b[1minduce\u001b[0m-\u001b[34marthritis\u001b[0m\tLINEAR: \u001b[31malphavirus\u001b[0m infections , such as those involving CHIKV , Ross River virus ( RRV ) , and Sindbis virus ( SINV ) , induce debilitating \u001b[34marthritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-atrophy-intestine-result-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is characterized by severe villous atrophy in the small intestine that results in watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mable\u001b[0m-cross-stimulate-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m is able to cross the blood-brain barrier and stimulate \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmnv\u001b[0m-infection-\u001b[1mresult\u001b[0m-replication-associate-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mMNV\u001b[0m infection in immunocompromised mice lacking innate immunity factors such as STAT1 or interferon receptors can result in persistent or acute virus replication associated with severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-severe-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in severe and even fatal lung \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiv\u001b[0m-\u001b[1minduce\u001b[0m-splenomegaly-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mBIV\u001b[0m induces splenomegaly and lymphademopathy \u001b[34msyndromes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-consequence-\u001b[1mreport\u001b[0m-result-disease-cns-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , such as acute flaccid paralysis , myocarditis , and Reye syndrome , have been reported [ 13 , 18 ] ; HPeV3 infection results in severe diseases of the CNS and neonatal \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjhmv\u001b[0m-strain-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mjHMV\u001b[0m cause a subacute or persistent \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmarv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-mouse-infection-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m produces clinical \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mterm\u001b[0m-cause-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , also termed epizootic catarrhal \u001b[34menteritis\u001b[0m or ECE , causes mucoid enteritis\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m-infection-\u001b[1mresult\u001b[0m-symptom-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection usually results in mild \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-model-\u001b[1mreveal\u001b[0m-cause-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have revealed that this lethal pulmonary infection causes a denuding bronchiolitis and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-stage-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-course-\u001b[1minduce\u001b[0m-\u001b[34msg\u001b[0m\tLINEAR: induces \u001b[34mSGs\u001b[0m during the course of \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msystemic\u001b[0m-characterize-hemorrhage-\u001b[34medema\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds is systemic , characterized by hemorrhage and \u001b[34medema\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-disease-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes Ebola virus disease ( EVD ) , which is an acute systemic \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m-infection-\u001b[1mlead\u001b[0m-mild-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfluenza\u001b[0m virus infection in humans can lead to mild to severe \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcytolytic\u001b[0m-lead-\u001b[34matrophy\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infection is cytolytic and causes acute necrosis of the infected enterocytes , leading to marked intestinal villous \u001b[34matrophy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnidovirus\u001b[0m-infection-\u001b[1minduce\u001b[0m-inflammation-tract-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mnidovirus\u001b[0m infection induces an inflammation of the upper respiratory and alimentary tract which can develop into a severe and often fatal proliferative \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-range-sign-infection-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with FCoV can result in a diverse range of signs from clinically inapparent infections to a highly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msystemic\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses from an atypical pneumonia to acute diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-fever-cough-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m often causes fever , cough , and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvsv\u001b[0m-infection-\u001b[1masymptomatic\u001b[0m-cause-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mVSV\u001b[0m infection of humans is typically either asymptomatic or causes a mild influenza-like \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mtrigger\u001b[0m-lesion-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in human , or MERS , commonly manifests as a severe acute respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchikv\u001b[0m-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfpv\u001b[0m-\u001b[1mresponsible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mFPV\u001b[0m is responsible of systemic \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m-BRDC-\u001b[1mprecede\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m BRDC \u001b[34mis\u001b[0m often preceded\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1m12\u001b[0m-,-replicate-mucosa-lead-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , RSV replicates in the respiratory mucosa leading to epithelial \u001b[34mdamage\u001b[0m [ 11 ] and perivascular mononuclear infiltration [ 12\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mjcv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-co-infection-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m and S. suis generally induces exacerbated \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1maggravate\u001b[0m-\u001b[34mcondition\u001b[0m\tLINEAR: \u001b[34mcondition\u001b[0m is aggravated by mixed \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjcpyv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1moccur\u001b[0m-follow-viremia-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m occurs predominately in alveolar macrophages of the lung [ 3 ] , followed by viremia and subsequent interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfilovirus\u001b[0m-infection-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mfilovirus\u001b[0m infections \u001b[34mare\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-degree-manifestation-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes varying degrees of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-seriousness-\u001b[1mlie\u001b[0m-complication-include-disease-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m lies in its complications , which include hand-foot-and-mouth disease , herpangina , aseptic meningitis , poliomyelitis-like paralysis , and fatal \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-complication-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PRRSV leads to reproductive complications , respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfipv\u001b[0m-\u001b[1mtropic\u001b[0m-result-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m is macrophage tropic and may cause aberrant cytokine and/or chemokine expression and lymphocyte depletion , which results in a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-disorder-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-condition-know-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by the SARS-CoV-2 causes an inflammatory condition also known as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhcov\u001b[0m-infection-\u001b[1mlead\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mHCoV\u001b[0m infection in immunosuppressed populations can lead to significant lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mveev\u001b[0m-exposure-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mVEEV\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 1\n",
      "PATH: \u001b[31mphev\u001b[0m-\u001b[1mvirus\u001b[0m-cause-symptom-\u001b[34mneurological\u001b[0m\tLINEAR: \u001b[31mPHEV\u001b[0m is a neurovirulent virus that spreads to the central nervous system ( CNS ) via peripheral nerves , where neurite damage and neuronal death are observed , causing \u001b[34mneurological\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in human \u001b[31minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by these human coronaviruses , SARS \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m \u001b[31mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdie\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-lead-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of human \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdevelop\u001b[0m-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m may develop a wide range of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-picture-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-picture-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdie\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1moccur\u001b[0m-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-suckle-growth-\u001b[1mcharacterize\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-suckle-growth-\u001b[1mcharacterize\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-lead-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung , and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent adult \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdevelop\u001b[0m-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m may develop a wide range of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m typically associated with acute cholestatic hepatic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1moccur\u001b[0m-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m-young-have-\u001b[1mprofuse\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m-young-have-\u001b[1mprofuse\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpeople\u001b[0m-\u001b[1mmanifest\u001b[0m-feature-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpeople\u001b[0m commonly manifest features of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexhibit\u001b[0m-encephalopathy-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m suffering from severe DENV infection often exhibit encephalopathy and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mshow\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mhave\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with signs from FIV often \u001b[34mhave\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34menteric\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-illness-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-stage-\u001b[1minclude\u001b[0m-\u001b[34mbleeding\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1masymptomatic\u001b[0m-occur-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic , although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-headache-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdeteriorate\u001b[0m-present-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with EVD rapidly deteriorate and commonly present with gastrointestinal \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-course-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1minfect\u001b[0m-manifest-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m are primarily infected subclinically , but gastrointestinal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmarmoset\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mcause\u001b[0m-onset-\u001b[34msudden\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , VEEV infection causes a \u001b[34msudden\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-subset-progress-\u001b[1massociate\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is associated with fever and liver damage , but a subset of \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mhave\u001b[0m-worsen-symptom-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by SARS-CoV typically has an insidious onset , and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m-\u001b[1msuffer\u001b[0m-progress-inflammation-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m infected with SARS suffer fever , cough , muscle aches , and shortness of breath and often progress to severe \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mleptospirosis\u001b[0m\tLINEAR: \u001b[31mHuman\u001b[0m \u001b[34mleptospirosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m-\u001b[1mpresent\u001b[0m-symptom-as-vomiting-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPigs\u001b[0m that are infected with TGEV usually present symptoms such as vomiting , dehydration , and severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrat\u001b[0m-\u001b[1msusceptible\u001b[0m-occur-result-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mrats\u001b[0m are especially susceptible to SDA , and the infection can occur in the lower respiratory tract , resulting in \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mbecome\u001b[0m-\u001b[34mill\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m typically become acutely \u001b[34mill\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mmanifest\u001b[0m-fever-\u001b[34mdiarrhoea\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , adenovirus infections often manifest as upper respiratory tract infections , pharyngoconjunctival fever , or \u001b[34mdiarrhoea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually leads to the development of CHIKF and \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-after-onset-of-\u001b[34mrash\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m develops insidiously , usually a few days after the onset of \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifest\u001b[0m-occur-symptom-\u001b[34mrash\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m manifests as fever , headache , weakness , and myalgias/ arthralgias ; gastrointestinal symptoms and a maculopapular \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-nonlethal-incapacitate-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes nonlethal , incapacitating \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-rvf-\u001b[1mbegin\u001b[0m-progress-to-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually begins with a nonspecific influenza-like acute \u001b[34mfever\u001b[0m , but can progress to serious hemorrhagic fever\tCOUNT: 1\n",
      "PATH: \u001b[31mleptospirosis\u001b[0m-call-\u001b[1mhave\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m , also called Pretibial fever or Fort Bragg fever , \u001b[34mhas\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexperience\u001b[0m-\u001b[34monset\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdog\u001b[0m-\u001b[1mexhibit\u001b[0m-\u001b[34mparalysis\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m exhibit pharyngeal \u001b[34mparalysis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-plague-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m \u001b[34mis\u001b[0m usually characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mlesion\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-%-\u001b[1mappear\u001b[0m-\u001b[34mFever\u001b[0m\tLINEAR: \u001b[34mFever\u001b[0m , absolute lymphopenia , inappetence , jaundice , and abdominal effusion appear 2 - 3 weeks after infection in around 80 % of \u001b[31mcats\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-%-\u001b[1mshow\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m show acute \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mself-limiting\u001b[0m-progress-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , infection is usually self-limiting , but a small percent of cases ( 1 - 2 % ) can progress to severe \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-infect-\u001b[1mreach\u001b[0m-%-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m are infected by the virus , mortality can reach up to 50 % of affected horses , and \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1masymptomatic\u001b[0m-observe-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-range-\u001b[1minclude\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m severities range from asymptomatic infection to fatal HF ( Fisher-Hoch et al. , 1995 ) and commonly resulting from other viral infections , nonspecific \u001b[34msymptoms\u001b[0m beginning several days after infection include\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrestricted\u001b[0m-lead-onset-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is generally restricted to the alimentary tract , leading to the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mdevelop\u001b[0m-illness-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcalf\u001b[0m-of-BRDC-\u001b[1mcharacterize\u001b[0m-fever-lesion-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m is characterized by fever , dyspnea , inflammatory and necrotizing \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m-infection-picture-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection of the respiratory tract is mild self-limiting upper respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrsv\u001b[0m-infection-\u001b[1mbegin\u001b[0m-associate-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m infection begins in the upper respiratory tract with nasal congestion and pharyngitis and is associated with \u001b[34mfever\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifestation\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexperience\u001b[0m-onset-of-fever-chill-develop-tachypnea-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience the abrupt onset of high fever , chills , and rapidly developing tachypnea and \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mshow\u001b[0m-sign-anemia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with acute leukemia usually show signs of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-infection-\u001b[1myield\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-onset-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with E coli may develop an acute onset of watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m-\u001b[1mdevelop\u001b[0m-anemia-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m commonly develop anemia and secondary infections , especially bacterial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-presentation-failure-\u001b[34mshock\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant presentation with progressive respiratory failure and \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-percentage-\u001b[1mdevelop\u001b[0m-asymptomatic-have-\u001b[34millness\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m , a small percentage of affected \u001b[31mindividuals\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-%-occur-\u001b[1minvolve\u001b[0m-outcome-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m usually involves mild upper respiratory tract infections ; however , more severe conditions , such as pneumonia and bronchiolitis occur in 25 - 40 % of \u001b[31mchildren\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-symptom-\u001b[1mmild\u001b[0m-include-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m are usually mild and include febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madult\u001b[0m-case-\u001b[1mresult\u001b[0m-in-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m usually result in \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-of-\u001b[1mperiod\u001b[0m-progress-\u001b[34mpneumonia\u001b[0m\tLINEAR: period of 2 - 14 days \u001b[31mpatients\u001b[0m initially present with influenza-like symptoms , fever , and cough that can progress to atypic \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mViral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m-\u001b[1mdevelop\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m-\u001b[1mdevelop\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-result-failure-\u001b[34mcardiac\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-result-failure-\u001b[34mcardiac\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mprogress\u001b[0m-syndrome-\u001b[34mand\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mprogress\u001b[0m-syndrome-\u001b[34mand\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-infection-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops rapidly and eventually progresses after 2 to 4 days into \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-infection-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdevelop\u001b[0m-edema-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdevelop\u001b[0m-edema-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31millnesses\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m-\u001b[1mresult\u001b[0m-complication-involvement-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m-\u001b[1mresult\u001b[0m-complication-involvement-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-response-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-response-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-form-\u001b[1mexperience\u001b[0m-suffer-complication-\u001b[34msevere\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-form-\u001b[1mexperience\u001b[0m-suffer-complication-\u001b[34msevere\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-have-\u001b[1mdevelop\u001b[0m-lead-\u001b[34mdeath\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-have-\u001b[1mdevelop\u001b[0m-lead-\u001b[34mdeath\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mresult\u001b[0m-syndrome-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mresult\u001b[0m-syndrome-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-lymphadenopathy-\u001b[34mgeneralize\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-lymphadenopathy-\u001b[34mgeneralize\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m may \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mform\u001b[0m-\u001b[34mthis\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mform\u001b[0m-\u001b[34mthis\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mbegin\u001b[0m-case-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mbegin\u001b[0m-case-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-plague-pneumonic-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-plague-pneumonic-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mprogress\u001b[0m-to-state-\u001b[34mtoxic\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mprogress\u001b[0m-to-state-\u001b[34mtoxic\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-asymptomatic-\u001b[1mcause\u001b[0m-symptom-\u001b[34mserious\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-asymptomatic-\u001b[1mcause\u001b[0m-symptom-\u001b[34mserious\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mdevelop\u001b[0m-presentation-include-pharyngitis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mdevelop\u001b[0m-presentation-include-pharyngitis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-lead-to-dyspnea-stridor-cyanosis-shock-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-lead-to-dyspnea-stridor-cyanosis-shock-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mlimited\u001b[0m-progress-infection-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mlimited\u001b[0m-progress-infection-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-some-\u001b[1msevere\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-some-\u001b[1msevere\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mshock\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdie\u001b[0m-have-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdie\u001b[0m-have-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m-decompensation-\u001b[1mcoincide\u001b[0m-development-syndrome-difficult-differentiate-infection-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m-decompensation-\u001b[1mcoincide\u001b[0m-development-syndrome-difficult-differentiate-infection-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-spectrum-\u001b[1mrange\u001b[0m-infection-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-spectrum-\u001b[1mrange\u001b[0m-infection-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mpresent\u001b[0m-associate-damage-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mpresent\u001b[0m-associate-damage-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mshock\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-course-\u001b[1mlast\u001b[0m-result-in-\u001b[34mcoma\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-course-\u001b[1mlast\u001b[0m-result-in-\u001b[34mcoma\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-after-\u001b[1moccur\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , dyspnea and/or hypoxemia usually occur one week after the onset of the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-mild-\u001b[1mprogress\u001b[0m-to-presentation-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is often mild with cold-like symptoms , it can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1moccur\u001b[0m\u001b[0m-progression-\u001b[34mrapid\u001b[0m\tLINEAR: \u001b[34mrapid\u001b[0m progression of lung consolidation \u001b[31moccurs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mself-limiting\u001b[0m-develop-symptom-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be self-limiting in few days , but in some cases the \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-patient-\u001b[34mcritical\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31msymptom\u001b[0m-\u001b[1mprogress\u001b[0m-form-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-associate-bacteremia-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , pneumonia , associated with bacteremia and \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mmild\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-case-\u001b[1mhave\u001b[0m-opacity-failure-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m have a rapid and relentless fatal course , with generalized alveolar and interstitial opacities , development of the adult respiratory distress syndrome ( ARDS ) , and \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mprogress\u001b[0m-anemia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mlead\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34m-PRON-\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mit\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcondition\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31mconditions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mbecome\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m becomes relentlessly \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-mild-\u001b[1mcause\u001b[0m-manifestation-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is mild in most of the affected individuals , it may cause \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mips\u001b[0m-\u001b[1mprogress\u001b[0m-dysfunction-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m-infection-\u001b[1mbegin\u001b[0m-croup-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m infection usually begins as a \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-%-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m , and potentially fatal , systemic \u001b[31mdisease\u001b[0m may develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-associate-\u001b[1mfollow\u001b[0m-infection-bronchitis-abscess-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , this may be followed by persistent , chronic infection , including chronic bronchitis , bronchiectasis , and \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mprogressive\u001b[0m-development-opacity-\u001b[34mbilateral\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m can be rapidly progressive with the development of multifocal \u001b[34mbilateral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mcause\u001b[0m-failure-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m onset can cause \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME can develop aseptic meningitis and meningoencephalitis or progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-development-encephalitis-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mdevelop\u001b[0m-pain-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m develop , with high fever , \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-form-\u001b[1mprogression\u001b[0m-\u001b[34mrapid\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , in the absence of appropriate treatment , there may be \u001b[34mrapid\u001b[0m progression\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-damage-\u001b[34malveolar\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-phase-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can rapidly progress to the hemorrhagic phase of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mprogress\u001b[0m-bronchiectasis-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with compromised immune systems are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to bacterial , fungal , viral , and parasitic \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at risk of serious \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression can develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients who require surgery may be at risk of coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at the risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mvulnerable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-develop-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at higher risk for developing fulminant acute \u001b[34mhepatitis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mvulnerable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are at an increased risk for these \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-develop-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for developing acute fulminant \u001b[34mhepatitis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-bacterial-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly susceptible to bacterial and candidal \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfibrosis\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m-cause-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by encapsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-increase-depletion-\u001b[1mrelated\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are more heavily immunosuppressed and who are suffering from other immunologic and infectious complications of transplant are at higher risk for \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m frequently cause persistent \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m upon primary HRSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m-cause-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by capsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m to secondary bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m of the lower respiratory tract may increase the risk of secondary bacterial \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-bacterial-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m on high dose corticosteroids and mechanical ventilation are particularly susceptible to superimposed bacterial and opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfibrosis\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic Pa \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-increase-depletion-\u001b[1mrelated\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m by \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with GI bleeding are at risk of developing bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m with \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause asthma or chronic obstructive pulmonary disease in chronic \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-reservoir-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-antibiotic-use-\u001b[1mpromote\u001b[0m-emergence-colonization-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-antibiotic-use-\u001b[1mpromote\u001b[0m-emergence-colonization-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mmake\u001b[0m-vulnerable-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mmake\u001b[0m-vulnerable-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-reservoir-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with acute respiratory distress syndrome ( ARDS ) due to viral \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m including \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m increases the risk for subsequent or secondary bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mards\u001b[0m\u001b[0m-trigger-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m triggered by viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m-individual-\u001b[1msusceptible\u001b[0m-\u001b[34morganism\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdiabetes\u001b[0m-individual-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-receive-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m receiving immunomodulatory or immunosuppressive therapies due to malignancy , transplantation , or autoimmune disease are more susceptible to viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mprimary\u001b[0m\tLINEAR: \u001b[34mprimary\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-prone-superinfection-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for gram-negative and anaerobic polymicrobial aspiration pneumonia , and on the other hand are more prone to bacterial superinfections following influenza \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mknow\u001b[0m-risk-virus-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are known to be at an increased risk for community-acquired respiratory viruses , such as \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maml\u001b[0m-patient-\u001b[1mlow\u001b[0m-incidence-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is low among patients with \u001b[31mAML\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhowever\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mHowever\u001b[0m , neonates , older individuals , and those with immune deficiencies are prone to more frequent and more serious CNS viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-result-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m as a result of HPIV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mhave\u001b[0m-therapy-predispose-risk-contract-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m have immune dysfunction and are often on glucocorticoid and immunosuppressant therapy , which in turn predispose them to an increased risk of contracting SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mhave\u001b[0m-risk-of-develop-complication-as-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild to moderate symptoms or are even asymptomatic , older patients or those with existing chronic diseases are at greater risk of developing serious complications such as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcf\u001b[0m-fibrosis-those-\u001b[1mbe\u001b[0m-prone-develop-pneumonia-cause-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m ) , chronic obstructive pulmonary disease ( COPD ) , and on mechanical ventilation are particularly prone to develop pneumonia caused by PA \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mimmunosuppressed\u001b[0m-susceptible-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m are immunosuppressed , and therefore , are more susceptible to \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mfungal\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-extension-lung-\u001b[34msuperinfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , which may be due to viral extension to the lungs or bacterial \u001b[34msuperinfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-development-risk-lead-\u001b[1mprolonged\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m in patients with hematological malignancy ( particularly after HSCT ) are more prolonged , lasting weeks and even months , and lead to an increased risk of respiratory compromise due to the development of viral or secondary bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-patient-\u001b[1mlikely\u001b[0m-co-infecte-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m are more likely to be co-infected with \u001b[34mbacteria\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msuffer\u001b[0m-be-coinfection-sa-\u001b[34mAspergillus\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with NTM suffer from a more rapid decline in pulmonary function than control patients without NTM although coinfections with SA and \u001b[34mAspergillus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-\u001b[1msusceptible\u001b[0m-incidence-from-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m that are immunosuppressed such as those that are severely malnourished or HIV-infected are susceptible not only to a higher incidence and mortality from \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mhave\u001b[0m-risk-of-develop-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are immunocompromised , as a result of disease or therapeutic interventions , have the greatest risk of developing a fatal \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mincrease\u001b[0m-influenza-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mincrease\u001b[0m-influenza-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mconsider\u001b[0m-management-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-virus-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-be-prove-effective-occur-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-be-prove-effective-occur-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-cidofovir-\u001b[1magent\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-cidofovir-\u001b[1magent\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-virus-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m-therapy-efficacy-effect-\u001b[1mcompromise\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mconsider\u001b[0m-management-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-sufficient-\u001b[1mthink\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-sufficient-\u001b[1mthink\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m-therapy-efficacy-effect-\u001b[1mcompromise\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m-available-practice-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-\u001b[1meffective\u001b[0m-%-form-\u001b[34mttp\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-\u001b[1meffective\u001b[0m-%-form-\u001b[34mttp\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-induce-rejection-\u001b[34morgan\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-induce-rejection-\u001b[34morgan\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m-available-practice-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mbe\u001b[0m-agent-patient-active-\u001b[34mtuberculosis\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1msufficient\u001b[0m-suppress-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1museful\u001b[0m-treat-infection-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mrecommend\u001b[0m-treatment-sars-cov-2-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mrecommend\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-fail-\u001b[1mdie\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1meffective\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-recommend-\u001b[1mdelay\u001b[0m-clearance-\u001b[34mvirus\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mavailable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mlicense\u001b[0m-treatment-infection-\u001b[34mcmv\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-of-Most-\u001b[1meffective\u001b[0m-use-progression-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-case-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-ineffective-\u001b[1mbe\u001b[0m-low-in-\u001b[34mchild\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-use-\u001b[1mcause\u001b[0m-suppression-\u001b[34mhost\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minterferon\u001b[0m-\u001b[1muse\u001b[0m-treat-\u001b[34mdengue\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-trial-\u001b[1mobserve\u001b[0m-consider-be-drug-of-choice-for-\u001b[34minfluenza\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maciclovir\u001b[0m-monotherapy-efficacy-\u001b[1mhamper\u001b[0m-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m-\u001b[1mhave\u001b[0m-efficacy-prevent-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfam\u001b[0m-therapy-\u001b[1margue\u001b[0m-use-prophylaxis-\u001b[34msurvival\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mhave\u001b[0m-available-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1mlimit\u001b[0m-response-therapy-suppression-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-demonstrate-\u001b[1mbe\u001b[0m-treatment-\u001b[34mcchf\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiologic\u001b[0m-therapy-\u001b[1mprovide\u001b[0m-option-\u001b[34mUC\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-therapy-use-\u001b[1mbe\u001b[0m-vaccine-prevent-\u001b[34mrsv\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1muse\u001b[0m-resistance-association-shedding-\u001b[34mvirus\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mzanamivir\u001b[0m-\u001b[1minduce\u001b[0m-be-benefit-prove-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mtherapy\u001b[0m-\u001b[34mspecific\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mbe\u001b[0m-choice-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcontraindicate\u001b[0m-\u001b[34mcirrhosis\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1minduce\u001b[0m-effective-c-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mcidofovir\u001b[0m-\u001b[1mremain\u001b[0m-treatment-death-report-secondary-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mhave\u001b[0m-efficacy-pneumonia-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1meffective\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-toxicity-associate-\u001b[1mcomplicated\u001b[0m-treatment-recipient-develop-cre-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-treatment-\u001b[1mtherapy\u001b[0m-\u001b[34mkd\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-\u001b[1mlimit\u001b[0m-\u001b[34mad\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1mchallenging\u001b[0m-alleviate-symptom-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-interaction-\u001b[1mpose\u001b[0m-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-use-\u001b[1mcontroversial\u001b[0m-impact-response-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-switch-\u001b[1mrecommend\u001b[0m-worsen-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhaart\u001b[0m-\u001b[1massociate\u001b[0m-make-timing-controversial-patient-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-\u001b[1mneed\u001b[0m-absence-intervention-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malthough\u001b[0m-\u001b[1madopt\u001b[0m-treatment-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-need-\u001b[1mrespond\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mapprove\u001b[0m-treatment-infection-\u001b[34mhrsv\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1minhibit\u001b[0m-replication-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-drug-benefit-\u001b[1mestablish\u001b[0m-treatment-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-use-be-\u001b[1mconvenient\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-need-\u001b[1mrespond\u001b[0m-proportion-involvement-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvzig\u001b[0m-efficient-\u001b[1mbeneficial\u001b[0m-therapy-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-class-efficacy-\u001b[1mlimit\u001b[0m-development-resistance-\u001b[34mantiviral\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mtreatment\u001b[0m-\u001b[34mCRS\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mefficacious\u001b[0m-reduce-level-patient-infection-\u001b[34mhbv\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-profile-\u001b[1mlimit\u001b[0m-use-treat-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-conjunction-\u001b[1mtoxicity\u001b[0m-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-mainstay-\u001b[1mcontroversial\u001b[0m-use-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m-treatment-\u001b[34mvhf\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-treatment-initiation-\u001b[1mresult\u001b[0m-\u001b[34mkd\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-therapy-\u001b[1mneed\u001b[0m-control-\u001b[34mvasculitis\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1mefficacy\u001b[0m-\u001b[34mtreatment\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mhave\u001b[0m-that-effective-control-activity-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-option-\u001b[1mlimited\u001b[0m-trial-lopinavir/ritonavir-medication-\u001b[34mhiv\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mcombination\u001b[0m-treatment-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-effect-\u001b[1mcontraindicate\u001b[0m-patient-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-bronchodilator-include-\u001b[1mbenefit\u001b[0m-plan-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m-treat-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-refractory-\u001b[1mremain\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-therapy-use-\u001b[1mrefractory\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mRibavirin\u001b[0m\u001b[0m-option-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maminoglycoside\u001b[0m-\u001b[1mmonotherapy\u001b[0m-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhydroxychloroquine\u001b[0m-\u001b[1mworsen\u001b[0m-covid-19-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mbenefit\u001b[0m-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrituximab\u001b[0m-experience-encourage-\u001b[1mdevelop\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1mcontraindicate\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-become-\u001b[1mpersist\u001b[0m-success-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJakinibs\u001b[0m-\u001b[1mshow\u001b[0m-efficacy-treatment-condition-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdaptomycin\u001b[0m-vancomycin-\u001b[1mtherapy\u001b[0m-bacteremia-\u001b[34mmrsa\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-agent-\u001b[1msee\u001b[0m-occur-result-response-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mapprove\u001b[0m-for-treat-covid-19-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcart\u001b[0m-\u001b[1mtolerate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not tolerate \u001b[31mcART\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-use-\u001b[1mlimited\u001b[0m-remain-effect-outcome-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is still limited because beneficial effects on \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mrecommend\u001b[0m-treatment-mers-cov-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1msuggest\u001b[0m-use-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not suggested to systemically use in SARS-CoV-2 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1muse\u001b[0m-treat-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: using HIV antiretroviral \u001b[31mtherapy\u001b[0m to treat \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-use-\u001b[1mresult\u001b[0m-\u001b[34m[\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m or second line foscarnet and cidofovir can result in substantial hematotoxicity and nephrotoxicity \u001b[34m[\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m-dose-\u001b[1memerge\u001b[0m-resistance-\u001b[34mantiviral\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1maddition\u001b[0m-treat-mas-associate-\u001b[34msjia\u001b[0m\tLINEAR: addition to \u001b[31mcorticosteroids\u001b[0m and CsA in treating MAS associated with \u001b[34msJIA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1madvance\u001b[0m-show-result-decrease-severity-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been advanced to clinical trials and shown modest results in decreasing either \u001b[34msymptom\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1meffective\u001b[0m-rapid-kinetic-\u001b[34mcmv\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m may not be completely effective in \u001b[34mCMV\u001b[0m D+/R liver transplant recipients because the replication kinetics of CMV\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1msuccessful\u001b[0m-patient-\u001b[34mms\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mindicate\u001b[0m-\u001b[34muri\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantibiotic\u001b[0m-\u001b[1moverprescribe\u001b[0m-difficulty-distinguish-etiology-\u001b[34mcap\u001b[0m\tLINEAR: \u001b[34mCAP\u001b[0m , especially in young children , \u001b[31mantibiotics\u001b[0m often are overprescribed\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1meffective\u001b[0m-treatment-injury-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mhave\u001b[0m-effective-subset-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-efficacy-establish-\u001b[1mtreat\u001b[0m-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[34mInfluenza\u001b[0m infections have been successfully treated with neuraminidase inhibitors ( oseltamivir or zanamivir ) ; however , the efficacy of these \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-treatment-infection-\u001b[34mfilovirus\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1minduction\u001b[0m-immunosuppression-\u001b[34mof\u001b[0m\tLINEAR: induction \u001b[34mof\u001b[0m immunosuppression by \u001b[31msteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-make-treatment-crucial-management-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m options are still limited and vaccines are often not available , which makes supportive treatment crucial in the clinical management of these often lifethreatening \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-prove-\u001b[1mrecommend\u001b[0m-patient-\u001b[34mra\u001b[0m\tLINEAR: recommending allo-HSCT to \u001b[34mRA\u001b[0m patients unless all other standard \u001b[31mtreatments\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msteroid\u001b[0m\u001b[0m-\u001b[34mmers\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1muse\u001b[0m-treat-itp-associate-\u001b[34mcvid\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are used to treat ITP associated with \u001b[34mCVID\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m-\u001b[1mexpensive\u001b[0m-use-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m is expensive and may not provide additional benefit compared to the use of oral antiviral agents alone , especially in low-risk \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-use-rationale-be-\u001b[1mconduct\u001b[0m-remain-use-treatment-tss-\u001b[34mstss\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m use in these syndromes based in theory , several lines of laboratory investigation , and retrospective clinical series , no definitive clinical trial has been conducted and there remains clinical equipoise as to whether IVIG should be used in the treatment of TSS and \u001b[34mSTSS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mtreatment\u001b[0m of PYR has been associated\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m-therapy-\u001b[1mineffective\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1meffective\u001b[0m-enough-genotype-\u001b[34mhcv\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not effective enough for some \u001b[34mHCV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtocilizumab\u001b[0m-\u001b[1mappear\u001b[0m-effective-\u001b[34micans\u001b[0m\tLINEAR: \u001b[31mTocilizumab\u001b[0m appears to be not as effective for \u001b[34mICANS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-treatment-\u001b[1mrecommend\u001b[0m-option-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m treatment is not routinely recommended as a therapeutic option for COVID-19 \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mneed\u001b[0m-administer-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-duration-\u001b[1mdepend\u001b[0m-need-\u001b[34mresponse\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapy in immunosuppressed hosts depends on clinical and radiological resolution , the degree and duration of immunosuppression , and therefore maintenance therapy is sometimes needed after the initial \u001b[34mresponse\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmpa\u001b[0m-discontinuation-\u001b[1mpropose\u001b[0m-case-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[34mpneumonia\u001b[0m , discontinuation of \u001b[31mMPA\u001b[0m has also been proposed\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-utility-\u001b[1mlimit\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the clinical utility of \u001b[31mribavirin\u001b[0m may be limited\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-therapeutic-think-\u001b[1mdrive\u001b[0m-development-use-stage-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m drives us to think that \u001b[31mRibavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mpreferred\u001b[0m-h-onset-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m are usually preferred within 48 h of the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrecommend\u001b[0m-rate-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m not recommended due to low treatment response rates in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m-addition-\u001b[1mprovide\u001b[0m-\u001b[34msetting\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mavailable\u001b[0m-hpev-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not available for HPeV or enterovirus \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-\u001b[1minadequate\u001b[0m-due-to-window-\u001b[34madministration\u001b[0m\tLINEAR: \u001b[34madministration\u001b[0m window , current \u001b[31mantiviral\u001b[0m therapies are often inadequate\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mneed\u001b[0m-help-control-response-associate-\u001b[34mfip\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are needed to help control the immune response associated with clinical \u001b[34mFIP\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mdrug\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is a controversial \u001b[34mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m-approve-\u001b[1mlimit\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , although type I \u001b[31mIFNs\u001b[0m have been approved for diverse indications including genital warts , viral hepatitis , hairy cell leukemia and chronic myelogenous leukemia , their use in the clinic is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtegobuvir\u001b[0m-use-\u001b[1mlimit\u001b[0m-offer-\u001b[34mactivity\u001b[0m\tLINEAR: \u001b[31mtegobuvir\u001b[0m is limited in that advanced DAAs offer pan-genotypic \u001b[34mactivity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m-\u001b[1mtreatable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are treatable with \u001b[31mIFN\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maspirin\u001b[0m-nsaid-effective-\u001b[1meffective\u001b[0m-achieve-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31maspirin\u001b[0m , have been effective in systemic JIA , they are rarely effective in AoSD ; only 20 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mgc\u001b[0m-dose-treatment-\u001b[1mdemonstrate\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: demonstrate persistent tissue \u001b[34minflammation\u001b[0m despite treatment with high doses of \u001b[31mGC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mtreatment\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-need-those-effect-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m associated with potentially serious side effects , including those requiring ICU-level resources and need for high-dose \u001b[31mglucocorticoids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m for COVID-19 \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mimpaired\u001b[0m-reconstitution-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m as cidofovir ( ADV ) and Rituximab ( EBV ) , their effi ciency is impaired in absence of specifi c \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m-\u001b[1mresistance\u001b[0m-h5n1-strain-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31moseltamivir\u001b[0m resistance in HPAI H5N1 as well as in seasonal human \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a known complication among critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: complications of viral \u001b[31mpneumonia\u001b[0m , especially in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication for \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in infected \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of APSCT in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m uncommon complications of SARS-CoV-2 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m necrotizing CA-MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an important cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a frequent infectious complication in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1moccur\u001b[0m-patient-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1moccur\u001b[0m-patient-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-associate-mortality-cause-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-associate-mortality-cause-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mchild\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mchild\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m-superinfection-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m-superinfection-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mobserve\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-affect-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m affecting 1.5 to 7 % of KD \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m-covid-19-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mproblem\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mproblem\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with ARDS , superinfection is frequently associated with septic \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m-covid-19-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , superinfection is often associated with \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m-develop-\u001b[1mrisk\u001b[0m-be-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m-develop-\u001b[1mrisk\u001b[0m-be-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-arise-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-arise-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a serious lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m-\u001b[1mfinding\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m-\u001b[1mfinding\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m-syndrome-\u001b[1mbe\u001b[0m-among-cause-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m-syndrome-\u001b[1mbe\u001b[0m-among-cause-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mfeature\u001b[0m-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mfeature\u001b[0m-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m and renal injury are common in severe or critical COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mobserve\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrecipient\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m among lung transplant \u001b[34mrecipients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m following primary influenza virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-affect-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m affecting 11 % of \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m after or during an RSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m-\u001b[1mresponsible\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m-\u001b[1mresponsible\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrecipient\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m in SOT \u001b[34mrecipients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an uncommon but serious \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mmanifestation\u001b[0m-form-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a possible manifestation in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhypoxia\u001b[0m-\u001b[1mbe\u001b[0m-manifestation-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mcomplication\u001b[0m-related-aspiration-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common and severe complication that is related to aspiration in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbarotrauma\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m one\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumothorax\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-covid-19-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most frequent and serious complication \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-patient-develop-syndrome-\u001b[1massociate\u001b[0m-be-cause-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m-ards-\u001b[1mbe\u001b[0m-complication-lead-death-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m are common complications that can lead to death in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mevident\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mih\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfusion\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m-coagulation-failure-\u001b[1mobserve\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m ) are also frequently observed during COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m-syndrome-\u001b[1mone\u001b[0m-complication-develop-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m ) is one of the commonest complications developing in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m-be-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m is a severe complication in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmortality\u001b[0m\u001b[0m-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmortality\u001b[0m in patients with COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mextend\u001b[0m-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-length-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-length-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mextend\u001b[0m-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-period-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days should be the period of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mlong\u001b[0m\tLINEAR: \u001b[34mLonger\u001b[0m \u001b[31mquarantine\u001b[0m periods\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msuspend\u001b[0m-for-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m day \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-be-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mprolong\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mprolong\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-period-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-be-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days minimum \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mapproximate\u001b[0m-value-\u001b[34mthese\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mapproximate\u001b[0m-value-\u001b[34mthese\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mlong\u001b[0m\tLINEAR: \u001b[34mlong\u001b[0m \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m-make-order-in-\u001b[1mfall\u001b[0m-under-hour-8-\u001b[34m12\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m-make-order-in-\u001b[1mfall\u001b[0m-under-hour-8-\u001b[34m12\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mextend\u001b[0m-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m9\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1moccur\u001b[0m-wait-day-\u001b[34m62\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1mreduce\u001b[0m-in-order-have-after-day-\u001b[34m60\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1mreduce\u001b[0m-in-order-have-after-day-\u001b[34m60\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m9\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1moccur\u001b[0m-wait-day-\u001b[34m62\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mextend\u001b[0m-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msuspend\u001b[0m-for-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m-mg-\u001b[1mtreatment\u001b[0m-for-day-\u001b[34mten\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m-mg-\u001b[1mtreatment\u001b[0m-for-day-\u001b[34mten\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m-level-reach-\u001b[1mbe\u001b[0m-after-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m-level-reach-\u001b[1mbe\u001b[0m-after-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m-to-delay-\u001b[1mestimate\u001b[0m-maximum-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m-to-delay-\u001b[1mestimate\u001b[0m-maximum-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-bip-between-transport-distance-\u001b[1mreduce\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-bip-between-transport-distance-\u001b[1mreduce\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-take-=-day-\u001b[34m11\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-take-=-day-\u001b[34m11\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m22\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-\u001b[1mday\u001b[0m-\u001b[34m22\u001b[0m\tLINEAR: \u001b[34m22\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mneed\u001b[0m-implement-\u001b[34mwithin\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m from symptom onset needs to be implemented \u001b[34mwithin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-after-week-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mextend\u001b[0m-to-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-last-be-\u001b[1mvary\u001b[0m-day-7-\u001b[34m14\u001b[0m\tLINEAR: varies between 7 and \u001b[34m14\u001b[0m days for moderate cases according to [ 3 ] , and this is why \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m15\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-base-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mexceed\u001b[0m-hour-\u001b[34m24\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-duration-\u001b[1mdepend\u001b[0m-be-minimum-of-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m duration depends on national regulations but should be a minimum of \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of 60 to \u001b[34m90\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-less-than-week-\u001b[34mseveral\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period , which starts when the most recently received animals are placed into a quarantine , should not be less than \u001b[34mseveral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-officer-detain-mean-\u001b[1mdescribe\u001b[0m-day-\u001b[34m20\u001b[0m\tLINEAR: described as \u001b[34m20\u001b[0m days , meaning a \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mextend\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-buffer-\u001b[1mbe\u001b[0m-d-\u001b[34m15\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m buffer in January is around \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2.73 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-in-\u001b[1mbe\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: be in \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mdepend\u001b[0m-on-period-be-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m depends on the incubation period of COVID-19 , which is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mrecommend\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantining\u001b[0m-\u001b[1mextend\u001b[0m-to-day-\u001b[34m70\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrelax\u001b[0m-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed only after 27 , 26 and 53 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mexposure\u001b[0m-time-\u001b[1mbe\u001b[0m-minute-\u001b[34m1\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mself-quarantine\u001b[0m-for-cut-off-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days is the chosen cut-off for \u001b[31mself-quarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mof\u001b[0m-isolation-\u001b[1mneed\u001b[0m-impose-within-day-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mof\u001b[0m persons exposed to the virus needs to be imposed within \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m-\u001b[34moptimal\u001b[0m\tLINEAR: \u001b[34moptimal\u001b[0m \u001b[31mtime\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mlatent\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34mfour\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-recommendation-\u001b[1mbe\u001b[0m-with-time-of-day-\u001b[34m5\u001b[0m\tLINEAR: \u001b[34m5\u001b[0m days on average , 15 initial recommendations for \u001b[31mquarantine\u001b[0m of exposed health care workers were\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mshorten\u001b[0m-to-day-\u001b[34m6\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mbe\u001b[0m-mandatory-for-day-\u001b[34m17\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m with respiratory isolation is also mandatory for \u001b[34m17\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrelaxed\u001b[0m-for-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed for the young , adults and elderly after 13 , 11 and 47 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-diagnose-\u001b[1mrequire\u001b[0m-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is diagnosed at sentinel medical institutions , at least \u001b[34m10\u001b[0m days are required\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-spreading-prevent-\u001b[1mgo\u001b[0m-into-isolation-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m spreading , any individual who may have been exposed should go into isolation for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mincrease\u001b[0m-to-day-\u001b[34m22\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-rule-control-to-accord-\u001b[1mbe\u001b[0m-within-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m rules at airports , the time taken between specimen collection and the reporting of results was within \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mlast\u001b[0m-for-week-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mtake\u001b[0m-\u001b[34mweek\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should take at least 4 - 6 \u001b[34mweeks\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mborehole\u001b[0m-%-to-\u001b[1mincrease\u001b[0m-latrine-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m latrines should be increased to 16.1 % and \u001b[31mboreholes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccine\u001b[0m-availability-\u001b[1moccur\u001b[0m-within-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-onset-\u001b[1moccur\u001b[0m-day-\u001b[34m8\u001b[0m\tLINEAR: occur within \u001b[34m8\u001b[0m days following the onset of symptoms in the last resident \u001b[31mcase\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-minimum-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for a minimum of \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-be-\u001b[1mrecommend\u001b[0m-be-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be of sufficient length to allow risk periods for respiratory and digestive diseases to pass ; this has generally been recommended to be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrecommend\u001b[0m-confinement-of-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days has generally been recommended to \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcontrol\u001b[0m-view-from-treat-show-\u001b[1mrequire\u001b[0m-pair-\u001b[34m20\u001b[0m\tLINEAR: \u001b[34m20\u001b[0m pairs of gloves/doctor ( high risk)/day will be required because 1 SARS report showed that 1 doctor can treat 5 to 10 patients per day from the view of infection \u001b[31mcontrol\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31misolation\u001b[0m-period-\u001b[1mneed\u001b[0m-extend-to-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31misolation\u001b[0m periods may need to be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-case-\u001b[1mreport\u001b[0m-be-week-\u001b[34m8\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have been officially reported for a few days , at least \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-detect-\u001b[1mtake\u001b[0m-average-of-day-\u001b[34m3\u001b[0m\tLINEAR: \u001b[34m3\u001b[0m days was taken to detect imported \u001b[31mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m-period-\u001b[1mreduce\u001b[0m-day-\u001b[34m50\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m period is reduced to \u001b[34m50\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-start-\u001b[1mwait\u001b[0m-day-10-\u001b[34m20\u001b[0m\tLINEAR: waiting 10 or \u001b[34m20\u001b[0m days , respectively , to start the \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mduration\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m-minimum-\u001b[1mbe\u001b[0m-month-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m necessary to complete reference virus development and safety testing is \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m are infected by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE2 ) as a viral receptor to enter the target \u001b[34mcell\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use host receptor angiotensin-converting enzyme 2 ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: entry of \u001b[31mSARS-CoV-2\u001b[0m into host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: Entry of \u001b[31mSARS-CoV-2\u001b[0m into a host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: entry into target \u001b[34mcells\u001b[0m by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m entry into the host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m , SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSars-CoV-2\u001b[0m infects the respiratory \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mairway\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-receptor-allow-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-receptor-allow-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the cellular receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mairway\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor for entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE-2 receptors for pulmonary \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-surface-exposed-mediate-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-surface-exposed-mediate-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minitiate\u001b[0m-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m initiates the entry into \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters human target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: receptor for SARS-CoV-1 and presumably for \u001b[31mSARS-CoV-2\u001b[0m to infect the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-enzyme-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enters into host \u001b[34mcells\u001b[0m via cell receptor angiotensin converting enzyme II ( \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhave\u001b[0m-potential-replicate-\u001b[34mcardiomyocyte\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhave\u001b[0m-potential-replicate-\u001b[34mcardiomyocyte\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minitiate\u001b[0m-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m initiates its entry into human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-virus-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: use the angiotensin converting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as a receptor for \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: uses angiotensinconverting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as a receptor and primarily infects ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcause\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes COVID-19 by infecting host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-tract-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mattach\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches to the target \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: receptor by \u001b[31mSARS-CoV-2\u001b[0m to infect human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-virus-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mattach\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches the human host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-enzyme-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enter human host \u001b[34mcells\u001b[0m mainly via a cellular receptor angiotensin-converting enzyme ( \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-enzyme-dominate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-enzyme-dominate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-tract-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: uses angiotensin-converting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as the receptor for \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcause\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes respiratory symptoms by infecting alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1mtarget\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: targets human angiotensin-converting enzyme \u001b[31m2\u001b[0m ( hACE2 ) and infects intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-ace2-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msara-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-type-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-protein-interaction-involve-mechanism-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enters host \u001b[34mcells\u001b[0m by a mechanism involving the interaction between its spike ( S ) protein and human angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) , which enters the \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mexploit\u001b[0m-receptor-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to invade \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-target-mucosa-\u001b[1mact\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is the upper respiratory mucosa , and angiotensin-converting enzyme 2 ( ACE2 ) acts as a functional receptor for the viral spikes and eventually viral entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-bind-protein-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: infects \u001b[34mcells\u001b[0m through the S protein , which binds to cell surface receptor-angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-bind-replicate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly invades alveolar epithelial \u001b[34mcells\u001b[0m by binding to the ACE-2 receptor and then replicates within cells\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mconsider\u001b[0m-pathogen-gain-access-to-\u001b[34mbody\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is considered a lower respiratory tract pathogen that gains access to the \u001b[34mbody\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-pathogenesis-\u001b[1minvolve\u001b[0m-binding-\u001b[34mhost\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m involves the binding of its spike protein to angiotensin converting enzyme-2 ( ACE2 ) in the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds with the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can bind to human angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , \u001b[31mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the same receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV employ \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m similarly to SARS-CoV requires angiotensin-converting enzyme 2 ( \u001b[34mAcE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-receptor-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the same receptor of SARS-CoV , which is angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-bind-domain-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1mshow\u001b[0m-use-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1mshow\u001b[0m-use-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-bind-domain-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcell\u001b[0m \u001b[31mACE2\u001b[0m receptors\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1menzyme-2\u001b[0m\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31menzyme-2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-receptor-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-identify-\u001b[1msurprising\u001b[0m-adapt-bind-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-identify-\u001b[1msurprising\u001b[0m-adapt-bind-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mshow\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mshow\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-invade-\u001b[1mbelong\u001b[0m-covid-19-\u001b[34mboth\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-invade-\u001b[1mbelong\u001b[0m-covid-19-\u001b[34mboth\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-protein-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-protein-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m angiotensin-converting enzyme ( ACE ) \u001b[31m2\u001b[0m receptor\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1marmed\u001b[0m-with-protein-use-gain-membrane-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1marmed\u001b[0m-with-protein-use-gain-membrane-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-protein-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-protein-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mreceptor\u001b[0m\tLINEAR: uses \u001b[31mACE2\u001b[0m as the \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-entry-\u001b[1midentify\u001b[0m-use-\u001b[34mreceptor\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1minteract\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-bind-receptor-\u001b[34menzyme-2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-bind-receptor-\u001b[34menzyme-2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1mbind\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds weakly to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mace2\u001b[0m\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[34mhuman\u001b[0m \u001b[31mace2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-entry-\u001b[1midentify\u001b[0m-use-\u001b[34mreceptor\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1mbind\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m spike protein binds \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-glycoprotein-receptor-\u001b[1midentify\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-mean-binding-receptor(s-\u001b[34mcellular\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-mean-binding-receptor(s-\u001b[34mcellular\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-entry-receptor-\u001b[1midentify\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for 25 entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhomologous\u001b[0m-infect-binding-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhomologous\u001b[0m-infect-binding-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34m2\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mcell\u001b[0m receptor\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mconverting\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mconverting\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSars-CoV-2\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"lemmas\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: lemmas along dep path (PyBART)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans can cause a wide range of clinical manifestations , from mild febrile \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans is characterized by extensive pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mibv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34mInfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV can cause a spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-result-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-result-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m characterized by severe clinical manifestations of the lower respiratory tract , resulting in diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m-\u001b[1mestablish\u001b[0m-cause-number-\u001b[34mdisorder\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbkv\u001b[0m-\u001b[1mestablish\u001b[0m-cause-number-\u001b[34mdisorder\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m establishes infection in the kidney and the urinary tract , and its activation causes a number of \u001b[34mdisorders\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-onset-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-onset-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[34menteritis\u001b[0m is associated with \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an important systemic parvoviral \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-spectrum-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , SARS-CoV-2 causes \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections \u001b[34mare\u001b[0m characterized\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-loss-\u001b[34mfocal\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-loss-\u001b[34mfocal\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-manifestation-\u001b[34mneurologic\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-manifestation-\u001b[34mneurologic\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m the major cause of lower respiratory tract infections in infants and \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1minduce\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-immunosuppression-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-encephalitis-disorder-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause Japanese encephalitis ( JE ) with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-illness-\u001b[34mfebrile\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbrv\u001b[0m-infection-\u001b[1mcomponent\u001b[0m-pathogenesis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mBRV\u001b[0m is a lytic infection and destruction of infected mucosal epithelial cells is an important component of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mbegin\u001b[0m-progress-stage-infection-characterize-fever-\u001b[34mshock\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m begins with flu-like symptoms and progresses rapidly to the final stages of viral hemorrhagic fever infection , which are characterized by fever , hemorrhage , and hypotensive \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m-\u001b[1minfect\u001b[0m-cause-atrophy-villi-result-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infects the epithelium of the small intestine , an environment rich in proteases , and causes atrophy of the villi resulting in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-associate-\u001b[34mgastroenteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in respiratory tract complications with varying degree of severity and has been associated with \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfect\u001b[0m-human-\u001b[1mdevelop\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31minfected\u001b[0m with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-\u001b[1mincrease\u001b[0m-result-\u001b[34mseverity\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m increases the susceptibility of the host to a wide range of viral and bacterial respiratory pathogens , resulting in increased \u001b[34mseverity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-spread-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m characterized by a rapid and extensive spread of the \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrepresent\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-ability-\u001b[1mresult\u001b[0m-\u001b[34mdamage\u001b[0m\tLINEAR: results from overwhelming cytopathic \u001b[34mdamage\u001b[0m due to the ability of Ebola \u001b[31mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-infect-human-\u001b[1mreport\u001b[0m-develop-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m have been reported to develop a severe acute respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJEV\u001b[0m-\u001b[1minvade\u001b[0m-trigger-response-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mJEV\u001b[0m invades the central nervous system , wherein virus replication triggers a massive \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmcmv\u001b[0m-\u001b[1mcause\u001b[0m-cause-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mMCMV\u001b[0m causes asymptomatic infection in adult immunocompetent mice , but experimental inoculation of neonates has caused lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-viremia-\u001b[34mto\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m-pathogen-\u001b[1mcause\u001b[0m-degeneration-function-lead-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m is an important viral pathogen worldwide in the domestic cat ( Felis catus ) , causes a slow progressive degeneration of immune functions that eventually leads to a \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34monset\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-immunosuppression-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-\u001b[1mreplicate\u001b[0m-lead-infection-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m replicates mainly in porcine alveolar macrophages ( PAMs ) and dendritic cells ( DCs ) and leads to persistent infection , interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-characterize-cascade-event-lead-inflammation-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of SARS-CoV causes severe acute respiratory syndrome ( SARS ) , which is an emerging infectious disease and characterized by a cascade of immunological events leading to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmhv\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malphavirus\u001b[0m-infection-\u001b[1minduce\u001b[0m-\u001b[34marthritis\u001b[0m\tLINEAR: \u001b[31malphavirus\u001b[0m infections , such as those involving CHIKV , Ross River virus ( RRV ) , and Sindbis virus ( SINV ) , induce debilitating \u001b[34marthritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-atrophy-intestine-result-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is characterized by severe villous atrophy in the small intestine that results in watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mable\u001b[0m-cross-stimulate-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m is able to cross the blood-brain barrier and stimulate \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmnv\u001b[0m-infection-\u001b[1mresult\u001b[0m-replication-associate-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mMNV\u001b[0m infection in immunocompromised mice lacking innate immunity factors such as STAT1 or interferon receptors can result in persistent or acute virus replication associated with severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-severe-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in severe and even fatal lung \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiv\u001b[0m-\u001b[1minduce\u001b[0m-splenomegaly-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mBIV\u001b[0m induces splenomegaly and lymphademopathy \u001b[34msyndromes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-consequence-\u001b[1mreport\u001b[0m-result-disease-cns-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , such as acute flaccid paralysis , myocarditis , and Reye syndrome , have been reported [ 13 , 18 ] ; HPeV3 infection results in severe diseases of the CNS and neonatal \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjhmv\u001b[0m-strain-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mjHMV\u001b[0m cause a subacute or persistent \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmarv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-mouse-infection-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m produces clinical \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mterm\u001b[0m-cause-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , also termed epizootic catarrhal \u001b[34menteritis\u001b[0m or ECE , causes mucoid enteritis\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m-infection-\u001b[1mresult\u001b[0m-symptom-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection usually results in mild \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-model-\u001b[1mreveal\u001b[0m-cause-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have revealed that this lethal pulmonary infection causes a denuding bronchiolitis and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-stage-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-course-\u001b[1minduce\u001b[0m-\u001b[34msg\u001b[0m\tLINEAR: induces \u001b[34mSGs\u001b[0m during the course of \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msystemic\u001b[0m-characterize-hemorrhage-\u001b[34medema\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds is systemic , characterized by hemorrhage and \u001b[34medema\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-disease-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes Ebola virus disease ( EVD ) , which is an acute systemic \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m-infection-\u001b[1mlead\u001b[0m-mild-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfluenza\u001b[0m virus infection in humans can lead to mild to severe \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpedv\u001b[0m-infection-\u001b[1mcytolytic\u001b[0m-lead-\u001b[34matrophy\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infection is cytolytic and causes acute necrosis of the infected enterocytes , leading to marked intestinal villous \u001b[34matrophy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnidovirus\u001b[0m-infection-\u001b[1minduce\u001b[0m-inflammation-tract-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mnidovirus\u001b[0m infection induces an inflammation of the upper respiratory and alimentary tract which can develop into a severe and often fatal proliferative \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-range-sign-infection-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with FCoV can result in a diverse range of signs from clinically inapparent infections to a highly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msystemic\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses from an atypical pneumonia to acute diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-fever-cough-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m often causes fever , cough , and severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvsv\u001b[0m-infection-\u001b[1masymptomatic\u001b[0m-cause-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mVSV\u001b[0m infection of humans is typically either asymptomatic or causes a mild influenza-like \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34menteritis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mtrigger\u001b[0m-lesion-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mfiv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in human , or MERS , commonly manifests as a severe acute respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchikv\u001b[0m-\u001b[1mproduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfpv\u001b[0m-\u001b[1mresponsible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mFPV\u001b[0m is responsible of systemic \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msevere\u001b[0m-BRDC-\u001b[1mprecede\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m BRDC \u001b[34mis\u001b[0m often preceded\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1m12\u001b[0m-,-replicate-mucosa-lead-\u001b[34mdamage\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , RSV replicates in the respiratory mucosa leading to epithelial \u001b[34mdamage\u001b[0m [ 11 ] and perivascular mononuclear infiltration [ 12\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mjcv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 1\n",
      "PATH: \u001b[31mprrsv\u001b[0m-co-infection-\u001b[1minduce\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m and S. suis generally induces exacerbated \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1maggravate\u001b[0m-\u001b[34mcondition\u001b[0m\tLINEAR: \u001b[34mcondition\u001b[0m is aggravated by mixed \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mjcpyv\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1moccur\u001b[0m-follow-viremia-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m occurs predominately in alveolar macrophages of the lung [ 3 ] , followed by viremia and subsequent interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfilovirus\u001b[0m-infection-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mfilovirus\u001b[0m infections \u001b[34mare\u001b[0m associated\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-degree-manifestation-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes varying degrees of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-seriousness-\u001b[1mlie\u001b[0m-complication-include-disease-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m lies in its complications , which include hand-foot-and-mouth disease , herpangina , aseptic meningitis , poliomyelitis-like paralysis , and fatal \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-complication-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PRRSV leads to reproductive complications , respiratory \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfipv\u001b[0m-\u001b[1mtropic\u001b[0m-result-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m is macrophage tropic and may cause aberrant cytokine and/or chemokine expression and lymphocyte depletion , which results in a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-disorder-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-condition-know-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by the SARS-CoV-2 causes an inflammatory condition also known as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhcov\u001b[0m-infection-\u001b[1mlead\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mHCoV\u001b[0m infection in immunosuppressed populations can lead to significant lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mveev\u001b[0m-exposure-\u001b[1mresult\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mVEEV\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 1\n",
      "PATH: \u001b[31mphev\u001b[0m-\u001b[1mvirus\u001b[0m-cause-symptom-\u001b[34mneurological\u001b[0m\tLINEAR: \u001b[31mPHEV\u001b[0m is a neurovirulent virus that spreads to the central nervous system ( CNS ) via peripheral nerves , where neurite damage and neuronal death are observed , causing \u001b[34mneurological\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in human \u001b[31minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by these human coronaviruses , SARS \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m \u001b[31mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdie\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-lead-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of human \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdevelop\u001b[0m-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m may develop a wide range of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-picture-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-picture-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfant\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdie\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhost\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1msign\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1moccur\u001b[0m-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-suckle-growth-\u001b[1mcharacterize\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-suckle-growth-\u001b[1mcharacterize\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is characterized by retarded growth , ruffled fur , soft feces or diarrhea , rectal prolapse , and moderate mortality in older suckling or recently weaned \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-lead-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung , and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msevere\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m \u001b[31mis\u001b[0m usually more severe\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbe\u001b[0m\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually a self-limited \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent adult \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31manimal\u001b[0m-\u001b[1mdevelop\u001b[0m-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m may develop a wide range of \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m typically associated with acute cholestatic hepatic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1moccur\u001b[0m-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1msymptom\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmouse\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent \u001b[31mmice\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m-young-have-\u001b[1mprofuse\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcat\u001b[0m-young-have-\u001b[1mprofuse\u001b[0m-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m with cryptosporidiosis will have profuse , watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpeople\u001b[0m-\u001b[1mmanifest\u001b[0m-feature-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpeople\u001b[0m commonly manifest features of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexhibit\u001b[0m-encephalopathy-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m suffering from severe DENV infection often exhibit encephalopathy and \u001b[34mencephalitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mshow\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mhave\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with signs from FIV often \u001b[34mhave\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34menteric\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-illness-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-stage-\u001b[1minclude\u001b[0m-\u001b[34mbleeding\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1masymptomatic\u001b[0m-occur-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic , although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mpresent\u001b[0m-headache-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdeteriorate\u001b[0m-present-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with EVD rapidly deteriorate and commonly present with gastrointestinal \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-course-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1minfect\u001b[0m-manifest-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m are primarily infected subclinically , but gastrointestinal \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmarmoset\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mcause\u001b[0m-onset-\u001b[34msudden\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , VEEV infection causes a \u001b[34msudden\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-subset-progress-\u001b[1massociate\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is associated with fever and liver damage , but a subset of \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mpresent\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mhave\u001b[0m-worsen-symptom-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by SARS-CoV typically has an insidious onset , and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthose\u001b[0m-\u001b[1msuffer\u001b[0m-progress-inflammation-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mThose\u001b[0m infected with SARS suffer fever , cough , muscle aches , and shortness of breath and often progress to severe \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mleptospirosis\u001b[0m\tLINEAR: \u001b[31mHuman\u001b[0m \u001b[34mleptospirosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m-\u001b[1mpresent\u001b[0m-symptom-as-vomiting-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPigs\u001b[0m that are infected with TGEV usually present symptoms such as vomiting , dehydration , and severe \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrat\u001b[0m-\u001b[1msusceptible\u001b[0m-occur-result-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mrats\u001b[0m are especially susceptible to SDA , and the infection can occur in the lower respiratory tract , resulting in \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mbecome\u001b[0m-\u001b[34mill\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m typically become acutely \u001b[34mill\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mmanifest\u001b[0m-fever-\u001b[34mdiarrhoea\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , adenovirus infections often manifest as upper respiratory tract infections , pharyngoconjunctival fever , or \u001b[34mdiarrhoea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mlead\u001b[0m-characterize-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually leads to the development of CHIKF and \u001b[34mis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-after-onset-of-\u001b[34mrash\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m develops insidiously , usually a few days after the onset of \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifest\u001b[0m-occur-symptom-\u001b[34mrash\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m manifests as fever , headache , weakness , and myalgias/ arthralgias ; gastrointestinal symptoms and a maculopapular \u001b[34mrash\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-infection-\u001b[1mcause\u001b[0m-nonlethal-incapacitate-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes nonlethal , incapacitating \u001b[34msymptoms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-rvf-\u001b[1mbegin\u001b[0m-progress-to-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually begins with a nonspecific influenza-like acute \u001b[34mfever\u001b[0m , but can progress to serious hemorrhagic fever\tCOUNT: 1\n",
      "PATH: \u001b[31mleptospirosis\u001b[0m-call-\u001b[1mhave\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m , also called Pretibial fever or Fort Bragg fever , \u001b[34mhas\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexperience\u001b[0m-\u001b[34monset\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdog\u001b[0m-\u001b[1mexhibit\u001b[0m-\u001b[34mparalysis\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m exhibit pharyngeal \u001b[34mparalysis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-plague-\u001b[1mcharacterize\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m \u001b[34mis\u001b[0m usually characterized\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mlesion\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-%-\u001b[1mappear\u001b[0m-\u001b[34mFever\u001b[0m\tLINEAR: \u001b[34mFever\u001b[0m , absolute lymphopenia , inappetence , jaundice , and abdominal effusion appear 2 - 3 weeks after infection in around 80 % of \u001b[31mcats\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-%-\u001b[1mshow\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m show acute \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mresult\u001b[0m-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-\u001b[1mself-limiting\u001b[0m-progress-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , infection is usually self-limiting , but a small percent of cases ( 1 - 2 % ) can progress to severe \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-infect-\u001b[1mreach\u001b[0m-%-range-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m are infected by the virus , mortality can reach up to 50 % of affected horses , and \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1masymptomatic\u001b[0m-observe-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is usually asymptomatic although nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-range-\u001b[1minclude\u001b[0m-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m severities range from asymptomatic infection to fatal HF ( Fisher-Hoch et al. , 1995 ) and commonly resulting from other viral infections , nonspecific \u001b[34msymptoms\u001b[0m beginning several days after infection include\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrestricted\u001b[0m-lead-onset-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is generally restricted to the alimentary tract , leading to the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mdevelop\u001b[0m-illness-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcalf\u001b[0m-of-BRDC-\u001b[1mcharacterize\u001b[0m-fever-lesion-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m is characterized by fever , dyspnea , inflammatory and necrotizing \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madenovirus\u001b[0m-infection-picture-\u001b[1mdisease\u001b[0m\tLINEAR: \u001b[31madenovirus\u001b[0m infection of the respiratory tract is mild self-limiting upper respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrsv\u001b[0m-infection-\u001b[1mbegin\u001b[0m-associate-\u001b[34mfever\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m infection begins in the upper respiratory tract with nasal congestion and pharyngitis and is associated with \u001b[34mfever\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mmanifestation\u001b[0m-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mexperience\u001b[0m-onset-of-fever-chill-develop-tachypnea-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience the abrupt onset of high fever , chills , and rapidly developing tachypnea and \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-\u001b[1mhave\u001b[0m-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcat\u001b[0m-\u001b[1mshow\u001b[0m-sign-anemia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with acute leukemia usually show signs of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhorse\u001b[0m-infection-\u001b[1myield\u001b[0m-\u001b[34msyndrome\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-onset-\u001b[34mdiarrhea\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with E coli may develop an acute onset of watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpig\u001b[0m-\u001b[1mdevelop\u001b[0m-anemia-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m commonly develop anemia and secondary infections , especially bacterial \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mclinical\u001b[0m-manifestation-\u001b[1mevolve\u001b[0m-presentation-failure-\u001b[34mshock\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant presentation with progressive respiratory failure and \u001b[34mshock\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-percentage-\u001b[1mdevelop\u001b[0m-asymptomatic-have-\u001b[34millness\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m , a small percentage of affected \u001b[31mindividuals\u001b[0m develop\tCOUNT: 1\n",
      "PATH: \u001b[31mrabbit\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-%-occur-\u001b[1minvolve\u001b[0m-outcome-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m usually involves mild upper respiratory tract infections ; however , more severe conditions , such as pneumonia and bronchiolitis occur in 25 - 40 % of \u001b[31mchildren\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhuman\u001b[0m-in-symptom-\u001b[1mmild\u001b[0m-include-\u001b[34millness\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m are usually mild and include febrile \u001b[34millness\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31madult\u001b[0m-case-\u001b[1mresult\u001b[0m-in-\u001b[34mdyspnea\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m usually result in \u001b[34mdyspnea\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-of-\u001b[1mperiod\u001b[0m-progress-\u001b[34mpneumonia\u001b[0m\tLINEAR: period of 2 - 14 days \u001b[31mpatients\u001b[0m initially present with influenza-like symptoms , fever , and cough that can progress to atypic \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mViral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mclinic\u001b[0m-progress-\u001b[34mdisease\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m-\u001b[1mdevelop\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31mcondition\u001b[0m-\u001b[1mdevelop\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-pneumonia-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-result-failure-\u001b[34mcardiac\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-result-failure-\u001b[34mcardiac\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mprogress\u001b[0m-syndrome-\u001b[34mand\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mprogress\u001b[0m-syndrome-\u001b[34mand\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-infection-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops rapidly and eventually progresses after 2 to 4 days into \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-infection-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdevelop\u001b[0m-edema-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdevelop\u001b[0m-edema-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31millnesses\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m-\u001b[1mresult\u001b[0m-complication-involvement-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mcan\u001b[0m-\u001b[1mresult\u001b[0m-complication-involvement-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-response-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-failure-response-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-form-\u001b[1mexperience\u001b[0m-suffer-complication-\u001b[34msevere\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-form-\u001b[1mexperience\u001b[0m-suffer-complication-\u001b[34msevere\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-have-\u001b[1mdevelop\u001b[0m-lead-\u001b[34mdeath\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-have-\u001b[1mdevelop\u001b[0m-lead-\u001b[34mdeath\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild symptoms such as fever , headache , cough , myalgia and anosmia , some develop acute respiratory distress syndrome , leading to \u001b[34mdeath\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[34mprogressive\u001b[0m local \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mresult\u001b[0m-syndrome-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mresult\u001b[0m-syndrome-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may result in adult \u001b[34mrespiratory\u001b[0m distress syndrome and respiratory\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-lymphadenopathy-\u001b[34mgeneralize\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-lymphadenopathy-\u001b[34mgeneralize\u001b[0m\tLINEAR: results in \u001b[31mdisease\u001b[0m that is less severe and commonly presents as nondescript , consisting of fever , myalgia , and \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m may \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mform\u001b[0m-\u001b[34mthis\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mform\u001b[0m-\u001b[34mthis\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m form of the \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mbegin\u001b[0m-case-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mbegin\u001b[0m-case-\u001b[34msymptomatic\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m cases , the onset of \u001b[31mdisease\u001b[0m begins\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-plague-pneumonic-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-plague-pneumonic-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mprogress\u001b[0m-to-state-\u001b[34mtoxic\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mprogress\u001b[0m-to-state-\u001b[34mtoxic\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to an increasingly \u001b[34mtoxic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-asymptomatic-\u001b[1mcause\u001b[0m-symptom-\u001b[34mserious\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-asymptomatic-\u001b[1mcause\u001b[0m-symptom-\u001b[34mserious\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m usually asymptomatic , cryptococcosis can cause \u001b[34mserious\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mdevelop\u001b[0m-presentation-include-pharyngitis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mdevelop\u001b[0m-presentation-include-pharyngitis-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually develops within the first 3 months of transplantation , with a presentation that might include pharyngitis , tracheitis , bronchitis , pneumonitis , enteritis , hemorrhagic cystitis , or disseminated \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-lead-to-dyspnea-stridor-cyanosis-shock-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-lead-to-dyspnea-stridor-cyanosis-shock-\u001b[34mseptic\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , leading to dyspnea , stridor , cyanosis , and \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mlimited\u001b[0m-progress-infection-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mDisease\u001b[0m-\u001b[1mlimited\u001b[0m-progress-infection-bronchiolitis-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m is mostly limited to the upper airways and is self-limiting , but a small percentage can progress to lower respiratory tract infections as bronchiolitis and \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-some-\u001b[1msevere\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-some-\u001b[1msevere\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mshock\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdie\u001b[0m-have-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mdie\u001b[0m-have-sign-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may die within 1 to 2 days because of overwhelming viremia and vasculitis of all major organs and yet have minimal \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m-decompensation-\u001b[1mcoincide\u001b[0m-development-syndrome-difficult-differentiate-infection-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrespiratory\u001b[0m-decompensation-\u001b[1mcoincide\u001b[0m-development-syndrome-difficult-differentiate-infection-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mRespiratory\u001b[0m decompensation often coincides with the development of adult respiratory disease syndrome ( ARDS ) , which can be difficult to differentiate from a confluent \u001b[34mpulmonary\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-spectrum-\u001b[1mrange\u001b[0m-infection-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-spectrum-\u001b[1mrange\u001b[0m-infection-disease-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can range from asymptomatic infections to \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mpresent\u001b[0m-associate-damage-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mpresent\u001b[0m-associate-damage-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually presents in the second to fourth day of life and may be associated with \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mshock\u001b[0m\tLINEAR: \u001b[34mshock\u001b[0m in approximately 15 % \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-course-\u001b[1mlast\u001b[0m-result-in-\u001b[34mcoma\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mclinical\u001b[0m-course-\u001b[1mlast\u001b[0m-result-in-\u001b[34mcoma\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m course of SSPE may last either months or years and ultimately results in \u001b[34mcoma\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-after-\u001b[1moccur\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , dyspnea and/or hypoxemia usually occur one week after the onset of the \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-mild-\u001b[1mprogress\u001b[0m-to-presentation-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is often mild with cold-like symptoms , it can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1moccur\u001b[0m\u001b[0m-progression-\u001b[34mrapid\u001b[0m\tLINEAR: \u001b[34mrapid\u001b[0m progression of lung consolidation \u001b[31moccurs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mself-limiting\u001b[0m-develop-symptom-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may be self-limiting in few days , but in some cases the \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mprogress\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-patient-\u001b[34mcritical\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31msymptom\u001b[0m-\u001b[1mprogress\u001b[0m-form-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-pneumonia-associate-bacteremia-failure-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , pneumonia , associated with bacteremia and \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mmild\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-case-\u001b[1mhave\u001b[0m-opacity-failure-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m have a rapid and relentless fatal course , with generalized alveolar and interstitial opacities , development of the adult respiratory distress syndrome ( ARDS ) , and \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mprogress\u001b[0m-anemia-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mlead\u001b[0m-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mprogress\u001b[0m-\u001b[34m-PRON-\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mit\u001b[0m progresses\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mcondition\u001b[0m\u001b[0m-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31mconditions\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mbecome\u001b[0m-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m becomes relentlessly \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-mild-\u001b[1mcause\u001b[0m-manifestation-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is mild in most of the affected individuals , it may cause \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mips\u001b[0m-\u001b[1mprogress\u001b[0m-dysfunction-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m-infection-\u001b[1mbegin\u001b[0m-croup-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m infection usually begins as a \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-%-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m , and potentially fatal , systemic \u001b[31mdisease\u001b[0m may develop\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-associate-\u001b[1mfollow\u001b[0m-infection-bronchitis-abscess-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , this may be followed by persistent , chronic infection , including chronic bronchitis , bronchiectasis , and \u001b[34mpulmonary\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mprogressive\u001b[0m-development-opacity-\u001b[34mbilateral\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m can be rapidly progressive with the development of multifocal \u001b[34mbilateral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-onset-\u001b[1mcause\u001b[0m-failure-\u001b[34mprogressive\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m onset can cause \u001b[34mprogressive\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mdevelop\u001b[0m-progress-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME can develop aseptic meningitis and meningoencephalitis or progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mprogress\u001b[0m-development-encephalitis-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmay\u001b[0m-\u001b[1mdevelop\u001b[0m-pain-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m develop , with high fever , \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mmanifest\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-form-\u001b[1mprogression\u001b[0m-\u001b[34mrapid\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , in the absence of appropriate treatment , there may be \u001b[34mrapid\u001b[0m progression\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mresult\u001b[0m-damage-\u001b[34malveolar\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mprogress\u001b[0m-phase-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can rapidly progress to the hemorrhagic phase of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-\u001b[1mprogress\u001b[0m-bronchiectasis-failure-\u001b[34mrespiratory\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcopd\u001b[0m-subject-exacerbation-trigger-\u001b[1mknow\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with compromised immune systems are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to bacterial , fungal , viral , and parasitic \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 4\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mds\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-lower-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-status-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at risk of serious \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-dentition-patient-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mdevelop\u001b[0m-form-\u001b[34maspergillosis\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression can develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mrisk\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients who require surgery may be at risk of coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at the risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mvulnerable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-develop-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at higher risk for developing fulminant acute \u001b[34mhepatitis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mvulnerable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are at an increased risk for these \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mibd\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-develop-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for developing acute fulminant \u001b[34mhepatitis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-bacterial-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly susceptible to bacterial and candidal \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfibrosis\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m-cause-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by encapsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-increase-depletion-\u001b[1mrelated\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are more heavily immunosuppressed and who are suffering from other immunologic and infectious complications of transplant are at higher risk for \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m frequently cause persistent \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m upon primary HRSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msinusitis\u001b[0m\u001b[0m-cause-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by capsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m to secondary bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m of the lower respiratory tract may increase the risk of secondary bacterial \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msusceptible\u001b[0m-bacterial-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m on high dose corticosteroids and mechanical ventilation are particularly susceptible to superimposed bacterial and opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfibrosis\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic Pa \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-severity-increase-depletion-\u001b[1mrelated\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are also related to lymphoid depletion and immunosuppression , which likely increase the severity of secondary \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: developing severe \u001b[31mdisease\u001b[0m by \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with GI bleeding are at risk of developing bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m with \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause asthma or chronic obstructive pulmonary disease in chronic \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1msusceptible\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mrisk\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-reservoir-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-antibiotic-use-\u001b[1mpromote\u001b[0m-emergence-colonization-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-antibiotic-use-\u001b[1mpromote\u001b[0m-emergence-colonization-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m might promote the emergence of gram-negative bacterial colonization or \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mmake\u001b[0m-vulnerable-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpatient\u001b[0m-be-\u001b[1mmake\u001b[0m-vulnerable-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are smokers , passive smokers or ex-smokers and the frequent use of inhaled corticosteroids make them more vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-reservoir-\u001b[1mlikely\u001b[0m-develop-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop hospital-acquired \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with acute respiratory distress syndrome ( ARDS ) due to viral \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m including \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mincrease\u001b[0m-risk-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m increases the risk for subsequent or secondary bacterial \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mards\u001b[0m\u001b[0m-trigger-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m triggered by viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mscd\u001b[0m-individual-\u001b[1msusceptible\u001b[0m-\u001b[34morganism\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdiabetes\u001b[0m-individual-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-receive-\u001b[1msusceptible\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m receiving immunomodulatory or immunosuppressive therapies due to malignancy , transplantation , or autoimmune disease are more susceptible to viral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mprimary\u001b[0m\tLINEAR: \u001b[34mprimary\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mrisk\u001b[0m-prone-superinfection-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk for gram-negative and anaerobic polymicrobial aspiration pneumonia , and on the other hand are more prone to bacterial superinfections following influenza \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcancer\u001b[0m-patient-\u001b[1mknow\u001b[0m-risk-virus-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are known to be at an increased risk for community-acquired respiratory viruses , such as \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maml\u001b[0m-patient-\u001b[1mlow\u001b[0m-incidence-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is low among patients with \u001b[31mAML\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhowever\u001b[0m-\u001b[1mprone\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mHowever\u001b[0m , neonates , older individuals , and those with immune deficiencies are prone to more frequent and more serious CNS viral \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31millness\u001b[0m-\u001b[1mdevelop\u001b[0m-result-\u001b[34minfection\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m as a result of HPIV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-patient-\u001b[1mhave\u001b[0m-therapy-predispose-risk-contract-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m have immune dysfunction and are often on glucocorticoid and immunosuppressant therapy , which in turn predispose them to an increased risk of contracting SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mhave\u001b[0m-risk-of-develop-complication-as-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m have mild to moderate symptoms or are even asymptomatic , older patients or those with existing chronic diseases are at greater risk of developing serious complications such as \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcf\u001b[0m-fibrosis-those-\u001b[1mbe\u001b[0m-prone-develop-pneumonia-cause-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m ) , chronic obstructive pulmonary disease ( COPD ) , and on mechanical ventilation are particularly prone to develop pneumonia caused by PA \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mindividual\u001b[0m-\u001b[1mimmunosuppressed\u001b[0m-susceptible-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m are immunosuppressed , and therefore , are more susceptible to \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mfungal\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-extension-lung-\u001b[34msuperinfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m , which may be due to viral extension to the lungs or bacterial \u001b[34msuperinfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-development-risk-lead-\u001b[1mprolonged\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m in patients with hematological malignancy ( particularly after HSCT ) are more prolonged , lasting weeks and even months , and lead to an increased risk of respiratory compromise due to the development of viral or secondary bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-patient-\u001b[1mlikely\u001b[0m-co-infecte-\u001b[34mbacteria\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m are more likely to be co-infected with \u001b[34mbacteria\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1msuffer\u001b[0m-be-coinfection-sa-\u001b[34mAspergillus\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with NTM suffer from a more rapid decline in pulmonary function than control patients without NTM although coinfections with SA and \u001b[34mAspergillus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mchild\u001b[0m-\u001b[1msusceptible\u001b[0m-incidence-from-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m that are immunosuppressed such as those that are severely malnourished or HIV-infected are susceptible not only to a higher incidence and mortality from \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mhave\u001b[0m-risk-of-develop-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are immunocompromised , as a result of disease or therapeutic interventions , have the greatest risk of developing a fatal \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mincrease\u001b[0m-influenza-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mincrease\u001b[0m-influenza-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mconsider\u001b[0m-management-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-virus-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-be-prove-effective-occur-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-be-prove-effective-occur-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-cidofovir-\u001b[1magent\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-cidofovir-\u001b[1magent\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-virus-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m-therapy-efficacy-effect-\u001b[1mcompromise\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mconsider\u001b[0m-management-case-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-sufficient-\u001b[1mthink\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-sufficient-\u001b[1mthink\u001b[0m-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mof\u001b[0m-therapy-efficacy-effect-\u001b[1mcompromise\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m-available-practice-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-\u001b[1meffective\u001b[0m-%-form-\u001b[34mttp\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-therapy-\u001b[1meffective\u001b[0m-%-form-\u001b[34mttp\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-induce-rejection-\u001b[34morgan\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-induce-rejection-\u001b[34morgan\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m-available-practice-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m-PRON-\u001b[0m-\u001b[1mbe\u001b[0m-agent-patient-active-\u001b[34mtuberculosis\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1msufficient\u001b[0m-suppress-\u001b[34minflammation\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1museful\u001b[0m-treat-infection-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mrecommend\u001b[0m-treatment-sars-cov-2-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mrecommend\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-fail-\u001b[1mdie\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1meffective\u001b[0m-treatment-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-recommend-\u001b[1mdelay\u001b[0m-clearance-\u001b[34mvirus\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mavailable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mlicense\u001b[0m-treatment-infection-\u001b[34mcmv\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-of-Most-\u001b[1meffective\u001b[0m-use-progression-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mhave\u001b[0m-case-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-ineffective-\u001b[1mbe\u001b[0m-low-in-\u001b[34mchild\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-use-\u001b[1mcause\u001b[0m-suppression-\u001b[34mhost\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minterferon\u001b[0m-\u001b[1muse\u001b[0m-treat-\u001b[34mdengue\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-trial-\u001b[1mobserve\u001b[0m-consider-be-drug-of-choice-for-\u001b[34minfluenza\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maciclovir\u001b[0m-monotherapy-efficacy-\u001b[1mhamper\u001b[0m-\u001b[34mencephalitis\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m-\u001b[1mhave\u001b[0m-efficacy-prevent-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mfam\u001b[0m-therapy-\u001b[1margue\u001b[0m-use-prophylaxis-\u001b[34msurvival\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mhave\u001b[0m-available-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1mlimit\u001b[0m-response-therapy-suppression-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-demonstrate-\u001b[1mbe\u001b[0m-treatment-\u001b[34mcchf\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbiologic\u001b[0m-therapy-\u001b[1mprovide\u001b[0m-option-\u001b[34mUC\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-therapy-use-\u001b[1mbe\u001b[0m-vaccine-prevent-\u001b[34mrsv\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1muse\u001b[0m-resistance-association-shedding-\u001b[34mvirus\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mzanamivir\u001b[0m-\u001b[1minduce\u001b[0m-be-benefit-prove-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mtherapy\u001b[0m-\u001b[34mspecific\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mbe\u001b[0m-choice-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcontraindicate\u001b[0m-\u001b[34mcirrhosis\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1minduce\u001b[0m-effective-c-\u001b[34mhepatitis\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mcidofovir\u001b[0m-\u001b[1mremain\u001b[0m-treatment-death-report-secondary-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mhave\u001b[0m-efficacy-pneumonia-\u001b[34mbacterial\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1meffective\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-toxicity-associate-\u001b[1mcomplicated\u001b[0m-treatment-recipient-develop-cre-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-treatment-\u001b[1mtherapy\u001b[0m-\u001b[34mkd\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-\u001b[1mlimit\u001b[0m-\u001b[34mad\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1mchallenging\u001b[0m-alleviate-symptom-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-interaction-\u001b[1mpose\u001b[0m-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-use-\u001b[1mcontroversial\u001b[0m-impact-response-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-switch-\u001b[1mrecommend\u001b[0m-worsen-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhaart\u001b[0m-\u001b[1massociate\u001b[0m-make-timing-controversial-patient-\u001b[34msepsis\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-\u001b[1mneed\u001b[0m-absence-intervention-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31malthough\u001b[0m-\u001b[1madopt\u001b[0m-treatment-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-need-\u001b[1mrespond\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mapprove\u001b[0m-treatment-infection-\u001b[34mhrsv\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1minhibit\u001b[0m-replication-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-drug-benefit-\u001b[1mestablish\u001b[0m-treatment-\u001b[34msars\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-use-be-\u001b[1mconvenient\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-use-need-\u001b[1mrespond\u001b[0m-proportion-involvement-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvzig\u001b[0m-efficient-\u001b[1mbeneficial\u001b[0m-therapy-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-class-efficacy-\u001b[1mlimit\u001b[0m-development-resistance-\u001b[34mantiviral\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mtreatment\u001b[0m-\u001b[34mCRS\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mefficacious\u001b[0m-reduce-level-patient-infection-\u001b[34mhbv\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-profile-\u001b[1mlimit\u001b[0m-use-treat-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-conjunction-\u001b[1mtoxicity\u001b[0m-\u001b[34mpulmonary\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-mainstay-\u001b[1mcontroversial\u001b[0m-use-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m-treatment-\u001b[34mvhf\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-treatment-initiation-\u001b[1mresult\u001b[0m-\u001b[34mkd\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-therapy-\u001b[1mneed\u001b[0m-control-\u001b[34mvasculitis\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1mefficacy\u001b[0m-\u001b[34mtreatment\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mhave\u001b[0m-that-effective-control-activity-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-option-\u001b[1mlimited\u001b[0m-trial-lopinavir/ritonavir-medication-\u001b[34mhiv\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mcombination\u001b[0m-treatment-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-effect-\u001b[1mcontraindicate\u001b[0m-patient-\u001b[34mmyocarditis\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-bronchodilator-include-\u001b[1mbenefit\u001b[0m-plan-\u001b[34mrsv\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m-treat-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-refractory-\u001b[1mremain\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-therapy-use-\u001b[1mrefractory\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mRibavirin\u001b[0m\u001b[0m-option-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maminoglycoside\u001b[0m-\u001b[1mmonotherapy\u001b[0m-treatment-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhydroxychloroquine\u001b[0m-\u001b[1mworsen\u001b[0m-covid-19-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mbenefit\u001b[0m-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mrituximab\u001b[0m-experience-encourage-\u001b[1mdevelop\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1mcontraindicate\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-become-\u001b[1mpersist\u001b[0m-success-\u001b[34mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mJakinibs\u001b[0m-\u001b[1mshow\u001b[0m-efficacy-treatment-condition-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdaptomycin\u001b[0m-vancomycin-\u001b[1mtherapy\u001b[0m-bacteremia-\u001b[34mmrsa\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-agent-\u001b[1msee\u001b[0m-occur-result-response-\u001b[34minflammatory\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1mapprove\u001b[0m-for-treat-covid-19-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcart\u001b[0m-\u001b[1mtolerate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not tolerate \u001b[31mcART\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-use-\u001b[1mlimited\u001b[0m-remain-effect-outcome-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is still limited because beneficial effects on \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1mrecommend\u001b[0m-treatment-mers-cov-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1msuggest\u001b[0m-use-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not suggested to systemically use in SARS-CoV-2 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1muse\u001b[0m-treat-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: using HIV antiretroviral \u001b[31mtherapy\u001b[0m to treat \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-use-\u001b[1mresult\u001b[0m-\u001b[34m[\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m or second line foscarnet and cidofovir can result in substantial hematotoxicity and nephrotoxicity \u001b[34m[\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m-dose-\u001b[1memerge\u001b[0m-resistance-\u001b[34mantiviral\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-\u001b[1maddition\u001b[0m-treat-mas-associate-\u001b[34msjia\u001b[0m\tLINEAR: addition to \u001b[31mcorticosteroids\u001b[0m and CsA in treating MAS associated with \u001b[34msJIA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1madvance\u001b[0m-show-result-decrease-severity-\u001b[34msymptom\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been advanced to clinical trials and shown modest results in decreasing either \u001b[34msymptom\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1meffective\u001b[0m-rapid-kinetic-\u001b[34mcmv\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m may not be completely effective in \u001b[34mCMV\u001b[0m D+/R liver transplant recipients because the replication kinetics of CMV\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1msuccessful\u001b[0m-patient-\u001b[34mms\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mindicate\u001b[0m-\u001b[34muri\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantibiotic\u001b[0m-\u001b[1moverprescribe\u001b[0m-difficulty-distinguish-etiology-\u001b[34mcap\u001b[0m\tLINEAR: \u001b[34mCAP\u001b[0m , especially in young children , \u001b[31mantibiotics\u001b[0m often are overprescribed\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-\u001b[1meffective\u001b[0m-treatment-injury-\u001b[34mlung\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mhave\u001b[0m-effective-subset-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-efficacy-establish-\u001b[1mtreat\u001b[0m-infection-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[34mInfluenza\u001b[0m infections have been successfully treated with neuraminidase inhibitors ( oseltamivir or zanamivir ) ; however , the efficacy of these \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1meffective\u001b[0m-treatment-infection-\u001b[34mfilovirus\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msteroid\u001b[0m-\u001b[1minduction\u001b[0m-immunosuppression-\u001b[34mof\u001b[0m\tLINEAR: induction \u001b[34mof\u001b[0m immunosuppression by \u001b[31msteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-option-\u001b[1mlimited\u001b[0m-make-treatment-crucial-management-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m options are still limited and vaccines are often not available , which makes supportive treatment crucial in the clinical management of these often lifethreatening \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-prove-\u001b[1mrecommend\u001b[0m-patient-\u001b[34mra\u001b[0m\tLINEAR: recommending allo-HSCT to \u001b[34mRA\u001b[0m patients unless all other standard \u001b[31mtreatments\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msteroid\u001b[0m\u001b[0m-\u001b[34mmers\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1muse\u001b[0m-treat-itp-associate-\u001b[34mcvid\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are used to treat ITP associated with \u001b[34mCVID\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m-\u001b[1mexpensive\u001b[0m-use-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m is expensive and may not provide additional benefit compared to the use of oral antiviral agents alone , especially in low-risk \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mivig\u001b[0m-use-rationale-be-\u001b[1mconduct\u001b[0m-remain-use-treatment-tss-\u001b[34mstss\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m use in these syndromes based in theory , several lines of laboratory investigation , and retrospective clinical series , no definitive clinical trial has been conducted and there remains clinical equipoise as to whether IVIG should be used in the treatment of TSS and \u001b[34mSTSS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mtreatment\u001b[0m of PYR has been associated\tCOUNT: 1\n",
      "PATH: \u001b[31macyclovir\u001b[0m-therapy-\u001b[1mineffective\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 1\n",
      "PATH: \u001b[31mtreatment\u001b[0m-\u001b[1meffective\u001b[0m-enough-genotype-\u001b[34mhcv\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not effective enough for some \u001b[34mHCV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtocilizumab\u001b[0m-\u001b[1mappear\u001b[0m-effective-\u001b[34micans\u001b[0m\tLINEAR: \u001b[31mTocilizumab\u001b[0m appears to be not as effective for \u001b[34mICANS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcorticosteroid\u001b[0m-treatment-\u001b[1mrecommend\u001b[0m-option-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m treatment is not routinely recommended as a therapeutic option for COVID-19 \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mneed\u001b[0m-administer-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-duration-\u001b[1mdepend\u001b[0m-need-\u001b[34mresponse\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapy in immunosuppressed hosts depends on clinical and radiological resolution , the degree and duration of immunosuppression , and therefore maintenance therapy is sometimes needed after the initial \u001b[34mresponse\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmpa\u001b[0m-discontinuation-\u001b[1mpropose\u001b[0m-case-\u001b[34mpneumonia\u001b[0m\tLINEAR: \u001b[34mpneumonia\u001b[0m , discontinuation of \u001b[31mMPA\u001b[0m has also been proposed\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-utility-\u001b[1mlimit\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the clinical utility of \u001b[31mribavirin\u001b[0m may be limited\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-therapeutic-think-\u001b[1mdrive\u001b[0m-development-use-stage-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m drives us to think that \u001b[31mRibavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-\u001b[1mpreferred\u001b[0m-h-onset-symptom-\u001b[34mclinical\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m are usually preferred within 48 h of the onset of \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrecommend\u001b[0m-rate-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m not recommended due to low treatment response rates in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhbig\u001b[0m-addition-\u001b[1mprovide\u001b[0m-\u001b[34msetting\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtherapy\u001b[0m-\u001b[1mavailable\u001b[0m-hpev-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not available for HPeV or enterovirus \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mantiviral\u001b[0m-therapy-\u001b[1minadequate\u001b[0m-due-to-window-\u001b[34madministration\u001b[0m\tLINEAR: \u001b[34madministration\u001b[0m window , current \u001b[31mantiviral\u001b[0m therapies are often inadequate\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mneed\u001b[0m-help-control-response-associate-\u001b[34mfip\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are needed to help control the immune response associated with clinical \u001b[34mFIP\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mribavirin\u001b[0m-\u001b[1mdrug\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is a controversial \u001b[34mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m-approve-\u001b[1mlimit\u001b[0m-\u001b[34mhowever\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , although type I \u001b[31mIFNs\u001b[0m have been approved for diverse indications including genital warts , viral hepatitis , hairy cell leukemia and chronic myelogenous leukemia , their use in the clinic is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mtegobuvir\u001b[0m-use-\u001b[1mlimit\u001b[0m-offer-\u001b[34mactivity\u001b[0m\tLINEAR: \u001b[31mtegobuvir\u001b[0m is limited in that advanced DAAs offer pan-genotypic \u001b[34mactivity\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mifn\u001b[0m-\u001b[1mtreatable\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are treatable with \u001b[31mIFN\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31maspirin\u001b[0m-nsaid-effective-\u001b[1meffective\u001b[0m-achieve-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31maspirin\u001b[0m , have been effective in systemic JIA , they are rarely effective in AoSD ; only 20 % of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mgc\u001b[0m-dose-treatment-\u001b[1mdemonstrate\u001b[0m-\u001b[34minflammation\u001b[0m\tLINEAR: demonstrate persistent tissue \u001b[34minflammation\u001b[0m despite treatment with high doses of \u001b[31mGC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31magent\u001b[0m-\u001b[1mtreatment\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mglucocorticoid\u001b[0m-need-those-effect-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m associated with potentially serious side effects , including those requiring ICU-level resources and need for high-dose \u001b[31mglucocorticoids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpatient\u001b[0m-\u001b[1mtreatment\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m for COVID-19 \u001b[31mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdrug\u001b[0m-\u001b[1mimpaired\u001b[0m-reconstitution-\u001b[34mimmune\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m as cidofovir ( ADV ) and Rituximab ( EBV ) , their effi ciency is impaired in absence of specifi c \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31moseltamivir\u001b[0m-\u001b[1mresistance\u001b[0m-h5n1-strain-\u001b[34minfluenza\u001b[0m\tLINEAR: \u001b[31moseltamivir\u001b[0m resistance in HPAI H5N1 as well as in seasonal human \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a known complication among critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: complications of viral \u001b[31mpneumonia\u001b[0m , especially in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication for \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in infected \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mrsv\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of APSCT in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mbe\u001b[0m-condition-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m uncommon complications of SARS-CoV-2 \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m necrotizing CA-MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an important cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a frequent infectious complication in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mof\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID19 \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1moccur\u001b[0m-patient-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1moccur\u001b[0m-patient-\u001b[34mdisease\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-associate-mortality-cause-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-associate-mortality-cause-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m one of the major causes of mortality associated with COVID-19 \u001b[31mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mchild\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mchild\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m-superinfection-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31mbacterial\u001b[0m-superinfection-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfluenza\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mobserve\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-affect-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m affecting 1.5 to 7 % of KD \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m-covid-19-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mproblem\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mproblem\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with ARDS , superinfection is frequently associated with septic \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31marf\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31msevere\u001b[0m-covid-19-\u001b[1mlead\u001b[0m-\u001b[34mcan\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m COVID-19 \u001b[34mcan\u001b[0m lead\tCOUNT: 2\n",
      "PATH: \u001b[31mshock\u001b[0m-\u001b[1massociate\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , superinfection is often associated with \u001b[31mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m-develop-\u001b[1mrisk\u001b[0m-be-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mILD\u001b[0m-develop-\u001b[1mrisk\u001b[0m-be-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 respiratory illness are at risk for developing \u001b[31mILD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcirci\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-arise-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-arise-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m that can arise after a MV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a serious lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m-\u001b[1mfinding\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mmeningitis\u001b[0m-\u001b[1mfinding\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m-syndrome-\u001b[1mbe\u001b[0m-among-cause-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mevent\u001b[0m-syndrome-\u001b[1mbe\u001b[0m-among-cause-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mevents\u001b[0m are among the leading causes of death in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34mviral\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mfeature\u001b[0m-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mfeature\u001b[0m-covid-19-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the main feature of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mcommon\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m and renal injury are common in severe or critical COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mfailure\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 2\n",
      "PATH: \u001b[31msepsis\u001b[0m-\u001b[1mobserve\u001b[0m-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrecipient\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m among lung transplant \u001b[34mrecipients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m following primary influenza virus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mcause\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-affect-%-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m affecting 11 % of \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m after or during an RSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m-\u001b[1mresponsible\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mexacerbation\u001b[0m-\u001b[1mresponsible\u001b[0m-morbidity-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcomplication\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mbacteremia\u001b[0m\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m among neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m-\u001b[34mrecipient\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m in SOT \u001b[34mrecipients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an uncommon but serious \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mmanifestation\u001b[0m-form-\u001b[34msevere\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a possible manifestation in \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mhypoxia\u001b[0m-\u001b[1mbe\u001b[0m-manifestation-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-be-\u001b[1mcomplication\u001b[0m-related-aspiration-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common and severe complication that is related to aspiration in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mbarotrauma\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mAKI\u001b[0m-\u001b[1mone\u001b[0m-\u001b[34mbe\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m one\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumothorax\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mlead\u001b[0m-\u001b[34mmay\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-covid-19-\u001b[34mof\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most frequent and serious complication \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-patient-develop-syndrome-\u001b[1massociate\u001b[0m-be-cause-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is associated with a high mortality rate and is the main cause of death in patients with SRAS-Cov-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpneumonia\u001b[0m-\u001b[1mbe\u001b[0m-complication-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mshock\u001b[0m-ards-\u001b[1mbe\u001b[0m-complication-lead-death-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m are common complications that can lead to death in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minjury\u001b[0m-\u001b[1mevident\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mih\u001b[0m-\u001b[1mcomplication\u001b[0m-\u001b[34minfusion\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m-coagulation-failure-\u001b[1mobserve\u001b[0m-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m ) are also frequently observed during COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mards\u001b[0m-syndrome-\u001b[1mone\u001b[0m-complication-develop-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m ) is one of the commonest complications developing in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdic\u001b[0m-be-\u001b[1mcomplication\u001b[0m-\u001b[34mpatient\u001b[0m\tLINEAR: \u001b[31mDIC\u001b[0m is a severe complication in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mmortality\u001b[0m\u001b[0m-patient-\u001b[34minfection\u001b[0m\tLINEAR: \u001b[31mmortality\u001b[0m in patients with COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mvaccination\u001b[0m-protocol-\u001b[1mbe\u001b[0m-administration-\u001b[34msingle\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34ma\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1misolate\u001b[0m-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1mrequire\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mincubation\u001b[0m-period-\u001b[1mestimate\u001b[0m-be-day-2-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcontagious\u001b[0m-period-be-\u001b[1mbe\u001b[0m-day-\u001b[34m12\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mextend\u001b[0m-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-length-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-length-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mextend\u001b[0m-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-period-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days should be the period of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mlong\u001b[0m\tLINEAR: \u001b[34mLonger\u001b[0m \u001b[31mquarantine\u001b[0m periods\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msuspend\u001b[0m-for-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m day \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-be-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mprolong\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mprolong\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-period-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-be-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days minimum \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mapproximate\u001b[0m-value-\u001b[34mthese\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mapproximate\u001b[0m-value-\u001b[34mthese\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mlong\u001b[0m\tLINEAR: \u001b[34mlong\u001b[0m \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31minfection\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m-make-order-in-\u001b[1mfall\u001b[0m-under-hour-8-\u001b[34m12\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnumber\u001b[0m-make-order-in-\u001b[1mfall\u001b[0m-under-hour-8-\u001b[34m12\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mextend\u001b[0m-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m9\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1moccur\u001b[0m-wait-day-\u001b[34m62\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1mreduce\u001b[0m-in-order-have-after-day-\u001b[34m60\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1mreduce\u001b[0m-in-order-have-after-day-\u001b[34m60\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m9\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtransmission\u001b[0m-\u001b[1moccur\u001b[0m-wait-day-\u001b[34m62\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mextend\u001b[0m-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mbe\u001b[0m-\u001b[1msuspend\u001b[0m-for-day-\u001b[34m21\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m-mg-\u001b[1mtreatment\u001b[0m-for-day-\u001b[34mten\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mchloroquine\u001b[0m-mg-\u001b[1mtreatment\u001b[0m-for-day-\u001b[34mten\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m-level-reach-\u001b[1mbe\u001b[0m-after-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mrisk\u001b[0m-level-reach-\u001b[1mbe\u001b[0m-after-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m-to-delay-\u001b[1mestimate\u001b[0m-maximum-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mepidemic\u001b[0m-to-delay-\u001b[1mestimate\u001b[0m-maximum-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-bip-between-transport-distance-\u001b[1mreduce\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-bip-between-transport-distance-\u001b[1mreduce\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-take-=-day-\u001b[34m11\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdisease\u001b[0m-\u001b[1mdevelop\u001b[0m-take-=-day-\u001b[34m11\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-day-\u001b[34m22\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-\u001b[1mday\u001b[0m-\u001b[34m22\u001b[0m\tLINEAR: \u001b[34m22\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mneed\u001b[0m-implement-\u001b[34mwithin\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m from symptom onset needs to be implemented \u001b[34mwithin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-after-week-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mextend\u001b[0m-to-week-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-last-be-\u001b[1mvary\u001b[0m-day-7-\u001b[34m14\u001b[0m\tLINEAR: varies between 7 and \u001b[34m14\u001b[0m days for moderate cases according to [ 3 ] , and this is why \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mbe\u001b[0m-day-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m15\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-base-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m-\u001b[1mexceed\u001b[0m-hour-\u001b[34m24\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-duration-\u001b[1mdepend\u001b[0m-be-minimum-of-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m duration depends on national regulations but should be a minimum of \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34m90\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of 60 to \u001b[34m90\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mbe\u001b[0m-less-than-week-\u001b[34mseveral\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period , which starts when the most recently received animals are placed into a quarantine , should not be less than \u001b[34mseveral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-officer-detain-mean-\u001b[1mdescribe\u001b[0m-day-\u001b[34m20\u001b[0m\tLINEAR: described as \u001b[34m20\u001b[0m days , meaning a \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mextend\u001b[0m-to-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-buffer-\u001b[1mbe\u001b[0m-d-\u001b[34m15\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m buffer in January is around \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-of-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2.73 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-in-\u001b[1mbe\u001b[0m-for-day-\u001b[34m14\u001b[0m\tLINEAR: be in \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-\u001b[1mdepend\u001b[0m-on-period-be-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m depends on the incubation period of COVID-19 , which is \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mperiod\u001b[0m-\u001b[34mrecommend\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantining\u001b[0m-\u001b[1mextend\u001b[0m-to-day-\u001b[34m70\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrelax\u001b[0m-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed only after 27 , 26 and 53 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mexposure\u001b[0m-time-\u001b[1mbe\u001b[0m-minute-\u001b[34m1\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mself-quarantine\u001b[0m-for-cut-off-\u001b[1mbe\u001b[0m-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days is the chosen cut-off for \u001b[31mself-quarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mof\u001b[0m-isolation-\u001b[1mneed\u001b[0m-impose-within-day-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mof\u001b[0m persons exposed to the virus needs to be imposed within \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mtime\u001b[0m\u001b[0m-\u001b[34moptimal\u001b[0m\tLINEAR: \u001b[34moptimal\u001b[0m \u001b[31mtime\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mlatent\u001b[0m-\u001b[1mperiod\u001b[0m-of-day-\u001b[34mfour\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-recommendation-\u001b[1mbe\u001b[0m-with-time-of-day-\u001b[34m5\u001b[0m\tLINEAR: \u001b[34m5\u001b[0m days on average , 15 initial recommendations for \u001b[31mquarantine\u001b[0m of exposed health care workers were\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mshorten\u001b[0m-to-day-\u001b[34m6\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mbe\u001b[0m-mandatory-for-day-\u001b[34m17\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m with respiratory isolation is also mandatory for \u001b[34m17\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrelaxed\u001b[0m-for-\u001b[34mday\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is relaxed for the young , adults and elderly after 13 , 11 and 47 \u001b[34mdays\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdisease\u001b[0m-diagnose-\u001b[1mrequire\u001b[0m-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m is diagnosed at sentinel medical institutions , at least \u001b[34m10\u001b[0m days are required\tCOUNT: 1\n",
      "PATH: \u001b[31mvirus\u001b[0m-spreading-prevent-\u001b[1mgo\u001b[0m-into-isolation-for-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m spreading , any individual who may have been exposed should go into isolation for \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mincrease\u001b[0m-to-day-\u001b[34m22\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-rule-control-to-accord-\u001b[1mbe\u001b[0m-within-\u001b[34m4\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m rules at airports , the time taken between specimen collection and the reporting of results was within \u001b[34m4\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mlast\u001b[0m-for-week-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-period-\u001b[1mtake\u001b[0m-\u001b[34mweek\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should take at least 4 - 6 \u001b[34mweeks\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mborehole\u001b[0m-%-to-\u001b[1mincrease\u001b[0m-latrine-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m latrines should be increased to 16.1 % and \u001b[31mboreholes\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mvaccine\u001b[0m-availability-\u001b[1moccur\u001b[0m-within-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-onset-\u001b[1moccur\u001b[0m-day-\u001b[34m8\u001b[0m\tLINEAR: occur within \u001b[34m8\u001b[0m days following the onset of symptoms in the last resident \u001b[31mcase\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m-for-minimum-of-day-\u001b[34m14\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for a minimum of \u001b[34m14\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-of-duration-be-\u001b[1mrecommend\u001b[0m-be-day-\u001b[34m30\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be of sufficient length to allow risk periods for respiratory and digestive diseases to pass ; this has generally been recommended to be 21 to \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mrecommend\u001b[0m-confinement-of-day-\u001b[34m10\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days has generally been recommended to \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcontrol\u001b[0m-view-from-treat-show-\u001b[1mrequire\u001b[0m-pair-\u001b[34m20\u001b[0m\tLINEAR: \u001b[34m20\u001b[0m pairs of gloves/doctor ( high risk)/day will be required because 1 SARS report showed that 1 doctor can treat 5 to 10 patients per day from the view of infection \u001b[31mcontrol\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31misolation\u001b[0m-period-\u001b[1mneed\u001b[0m-extend-to-week-\u001b[34mthree\u001b[0m\tLINEAR: \u001b[31misolation\u001b[0m periods may need to be extended to \u001b[34mthree\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31minfection\u001b[0m-case-\u001b[1mreport\u001b[0m-be-week-\u001b[34m8\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m have been officially reported for a few days , at least \u001b[34m8\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcase\u001b[0m-detect-\u001b[1mtake\u001b[0m-average-of-day-\u001b[34m3\u001b[0m\tLINEAR: \u001b[34m3\u001b[0m days was taken to detect imported \u001b[31mcases\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mthis\u001b[0m-period-\u001b[1mreduce\u001b[0m-day-\u001b[34m50\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m period is reduced to \u001b[34m50\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-start-\u001b[1mwait\u001b[0m-day-10-\u001b[34m20\u001b[0m\tLINEAR: waiting 10 or \u001b[34m20\u001b[0m days , respectively , to start the \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-for-\u001b[1mday\u001b[0m-\u001b[34m14\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mquarantine\u001b[0m-\u001b[1mduration\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mtime\u001b[0m-minimum-\u001b[1mbe\u001b[0m-month-\u001b[34m3\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m necessary to complete reference virus development and safety testing is \u001b[34m3\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m are infected by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mmers-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE2 ) as a viral receptor to enter the target \u001b[34mcell\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use host receptor angiotensin-converting enzyme 2 ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: entry of \u001b[31mSARS-CoV-2\u001b[0m into host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: Entry of \u001b[31mSARS-CoV-2\u001b[0m into a host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: entry into target \u001b[34mcells\u001b[0m by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mentry\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m entry into the host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-coronavirus-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mMERS-CoV\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m , SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-protein-\u001b[1mreport\u001b[0m-form-channel-associate-\u001b[34mpathogenesis\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfection\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mtract\u001b[0m\tLINEAR: \u001b[31mSars-CoV-2\u001b[0m infects the respiratory \u001b[34mtract\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mairway\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-receptor-allow-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-receptor-allow-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the cellular receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mairway\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor for entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE-2 receptors for pulmonary \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-surface-exposed-mediate-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-surface-exposed-mediate-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minitiate\u001b[0m-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m initiates the entry into \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters human target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: receptor for SARS-CoV-1 and presumably for \u001b[31mSARS-CoV-2\u001b[0m to infect the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-enzyme-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enters into host \u001b[34mcells\u001b[0m via cell receptor angiotensin converting enzyme II ( \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhave\u001b[0m-potential-replicate-\u001b[34mcardiomyocyte\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhave\u001b[0m-potential-replicate-\u001b[34mcardiomyocyte\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minitiate\u001b[0m-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m initiates its entry into human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-virus-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: use the angiotensin converting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as a receptor for \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: uses angiotensinconverting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as a receptor and primarily infects ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcause\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes COVID-19 by infecting host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-tract-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mattach\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches to the target \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: receptor by \u001b[31mSARS-CoV-2\u001b[0m to infect human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-virus-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov\u001b[0m-\u001b[1mattach\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches the human host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-enzyme-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enter human host \u001b[34mcells\u001b[0m mainly via a cellular receptor angiotensin-converting enzyme ( \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-enzyme-dominate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mreceptor\u001b[0m-enzyme-dominate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcells\u001b[0m , is the human cell receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-tract-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily invades \u001b[34mthe\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1muse\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: uses angiotensin-converting enzyme \u001b[31m2\u001b[0m ( ACE2 ) as the receptor for \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcause\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes respiratory symptoms by infecting alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-\u001b[1mtarget\u001b[0m-infect-\u001b[34mcell\u001b[0m\tLINEAR: targets human angiotensin-converting enzyme \u001b[31m2\u001b[0m ( hACE2 ) and infects intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-ace2-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msara-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minfect\u001b[0m-type-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-protein-interaction-involve-mechanism-\u001b[1menter\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: enters host \u001b[34mcells\u001b[0m by a mechanism involving the interaction between its spike ( S ) protein and human angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mcoronavirus\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) , which enters the \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mexploit\u001b[0m-receptor-invade-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( ACE2 ) as a receptor to invade \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-target-mucosa-\u001b[1mact\u001b[0m-receptor-entry-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is the upper respiratory mucosa , and angiotensin-converting enzyme 2 ( ACE2 ) acts as a functional receptor for the viral spikes and eventually viral entry into host \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m2\u001b[0m-enzyme-bind-protein-\u001b[1minfect\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: infects \u001b[34mcells\u001b[0m through the S protein , which binds to cell surface receptor-angiotensin-converting enzyme \u001b[31m2\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minvade\u001b[0m-bind-replicate-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly invades alveolar epithelial \u001b[34mcells\u001b[0m by binding to the ACE-2 receptor and then replicates within cells\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1minteract\u001b[0m-enter-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mconsider\u001b[0m-pathogen-gain-access-to-\u001b[34mbody\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is considered a lower respiratory tract pathogen that gains access to the \u001b[34mbody\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-pathogenesis-\u001b[1minvolve\u001b[0m-binding-\u001b[34mhost\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m involves the binding of its spike protein to angiotensin converting enzyme-2 ( ACE2 ) in the \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds with the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can bind to human angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mbind\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , \u001b[31mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the same receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV employ \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrequire\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m similarly to SARS-CoV requires angiotensin-converting enzyme 2 ( \u001b[34mAcE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m(ace)-2\u001b[0m-\u001b[1mreceptor\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mprotein\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-receptor-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the same receptor of SARS-CoV , which is angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-bind-domain-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1mshow\u001b[0m-use-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1mshow\u001b[0m-use-receptor-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-bind-domain-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[34mcell\u001b[0m \u001b[31mACE2\u001b[0m receptors\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mSARS-CoV-2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1menzyme-2\u001b[0m\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31menzyme-2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-\u001b[1minteract\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-receptor-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1memploy\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mrecognize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-identify-\u001b[1msurprising\u001b[0m-adapt-bind-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-identify-\u001b[1msurprising\u001b[0m-adapt-bind-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mshow\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mshow\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-invade-\u001b[1mbelong\u001b[0m-covid-19-\u001b[34mboth\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-invade-\u001b[1mbelong\u001b[0m-covid-19-\u001b[34mboth\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-protein-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1muse\u001b[0m-protein-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mthe\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m angiotensin-converting enzyme ( ACE ) \u001b[31m2\u001b[0m receptor\tCOUNT: 2\n",
      "PATH: \u001b[31mcovid-19\u001b[0m-\u001b[1muse\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1marmed\u001b[0m-with-protein-use-gain-membrane-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1marmed\u001b[0m-with-protein-use-gain-membrane-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-protein-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mknow\u001b[0m-enter-protein-\u001b[34m2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1muse\u001b[0m-\u001b[34mreceptor\u001b[0m\tLINEAR: uses \u001b[31mACE2\u001b[0m as the \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-entry-\u001b[1midentify\u001b[0m-use-\u001b[34mreceptor\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1minteract\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-bind-receptor-\u001b[34menzyme-2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mvirus\u001b[0m-be-evidence-associate-bind-receptor-\u001b[34menzyme-2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1mbind\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds weakly to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mace2\u001b[0m\u001b[0m-\u001b[34mhuman\u001b[0m\tLINEAR: \u001b[34mhuman\u001b[0m \u001b[31mace2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-entry-\u001b[1midentify\u001b[0m-use-\u001b[34mreceptor\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-protein-\u001b[1mbind\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m spike protein binds \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov2\u001b[0m-glycoprotein-receptor-\u001b[1midentify\u001b[0m-\u001b[34menzyme\u001b[0m\tLINEAR: \u001b[34menzyme\u001b[0m 2 ( ACE2 ) has been identified as the host cell-surface receptor for \u001b[31mSARS-CoV2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-mean-binding-receptor(s-\u001b[34mcellular\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1menter\u001b[0m-mean-binding-receptor(s-\u001b[34mcellular\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the cell by the means of binding of \u001b[34mcellular\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-sars-cov-entry-receptor-\u001b[1midentify\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for 25 entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhomologous\u001b[0m-infect-binding-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mhomologous\u001b[0m-infect-binding-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is highly homologous to SARS-CoV and infects humans through the binding of the spike protein to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace-2\u001b[0m-\u001b[1menzyme\u001b[0m-\u001b[34m2\u001b[0m\tLINEAR: enzyme \u001b[34m2\u001b[0m ( \u001b[31mACE-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-\u001b[1mutilize\u001b[0m-\u001b[34mace2\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mace2\u001b[0m-\u001b[1mreceptor\u001b[0m-\u001b[34mcell\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mcell\u001b[0m receptor\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mconverting\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31msars-cov-2\u001b[0m-receptor-\u001b[1mconverting\u001b[0m-enzyme-\u001b[34mace2\u001b[0m\tLINEAR: converting enzyme 2 ( \u001b[34mACE2\u001b[0m ) , is the host receptor by \u001b[31mSars-CoV-2\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"lemmas\", parse_type=\"pybart\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: dep labels along dep path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m causes a contagious intestinal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with brief two-to four-day incubation period , produces acute \u001b[34mencephalitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces diffuse \u001b[34minflammation\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoV\u001b[0m causes a fatal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFiloviruses\u001b[0m cause a severe and frequently fatal \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBVDV\u001b[0m can cause calf \u001b[34mdiarrhea\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes thymic \u001b[34matrophy\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m causes a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCDV\u001b[0m causes a systemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with the coronavirus , especially the severe acute respiratory syndrome coronavirus ( SARSCoV ) and the emerging Middle East respiratory syndrome coronavirus ( MERSCoV ) , induces acute respiratory \u001b[34mfailure\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSFV\u001b[0m causes \u001b[34mfever\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes a respiratory \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mencephalitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a fulminant \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mlesions\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIAV\u001b[0m initiates \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes a systemic \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m produces a self-limiting \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with SARS-CoV-2 show typical \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes significant acute lung \u001b[34minjury\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoVs\u001b[0m cause enteric \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mreplication\u001b[0m in vascular endothelial cells and hepatocytes produces acute necrohemorrhagic \u001b[34mhepatitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes an acute hemorrhagic \u001b[34mfever\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m shows SARS-like \u001b[34msymptoms\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m exposed to RVFV can present febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mLIV\u001b[0m causes a \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause \u001b[34masthma\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m also causes more severe and prolonged \u001b[34mbronchiolitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m can also cause a chronic wasting \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBetacoronavirus\u001b[0m , including SARS CoV 2 , elicits \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in human , or MERS , commonly manifests as a severe acute respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFPV\u001b[0m is responsible of systemic \u001b[34minfections\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can lead to lymphocytic \u001b[34mdepletion\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans can cause a wide range of clinical manifestations , from mild febrile \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually presents as an acute and self-limiting \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in \u001b[34mhepatitis\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in bursal \u001b[34matrophy\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m can cause re-infections throughout life with milder \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m commonly leads to a devastating viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHuNoV\u001b[0m in humans is typically an acute infection , with peak viral \u001b[34mshedding\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( FIPV ) manifests in a progressive and mostly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m often leads to severe \u001b[34mdamage\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( PEDV ) results in acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( SNV ) , a Hantavirus common in the southwestern United States , \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m caused by pathogenic hCoVs \u001b[34mis\u001b[0m often associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mencephalitis\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mLeptospirosis\u001b[0m in hamsters \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhPMV\u001b[0m induces \u001b[34mclinical\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with coronavirus primarily causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mBronchitis\u001b[0m ( IB ) causes severe \u001b[34minflammatory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mreproductive\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mKoRV\u001b[0m induces \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mgondii\u001b[0m induces \u001b[34minfectious\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m take\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mcan\u001b[0m progress\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m \u001b[34mcan\u001b[0m silently reactivate\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMCMV\u001b[0m causes asymptomatic infection in adult immunocompetent mice , but experimental inoculation of neonates has caused lethal \u001b[34mdisease\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of adult mice with MAdV-1 is most often subclinical and persistent but can cause fatal haemorrhagic \u001b[34mencephalomyelitis\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mDENV\u001b[0m does not replicate well or cause symptoms reflective of human disease in immunocompetent wild type ( WT ) mice [ 22 ] , but can cause a similar \u001b[34mpathology\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCoronavirus\u001b[0m is highly transmittable , causes fatal \u001b[34mpneumonia\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause a disseminated infection of the lung , liver , bone marrow , heart , and brain and produce fulminant \u001b[34mhepatitis\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIAV\u001b[0m infect the respiratory tract and can induce an acute pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m mainly damages pulmonary epithelial cells at the onset of infection and thereafter induces lymphohistiocytic interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is generally self-limiting , but it can induce severe \u001b[34millness\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial cells and type II pneumocytes and causes severe \u001b[34millness\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( MHV ) initially infects nasal epithelial cells but subsequently establishes a systemic \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m often fatal\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in domestic cat \u001b[34mis\u001b[0m analogous\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m generally restricted\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mPoliovirus\u001b[0m \u001b[34mis\u001b[0m highly pathogenic\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mJCV\u001b[0m \u001b[34mis\u001b[0m responsible\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m \u001b[34mis\u001b[0m a common enteric pathogen\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mreplication\u001b[0m \u001b[34mis\u001b[0m mainly limited\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of adult mice results in poor \u001b[34mviral\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 occasionally results in \u001b[34mneurologic\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes mild to severe respiratory tract \u001b[34minflammation\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m result in a \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 8\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m who die within 10 days of the onset of symptoms show diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mascariasis\u001b[0m causes Lffler 's \u001b[34msyndrome\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m develop acute , febrile respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msheep\u001b[0m develop chronic \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m 1 to 3 years of age commonly develop mediastinal or muticentric \u001b[34mlymphoma\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with fluid overload usually develop pulmonary or subcutaneous \u001b[34medema\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m infected with avirulent FCoV-strains usually develop mild \u001b[34menteritis\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m produce nonspecific acute \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually causes a mild dengue-like \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m has a sudden \u001b[34monset\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually experience \u001b[34mdyspnea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m that become infected by CPV show \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m show \u001b[34msevere\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m typically cause \u001b[34macute\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpiglets\u001b[0m usually show typical \u001b[34menteric\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with severe leptospirosis have isolated \u001b[34mpulmonary\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with EcE show general \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m can cause different \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m occasionally develop a \u001b[34mfatal\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m causes common \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with pure hepatosplenic lymphoma usually have \u001b[34mnonspecific\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m undergo \u001b[34msevere\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m with multicentric lymphoma often exhibit \u001b[34mnonspecific\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with pneumonia exhibit typical \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m or immunocompromised people develop \u001b[34mfatal\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcattle\u001b[0m with BVDV have mild \u001b[34mpulmonary\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually presents with mild \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with right heart failure usually develop \u001b[34mpleural\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mEncephalitis\u001b[0m caused by enterovirus A71 infection usually has brainstem \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually courses as a self-limited \u001b[34mdiarrhea\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m usually leads to an acute , often lethal \u001b[34mdiarrhea\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the respiratory tract by influenza virus classically results in acute \u001b[34monset\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m results in mild influenza-like \u001b[34msymptoms\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m show lethargy , fever , anorexia , diarrhea , stomatitis , weight loss , and/or lymphadenopathy during the acute \u001b[34mphase\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually die of cardio-respiratory \u001b[34mfailure\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m manifests with fever , dyspnoea and non-productive \u001b[34mcough\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m typically manifests as a severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , Marburg virus \u001b[34mdisease\u001b[0m ( MVD ) typically begins\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , \u001b[34minfection\u001b[0m results\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , RSV \u001b[34minfection\u001b[0m usually manifests\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mpups\u001b[0m , sometimes in combination with other pathogens , CCoV \u001b[34minfection\u001b[0m may cause\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m , acute graft-versus-host \u001b[34mdisease\u001b[0m develops\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mmeningitis\u001b[0m or meningoencephalitis is rare in \u001b[31mdogs\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mprimates\u001b[0m , the \u001b[34mdisease\u001b[0m is often mild\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , SARS-Cov-2 \u001b[34minfection\u001b[0m can cause\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mbirds\u001b[0m , adenovirus \u001b[34minfection\u001b[0m manifests\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m can occur in \u001b[31mhorses\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , the \u001b[34msymptoms\u001b[0m associated with CHIKV are nausea\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfants\u001b[0m , early-onset \u001b[34mdisease\u001b[0m occurs\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by PRDC \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in acutely infected \u001b[31mcalves\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in human \u001b[31minfections\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEarly\u001b[0m signs of \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfebrile\u001b[0m phase of \u001b[31millness\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m manifestations of IBVinfected \u001b[31mchickens\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m findings with enteroviral \u001b[31minfections\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with peracute \u001b[34mIHA\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m develop feline infectious \u001b[34mperitonitis\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with systemic coronavirus \u001b[34mdisease\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of human \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop bilateral \u001b[34mpneumonia\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m with canine \u001b[34minfluenza\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in \u001b[31mdogs\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in adult \u001b[31manimals\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m generally produces a nonfatal \u001b[34mdisease\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with disseminated \u001b[34msporotrichosis\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent adult \u001b[31mmice\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m include severe and sometimes prolonged incapacitating \u001b[34marthralgia\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSurvivors\u001b[0m of NiV \u001b[34minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m include respiratory or eye infections and intestinal or digestive \u001b[34millness\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with MERS-CoV infection usually present with acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m , usually less than 10 days of age , develop hemorrhagic , necrotic enteritis and enterotoxemia , often with \u001b[34mabdominal\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of ECoV are self-limiting with transient \u001b[34mclinical\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m result in a \u001b[34msevere\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with CDV may initially present with \u001b[34mclinical\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m , AHSV infection induces \u001b[34mlesions\u001b[0m\tCOUNT: 6\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can rapidly develop into a \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m will rapidly progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress quickly to \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m progresses to \u001b[34mpulmonary\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m disease can rapidly progress to severe\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can quickly progress to \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m generally begins with \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m may develop\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmalaria\u001b[0m can also evolve into \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m might progress rapidly to \u001b[34macute\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpatients\u001b[0m also experience\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in death due to \u001b[34mprogressive\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads to \u001b[34mchronic\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mmalaria\u001b[0m may present\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m typically progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mTB\u001b[0m with either a miliary or diffuse pneumonic pattern can progress to \u001b[34mseptic\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m usually begins with \u001b[34mgastrointestinal\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m go on to \u001b[34mchronic\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can evolve into a \u001b[34mchronic\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can progress from prerenal disease to \u001b[34macute\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m results in \u001b[34matypical\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into fulminant \u001b[34mhepatic\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m can present insidiously with \u001b[34mnonspecific\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may begin with an \u001b[34macute\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may lead to primary \u001b[34mviral\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can course with \u001b[34msevere\u001b[0m\tCOUNT: 51\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31millnesses\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSystemic\u001b[0m \u001b[31mmanifestations\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m fulminant \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mChronic\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mViral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msystemic\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mNeurological\u001b[0m \u001b[31msymptoms\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mBacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mDisseminated\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , of any age , may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m can have \u001b[34mprogressive\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m usually causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m typically develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may have \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience \u001b[34mprogressive\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minfected\u001b[0m \u001b[31mindividuals\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34madvanced\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mearly\u001b[0m disseminated \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mmultiple\u001b[0m diffusive \u001b[31mlesions\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m be rapidly fatal\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mmay\u001b[0m manifest\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mtuberculosis\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops rapidly and eventually progresses after 2 to 4 days into \u001b[34mrespiratory\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m result in \u001b[34mprogressive\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcan\u001b[0m be manifested as \u001b[34msevere\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcan\u001b[0m present as \u001b[34mprogressive\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is usually limited to the upper respiratory tract , and progression into the lower respiratory tract can result in \u001b[34mserious\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m lead to \u001b[34msymptomatic\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m is a progressive disease characterized by repeated episodes of infection and may be complicated by \u001b[34macute\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmay\u001b[0m cause unexpected death because of \u001b[34mmassive\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcan\u001b[0m present with \u001b[34mbiliary\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m often develop a viral pneumonia and cardiac complications , and older patients are more susceptible to \u001b[34mrespiratory\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m can be rapidly progressive with the development of multifocal \u001b[34mbilateral\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may progress rapidly , with occurrence of \u001b[34mviral\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m may worsen even further into an acute respiratory distress syndrome ( ARDS ) , as a result of \u001b[34mprogressive\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m infection \u001b[31mmay\u001b[0m result\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pneumonia \u001b[31mmay\u001b[0m further progresses\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m infection \u001b[31mmay\u001b[0m rapidly proceed\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m may develop into a diffuse ARDS type of \u001b[34mpulmonary\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m , long-standing airway obstruction \u001b[31mmay\u001b[0m progress\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mextensive\u001b[0m hematogenous spread of infection \u001b[31mcan\u001b[0m manifest\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrenal\u001b[0m failure \u001b[31mcan\u001b[0m progress\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses into acute respiratory distress syndrome ( ARDS ) with \u001b[34mdiffuse\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses to the central nervous system ( CNS ) and \u001b[34mneurological\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m are mild , but some patients develop \u001b[34msevere\u001b[0m\tCOUNT: 5\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m with congenital or acquired immunodeficiencies are more susceptible to viral \u001b[34mpathogens\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with immunocompromise or extremes of age are at higher risk for more severe \u001b[34mLRI\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to opportunistic \u001b[34mpathogens\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mwomen\u001b[0m may be at increased risk of \u001b[34mprogression\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are at the greatest risk for \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at increased risk for resistant \u001b[34morganisms\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with coronavirus are at increased risk of \u001b[34mthrombosis\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is also a risk factor for severe S. aureus \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are susceptible to \u001b[34mVAP\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause asthma or chronic obstructive pulmonary disease in chronic \u001b[34minfection\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with congenital anatomical defects , immunodefi ciencies , and genetic disorders are at increased risk for bacterial , viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with severe T cell defects are also susceptible to systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may present with more severe TB \u001b[34mdisease\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to bacterial , fungal , viral , and parasitic \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more predisposed to \u001b[34mpneumonia\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to \u001b[34mTB\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 43\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at increased risk for bacterial \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mimmunodeficiency\u001b[0m are at particular risk of severe RSV \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may particularly be vulnerable to respiratory \u001b[34mviruses\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at high risk of \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCOPD\u001b[0m are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31masthma\u001b[0m are at increased risk for pertussis \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCGD\u001b[0m are at increased risk of life-threatening \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m are particularly susceptible to late CMV \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMS\u001b[0m are susceptible to urinary tract \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m are susceptible to chronic \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m might be more susceptible to this \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCID\u001b[0m are extremely susceptible to progressive \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrespiratory\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSARS-CoV-2-infected\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minvasive\u001b[0m GAS \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mdisseminated\u001b[0m NTM \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minvasive\u001b[0m bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are at an increased risk for these \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m patients are , therefore , highly susceptible to chronic \u001b[34mcolonization\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMS\u001b[0m patients are at increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with compromised immune systems are especially susceptible to severe complications of adenovirus \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies who are undergoing aggressive chemotherapy and treatment with corticosteroids are at increased risk of HSV , as impairment of cellular immunity is a risk factor for HSV \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at an increased risk for developing airway disease such as bacterial tracheobronchitis , in addition to \u001b[34mpneumonia\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m remain at an increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancy ( HM ) are at risk for complications of respiratory viral \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m such as primary immunodeficiency , for example , may predispose to progression or reactivation of antecedent \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with prolonged immunosuppression , such as those with chronic graft-versus-host disease ( cGVHD ) , remain at risk for \u001b[34mTB\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are susceptible to unfavorable outcomes in case of an infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msmoking\u001b[0m and chronic lung diseases among these individuals may further predispose HIV-infected patients to respiratory tract \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m include higher rates of viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m have a particularly high risk of \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcoronavirus\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression can develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msarcoidosis\u001b[0m , particularly black people , as well as patients with silicosis , have an increased prevalence of \u001b[34mTB\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrejection\u001b[0m have an increased risk of NTM \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m have a propensity to \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m E virus \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are common in \u001b[31mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m may increase morbidity and mortality in PCMV \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-acl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m triggered by viral \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m are highly susceptible to cutaneous bacterial , viral , and fungal \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-cop-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at extremely high risk for disseminated bacterial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m prone to \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more vulnerable to \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more likely to develop bacterial or fungal \u001b[34msuperinfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m on maintenance \u001b[31mdialysis\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-cop-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk of \u001b[34mIC\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mGanciclovir\u001b[0m is the treatment of choice for invasive CMV \u001b[34mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may provide benefi t to certain subgroups of \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not possible in many patients either because disease-specific therapy may not be available , available disease-specific therapies may have failed , or due to late presentation with established \u001b[34mcirrhosis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m are the mainstay of treatment for acute \u001b[34mGVHD\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mare\u001b[0m refractory\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m or ValACV can still be effective treatments for recurrent \u001b[34mHSV\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcombination\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: therapy for \u001b[34mHPS\u001b[0m with \u001b[31mribavirin\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m who are unresponsive to or do not fit for splenectomy , have limited options including cytotoxic or immunosuppressive \u001b[31mmedications\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m \u001b[34mis\u001b[0m only moderately effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mvancomycin\u001b[0m is often indicated for these \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mdrug\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mClindamycin\u001b[0m alone ( 30 - 40 mg/kg per day in three divided doses ) may be used for suspected \u001b[34mPRSP\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with CF and ABPA often require prolonged therapy with oral \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mtherapies\u001b[0m involving sunitinib and regorafenib \u001b[34mare\u001b[0m also not effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m who develop mild toxicity , discontinuation of \u001b[31mbleomycin\u001b[0m may lead\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m and gancyclovir have been used in the \u001b[34mtreatment\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m is the only approved antiviral against \u001b[34mRSV\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has proven to be of little value in this \u001b[34msetting\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may be indicated with more advanced \u001b[34mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: Control of \u001b[34minfluenza\u001b[0m with antiviral \u001b[31mdrugs\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: use of \u001b[31msteroids\u001b[0m in \u001b[34msepsis\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are often used in viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mCMV\u001b[0m \u001b[31mantivirals\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m typically have less sustained effect on systemic \u001b[34msymptoms\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: pharmacotherapy for \u001b[34mSARS\u001b[0m with anti-inflammatory \u001b[31msteroids\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m require immediate immunosuppression with \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with respiratory failure , the use of systemic \u001b[31mcorticosteroids\u001b[0m is controversial\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mmTOR\u001b[0m \u001b[31minhibitors\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m often require prolonged therapy with \u001b[31mganciclovir\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mTocilizumab\u001b[0m appears to be not as effective for \u001b[34mICANS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not as potent as HAART in inhibiting \u001b[34mHIV\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31madamantines\u001b[0m are not recommended for treatment of novel \u001b[34minfluenza\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mganciclovir\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m is also utilized as a treatment against \u001b[34mRSV\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31mlinezolid\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are very effective in controlling acute \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mis\u001b[0m compounded\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not widely used in the treatment of \u001b[34mHIV\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31minfliximab\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m \u001b[34mis\u001b[0m complicated\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m \u001b[34mis\u001b[0m controversial\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minhibitors\u001b[0m may need to be stopped in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mare\u001b[0m significant\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCidofovir\u001b[0m is a broad-spectrum antiviral drug that has in vitro activity against monkeypox virus [ 102 ] , but because of its relative toxicity , it can be considered only in severe cases of human monkeypox virus \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m and drug combinations such as remdesivir , lopinavir-ritonavir , or lopinavir-ritonavir and interferon Beta-1b are under investigation and may be considered for compassionate use in severely ill \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mis\u001b[0m required\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31merlotinib\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mccomp\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-advcl-conj-xcomp-advcl-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-advcl-conj-xcomp-advcl-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m treatment is not routinely recommended as a therapeutic option for COVID-19 \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpneumonia\u001b[0m , discontinuation of \u001b[31mMPA\u001b[0m has also been proposed\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m are treatable with \u001b[31mIFN\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod-conj-nmod-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mccomp\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[34mURTI\u001b[0m , \u001b[31mantiviral\u001b[0m therapy is impractical\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-ccomp-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-ccomp-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not recommended as treatment of \u001b[34msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m do not add clinical benefits in the treatment of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDAAs\u001b[0m are highly effective , HCV can not be cleared in some difficult-to-treat \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfluconazole\u001b[0m in the absence of a polyene is not recommended given the fungistatic nature of this \u001b[34mdrug\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod-conj-nmod-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mpatients\u001b[0m receiving tocilizumab are often at an increased risk\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: are no proven effective preventive or therapeutic options for HEV \u001b[34minfection\u001b[0m , although small series reported a benefit of \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-amod-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mGanciclovir\u001b[0m resistance \u001b[34mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mLamivudine\u001b[0m and the other antiviral nucleos(t)ides for the treatment of \u001b[34mHBV\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpalivizumab\u001b[0m has safety and efficacy concerns such as anaphylaxis and hypersensitivity reactions , palivizumab is not recommended for the therapeutic-treatment post-RSV \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , side effects of \u001b[31mribavirin\u001b[0m , such as anaemia , limit\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mAHF\u001b[0m is limited to \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m , secondary \u001b[31mtreatment\u001b[0m options are limited\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mmost\u001b[0m \u001b[31mantivirals\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: is currently no effective treatment for JC virus \u001b[34minfection\u001b[0m , although one report suggested CNS viral clearance with high dose \u001b[31mIVIG\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has several weaknesses such as a narrow treatment window and borderline effects on \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31magents\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAntiviral\u001b[0m anti-influenza \u001b[31mdrugs\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m has broad \u001b[34mantiviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m , initiation of \u001b[31moseltamivir\u001b[0m beyond 48 h of symptom onset may still provide\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not respond to \u001b[31mIVIG\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantibiotics\u001b[0m are inappropriately prescribed to patients with viral \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34macute\u001b[0m hepatitis B may benefit from administration of \u001b[31mlamivudine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31msirolimus\u001b[0m can not be used as initial immunosuppression because clinical trials identified an increased risk of hepatic arterial and venous thromboses and incisional hernias due to poor \u001b[34mwound\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may be beneficial in cryptococcal meningitis in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m emerging \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m who develop clinical BOS respond to \u001b[31mazithromycin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mimmunosuppression\u001b[0m is not sufficient to treat progressive \u001b[34mMS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: Treatment with \u001b[31mfidoximicin\u001b[0m for recurrent \u001b[34mCDI\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m may worsen \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mIFN\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m for the prevention and treatment of \u001b[34mGVHD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mpatients\u001b[0m with advanced coma grades do not benefi\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with UL 97 mutations , and some with UL54 mutations , respond to \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpathogens\u001b[0m , the incidence of these \u001b[31magents\u001b[0m is not predictable\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-amod-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m in adenovirus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minhibitors\u001b[0m can also induce \u001b[34mresistance\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: use of \u001b[31mARBs\u001b[0m in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mBCG\u001b[0m is often poorly tolerated , leading to early \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31msorafenib\u001b[0m use in patients \u001b[34mis\u001b[0m clearly associated\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m agents are available for treating \u001b[34minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , safety concerns with combination \u001b[31mtherapy\u001b[0m remain\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are crucial to treat acute lifethreatening \u001b[34mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nsubj-nmod-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1macl:relcl\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj-\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-ccomp-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mconj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj-\u001b[1mROOT\u001b[0m-acomp-prep-\u001b[34mpobj\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m can be the primary presenting manifestation of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdamage\u001b[0m is a common feature in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31membolism\u001b[0m is an uncharacteristic presentation in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( PVP ) is a rare complication of seasonal \u001b[34minfluenza\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a cause of serious \u001b[34mdisease\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmyocarditis\u001b[0m is a relatively rare sequelae of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m is not uncommon in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mILD\u001b[0m is a rare but potentially fatal complication of RTX \u001b[34mtherapy\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m is a known complication of influenza-related \u001b[34mpneumonia\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a known complication among critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAspergillus\u001b[0m is a common superinfection in critically ill influenza \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfever\u001b[0m ( the most common initial symptom of COVID-19 ) frequently occurs in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCardiomyopathy\u001b[0m is a common consequence of EV \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m may occur as a post-operative \u001b[34mcomplication\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m with disseminated intravascular coagulopathy ( DIC ) is another fatal and unusual complication in severe dengue \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mimpairment\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with HIV infection , \u001b[31mPAH\u001b[0m is a life-threatening complication\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major clinical concern in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mALI\u001b[0m is an important complication of \u001b[34msepsis\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is an important feature of fatal SARS \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mEncephalitis\u001b[0m is a rare manifestation of hMPV \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minvolvement\u001b[0m is an important complication in adenovirus \u001b[34minfections\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mthrombosis\u001b[0m is a rare but severe complication of intra-abdominal \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mThrombosis\u001b[0m and disseminated intravascular clotting are common in SARS-CoV-2 \u001b[34minfections\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m leading to acute respiratory failure is a major cause of sepsis in neutropenic cancer \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m is an uncommon complication in \u001b[34mmalaria\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcandidosis\u001b[0m is the most common invasive fungal infection in critically ill nonneutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m and multiorgan involvement is a common feature in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a common respiratory viral infection in adult HM \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a problem in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m and renal injury are common in severe or critical COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a well-known clinical manifestation of CMV disease in immunocompromized \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minhalation\u001b[0m is an uncommon life threatening event ( 0.6 % of total admissions ) in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication for \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a common cause of acute lower respiratory \u001b[34minfections\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIPN\u001b[0m is a common dose-limiting complication for \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 57\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m one\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m a common consequence\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mALF\u001b[0m \u001b[34mis\u001b[0m a rare but potentially life\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m \u001b[34mis\u001b[0m an uncommon complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mcystitis\u001b[0m \u001b[34mis\u001b[0m a rare but serious complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m an accompanying presentation\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34mis\u001b[0m a severe but benign complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34mis\u001b[0m a very important pathogen\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mSOS\u001b[0m \u001b[34mis\u001b[0m a rare and serious complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mhypertension\u001b[0m \u001b[34mis\u001b[0m a known complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m \u001b[34mis\u001b[0m transfusion-related circulatory overload\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mmyocarditis\u001b[0m \u001b[34mis\u001b[0m a serious condition\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mreactivation\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m \u001b[34mis\u001b[0m a systemic inflammatory response syndrome\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mRD\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbronchiolitis\u001b[0m is one of the major outcomes of RSV \u001b[34minfection\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m may occur in a significant portion of \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is one of the well-recognized complications of \u001b[34mGBs\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdysfunction/failure\u001b[0m , including cardiovascular manifestations , has contributed to increased mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m is one of the common complications in \u001b[34mchildren\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a major cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in substantial mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is an important cause of morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbacteremia\u001b[0m is an independent predisposing factor for critical illness polyneuromyopathy Introduction Critical illness polyneuromyopathy ( CIPM ) is a major clinical problem in the \u001b[34mICU\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31medema\u001b[0m is present in 10 % of cancer \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m may be present in up to 30 % of \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mexacerbation\u001b[0m of IPF is responsible for substantial morbidity and mortality in \u001b[34mpatients\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a common presentation in COVID-19 infected \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMeningitis\u001b[0m is a rare but fatal complication of severe adenoviral \u001b[34mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBleeding\u001b[0m is a feared complication of severe dengue \u001b[34minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a frequent infectious complication in \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is one of the most common and severe complications in septic \u001b[34mshock\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a viral \u001b[31mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the leading cause of ARDS in this \u001b[34msetting\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31millness\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m from \u001b[34mHPeV\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m more common in severe \u001b[31msepsis\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an under-recognized cause of \u001b[31mstroke\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a recognized risk factor for COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a major risk factor for fulminant \u001b[31msepsis\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m uncommon complications of SARS-CoV-2 \u001b[31mpneumonia\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m closely related to \u001b[31mRSV\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a rare cause of \u001b[31mdeath\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common occurrence in systemic \u001b[31msepsis\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a well-known cause of fulminant hepatic \u001b[31mfailure\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m following primary influenza virus \u001b[34minfection\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCandidemia\u001b[0m in neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a significant cause of \u001b[31mNHAP\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m after or during an RSV \u001b[34minfection\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minvolvement\u001b[0m during SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 12\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mharvest\u001b[0m interval must be at least \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mreporting\u001b[0m delay on COVID-19 tests is about \u001b[34m6\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mcontact\u001b[0m time of items/tools with the disinfectant in the tank is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m threshold is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrecovery\u001b[0m timescale is about 20 - \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtravel\u001b[0m time is necessarily more than \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is \u001b[34mtwo\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34mone\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m10\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m from the main flock for at least \u001b[34m90\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m21\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m five-day \u001b[31mdelay\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mself-quarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34mfour\u001b[0m hours of \u001b[31mcontact\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m period for exposed individuals to be infectious is \u001b[34m1\u001b[0m day\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31moutbreak\u001b[0m is less than \u001b[34m100\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcold\u001b[0m \u001b[31mstorage\u001b[0m room\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m is \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time was established at \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mlong\u001b[0m \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for falciparum malaria is at least \u001b[34m7\u001b[0m days\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m \u001b[34mblocked\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for malaria is at least \u001b[34m6\u001b[0m days\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period lasted for at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mdaily\u001b[0m \u001b[31minfection\u001b[0m rate\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m threshold is \u001b[34m10\u001b[0m suspected cases/100,0000 population\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtravel\u001b[0m restriction might delay a pandemic wave by \u001b[34m2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdevelopment\u001b[0m period for the vaccine was taken as \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m campaign is completed in \u001b[34m66\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m would be around \u001b[34m19\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31msmallpox\u001b[0m outbreak will peak around day \u001b[34m150\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m for contacts should at least be for \u001b[34m8\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2 to \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m required for the laboratory confirmation of JEV is approximately \u001b[34m7\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m periods was \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 24-h \u001b[31mquarantine\u001b[0m strategy\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mpatient\u001b[0m beds should not be less than \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m135\u001b[0m days of \u001b[31mlock-down\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 21-day \u001b[31mwaiting\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj-\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34mFourteen\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time of \u001b[34m20\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period above \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days in \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mhatch\u001b[0m window of \u001b[34m24\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-advcl-\u001b[1mROOT\u001b[0m-prep-pobj-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m spreading , any individual who may have been exposed should go into isolation for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mnmod\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mnmod\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mconj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m45\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mconj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for \u001b[34m3\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mconj\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mconj\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m spaces will be required \u001b[34mfor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mROOT\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mROOT\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m periods for both staff and patients who have been exposed to any person under investigation have been set provisionally at \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mconj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m \" will be about \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m ends \u001b[34mafter\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mROOT\u001b[0m-xcomp-npadvmod-nummod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-\u001b[1mprep\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m 30-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m primarily infects human lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects types I and II \u001b[34mpneumocytes\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m mainly targets epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , infects the \u001b[34mhost\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the \u001b[34mhost\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches the human host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , responsible for the current coronavirus disease COVID-19 , not only affects the \u001b[34mlung\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects the \u001b[34mepithelium\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m preferentially infects airway epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily affects the \u001b[34mlungs\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSars-CoV-2\u001b[0m infects the respiratory \u001b[34mtract\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31m-II\u001b[0m enters the target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHCoV-229E\u001b[0m enters bone marrow \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the ACE2 receptor to invade human alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE-2 ) receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to access human \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV-1 , requires expression of the cellular receptor ACE2 to infect \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to enter its target \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also acts through similar receptors to enter \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to ACE2 with high affinity as a virus receptor to infect \u001b[34mhumans\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses the receptor dipeptidyl-peptidase-4 ( DPP-4 ) to enter its host \u001b[34mcell\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is able to enter human \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses dipeptidyl peptidase 4 ( DPP4 ) receptor and the carcinoembryonic antigen  related cell-adhesion molecule 5 ( CEACAM5 ) cofactor ligand to infect unciliated bronchial \u001b[34mcells\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARSCoV\u001b[0m grows in a variety of \u001b[34mtissues\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-nCoV-2\u001b[0m infects the gastrointestinal ( GI ) \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m attaches to angiotensinconverting enzyme 2 ( ACE2 ) on the surface of the \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m likely binds in the first instance to nasal epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m occurs in the same phenomena of SARS in \u001b[34mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mmacrophages\u001b[0m , \u001b[31mMERS-CoV\u001b[0m can establish\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , akin to several other coronaviruses , uses angiotensin-converting enzyme-2 ( ACE-2 ) as an entry port into a lung \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is believed to invade the \u001b[34mhost\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to infect \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is mainly considered to infect respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been found to infect host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m poorly infects \u001b[34mhuman\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect different \u001b[34mhuman\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) , the virus that causes COVID-19 , infects \u001b[34mhumans\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also attacks the lower \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) infects ACE2 expressing epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades especially \u001b[34mepithelial\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPIV3\u001b[0m infects ciliated \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly attacks the \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( ACE2 ) on pulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARSCoV2\u001b[0m binds to angiotensinconverting enzyme 2 ( ACE2 ) receptors for entry via endocytosis into alveolar epithelial \u001b[34mcells\u001b[0m , as well as other cells\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has a great similarity with to SARS-CoV and invades host human \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m initiates its entry into human \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects primary human bronchial epithelial Calu-3 \u001b[34mcells\u001b[0m and primary human kidney cells\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has a predilection for type II epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m binds to the target \u001b[34mcell\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches to the target \u001b[34mcell\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 \u001b[34mreceptors\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mhumans\u001b[0m , \u001b[31mSARS-CoV-2\u001b[0m uses\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m bind to their target \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m begins at the mucosal surface of the respiratory system , and the virus infects the lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits the endogenous transcriptional machinery of alveolar \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m also infects monocytes/macrophages [ 68 , 86 ] and dendritic \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may exert a direct toxic action on \u001b[34mmyocytes\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can further use transmembrane \u001b[34mprotease\u001b[0m serine 2 ( TMPRSS2 ) , a serine protease\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , the pathogenic agent of COVID-19 , employs angiotensin converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m similarly to SARS-CoV requires angiotensin-converting enzyme 2 ( \u001b[34mAcE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCoV-2\u001b[0m uses the ' Angiotensin Converting Enzyme-2 ' ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the same receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m hijacks the same entry receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m share the same \u001b[34mhost\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , which also infects human respiratory tract epithelium , employs dipeptidyl \u001b[34mpeptidase\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the cellular transmembrane serine \u001b[34mprotease\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARSCoV2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV employ \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits the \u001b[34mACE-2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , responsible for Coronavirus disease ( COVID-19 ) , shares the same \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the human \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m does not use other \u001b[34mCoV\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV shared the same \u001b[34mhost\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the cell entry \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m requires the angiotensin-converting enzyme 2 ( ACE-2 ) \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV utilize the same \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m utilizes angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same cellular receptor , \u001b[34mhACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect cells via the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m penetrates via human angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T cells from human blood and lymphoid organs via DPP4 \u001b[34mreceptor\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV utilize the same receptor , \u001b[34mACE-2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host cells via the cell surface angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds with the \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host cells through the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for COVID-19 , is known to gain entry into cells via the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been confirmed to use this same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been reported to gain cellular entry via the surface angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to bind to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , the coronavirus causing COVID-19 , has been proved to bind the \u001b[34mentry\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is thought to gain entry to human host cells via the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also leverages the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use \u001b[34mhost\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARSCoV-2\u001b[0m has a similar \u001b[34mbinding\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mTMPRSS2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m needs the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is considered to be the receptor for \u001b[31mSARS-COV-2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is known to be the likely host receptor for the coronavirus \u001b[31m2019-nCoV/SARS-CoV-2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been proved to be the cellular receptor of \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) protein\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus , the causative viral agent for COVID-19 , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m S glycoprotein harbors a \u001b[34mFurin\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mbeta\u001b[0m 2b CoV , recombinant Bat-CoV HKU3 , has a modified \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m bind to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"deps\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pattern: dep labels along dep path (pyBART)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m causes a contagious intestinal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with brief two-to four-day incubation period , produces acute \u001b[34mencephalitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces diffuse \u001b[34minflammation\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoV\u001b[0m causes a fatal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFiloviruses\u001b[0m cause a severe and frequently fatal \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBVDV\u001b[0m can cause calf \u001b[34mdiarrhea\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes thymic \u001b[34matrophy\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m causes a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCDV\u001b[0m causes a systemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with the coronavirus , especially the severe acute respiratory syndrome coronavirus ( SARSCoV ) and the emerging Middle East respiratory syndrome coronavirus ( MERSCoV ) , induces acute respiratory \u001b[34mfailure\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSFV\u001b[0m causes \u001b[34mfever\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes a respiratory \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mencephalitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a fulminant \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mlesions\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIAV\u001b[0m initiates \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes a systemic \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m produces a self-limiting \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with SARS-CoV-2 show typical \u001b[34mpneumonia\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes significant acute lung \u001b[34minjury\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoVs\u001b[0m cause enteric \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mreplication\u001b[0m in vascular endothelial cells and hepatocytes produces acute necrohemorrhagic \u001b[34mhepatitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes an acute hemorrhagic \u001b[34mfever\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m shows SARS-like \u001b[34msymptoms\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m exposed to RVFV can present febrile \u001b[34millness\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mLIV\u001b[0m causes a \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause \u001b[34masthma\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m also causes more severe and prolonged \u001b[34mbronchiolitis\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m can also cause a chronic wasting \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBetacoronavirus\u001b[0m , including SARS CoV 2 , elicits \u001b[34minfection\u001b[0m\tCOUNT: 59\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m mostly represented\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( SNV ) , a Hantavirus common in the southwestern United States , \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m caused by pathogenic hCoVs \u001b[34mis\u001b[0m often associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mencephalitis\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mLeptospirosis\u001b[0m in hamsters \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in piglets triggers \u001b[34minflammatory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhPMV\u001b[0m induces \u001b[34mclinical\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with coronavirus primarily causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mBronchitis\u001b[0m ( IB ) causes severe \u001b[34minflammatory\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mreproductive\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mKoRV\u001b[0m induces \u001b[34msevere\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mgondii\u001b[0m induces \u001b[34minfectious\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in \u001b[34mhepatitis\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in bursal \u001b[34matrophy\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( FIPV ) manifests in a progressive and mostly fatal \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( PEDV ) results in acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m lead\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mmay\u001b[0m lead\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of humans \u001b[34mcan\u001b[0m result\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m take\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mcan\u001b[0m progress\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m results\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mBKV\u001b[0m \u001b[34mcan\u001b[0m silently reactivate\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in birds \u001b[34mis\u001b[0m systemic\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m particularly severe\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m often fatal\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in domestic cat \u001b[34mis\u001b[0m analogous\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m generally restricted\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of adult mice results in poor \u001b[34mviral\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 occasionally results in \u001b[34mneurologic\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m result in a \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mPoliovirus\u001b[0m \u001b[34mis\u001b[0m highly pathogenic\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mJCV\u001b[0m \u001b[34mis\u001b[0m responsible\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mreplication\u001b[0m \u001b[34mis\u001b[0m mainly limited\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans resulted in an acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31malphavirus\u001b[0m infections , such as those involving CHIKV , Ross River virus ( RRV ) , and Sindbis virus ( SINV ) , induce debilitating \u001b[34marthritis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mDENV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34mInfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPDCoV\u001b[0m infections also cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mJCV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mHEV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBDV\u001b[0m infection in sheep and goats causes \u001b[34mplacentitis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m strains induce \u001b[34mmeningitis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can lead to lymphocytic \u001b[34mdepletion\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m commonly leads to a devastating viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m often leads to severe \u001b[34mdamage\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBIV\u001b[0m induces splenomegaly and lymphademopathy \u001b[34msyndromes\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mfilovirus\u001b[0m infections \u001b[34mare\u001b[0m associated\tCOUNT: 4\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m who die within 10 days of the onset of symptoms show diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mascariasis\u001b[0m causes Lffler 's \u001b[34msyndrome\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m develop acute , febrile respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msheep\u001b[0m develop chronic \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m 1 to 3 years of age commonly develop mediastinal or muticentric \u001b[34mlymphoma\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with fluid overload usually develop pulmonary or subcutaneous \u001b[34medema\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m infected with avirulent FCoV-strains usually develop mild \u001b[34menteritis\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m produce nonspecific acute \u001b[34msymptoms\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually causes a mild dengue-like \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m has a sudden \u001b[34monset\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually experience \u001b[34mdyspnea\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m that become infected by CPV show \u001b[34millness\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 33\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m show \u001b[34msevere\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m typically cause \u001b[34macute\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpiglets\u001b[0m usually show typical \u001b[34menteric\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with severe leptospirosis have isolated \u001b[34mpulmonary\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with EcE show general \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m can cause different \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m occasionally develop a \u001b[34mfatal\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m causes common \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with pure hepatosplenic lymphoma usually have \u001b[34mnonspecific\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m undergo \u001b[34msevere\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m with multicentric lymphoma often exhibit \u001b[34mnonspecific\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with pneumonia exhibit typical \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m or immunocompromised people develop \u001b[34mfatal\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcattle\u001b[0m with BVDV have mild \u001b[34mpulmonary\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually presents with mild \u001b[34mrespiratory\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with right heart failure usually develop \u001b[34mpleural\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mEncephalitis\u001b[0m caused by enterovirus A71 infection usually has brainstem \u001b[34mclinical\u001b[0m\tCOUNT: 21\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by PRDC \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m , Marburg virus \u001b[34mdisease\u001b[0m ( MVD ) typically begins\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , \u001b[34minfection\u001b[0m results\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mpups\u001b[0m , sometimes in combination with other pathogens , CCoV \u001b[34minfection\u001b[0m may cause\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m , acute graft-versus-host \u001b[34mdisease\u001b[0m develops\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEarly\u001b[0m signs of \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfebrile\u001b[0m phase of \u001b[31millness\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , SARS-Cov-2 \u001b[34minfection\u001b[0m can cause\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mbirds\u001b[0m , adenovirus \u001b[34minfection\u001b[0m manifests\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m can occur in \u001b[31mhorses\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m manifestations of IBVinfected \u001b[31mchickens\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of norovirus \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfants\u001b[0m , early-onset \u001b[34mdisease\u001b[0m occurs\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in \u001b[31mdogs\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in adult \u001b[31manimals\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent adult \u001b[31mmice\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mmarmosets\u001b[0m with measles \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with peracute \u001b[34mIHA\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with systemic coronavirus \u001b[34mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m with canine \u001b[34minfluenza\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with disseminated \u001b[34msporotrichosis\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with HME \u001b[34mcan\u001b[0m develop\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m develop feline infectious \u001b[34mperitonitis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop bilateral \u001b[34mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m , AHSV infection induces \u001b[34mlesions\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , primary infection with HHV-6 can produce a mononucleosis-like \u001b[34millness\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , after an incubation period of 4 - 5 days , an astrovirus infection will induce a mild \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m take\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with pulmonary cryptococcosis \u001b[34mcan\u001b[0m present\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpigs\u001b[0m generally produces a nonfatal \u001b[34mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m , Microsporum canis usually causes a mild , self-limiting \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , pulmonary viral infections typically produce a mild and self-limited upper respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m result\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of Shigella dysentery \u001b[34mmay\u001b[0m become\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m include severe and sometimes prolonged incapacitating \u001b[34marthralgia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mALI\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m CCoV generally causes mild , self-limiting \u001b[34minfections\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the respiratory tract by influenza virus classically results in acute \u001b[34monset\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m results in mild influenza-like \u001b[34msymptoms\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with signs from FIV often \u001b[34mhave\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m yields a predominantly respiratory \u001b[34msyndrome\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34millness\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:as\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually courses as a self-limited \u001b[34mdiarrhea\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minfected\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m \u001b[31mis\u001b[0m associated\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with MERS-CoV infection usually present with acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34msyndrome\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mCSD\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMost\u001b[0m adults and children present mild flu-like \u001b[34msymptoms\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcalves\u001b[0m , usually less than 10 days of age , develop hemorrhagic , necrotic enteritis and enterotoxemia , often with \u001b[34mabdominal\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPrimary\u001b[0m HHV-6 infection causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with AVRS typically develop \u001b[34msymptoms\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mAcute\u001b[0m swine influenza virus infection causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31millnesses\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSystemic\u001b[0m \u001b[31mmanifestations\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m fulminant \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mChronic\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mViral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msystemic\u001b[0m \u001b[31millness\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mNeurological\u001b[0m \u001b[31msymptoms\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mBacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mDisseminated\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m will rapidly progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress quickly to \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m progresses to \u001b[34mpulmonary\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m disease can rapidly progress to severe\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can quickly progress to \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m might progress rapidly to \u001b[34macute\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads to \u001b[34mchronic\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m typically progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mTB\u001b[0m with either a miliary or diffuse pneumonic pattern can progress to \u001b[34mseptic\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m go on to \u001b[34mchronic\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can progress from prerenal disease to \u001b[34macute\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may lead to primary \u001b[34mviral\u001b[0m\tCOUNT: 24\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , of any age , may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m may develop\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m can have \u001b[34mprogressive\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m usually causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m typically develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpatients\u001b[0m also experience\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mmalaria\u001b[0m may present\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may have \u001b[34mpulmonary\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m results in \u001b[34matypical\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m experience \u001b[34mprogressive\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mmay\u001b[0m manifest\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mtuberculosis\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 9\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m infection \u001b[31mmay\u001b[0m result\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pneumonia \u001b[31mmay\u001b[0m further progresses\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m infection \u001b[31mmay\u001b[0m rapidly proceed\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m , long-standing airway obstruction \u001b[31mmay\u001b[0m progress\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mextensive\u001b[0m hematogenous spread of infection \u001b[31mcan\u001b[0m manifest\tCOUNT: 6\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrenal\u001b[0m failure \u001b[31mcan\u001b[0m progress\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:into-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:into-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can rapidly develop into a \u001b[34msevere\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m generally begins with \u001b[34mrespiratory\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:into-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mmalaria\u001b[0m can also evolve into \u001b[34msevere\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m usually begins with \u001b[34mgastrointestinal\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:into-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can evolve into a \u001b[34mchronic\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msymptomatic\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:into-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into fulminant \u001b[34mhepatic\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m can present insidiously with \u001b[34mnonspecific\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:in\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may begin with an \u001b[34macute\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can course with \u001b[34msevere\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m becomes relentlessly \u001b[34mprogressive\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may \u001b[34mrapidly\u001b[0m progress\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can \u001b[34mrapidly\u001b[0m progress\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34madvanced\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress rapidly to \u001b[34mdevelop\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mdiarrhea\u001b[0m may \u001b[34mrapidly\u001b[0m develop\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the \u001b[31mdisease\u001b[0m can progress\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mxcomp\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m may present in acute , subacute , and chronic forms and is potentially \u001b[34mfatal\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mmultiple\u001b[0m diffusive \u001b[31mlesions\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop ARDS or \u001b[34mbacterial\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually involves fever , arthralgia , and rash , but \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31mconditions\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to life-threatening \u001b[34mdengue\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod:with-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minfected\u001b[0m \u001b[31mindividuals\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m characterized by high fever , malaise , rigor , headache and dyspnoea and may progress to \u001b[34mgeneralized\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-nmod:to-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m manifested by diffuse infiltrates , hypoxia , and airflow limitation , and may lead to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m flu-like \u001b[31msyndrome\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m type \u001b[31mmay\u001b[0m rapidly progress\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mSome\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m with congenital or acquired immunodeficiencies are more susceptible to viral \u001b[34mpathogens\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to opportunistic \u001b[34mpathogens\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may particularly be vulnerable to respiratory \u001b[34mviruses\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCOPD\u001b[0m are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m are particularly susceptible to late CMV \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with compromised immune systems are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mMS\u001b[0m are susceptible to urinary tract \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m are susceptible to chronic \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are susceptible to \u001b[34mVAP\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m might be more susceptible to this \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with severe T cell defects are also susceptible to systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSCID\u001b[0m are extremely susceptible to progressive \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more predisposed to \u001b[34mpneumonia\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to \u001b[34mTB\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-dobj-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mwomen\u001b[0m may be at increased risk of \u001b[34mprogression\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with coronavirus are at increased risk of \u001b[34mthrombosis\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at high risk of \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mCGD\u001b[0m are at increased risk of life-threatening \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m patients are , therefore , highly susceptible to chronic \u001b[34mcolonization\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mtuberculosis\u001b[0m are at greater risk of secondary bacterial \u001b[34mpneumonia\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with immunocompromise or extremes of age are at higher risk for more severe \u001b[34mLRI\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcoronavirus\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are at the greatest risk for \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at increased risk for resistant \u001b[34morganisms\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mdisseminated\u001b[0m NTM \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m E virus \u001b[31minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:to\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minvasive\u001b[0m bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:to-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:to-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:to-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:to-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m are highly susceptible to cutaneous bacterial , viral , and fungal \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m prone to \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more vulnerable to \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more likely to develop bacterial or fungal \u001b[34msuperinfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrespiratory\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m have a particularly high risk of \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in LT recipients is more likely to cause tissue-invasive \u001b[34mdisease\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m or milder forms of immunosuppression can develop semi-invasive forms of \u001b[34maspergillosis\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with granulocytopenia are apt to develop severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m more susceptible to \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m is more likely to involve resistant \u001b[34mbacteria\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31msarcoidosis\u001b[0m , particularly black people , as well as patients with silicosis , have an increased prevalence of \u001b[34mTB\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mrejection\u001b[0m have an increased risk of NTM \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mprimary\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , especially haematopoietic stem cell transplantation ( HSCT ) recipients , are more likely to develop more severe \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-ev-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk of \u001b[34mIC\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:of-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:of-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:of-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-acl-\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by encapsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mILD\u001b[0m may be more prone to develop a severe COVID-19 lung \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-acl-\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m caused by capsulated \u001b[34mbacteria\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nmod:with-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nmod:with-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nmod:with-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-acl-\u001b[34mnmod:by\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m triggered by influenza \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-ev-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with GI bleeding are at risk of developing bacterial \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PVL-positive MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with \u001b[31mMSMD\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-ev-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with underlying medical conditions are at higher risk of MERS-CoV \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mnmod:for\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mNBS\u001b[0m are susceptible to develop \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with coronavirus \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mnmod:@\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:after\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mare\u001b[0m refractory\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m \u001b[34mis\u001b[0m only moderately effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mtherapies\u001b[0m involving sunitinib and regorafenib \u001b[34mare\u001b[0m also not effective\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m to oral antiviral agents may not provide additional benefit in this \u001b[34msetting\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mganciclovir\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31mlinezolid\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mis\u001b[0m compounded\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31minfliximab\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m \u001b[34mis\u001b[0m complicated\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may have deleterious effects ( i.e. , inhibition of immune response and pathogen clearance ) in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with CF and ABPA often require prolonged therapy with oral \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m who develop mild toxicity , discontinuation of \u001b[31mbleomycin\u001b[0m may lead\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mimmunosuppression\u001b[0m is not sufficient to treat progressive \u001b[34mMS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m with amphotericin B is usually sufficient to control \u001b[34mHLH\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m require immediate immunosuppression with \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are crucial to treat acute lifethreatening \u001b[34mcases\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mis\u001b[0m required\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31merlotinib\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-dobj-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m often require prolonged therapy with \u001b[31mganciclovir\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-amod-nmod:for-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-amod-nmod:for-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mccomp\u001b[0m-nmod:for-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-nmod:against-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-advcl:because-advcl:because-xcomp-advcl:once-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-advcl:because-advcl:because-xcomp-advcl:once-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-nmod:in-nmod:of-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-nmod:in-nmod:of-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:such_as\u001b[0m-nmod:such_as-\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:such_as\u001b[0m-nmod:such_as-\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-nmod:against-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod:of-nmod:agent-nmod:agent-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:in-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not as potent as HAART in inhibiting \u001b[34mHIV\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mccomp\u001b[0m-nmod:for-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m or ValACV can still be effective treatments for recurrent \u001b[34mHSV\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msystemic\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcombination\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-nmod:of-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mGanciclovir\u001b[0m is the treatment of choice for invasive CMV \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-amod-\u001b[1mroot\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-amod-\u001b[1mroot\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: therapy for \u001b[34mHPS\u001b[0m with \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:in-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are very effective in controlling acute \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod:of-nmod:agent-nmod:agent-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-amod-nmod:in-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mGanciclovir\u001b[0m resistance \u001b[34mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mLamivudine\u001b[0m and the other antiviral nucleos(t)ides for the treatment of \u001b[34mHBV\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:in-nmod:of-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:in-nmod:of-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mdrug\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mmost\u001b[0m \u001b[31mantivirals\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthe\u001b[0m \u001b[31magents\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAntiviral\u001b[0m anti-influenza \u001b[31mdrugs\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m \u001b[34mis\u001b[0m controversial\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m has broad \u001b[34mantiviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mthis\u001b[0m emerging \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m may worsen \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnmod:of\u001b[0m\tLINEAR: \u001b[31mIFN\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mare\u001b[0m significant\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-nmod:of-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m are the mainstay of treatment for acute \u001b[34mGVHD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m for the prevention and treatment of \u001b[34mGVHD\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-amod-nmod:in-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are often used in viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnmod:with\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m in adenovirus \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: pharmacotherapy for \u001b[34mSARS\u001b[0m with anti-inflammatory \u001b[31msteroids\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minhibitors\u001b[0m can also induce \u001b[34mresistance\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31msorafenib\u001b[0m use in patients \u001b[34mis\u001b[0m clearly associated\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nsubj-nmod:in-nmod:with-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:for-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:for-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-nmod:of-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj:and-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-nmod:for-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-ccomp-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-nmod:of-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mamod\u001b[0m-conj:and-nmod:due_to-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-nmod:of-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-amod-\u001b[1mroot\u001b[0m-acomp-prep-\u001b[34mpobj\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mnsubj\u001b[0m-acl:to-\u001b[34mdobj\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:in\u001b[0m-nmod:in-\u001b[1mroot\u001b[0m-conj-xcomp-attr-prep-pobj-prep-\u001b[34mpobj\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:of-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1madvcl:although\u001b[0m-dobj-acl:for-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-advcl:against-nmod:as-\u001b[34mnmod:due_to\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:agent-nmod:to-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl:though-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mnmod:for\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1madvcl:although\u001b[0m-dobj-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubjpass-conj:and-\u001b[1mev\u001b[0m-nsubj-acl:to-\u001b[34mdobj\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:because_of-appos-nmod:with-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-ccomp-attr-acl-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mev\u001b[0m-attr-nmod:in-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-nmod:with-acl-xcomp-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-nmod:in-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:with-conj:and-\u001b[1mamod\u001b[0m-nsubj-nmod:of-acl:relcl-dobj-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:as-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:between\u001b[0m-nmod:because_of-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mamod\u001b[0m-nmod:due_to-nmod:on-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-amod-nmod:in-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-conj:and-nmod:of-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmark\u001b[0m-\u001b[1madvcl:although\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-dobj-advcl-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl:although\u001b[0m-nmod:for-nmod:of-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nmod:of-nsubjpass-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-ev-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-dobj-advcl-\u001b[1mroot\u001b[0m-nsubj-nmod:including-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-amod-\u001b[1mamod\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nmod:for-nsubjpass-\u001b[1mroot\u001b[0m-nmod:due_to-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-advcl:although-dobj-nmod:in-nmod:with-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-acl:to-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nmod:in-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-xcomp-\u001b[1mamod\u001b[0m-nsubj-\u001b[34mnmod:during\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod:of-nsubj-\u001b[1mccomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-amod-advcl:in-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mamod\u001b[0m-xcomp-nmod:of-appos-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-nsubj-nmod:for-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdep\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdobj\u001b[0m-dobj-conj:and-\u001b[1mnmod:of\u001b[0m-nsubj-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-acl:to-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:to\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:such_as\u001b[0m-nsubjpass-advcl:although-\u001b[1mamod\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-appos-\u001b[34mnmod:for\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubjpass\u001b[0m-nmod:for-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-nmod:in-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:from\u001b[0m-\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mnmod:with\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-nsubj-advcl:although-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mnmod:of\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvcl\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj:and-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1madvcl:whereas\u001b[0m-dobj-nmod:in-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-nmod:for-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod:such_as\u001b[0m-nmod:with-\u001b[1mroot\u001b[0m-advcl:because-nmod:as-nmod:of-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-prep-pcomp-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdamage\u001b[0m is a common feature in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31membolism\u001b[0m is an uncharacteristic presentation in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mAspergillus\u001b[0m is a common superinfection in critically ill influenza \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m with disseminated intravascular coagulopathy ( DIC ) is another fatal and unusual complication in severe dengue \u001b[34minfection\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with HIV infection , \u001b[31mPAH\u001b[0m is a life-threatening complication\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major clinical concern in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31msepsis\u001b[0m is a major problem in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minvolvement\u001b[0m is an important complication in adenovirus \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m is a common finding in many systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m leading to acute respiratory failure is a major cause of sepsis in neutropenic cancer \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m is an uncommon complication in \u001b[34mmalaria\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcandidosis\u001b[0m is the most common invasive fungal infection in critically ill nonneutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m and multiorgan involvement is a common feature in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a common respiratory viral infection in adult HM \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a problem in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a well-known clinical manifestation of CMV disease in immunocompromized \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minhalation\u001b[0m is an uncommon life threatening event ( 0.6 % of total admissions ) in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common complication in COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 29\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m \u001b[34mis\u001b[0m a common consequence\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mALF\u001b[0m \u001b[34mis\u001b[0m a rare but potentially life\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m the most frequent cause\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m \u001b[34mis\u001b[0m an uncommon complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mcystitis\u001b[0m \u001b[34mis\u001b[0m a rare but serious complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m an accompanying presentation\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34mis\u001b[0m a severe but benign complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34mis\u001b[0m a very important pathogen\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mSOS\u001b[0m \u001b[34mis\u001b[0m a rare and serious complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mhypertension\u001b[0m \u001b[34mis\u001b[0m a known complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m an important cause\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m \u001b[34mis\u001b[0m transfusion-related circulatory overload\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mmyocarditis\u001b[0m \u001b[34mis\u001b[0m a serious condition\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m \u001b[34mis\u001b[0m a systemic inflammatory response syndrome\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[31mRD\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 22\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m can be the primary presenting manifestation of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m ( CSS ) is a serious complication of COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( PVP ) is a rare complication of seasonal \u001b[34minfluenza\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a cause of serious \u001b[34mdisease\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mmyocarditis\u001b[0m is a relatively rare sequelae of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mILD\u001b[0m is a rare but potentially fatal complication of RTX \u001b[34mtherapy\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m is a known complication of influenza-related \u001b[34mpneumonia\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mCardiomyopathy\u001b[0m is a common consequence of EV \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mALI\u001b[0m is an important complication of \u001b[34msepsis\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is an important feature of fatal SARS \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mEncephalitis\u001b[0m is a rare manifestation of hMPV \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mthrombosis\u001b[0m is a rare but severe complication of intra-abdominal \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a common cause of acute lower respiratory \u001b[34minfections\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a potentially devastating \u001b[31mcomplication\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a systemic \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a life-threatening \u001b[31mcomplication\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a viral \u001b[31mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31millness\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mMERS\u001b[0m \u001b[34mis\u001b[0m often complicated\tCOUNT: 9\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m , which significantly increases mortality , is often evident in \u001b[34mpatients\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m is not uncommon in \u001b[34mpatients\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mimpairment\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mamod\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mThrombosis\u001b[0m and disseminated intravascular clotting are common in SARS-CoV-2 \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mProlonged\u001b[0m thrombocytopenia is a rare but potentially devastating complication of \u001b[34mDHF\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mViral-induced\u001b[0m coagulopathy is a common feature of \u001b[34mMVD\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAcute\u001b[0m myositis is an important , severe , but rare , complication of influenza \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m community-acquired pneumonia ( SCAP ) is a known infectious complication of respiratory \u001b[34mviruses\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mAcute\u001b[0m cor pulmonale is a complication of ARDS \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an under-recognized cause of \u001b[31mstroke\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mare\u001b[0m uncommon complications of SARS-CoV-2 \u001b[31mpneumonia\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a rare cause of \u001b[31mdeath\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a well-known cause of fulminant hepatic \u001b[31mfailure\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mCandidemia\u001b[0m in neutropenic \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmeningitis\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod:of\u001b[0m-\u001b[1mxcomp\u001b[0m-\u001b[34mev\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a significant cause of \u001b[31mNHAP\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mcomplication\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m in SOT \u001b[34mrecipients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with \u001b[31msepsis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mischemia\u001b[0m ( AMI ) has been reported in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmorbidity\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m has been observed in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with VGS \u001b[31mbacteriaemia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m has been observed , particularly in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with severe \u001b[31mmalaria\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mimpairment\u001b[0m has been observed in some \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnmod:of\u001b[0m\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mmortality\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod:with\u001b[0m-\u001b[1mnmod:in\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with prolonged \u001b[31mshock\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mTTP\u001b[0m is suspected in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m has been reported in \u001b[34mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mCAP\u001b[0m is a common and potentially serious \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:in-\u001b[34mnmod:of\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnmod:in\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mharvest\u001b[0m interval must be at least \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mreporting\u001b[0m delay on COVID-19 tests is about \u001b[34m6\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mcontact\u001b[0m time of items/tools with the disinfectant in the tank is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m threshold is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrecovery\u001b[0m timescale is about 20 - \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtravel\u001b[0m time is necessarily more than \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is \u001b[34mtwo\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34mone\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m10\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mroot\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m from the main flock for at least \u001b[34m90\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mduration\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m21\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m five-day \u001b[31mdelay\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mself-quarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34mfour\u001b[0m hours of \u001b[31mcontact\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period could be shortened to \u001b[34m6\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccine\u001b[0m availability must occur within just \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m period for exposed individuals to be infectious is \u001b[34m1\u001b[0m day\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31moutbreak\u001b[0m is less than \u001b[34m100\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcold\u001b[0m \u001b[31mstorage\u001b[0m room\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m is \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time was established at \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mlong\u001b[0m \u001b[31mquarantine\u001b[0m period\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for falciparum malaria is at least \u001b[34m7\u001b[0m days\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m \u001b[34mblocked\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for malaria is at least \u001b[34m6\u001b[0m days\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period lasted for at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mdaily\u001b[0m \u001b[31minfection\u001b[0m rate\tCOUNT: 4\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mxcomp\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m threshold is \u001b[34m10\u001b[0m suspected cases/100,0000 population\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtravel\u001b[0m restriction might delay a pandemic wave by \u001b[34m2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdevelopment\u001b[0m period for the vaccine was taken as \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m campaign is completed in \u001b[34m66\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m would be around \u001b[34m19\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31msmallpox\u001b[0m outbreak will peak around day \u001b[34m150\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m would extend the median delay to \u001b[34m70\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: increase the \u001b[31mquarantine\u001b[0m period to \u001b[34m22\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m of newly arriving dogs , if feasible in training kennels or shelters , should therefore last for at least \u001b[34m2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m for contacts should at least be for \u001b[34m8\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2 to \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m required for the laboratory confirmation of JEV is approximately \u001b[34m7\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 24-h \u001b[31mquarantine\u001b[0m strategy\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m135\u001b[0m days of \u001b[31mlock-down\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 21-day \u001b[31mwaiting\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj:and-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj:and-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-conj:and-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34mFourteen\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m time of \u001b[34m20\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period above \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days in \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mhatch\u001b[0m window of \u001b[34m24\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mroot\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mnmod:for\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mnmod:for\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mroot\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mconj:and\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for \u001b[34m3\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mconj:and\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mconj:and\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m spaces will be required \u001b[34mfor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mroot\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mroot\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mroot\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m periods was \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m \" will be about \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m ends \u001b[34mafter\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m between an infection and its reporting to the government is rarely below \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-xcomp-npadvmod-nummod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-\u001b[1mprep\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m 30-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantining\u001b[0m might last for \u001b[34mtwo\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mnsubj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m \u001b[31mincubation\u001b[0m periods\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-nmod:for-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mpobj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msingle\u001b[0m trough \u001b[31mgeneration\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m primarily infects human lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects types I and II \u001b[34mpneumocytes\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m mainly targets epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , infects the \u001b[34mhost\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the \u001b[34mhost\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches the human host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , responsible for the current coronavirus disease COVID-19 , not only affects the \u001b[34mlung\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects the \u001b[34mepithelium\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m preferentially infects airway epithelial \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily affects the \u001b[34mlungs\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSars-CoV-2\u001b[0m infects the respiratory \u001b[34mtract\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31m-II\u001b[0m enters the target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHCoV-229E\u001b[0m enters bone marrow \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 76\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with a membrane protein , Angiotensin Converting Enzyme 2 ( ACE-2 ) , to enter the host s \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the ACE2 receptor to invade human alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE-2 ) receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to access human \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV-1 , requires expression of the cellular receptor ACE2 to infect \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to enter its target \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also acts through similar receptors to enter \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to ACE2 with high affinity as a virus receptor to infect \u001b[34mhumans\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses the receptor dipeptidyl-peptidase-4 ( DPP-4 ) to enter its host \u001b[34mcell\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses dipeptidyl peptidase 4 ( DPP4 ) receptor and the carcinoembryonic antigen  related cell-adhesion molecule 5 ( CEACAM5 ) cofactor ligand to infect unciliated bronchial \u001b[34mcells\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-nCoV-2\u001b[0m infects the gastrointestinal ( GI ) \u001b[34mtract\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is believed to invade the \u001b[34mhost\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to infect \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is mainly considered to infect respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been found to infect host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m poorly infects \u001b[34mhuman\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect different \u001b[34mhuman\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) , the virus that causes COVID-19 , infects \u001b[34mhumans\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also attacks the lower \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) infects ACE2 expressing epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades especially \u001b[34mepithelial\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPIV3\u001b[0m infects ciliated \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly attacks the \u001b[34mrespiratory\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARSCoV2\u001b[0m binds to angiotensinconverting enzyme 2 ( ACE2 ) receptors for entry via endocytosis into alveolar epithelial \u001b[34mcells\u001b[0m , as well as other cells\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has a great similarity with to SARS-CoV and invades host human \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects primary human bronchial epithelial Calu-3 \u001b[34mcells\u001b[0m and primary human kidney cells\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-conj:and-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m begins at the mucosal surface of the respiratory system , and the virus infects the lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m also infects monocytes/macrophages [ 68 , 86 ] and dendritic \u001b[34mcells\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m both enter \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus infects \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31m(MERS)-CoV\u001b[0m infect intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m facilitates \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly infect lower \u001b[34mairways\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m can infect multiple \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m binds to the target \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m attaches to the target \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 \u001b[34mreceptors\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mnmod:to\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m bind to their target \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , which is a more severe and aggressive virus , directly targets \u001b[34mT\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus enters the \u001b[34mbody\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mMAV-1\u001b[0m infects \u001b[34mbrain\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use angiotensin-converting enzyme 2 ( ACE2 ) as receptor to infect ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mnmod:into\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( ACE2 ) as the key receptor to facilitate its entry into host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mroot\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infection \u001b[34mis\u001b[0m triggered\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m requires the angiotensin-converting enzyme 2 ( ACE-2 ) receptor to enter the \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can further use transmembrane \u001b[34mprotease\u001b[0m serine 2 ( TMPRSS2 ) , a serine protease\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , the pathogenic agent of COVID-19 , employs angiotensin converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m similarly to SARS-CoV requires angiotensin-converting enzyme 2 ( \u001b[34mAcE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCoV-2\u001b[0m uses the ' Angiotensin Converting Enzyme-2 ' ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the same receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( \u001b[34mhACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m hijacks the same entry receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m share the same \u001b[34mhost\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , which also infects human respiratory tract epithelium , employs dipeptidyl \u001b[34mpeptidase\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the cellular transmembrane serine \u001b[34mprotease\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes 39 \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARSCoV2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV employ \u001b[34mACE2\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m exploits the \u001b[34mACE-2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , responsible for Coronavirus disease ( COVID-19 ) , shares the same \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the human \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m does not use other \u001b[34mCoV\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV shared the same \u001b[34mhost\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the cell entry \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m requires the angiotensin-converting enzyme 2 ( ACE-2 ) \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV utilize the same \u001b[34mreceptor\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m utilizes angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same cellular receptor , \u001b[34mhACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV utilize the same receptor , \u001b[34mACE-2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for COVID-19 , is known to gain entry into cells via the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been confirmed to use this same \u001b[34mcell\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been reported to gain cellular entry via the surface angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to bind to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , the coronavirus causing COVID-19 , has been proved to bind the \u001b[34mentry\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is thought to gain entry to human host cells via the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also leverages the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use \u001b[34mhost\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARSCoV-2\u001b[0m has a similar \u001b[34mbinding\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mTMPRSS2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m needs the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:for\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:for\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) protein\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus , the causative viral agent for COVID-19 , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m S glycoprotein harbors a \u001b[34mFurin\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:for\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is considered to be the receptor for \u001b[31mSARS-COV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod:for\u001b[0m-xcomp-\u001b[1mroot\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) is known to be the likely host receptor for the coronavirus \u001b[31m2019-nCoV/SARS-CoV-2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mbeta\u001b[0m 2b CoV , recombinant Bat-CoV HKU3 , has a modified \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus likely uses \u001b[34mACE-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect cells via the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:as-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:as-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus also requires \u001b[34mACE-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , SARS-CoV , and HCoV-NL63 , a virus that causes a mild respiratory infection , are all known to employ \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mroot\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus shares the same human receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host cells via the cell surface angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is thought to use \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod:as-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mroot\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host cells through the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mroot\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mTMPRSS2\u001b[0m is also known to cleave the Spike \u001b[34mprotein\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"deps\", parse_type=\"pybart\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Pattern: dep labels + root lemma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 0:\n",
      "\t<>arg1:virus $infection $causes a <>arg2:condition .\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m cause a debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m , in domestic cats , causes a variable immunodeficiency \u001b[34msyndrome\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes severe \u001b[34minfection\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes interstitial \u001b[34mpneumonia\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mmyocarditis\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a sudden \u001b[34monset\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMARV\u001b[0m causes an acute febrile \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a febrile \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m causes a contagious intestinal \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoV\u001b[0m causes a fatal \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of humans with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFiloviruses\u001b[0m cause a severe and frequently fatal \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBVDV\u001b[0m can cause calf \u001b[34mdiarrhea\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes thymic \u001b[34matrophy\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFIPV\u001b[0m causes a lethal \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCDV\u001b[0m causes a systemic \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSFV\u001b[0m causes \u001b[34mfever\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m causes a respiratory \u001b[34millness\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes a fulminant \u001b[34minfection\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m causes a systemic \u001b[34minfection\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of JEV can cause nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with LIV in humans can cause a neurological \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes significant acute lung \u001b[34minjury\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFCoVs\u001b[0m cause enteric \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with Ebola virus causes an acute hemorrhagic \u001b[34mfever\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of mice can cause \u001b[34mmyocarditis\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mLIV\u001b[0m causes a \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with SARS-CoV causes lower respiratory tract \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m causes \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m may cause \u001b[34masthma\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m also causes more severe and prolonged \u001b[34mbronchiolitis\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MAdV-1 causes multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m can also cause a chronic wasting \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause severe lung \u001b[34mdisease\u001b[0m\tCOUNT: 41\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in severe respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in an acute , self-limiting and icteric \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can result in \u001b[34mhepatitis\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans often results in a severe , life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with encephalitic alphaviruses may result in severe neurologic \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in bursal \u001b[34matrophy\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with CHIKV often results in acute \u001b[34millness\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m by LCMV can result in acute central nervous system \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of cattle with BoHV-1 generally results in inflammatory \u001b[34mdisease\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( PEDV ) results in acute \u001b[34mdiarrhea\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mprogressive\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34msevere\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with coronavirus primarily causes \u001b[34mrespiratory\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a \u001b[34msevere\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mBronchitis\u001b[0m ( IB ) causes severe \u001b[34minflammatory\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes \u001b[34mreproductive\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can also cause \u001b[34mneurologic\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m , like MHV-3 infection in mice , can induce exaggerated \u001b[34minflammation\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m induces acute \u001b[34mpneumonia\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MV typically results in an acute \u001b[34mfebrile\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in young chickens results in \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfluenza\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m of adult mice results in poor \u001b[34mviral\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 occasionally results in \u001b[34mneurologic\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces diffuse \u001b[34minflammation\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m causes mild to severe respiratory tract \u001b[34minflammation\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of both susceptible and resistant mouse strains induces an early acute \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with the coronavirus , especially the severe acute respiratory syndrome coronavirus ( SARSCoV ) and the emerging Middle East respiratory syndrome coronavirus ( MERSCoV ) , induces acute respiratory \u001b[34mfailure\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m result in a \u001b[34msevere\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mencephalitis\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m induces \u001b[34mlesions\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a wide spectrum of \u001b[34mdiseases\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mVEEV\u001b[0m usually causes mild to severe influenza-like \u001b[34msymptoms\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the brain with the JHM strain of MHV ( JHMV ) results in \u001b[34mfocal\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV causes a spectrum of clinical \u001b[34millness\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mencephalitis\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mLeptospirosis\u001b[0m in hamsters \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes clusters of severe respiratory \u001b[34millness\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in dogs generally induces a multisystemic \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans resulted in an acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mreactivation\u001b[0m after stem cell transplantation causes multiorgan toxicities , including \u001b[34mencephalitis\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHeV\u001b[0m in humans causes , after an incubation period of 5 - 21 days , a severe influenza like \u001b[34mdisease\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m also characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans \u001b[34mis\u001b[0m characterized\tCOUNT: 8\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mFIV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mDENV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34mInfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mJCV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mHEV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with hMPV \u001b[34mis\u001b[0m associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m ( SNV ) , a Hantavirus common in the southwestern United States , \u001b[34mis\u001b[0m associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m caused by pathogenic hCoVs \u001b[34mis\u001b[0m often associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with HHV-6 can produce a mononucleosis-like illness and , more rarely , severe \u001b[34mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMHV\u001b[0m infection causes \u001b[34mencephalitis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCHIKV\u001b[0m produces a sudden debilitating \u001b[34mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m leads to progressive severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by HAdV-7 , commonly associated with lower respiratory tract infection , can lead to severe \u001b[34mdisease\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m with brief two-to four-day incubation period , produces acute \u001b[34mencephalitis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPEDV\u001b[0m infections cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can lead to lymphocytic \u001b[34mdepletion\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m produces a self-limiting \u001b[34millness\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPDCoV\u001b[0m infections also cause acute , severe atrophic \u001b[34menteritis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m commonly leads to a devastating viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mreplication\u001b[0m in vascular endothelial cells and hepatocytes produces acute necrohemorrhagic \u001b[34mhepatitis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mBDV\u001b[0m infection in sheep and goats causes \u001b[34mplacentitis\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m often leads to severe \u001b[34mdamage\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can cause Japanese encephalitis ( JE ) with \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mJCPyV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mJEV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with DENV can cause a spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m ( COVID-19 ) caused by the SARS-CoV-2 virus is frequently characterized by pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mLASV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans is characterized by extensive pulmonary \u001b[34minflammation\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mIBV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m by SFTSV \u001b[34mcan\u001b[0m cause\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mHRSV\u001b[0m \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m cause\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes a broad spectrum of \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m are characterized by \u001b[34minflammation\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31macl\u001b[0m-nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfected\u001b[0m with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mjHMV\u001b[0m cause a subacute or persistent \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m , \u001b[31mJCV\u001b[0m can cause\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mhPMV\u001b[0m induces \u001b[34mclinical\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl:relcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mWNV\u001b[0m causes an acute febrile illness that can progress to severe and sometimes lethal neuroinvasive \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with MERS-CoV in humans results in a range of different clinical manifestations , from mild to severe \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl:relcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m causes upper respiratory infection ( URI ) , which may progress to fatal \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads \u001b[34mto\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mVSV\u001b[0m can cause acute brain infection and fatal \u001b[34mencephalitis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in humans can cause a wide range of clinical manifestations , from mild febrile \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 1:\n",
      "\tinfected arg1:patients $usually $develop <>arg2:[entity]respiratory illness.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who have pneumonic plague typically develop fulminant \u001b[34mpneumonia\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHumans\u001b[0m infected with RVFV usually develop an acute febrile myalgic \u001b[34msyndrome\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with bubonic plague usually develop \u001b[34msymptoms\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop rapid onset \u001b[34mfever\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP develop \u001b[34mlesions\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m infected with RDHV often develop acute necrotizing \u001b[34mhepatitis\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m develop acute , febrile respiratory \u001b[34mdisease\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msheep\u001b[0m develop chronic \u001b[34mdiarrhea\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhosts\u001b[0m usually develop self-limiting \u001b[34mdiarrhea\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m 1 to 3 years of age commonly develop mediastinal or muticentric \u001b[34mlymphoma\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe cases usually develop \u001b[34mpneumonia\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with BCC develop a life-threatening , sometimes necrotizing , \u001b[34mpneumonia\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34mfever\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with fluid overload usually develop pulmonary or subcutaneous \u001b[34medema\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m infected with avirulent FCoV-strains usually develop mild \u001b[34menteritis\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m usually develop \u001b[34mfever\u001b[0m\tCOUNT: 18\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m with PEDV \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m caused by PRDC \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m clinically characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in neonatal kids \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m \u001b[34mare\u001b[0m characterized\tCOUNT: 13\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs of CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in acutely infected \u001b[31mcalves\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m signs in human \u001b[31minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEarly\u001b[0m signs of \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of respiratory \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of BDV \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of FPV \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m initially causes non-specific \u001b[34msymptoms\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mascariasis\u001b[0m causes Lffler 's \u001b[34msyndrome\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually causes mild \u001b[34msymptoms\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m usually causes a mild dengue-like \u001b[34millness\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with COVID-19 typically present with fever , cough , dyspnea , and myalgia , and the infection may cause severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with MERS develop severe acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m infected with MERS-CoV develop a severe \u001b[34mrespiratory\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of the respiratory tract by influenza virus classically results in acute \u001b[34monset\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m occasionally develop a \u001b[34mfatal\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m results in mild influenza-like \u001b[34msymptoms\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m or immunocompromised people develop \u001b[34mfatal\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of ZV results in a self-limiting mild \u001b[34millness\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m usually result in \u001b[34mdiarrhea\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with right heart failure usually develop \u001b[34mpleural\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m results in profuse greenish , mucoid \u001b[34mdiarrhea\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with FIP show nonspecific \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m have a mild \u001b[34millness\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m show \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m typically cause \u001b[34macute\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpiglets\u001b[0m usually show typical \u001b[34menteric\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with EcE show general \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m can cause different \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mInfants\u001b[0m with myocarditis usually have \u001b[34msymptoms\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPRRSV\u001b[0m causes common \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in \u001b[31mdogs\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of rapidly-lethal \u001b[31minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m and hypoxemia usually occur\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m causes various \u001b[34mclinical\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m manifests with fever , dyspnoea and non-productive \u001b[34mcough\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m can occur in \u001b[31mhorses\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minfection\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m in immunocompetent adult \u001b[31mmice\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m typically manifests as a severe \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m caused by the virus manifests in most cases as a lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of calicivirus \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , \u001b[34mdyspnea\u001b[0m occurs\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m has a sudden \u001b[34monset\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mSymptoms\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31minfants\u001b[0m , early-onset \u001b[34mdisease\u001b[0m occurs\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m infected with SARS-CoV often present with \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1minclude\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m usually include diffuse \u001b[34mbleeding\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can present with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop \u001b[34msepsis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m usually causes a self-limiting , acute and febrile \u001b[34millness\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with MERS-CoV infection usually present with acute \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34msyndrome\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with pure hepatosplenic lymphoma usually have \u001b[34mnonspecific\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mCSD\u001b[0m \u001b[31mis\u001b[0m characterized\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with severe MERS often present with pneumonic \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m with SARS-CoV typically causes an influenza-like \u001b[34msyndrome\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcattle\u001b[0m with BVDV have mild \u001b[34mpulmonary\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with CDV may initially present with \u001b[34mclinical\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1minclude\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m include severe and sometimes prolonged incapacitating \u001b[34marthralgia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m generally present with mild upper respiratory infection \u001b[34msymptoms\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1minclude\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhumans\u001b[0m include respiratory or eye infections and intestinal or digestive \u001b[34millness\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mEncephalitis\u001b[0m caused by enterovirus A71 infection usually has brainstem \u001b[34mclinical\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mEnteric\u001b[0m FCoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mrabbits\u001b[0m usually develop a chronic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: presents in \u001b[31mhumans\u001b[0m as a lower respiratory \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSymptomatic\u001b[0m CHIKV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with infectious mononucleosis usually experience an abrupt \u001b[34monset\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mappear\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mFever\u001b[0m , absolute lymphopenia , inappetence , jaundice , and abdominal effusion appear 2 - 3 weeks after infection in around 80 % of \u001b[31mcats\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m of kittens or adult cats results in \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msymptom\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m symptoms of MERS-CoV \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m manifestations of hantavirus \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mCats\u001b[0m with acute leukemia usually show signs of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m infected with E coli may develop an acute onset of watery \u001b[34mdiarrhea\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m who die within 10 days of the onset of symptoms show diffuse alveolar \u001b[34mdamage\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdog\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDogs\u001b[0m with peracute \u001b[34mIHA\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcats\u001b[0m develop feline infectious \u001b[34mperitonitis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIndividuals\u001b[0m with SARS usually develop a high fever followed by severe \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-conj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m , immature schistosomula pass through the lung and can lead to \u001b[34mfever\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of human \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m of mild COVID-19 may present with fever , fatigue , dry cough , but severe \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mevolve\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mclinical\u001b[0m manifestations of inhalational anthrax generally evolve to a fulminant \u001b[34mseptic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m presents about 1 - 6 days after the onset of \u001b[34mrash\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , RSV \u001b[34minfection\u001b[0m usually manifests\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop bilateral \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mhorses\u001b[0m , AHSV infection induces \u001b[34mlesions\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mproduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m , primary infection with HHV-6 can produce a mononucleosis-like \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mpups\u001b[0m , sometimes in combination with other pathogens , CCoV \u001b[34minfection\u001b[0m may cause\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPigs\u001b[0m affected by SIV usually show an abrupt outbreak of \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m , the infection is present as a febrile systemic \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m usually \u001b[34mdie\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msee\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs are usually seen in young and immunosuppressed \u001b[31mbirds\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mdog\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdogs\u001b[0m with canine \u001b[34minfluenza\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mRabbits\u001b[0m with multicentric lymphoma often exhibit \u001b[34mnonspecific\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mpresent\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with H7N9 virus infection usually present with fever and cough , with early sputum production , and the \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31manimals\u001b[0m \u001b[34mis\u001b[0m characterized\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mexhibit\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mFerrets\u001b[0m with pneumonia exhibit typical \u001b[34mclinical\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mPrimary\u001b[0m HHV-6 infection causes undifferentiated febrile \u001b[34millness\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m , after an incubation period of 4 - 5 days , an astrovirus infection will induce a mild \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msign\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mclinical\u001b[0m signs of \u001b[31msepsis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mappear\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34msymptoms\u001b[0m of COVID-19 usually appear 5 - 6 days after \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m result in a \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mdisease\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m in \u001b[31mhumans\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1msee\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mClinical\u001b[0m cryptosporidiosis is mostly seen in \u001b[31mcalves\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with symptomatic EPEC \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 2:\n",
      "\ta arg1:subset of patients $progress to arg2:hemorrhagic fever\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31millness\u001b[0m can progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mpneumonia\u001b[0m rapidly progresses\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcritical\u001b[0m patients , the \u001b[31mdisease\u001b[0m progresses\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSymptoms\u001b[0m can progress to a \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can progress to \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m quickly progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIPS\u001b[0m may rapidly progress to \u001b[34mpulmonary\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m will rapidly progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m progress quickly to \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msymptoms\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m progresses to \u001b[34mpulmonary\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mit\u001b[0m can progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m disease can rapidly progress to severe\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m may progress\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m can quickly progress to \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may progress to \u001b[34mrespiratory\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m might progress rapidly to \u001b[34macute\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can rapidly progress to \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mThis\u001b[0m typically progresses to a \u001b[34msevere\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mTB\u001b[0m with either a miliary or diffuse pneumonic pattern can progress to \u001b[34mseptic\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m can progress from prerenal disease to \u001b[34macute\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress into fulminant \u001b[34mhepatic\u001b[0m\tCOUNT: 31\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , of any age , may develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m often develop refractory \u001b[34mpulmonary\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m of every age can develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m typically develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m can develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m rapidly develop \u001b[34msevere\u001b[0m\tCOUNT: 12\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pediatric \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m fulminant \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mtuberculosis\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m in this age group \u001b[34mcan\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31millness\u001b[0m \u001b[34mmay\u001b[0m progress\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34madvanced\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mearly\u001b[0m disseminated \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m , infection can cause \u001b[34mpneumonia\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mconditions\u001b[0m may develop\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m can rapidly develop into a \u001b[34msevere\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , \u001b[31mpatients\u001b[0m may develop\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mViral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mBacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mMild\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m cases , the \u001b[31mdisease\u001b[0m can lead\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may rapidly progress toward the development of \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in \u001b[34malveolar\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may progress rapidly , with occurrence of \u001b[34mviral\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops with primary infection , occurs rarely in children , and progresses to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mcondition\u001b[0m may \u001b[34mrapidly\u001b[0m progress\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can \u001b[34mrapidly\u001b[0m progress\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m develops rapidly and eventually progresses after 2 to 4 days into \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , the clinical course can progress relentlessly to \u001b[34mseptic\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m whose condition deteriorates to critical status primarily decompensate from a respiratory standpoint , but may also develop multi-organ failure ( respiratory failure , cardiac failure , renal failure , hypercoagulable state , thrombotic microangiopathy ) , as well as \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m pneumonia \u001b[31mmay\u001b[0m further progresses\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , the syndrome progresses to \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31msyndrome\u001b[0m generally begins with \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , the \u001b[31mdisease\u001b[0m can progress\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m , long-standing airway obstruction \u001b[31mmay\u001b[0m progress\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: progress to \u001b[34mrespiratory\u001b[0m failure and death in 1 - 2 % of \u001b[31mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may result in death due to \u001b[34mprogressive\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m leads to \u001b[34mchronic\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with \u001b[34msevere\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m usually begins with \u001b[34mgastrointestinal\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrenal\u001b[0m failure \u001b[31mcan\u001b[0m progress\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m results in \u001b[34matypical\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may develop ARDS or \u001b[34mbacterial\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbegin\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m may begin with an \u001b[34macute\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mDisseminated\u001b[0m \u001b[31mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlead\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m may lead to primary \u001b[34mviral\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31madults\u001b[0m often develop a viral pneumonia and cardiac complications , and older patients are more susceptible to \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses into acute respiratory distress syndrome ( ARDS ) with \u001b[34mdiffuse\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpatient\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-\u001b[1mclinic\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mnsubj\u001b[0m\tLINEAR: clinic , COVID-19 \u001b[31mpatients\u001b[0m most commonly present with fever , cough and dyspnea , and from there the \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mcan\u001b[0m manifest\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can rapidly progress to the hemorrhagic phase of \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m of DPB typically progress to bronchiectasis and \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can rapidly progress to \u001b[34mshock\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1madvcl\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to \u001b[34mviral\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses very slowly , but can result in \u001b[34mcardiac\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mindividuals\u001b[0m \u001b[34mdevelop\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mconj\u001b[0m-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m may progress to \u001b[34macute\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcc\u001b[0m\tLINEAR: \u001b[31mDisease\u001b[0m can progress to acute respiratory distress syndrome \u001b[34mand\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifest\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34maux\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m \u001b[34mmay\u001b[0m manifest\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses to life-threatening \u001b[34mdengue\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m progresses rapidly , and \u001b[34mrespiratory\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mcase\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31mcases\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-conj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m progresses to the central nervous system ( CNS ) and \u001b[34mneurological\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mcases\u001b[0m may progress \u001b[34mto\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1millness\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSevere\u001b[0m \u001b[31millnesses\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can progress to pneumonia , respiratory failure and death when severe , and in this case , \u001b[34macute\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprogress\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m can progress to \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mcharacterize\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m characterized by high fever , malaise , rigor , headache and dyspnoea and may progress to \u001b[34mgeneralized\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31maux\u001b[0m-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m involvement \u001b[31mcan\u001b[0m result\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mAcute\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mexperience\u001b[0m.\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mamod\u001b[0m\tLINEAR: experience a mild form of \u001b[31mdisease\u001b[0m , but those with advanced age or underlying comorbidities may suffer \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 3:\n",
      "\tpeople with arg1:[e]asthma are $susceptible to arg2:[e]asthma\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are strongly susceptible to encapsulated bacterial \u001b[34morganisms\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiabetes\u001b[0m , immunosuppressive disorders , and liver disease including hemochromatosis and alcoholic liver disease are especially susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to the \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfibrosis\u001b[0m are particularly susceptible to chronic \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCOPD\u001b[0m are more susceptible to viral \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are generally more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m are particularly susceptible to late CMV \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMS\u001b[0m are susceptible to urinary tract \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m may be as susceptible to active Mycobacterium tuberculous \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m are susceptible to chronic \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m might be more susceptible to this \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCID\u001b[0m are extremely susceptible to progressive \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdiseases\u001b[0m are susceptible to respiratory lung \u001b[34minfections\u001b[0m\tCOUNT: 20\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including those with HIV/AIDS and patients taking immunosuppressants post-transplant , are at an increased risk for viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency due to human immunodeficiency virus ( HIV ) infection are highly susceptible to viral \u001b[34msepsis\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m with congenital or acquired immunodeficiencies are more susceptible to viral \u001b[34mpathogens\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with immunodeficiency syndromes are also at risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with immunocompromise or extremes of age are at higher risk for more severe \u001b[34mLRI\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with associated CD4 + cell depletion not receiving appropriate prophylaxis are at high risk for Pneumocystis jiroveci \u001b[34mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with a single LT may be at greater risk of \u001b[34mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iatrogenic or disease related immune suppression are highly susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with iron overload ( hemochromatosis ) are more susceptible to yersinial \u001b[34msepsis\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with defective cell-mediated immunity are at risk of \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with primary adrenal insufficiency including Addison 's disease and congenital adrenal hyperplasia are at an increased risk of \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mwomen\u001b[0m may be at increased risk of \u001b[34mprogression\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m who are immunocompromised such as due to steroids or organ and hematopoietic stem cell transplantation are highly susceptible to atypical viral \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are at the greatest risk for \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at increased risk for resistant \u001b[34morganisms\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with coronavirus are at increased risk of \u001b[34mthrombosis\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with prolonged neutropenia who have received intensive cytotoxic chemotherapy are at risk for invasive fungal \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are susceptible to \u001b[34mVAP\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , especially those with neutropenia , are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also susceptible to nosocomial viral \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with congenital anatomical defects , immunodefi ciencies , and genetic disorders are at increased risk for bacterial , viral and fungal \u001b[34mpneumonia\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with severe T cell defects are also susceptible to systemic viral \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies , especially in the neutropenic state after aggressive chemotherapy or HSCT and HSCT recipients with GVHD , are particularly susceptible to invasive fungal \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more susceptible to bacterial , fungal , viral , and parasitic \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with DAH are especially susceptible to pulmonary \u001b[34minfections\u001b[0m\tCOUNT: 15\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-dobj-xcomp-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubjpass\u001b[0m\tLINEAR: \u001b[34mInfection\u001b[0m with RV is known to trigger acute exacerbations and subjects with \u001b[31mCOPD\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mfungal\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrespiratory\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msevere\u001b[0m KIPyV \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minvasive\u001b[0m GAS \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mviral\u001b[0m \u001b[31minfections\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mdisseminated\u001b[0m NTM \u001b[31minfection\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at increased risk for bacterial \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcirrhosis\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIBD\u001b[0m are at increased risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mimmunodeficiency\u001b[0m are at particular risk of severe RSV \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSCD\u001b[0m are at high risk of \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31masthma\u001b[0m are at increased risk for pertussis \u001b[34minfection\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCGD\u001b[0m are at increased risk of life-threatening \u001b[34minfections\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients , particularly those under anticancer treatment , are potentially more susceptible for a severe \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients and immunocompromised hosts are particularly susceptible to lung \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcoronavirus\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are potentially more susceptible to Coronavirus \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCF\u001b[0m patients are , therefore , highly susceptible to chronic \u001b[34mcolonization\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCancer\u001b[0m patients are more susceptible to \u001b[34minfections\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m E virus \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m \u001b[31minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more vulnerable to \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are often vulnerable to opportunistic \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are vulnerable to \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to opportunistic \u001b[34mpathogens\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvulnerable\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are particularly vulnerable to \u001b[34mTB\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also more prone to RSV \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mDS\u001b[0m are highly susceptible to lower and higher respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m are highly susceptible to cutaneous bacterial , viral , and fungal \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with ESLD are prone to \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m on maintenance \u001b[31mdialysis\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m , including not only those with HIV \u001b[34minfection\u001b[0m but also those who undergo small bowel transplantation for short bowel syndrome , are prone to CMV infection\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at risk of \u001b[34mIC\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m who are more heavily immunosuppressed and who are suffering from other immunologic and infectious complications of transplant are at higher risk for \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mGVHD\u001b[0m have a particularly high risk of \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1msusceptible\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m are more susceptible to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m with GI bleeding are at risk of developing bacterial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PVL-positive MRSA \u001b[31mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with \u001b[31mMSMD\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msarcoidosis\u001b[0m , particularly black people , as well as patients with silicosis , have an increased prevalence of \u001b[34mTB\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-cop-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mChildren\u001b[0m with underlying medical conditions are at higher risk of MERS-CoV \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mrejection\u001b[0m have an increased risk of NTM \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdermatitis\u001b[0m have a propensity to \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with coronavirus \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mprone\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are also prone to other community acquired and nosocomial \u001b[34minfections\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at higher risk for developing fulminant acute \u001b[34mhepatitis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancies who are undergoing aggressive chemotherapy and treatment with corticosteroids are at increased risk of HSV , as impairment of cellular immunity is a risk factor for HSV \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are more likely to develop bacterial or fungal \u001b[34msuperinfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at an increased risk for developing airway disease such as bacterial tracheobronchitis , in addition to \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m are at greater risk of developing HSV \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcancer\u001b[0m patients ( whether caused by the disease itself or the treatment ) increases their risk of \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m undergoing allogeneic stem cell transplantation are at a much higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPatients\u001b[0m with hematologic malignancy ( HM ) are at risk for complications of respiratory viral \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with rheumatic and inflammatory bowel diseases ( IBDs ) may be at higher risk of \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfections\u001b[0m of the lower respiratory tract may increase the risk of secondary bacterial \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nsubj-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m are more likely to develop aspiration \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpatients\u001b[0m may have increased susceptibility to \u001b[34mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m in LT recipients is more likely to cause tissue-invasive \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m without prior exposure to varicella-zoster virus are at increased risk of severe \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrisk\u001b[0m.\u001b[1mROOT\u001b[0m-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mrecipients\u001b[0m are at an increased risk for acquiring \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlikely\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msinusitis\u001b[0m is more likely to involve resistant \u001b[34mbacteria\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mbacterial\u001b[0m \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mchildren\u001b[0m have increased susceptibility to virus \u001b[34minfections\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minvasive\u001b[0m bacterial \u001b[31mpneumonia\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mxcomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: develop severe \u001b[31millness\u001b[0m after \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 4:\n",
      "\targ1:[e]paracetamol is $not useful for treating arg2:[e]asthma.\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m and immunosuppressive drugs \u001b[34mare\u001b[0m not universally effective\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m with new \u001b[31magents\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31mlinezolid\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m \u001b[34mis\u001b[0m only moderately effective\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m with \u001b[31minfliximab\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with CF and ABPA often require prolonged therapy with oral \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mtherapies\u001b[0m involving sunitinib and regorafenib \u001b[34mare\u001b[0m also not effective\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m require immediate immunosuppression with \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m often require prolonged therapy with \u001b[31mganciclovir\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m is not recommended in the clinical treatment \u001b[34mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have limited efficacy in advanced \u001b[34mbacterial\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mincrease\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may increase the risk of mortality and morbidity ( e.g. secondary \u001b[34minfections\u001b[0m ) in severe influenza and other viral infections\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m and IgIV can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-conj-xcomp-advcl-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-conj-xcomp-advcl-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m treatment options are limited because no parenteral drug is available and no drug has been proved to be effective once life-threatening \u001b[34mdisease\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also not recommended for the treatment \u001b[34mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is indicated for RSV \u001b[34mURI\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m may be effective in the treatment of radiationassociated \u001b[34mlung\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is not effective in the treatment of \u001b[34mfilovirus\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m needs to be administered early during \u001b[34minfection\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-\u001b[1magent\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-\u001b[1magent\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34magents\u001b[0m ( such as cidofovir , foscarnet , and \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is only marginally effective against the \u001b[34mSARS\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod-conj-nmod-\u001b[1mcompromise\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after liver transplantation is often compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mconsider\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m with or without immunoglobulin can be considered for the management of \u001b[34msevere\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mtherapy\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcombination\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mganciclovir\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-ccomp-\u001b[1mthink\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-ccomp-\u001b[1mthink\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mdisease\u001b[0m , it is increasingly thought that \u001b[31mcorticosteroid\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcase\u001b[0m-nmod-conj-nmod-\u001b[1mcompromise\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m after LT is compromised by enhanced adverse effects and limited efficacy \u001b[31mof\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: are no proven effective preventive or therapeutic options for HEV \u001b[34minfection\u001b[0m , although small series reported a benefit of \u001b[31mribavirin\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-amod-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mGanciclovir\u001b[0m resistance \u001b[34mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroid\u001b[0m therapy is effective in 56 % of purely hematological forms of \u001b[34mTTP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mvancomycin\u001b[0m is often indicated for these \u001b[34minfections\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mtherapy\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mdrug\u001b[0m \u001b[31mtherapy\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: is currently no effective treatment for JC virus \u001b[34minfection\u001b[0m , although one report suggested CNS viral clearance with high dose \u001b[31mIVIG\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mClindamycin\u001b[0m alone ( 30 - 40 mg/kg per day in three divided doses ) may be used for suspected \u001b[34mPRSP\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has several weaknesses such as a narrow treatment window and borderline effects on \u001b[34mneurologic\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-conj-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mAntivirals\u001b[0m themselves have significant side effects , and their use may induce \u001b[34morgan\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mIFN\u001b[0m \u001b[34mtreatment\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minhibitors\u001b[0m may need to be stopped in \u001b[34mpatients\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mantiviral\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-amod-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m available in clinical practice for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are often used in viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31msorafenib\u001b[0m use in patients \u001b[34mis\u001b[0m clearly associated\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-nmod-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[31mit\u001b[0m is not an appropriate agent in patients with active or latent \u001b[34mtuberculosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msufficient\u001b[0m.\u001b[1macl:relcl\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m alone are not sufficient for suppressing \u001b[34minflammation\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1museful\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be useful for treating \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not recommended in COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj-\u001b[1mdie\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with PCP typically die due to refractory hypoxemia from severe respiratory failure , and \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are not effective for the treatment of lung injury or shock in adults ' SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-ccomp-\u001b[1mdelay\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mCorticosteroids\u001b[0m in the treatment of SARS-CoV-2 pneumonia are not usually recommended ; they may delay \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mavailable\u001b[0m.\u001b[1mconj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is available for CVB3 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mlicense\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mDrugs\u001b[0m currently licensed for the treatment of systemic \u001b[34mCMV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m are mildly effective and slow-acting , and therefore , should not be used as the only treatment modality due to the rapid progression of \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mantivirals\u001b[0m such as NA inhibitors and M2 blockers have limited efficacy in severe cases of \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-acomp-prep-\u001b[34mpobj\u001b[0m\tLINEAR: is also low in \u001b[34mchildren\u001b[0m , and the \u001b[31mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m in the treatment of COVID-19 can cause \u001b[34mhost\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mnsubj\u001b[0m-acl-\u001b[34mdobj\u001b[0m\tLINEAR: use of \u001b[31minterferon\u001b[0m to treat \u001b[34mdengue\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-conj-xcomp-attr-prep-pobj-prep-\u001b[34mpobj\u001b[0m\tLINEAR: observed in all clinical trials and \u001b[31mribavirin\u001b[0m is currently not considered to be a drug of choice for \u001b[34minfluenza\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubjpass-\u001b[1mhamper\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mencephalitis\u001b[0m , the efficacy of \u001b[31maciclovir\u001b[0m monotherapy may be hampered\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1madvcl\u001b[0m-dobj-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m has had certain efficacy for preventing CMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1margue\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mFAM\u001b[0m is standard therapy for established BOS , recent data argue strongly against using azithromycin as prophylaxis against BOS due to decreased \u001b[34msurvival\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34minfluenza\u001b[0m infections ( e.g. , M2 and neuraminidase inhibitors ) , these \u001b[31mdrugs\u001b[0m have\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is frequently limited by insufficient response to therapy or side effects of \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: been no specific treatment for \u001b[34mCCHF\u001b[0m , though \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mprovide\u001b[0m.\u001b[1madvcl\u001b[0m-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbiologic\u001b[0m therapies provide a valuable treatment option in \u001b[34mUC\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubjpass-conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-acl-\u001b[34mdobj\u001b[0m\tLINEAR: is no vaccine to prevent \u001b[34mRSV\u001b[0m , and the only accepted therapy ( \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-appos-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mTreatment\u001b[0m with M2 inhibitors , such as amantadine , is generally not used in transplant recipients because of widespread resistance , the association with prolonged shedding of \u001b[34mvirus\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-ccomp-attr-acl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m outside of these specific circumstances , as it comes at a cost and may be associated with side effects ; for example , \u001b[31mzanamivir\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mtherapy\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mSpecific\u001b[0m \u001b[31mantiviral\u001b[0m therapies\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m may not be a standard choice in patients with influenza A \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m contraindicated in advanced \u001b[34mcirrhosis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minduce\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mhepatitis\u001b[0m C , \u001b[31mribavirin\u001b[0m can induce\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mremain\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-acl-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcidofovir\u001b[0m remains an imperfect treatment , with deaths reported secondary to disseminated adenoviral \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-conj-\u001b[1mcomplicated\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-acl:relcl-dobj-\u001b[34mdep\u001b[0m\tLINEAR: \u001b[34minfections\u001b[0m is quite complicated , often requires combination antimicrobial therapy , and can also be associated with \u001b[31mdrug\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m is an effective therapy for \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mAD\u001b[0m , continuous use of systemic immunosuppressive \u001b[31magents\u001b[0m is limited\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mchallenging\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is challenging as IL-1 inhibitors can alleviate the \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mpose\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mTreatment\u001b[0m of MTB after SOT poses special challenges because of potential interactions between anti-MTB \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mcontroversial\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m for the treatment of COVID-19 is controversial due to their negative impact on anti-viral \u001b[34mimmune\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mrecommend\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m [ 16 ] is not recommended during SARS-CoV-2 infection and may worsen the \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-amod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHAART\u001b[0m is associated with potentially deleterious sequelae , making timing of the therapy very controversial in patients with active \u001b[34msepsis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m therapies are needed due to troubles in maintaining adequate stocks of plasma and the absence of effective interventions for treated \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mmark\u001b[0m-\u001b[1madopt\u001b[0m.\u001b[1madvcl\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAlthough\u001b[0m lopinavir/ritonavir have been adopted for the treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mrespond\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs , and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1madvcl\u001b[0m-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m has been approved for the treatment of \u001b[34mHRSV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minhibit\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m inhibits \u001b[34mviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nmod-nsubjpass-\u001b[1mestablish\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m drugs or glucocorticoids has not been established for treatment of \u001b[34mSARS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-cop-\u001b[1mconvenient\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may not be convenient in \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-dobj-advcl-\u001b[1mrespond\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m musculoskeletal involvement respond well to conventional therapy such as NSAIDs , narcotic drugs and DMARDs , but refractory cases may need the use of biological \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1mbeneficial\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mVZIG\u001b[0m is clearly efficient in post-exposure prophylaxis , it is not beneficial for therapy of already established VZV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-nsubjpass-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m is limited due to the rapid development of \u001b[34mantiviral\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mtreatment\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSteroids\u001b[0m are also a used treatment in SARS-CoV-2 \u001b[34mCRS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mefficacious\u001b[0m.\u001b[1madvcl\u001b[0m-conj-dobj-nmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been efficacious in experimental animal studies and reduce \u001b[34mHBV\u001b[0m DNA levels in patients with chronic HBV\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mlimit\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m including teratogenicity limits its use to treat ZIKV \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mtoxicity\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mpulmonary\u001b[0m toxicity in conjunction with FOLFOX \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubj-\u001b[1mcontroversial\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m are the mainstay of any treatment plan however its use during COVID-19 \u001b[34minfection\u001b[0m is controversial\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m for the treatment of \u001b[34mVHF\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-\u001b[1mresult\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIVIg\u001b[0m treatment before Day 5 of fever can sometimes result in refractory \u001b[34mKD\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , and cyclophosphamide , or rituximab may be needed to control life-threatening \u001b[34mvasculitis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mefficacy\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: efficacy of \u001b[31mglucocorticoids\u001b[0m in the \u001b[34mtreatment\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-amod-advcl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have a downside in that they are not that effective in controlling MS \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-appos-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m options for COVID-19 are limited and may not be effective-a randomized trial of lopinavir/ritonavir , a common \u001b[34mHIV\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcombination\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m is the combination of \u001b[31mribavirin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdep\u001b[0m-nsubjpass-\u001b[1mcontraindicate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m may be contraindicated in patients with acute and chronic \u001b[34mmyocarditis\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mconj\u001b[0m-dobj-conj-\u001b[1mbenefit\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mRSV\u001b[0m are of limited benefit and include bronchodilators , \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mdrug\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-acl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m to treat HCMV \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mremain\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m remain refractory to immunoglobulin \u001b[31mtherapy\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-advcl-\u001b[1mrefractory\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[31msteroids\u001b[0m , plasma exchange ( PE ) , IVIG and immunosuppressive drugs are routinely used , many \u001b[34mpatients\u001b[0m are refractory\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1mRibavirin\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-appos-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRibavirin\u001b[0m , the only therapeutic option for LCMV \u001b[34mdisease\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mmonotherapy\u001b[0m.\u001b[1mnsubjpass\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAminoglycoside\u001b[0m monotherapy for the treatment of \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mworsen\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mhydroxychloroquine\u001b[0m may actually substantially worsen outcomes in COVID-19 + \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mbenefit\u001b[0m.\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34minfection\u001b[0m will benefit from \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-advcl-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: develops in about 20 % of \u001b[34mpatients\u001b[0m [ 71 ] [ 72 ] [ 73 ] [ 74 ] [ 75 ] [ 76 ] and may respond relatively poorly to ITP therapies , although recent experience with \u001b[31mrituximab\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mcontraindicate\u001b[0m.\u001b[1madvcl\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mglucocorticoids\u001b[0m are currently contraindicated in SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-conj-\u001b[1mpersist\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mtreatment\u001b[0m success specifically for BO often does not persist , and other immunosuppressive \u001b[31mdrugs\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1madvcl\u001b[0m-dobj-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mJakinibs\u001b[0m including tofacitinib have shown efficacy in the treatment of \u001b[34minflammatory\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1mtherapy\u001b[0m.\u001b[1mnsubjpass\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mdaptomycin\u001b[0m are the recommended first-line therapies for \u001b[34mMRSA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1msee\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34minflammatory\u001b[0m response to lung injury , a good treatment response is seen with broadspectrum anti-inflammatory agents , such as \u001b[31mcorticosteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mapprove\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pcomp-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not approved for treating COVID-19 or any viral \u001b[34mpneumonia\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mtolerate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m do not tolerate \u001b[31mcART\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nsubj-nmod-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mribavirin\u001b[0m is still limited because beneficial effects on \u001b[34mclinical\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1msuggest\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mcorticosteroids\u001b[0m are not suggested to systemically use in SARS-CoV-2 infected \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1madvcl\u001b[0m-xcomp-dobj-\u001b[34mamod\u001b[0m\tLINEAR: using HIV antiretroviral \u001b[31mtherapy\u001b[0m to treat \u001b[34msevere\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mresult\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mpunct\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m or second line foscarnet and cidofovir can result in substantial hematotoxicity and nephrotoxicity \u001b[34m[\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1memerge\u001b[0m.\u001b[1mccomp\u001b[0m-nsubj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mantiviral\u001b[0m resistance may emerge even with higher doses of \u001b[31moseltamivir\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1maddition\u001b[0m.\u001b[1mnsubj\u001b[0m-acl-dobj-acl-\u001b[34mnmod\u001b[0m\tLINEAR: addition to \u001b[31mcorticosteroids\u001b[0m and CsA in treating MAS associated with \u001b[34msJIA\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1madvance\u001b[0m.\u001b[1madvcl\u001b[0m-conj-dobj-acl-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31magents\u001b[0m have been advanced to clinical trials and shown modest results in decreasing either \u001b[34msymptom\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m may not be completely effective in \u001b[34mCMV\u001b[0m D+/R liver transplant recipients because the replication kinetics of CMV\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1msuccessful\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not successful in all \u001b[34mMS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1moverprescribe\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-acl-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mCAP\u001b[0m , especially in young children , \u001b[31mantibiotics\u001b[0m often are overprescribed\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-conj-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mtherapy\u001b[0m has a wide spectrum of toxic side effects and is only effective in a subset of \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-parataxis-\u001b[1mtreat\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mInfluenza\u001b[0m infections have been successfully treated with neuraminidase inhibitors ( oseltamivir or zanamivir ) ; however , the efficacy of these \u001b[31magents\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1minduction\u001b[0m.\u001b[1mnsubj\u001b[0m-nmod-\u001b[34mcase\u001b[0m\tLINEAR: induction \u001b[34mof\u001b[0m immunosuppression by \u001b[31msteroids\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubjpass-\u001b[1mlimited\u001b[0m.\u001b[1mROOT\u001b[0m-ccomp-dobj-amod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mantiviral\u001b[0m options are still limited and vaccines are often not available , which makes supportive treatment crucial in the clinical management of these often lifethreatening \u001b[34minfections\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-advcl-\u001b[1mrecommend\u001b[0m.\u001b[1mpcomp\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: recommending allo-HSCT to \u001b[34mRA\u001b[0m patients unless all other standard \u001b[31mtreatments\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31m\u001b[1msteroid\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31msteroid\u001b[0m in \u001b[34mMERS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-acl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdrugs\u001b[0m are used to treat ITP associated with \u001b[34mCVID\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mexpensive\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHBIG\u001b[0m is expensive and may not provide additional benefit compared to the use of oral antiviral agents alone , especially in low-risk \u001b[34mpatients\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nmod-nsubj-advcl-\u001b[1mconduct\u001b[0m.\u001b[1mROOT\u001b[0m-conj-advcl-nmod-nmod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mIVIG\u001b[0m use in these syndromes based in theory , several lines of laboratory investigation , and retrospective clinical series , no definitive clinical trial has been conducted and there remains clinical equipoise as to whether IVIG should be used in the treatment of TSS and \u001b[34mSTSS\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34madvmod\u001b[0m\tLINEAR: \u001b[34mHowever\u001b[0m , \u001b[31mtreatment\u001b[0m of PYR has been associated\tCOUNT: 1\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mineffective\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31macyclovir\u001b[0m , ganciclovir , or cidofovir \u001b[34mis\u001b[0m generally ineffective\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1meffective\u001b[0m.\u001b[1mconj\u001b[0m-advmod-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m is not effective enough for some \u001b[34mHCV\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 5:\n",
      "\targ1:[e]stroke is a $complication of :[e]COVID-19 arg2:infection\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumothorax\u001b[0m is a specific and potentially life-threatening complication in SARS \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mIH\u001b[0m is a significant complication of high-dose IVIg \u001b[34minfusion\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of VZV septicemia in \u001b[34mchildren\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( PVP ) is a rare complication of seasonal \u001b[34minfluenza\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication of respiratory virus \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mILD\u001b[0m is a rare but potentially fatal complication of RTX \u001b[34mtherapy\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a complication of S-OIV \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the most lethal complication of SARS-CoV-2 \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m is a known complication of influenza-related \u001b[34mpneumonia\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a known complication among critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mhemorrhage\u001b[0m with disseminated intravascular coagulopathy ( DIC ) is another fatal and unusual complication in severe dengue \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with HIV infection , \u001b[31mPAH\u001b[0m is a life-threatening complication\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m ( varicella ) is an uncommon but severe complication in SCT \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is a common complication in ICU \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mALI\u001b[0m is an important complication of \u001b[34msepsis\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a frequent complication in \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minvolvement\u001b[0m is an important complication in adenovirus \u001b[34minfections\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mthrombosis\u001b[0m is a rare but severe complication of intra-abdominal \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m is an uncommon complication in \u001b[34mmalaria\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m is the most frequent infectious complication in lung transplant \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is a well-recognized complication of pandemic H1N1 infl uenza \u001b[34minfection\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a common complication for \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIPN\u001b[0m is a common dose-limiting complication for \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m evolving to ARDS is the major complication in \u001b[34mpatients\u001b[0m\tCOUNT: 26\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mHypoxia\u001b[0m is the most common manifestation of \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBarotrauma\u001b[0m is a common complication in \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a life-threatening complication of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a common presentation in COVID-19 infected \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common infectious complication in multiple trauma \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMeningitis\u001b[0m is a rare but fatal complication of severe adenoviral \u001b[34mpneumonia\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is a common condition among the hospitalized \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBleeding\u001b[0m is a feared complication of severe dengue \u001b[34minfection\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is a frequent infectious complication in \u001b[34mpatients\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is one of the most common and severe complications in septic \u001b[34mshock\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the leading cause of ARDS in this \u001b[34msetting\u001b[0m\tCOUNT: 14\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m a complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mARDS\u001b[0m \u001b[34mis\u001b[0m an uncommon complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mcystitis\u001b[0m \u001b[34mis\u001b[0m a rare but serious complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mInfection\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m \u001b[34mis\u001b[0m a severe but benign complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mSOS\u001b[0m \u001b[34mis\u001b[0m a rare and serious complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m a life-threatening complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m ( caused by S. aureus , Streptococcus pneumoniae , and H. influenzae ) \u001b[34mis\u001b[0m a feared complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mhypertension\u001b[0m \u001b[34mis\u001b[0m a known complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mRD\u001b[0m \u001b[34mis\u001b[0m a common complication\tCOUNT: 13\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a common complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mBacterial\u001b[0m superinfection is a potential and serious complication of viral lower respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mProlonged\u001b[0m thrombocytopenia is a rare but potentially devastating complication of \u001b[34mDHF\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAcute\u001b[0m myositis is an important , severe , but rare , complication of influenza \u001b[34minfection\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSevere\u001b[0m community-acquired pneumonia ( SCAP ) is a known infectious complication of respiratory \u001b[34mviruses\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAcute\u001b[0m cor pulmonale is a complication of ARDS \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a novel respiratory \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a highly contagious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m during pregnancy \u001b[34mis\u001b[0m often associated\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute infectious \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mPulmonary\u001b[0m nocardiosis is a severe complication in heart-transplant ( HT ) \u001b[34mpatients\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an acute resolved \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1massociate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mauxpass\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mis\u001b[0m associated\tCOUNT: 7\n",
      "PATH: \u001b[31m\u001b[1mdisease\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common cardiovascular \u001b[31mdisease\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with \u001b[31msepsis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with severe COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with invasive GAS \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with communityacquired \u001b[31mpneumonia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mPatients\u001b[0m with VGS \u001b[31mbacteriaemia\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mIt\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with severe \u001b[31mmalaria\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mSARI\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mHC\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mToxoplasmosis\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mpatient\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with prolonged \u001b[31mshock\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m \u001b[34mis\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mCAP\u001b[0m is a common and potentially serious \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m is common in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mNPE\u001b[0m following febrile SE in children is a rare but serious life-threatening \u001b[34mcomplication\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCIRCI\u001b[0m is most common in \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mPeritonitis\u001b[0m associated with intestinal perforation is another serious HAI \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mThrombosis\u001b[0m and disseminated intravascular clotting are common in SARS-CoV-2 \u001b[34minfections\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is the most common \u001b[34minfection\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mBO\u001b[0m is the most common late onset noninfectious \u001b[34mcomplication\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m and renal injury are common in severe or critical COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 5\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most frequent and serious complication \u001b[34mof\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a complication in critically ill \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is the major complication of \u001b[34mSARS\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m in pediatric \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m is a major cause of death in \u001b[34mchildren\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m is a feared and frequent complication \u001b[34min\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m or acute respiratory distress syndrome ( ARDS ) in immunocompromised \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m is a life-threatening complication of \u001b[34mpneumonia\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of APSCT in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mcough\u001b[0m is the main clinical manifestation of COVID-19 \u001b[34min\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m an under-recognized cause of \u001b[31mstroke\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mfor\u001b[0m COVID-19 \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a rare cause of \u001b[31mdeath\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a well-known cause of fulminant hepatic \u001b[31mfailure\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m CPV-2 \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mdeath\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdeath\u001b[0m in \u001b[34mpatients\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m following primary influenza virus \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcop\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mis\u001b[0m a common complication of RSV upper respiratory tract \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a significant cause of \u001b[31mNHAP\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mpneumonia\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m after or during an RSV \u001b[34minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mDehydration\u001b[0m is the most common and serious complication of \u001b[34mgastroenteritis\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[34mof\u001b[0m COVID19 \u001b[31minfection\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-nmod-\u001b[34mcase\u001b[0m\tLINEAR: \u001b[31mPneumonia\u001b[0m is the most common cause \u001b[34mof\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m occurs frequently among patients with Covid-19 \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[34mpatients\u001b[0m with COVID-19 may develop \u001b[31mshock\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mmanifestation\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m can be the primary presenting manifestation of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mfeature\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mdamage\u001b[0m is a common feature in severe COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcause\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mRSV\u001b[0m is a cause of serious \u001b[34mdisease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muncommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mAKI\u001b[0m is not uncommon in \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mbronchiolitis\u001b[0m is one of the major outcomes of RSV \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31minjury\u001b[0m has been reported as the major outcome of COVID-19 \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mcomplication\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a common and potentially severe complication of \u001b[31minfluenza\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1minfection\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[34mis\u001b[0m a respiratory \u001b[31minfection\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mcommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mcop\u001b[0m\tLINEAR: \u001b[31mpneumonia\u001b[0m \u001b[34mis\u001b[0m common\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mobserve\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSepsis\u001b[0m has been observed in up to 59 % of hospitalized COVID-19 \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mshock\u001b[0m may occur in a significant portion of \u001b[34mpatients\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mone\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is one of the well-recognized complications of \u001b[34mGBs\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muncommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mARF\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muncommon\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mimpairment\u001b[0m is uncommon in \u001b[34mSARS\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mfeature\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mfailure\u001b[0m is an important feature of fatal SARS \u001b[34minfection\u001b[0m\tCOUNT: 3\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 6:\n",
      "\tthe recommended arg1:[w]quarantine period is arg2:14 :[w]days\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period must be at least \u001b[34m22\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mexposure\u001b[0m time for low-level disinfection of noncritical items is at least \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mharvest\u001b[0m interval must be at least \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m period for all felid species is typically \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mreporting\u001b[0m delay on COVID-19 tests is about \u001b[34m6\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mcontact\u001b[0m time of items/tools with the disinfectant in the tank is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m threshold is \u001b[34m10\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrecovery\u001b[0m timescale is about 20 - \u001b[34m30\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtravel\u001b[0m time is necessarily more than \u001b[34m1\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is \u001b[34mtwo\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34mone\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m10\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for at least \u001b[34m30\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mROOT\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m from the main flock for at least \u001b[34m90\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mlatent\u001b[0m period of \u001b[34mfour\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m9\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m21\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m is \u001b[34m4\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mccomp\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be at least \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m was \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of centralized \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mA\u001b[0m 14day \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31moutbreak\u001b[0m is less than \u001b[34m100\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mleptospirosis\u001b[0m is \u001b[34m10\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mvaccination\u001b[0m protocol in this situation would be a \u001b[34msingle\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThe\u001b[0m \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mxcomp\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m10\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubj\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 5-day \u001b[31mquarantine\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m would be around \u001b[34m19\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be 21 to \u001b[34m30\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 22-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of 2 to \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mday\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m period for exposed individuals to be infectious is \u001b[34m1\u001b[0m day\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mtreatment\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m required for the laboratory confirmation of JEV is approximately \u001b[34m7\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m periods was \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mdobj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mday\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for falciparum malaria is at least \u001b[34m7\u001b[0m days\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m before becoming contagious , or the latent period L , is around \u001b[34m4\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1misolate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m isolated for at least \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mday\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period for malaria is at least \u001b[34m6\u001b[0m days\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m week-long \u001b[31mquarantine\u001b[0m period\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-pobj-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mpatient\u001b[0m beds should not be less than \u001b[34m3\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m135\u001b[0m days of \u001b[31mlock-down\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mare\u001b[0m \u001b[34mrequired\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mamod\u001b[0m-nsubj-be.conj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: is \u001b[34m12\u001b[0m days , and early rash \u001b[31mcontagious\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34mFourteen\u001b[0m days of \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days in \u001b[31mquarantine\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be extended up to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period should be around \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34m3\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-prep-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period is \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be extended to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 14-day \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mrecommended\u001b[0m 14-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-dobj-\u001b[1mprolong\u001b[0m.\u001b[1mxcomp\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: prolonging the \u001b[31mquarantine\u001b[0m period to \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mattr\u001b[0m-acl:relcl-\u001b[1mday\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days , which is the longest predicted incubation \u001b[31mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-dobj-\u001b[1mapproximate\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34mThese\u001b[0m values approximate the duration of \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mconj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m for \u001b[34m45\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mlong\u001b[0m \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mconj\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m period is \u001b[34m4\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mfall\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-acl-pobj-prep-\u001b[1mfall\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-nummod-\u001b[34mcompound\u001b[0m\tLINEAR: fall under \u001b[34m12\u001b[0m - 8 hours in order to make the reproduction \u001b[31mnumber\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mtime\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mconj\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantined\u001b[0m for \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mdobj\u001b[0m-\u001b[1mreduce\u001b[0m.\u001b[1mxcomp\u001b[0m-prep-pobj-acl-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: reduce \u001b[31mtransmission\u001b[0m to zero in order to have about 100 cases after \u001b[34m60\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 2-week \u001b[31mquarantine\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mquarantine\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnsubjpass\u001b[0m\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m of \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-npadvmod-nummod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period was estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1moccur\u001b[0m.\u001b[1mROOT\u001b[0m-parataxis-nsubjpass-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtransmission\u001b[0m may still occur : if the surveillance sensitivity is only 40 % , then \u001b[34m62\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mextend\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m may be extended for up to \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34msingle\u001b[0m trough \u001b[31mgeneration\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31misolation\u001b[0m period will be at least \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-npadvmod-nummod-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mincubation\u001b[0m period is estimated to be between 2 and \u001b[34m10\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mperiod\u001b[0m is \u001b[34mthree\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 21-day \u001b[31mwaiting\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mtime\u001b[0m.\u001b[1mnsubj\u001b[0m\tLINEAR: \u001b[31minfection\u001b[0m \u001b[34mtime\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mauxpass\u001b[0m-\u001b[1msuspend\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mbe\u001b[0m suspended for \u001b[34m21\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nmod-\u001b[1mtreatment\u001b[0m.\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: treatment of 500 mg of \u001b[31mchloroquine\u001b[0m per day for \u001b[34mten\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-attr-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mseason\u001b[0m was approximately \u001b[34msix\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-advcl-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mrisk\u001b[0m level reach 20 % , the peak will be above 1000 active cases after \u001b[34m90\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mattr\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m period was 37 to 44 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-nsubjpass-\u001b[1mestimate\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-prep-\u001b[34mpobj\u001b[0m\tLINEAR: \u001b[31mepidemic\u001b[0m was estimated at a maximum of 2 \u001b[34mdays\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-pobj-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31munquarantined\u001b[0m infections as a criterion \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m\tLINEAR: \u001b[31mlockdown\u001b[0m \u001b[34mperiod\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-pobj-prep-relcl-nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-pobj-prep-relcl-nsubjpass-\u001b[1mreduce\u001b[0m.\u001b[1mccomp\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m should be \u001b[34mreduced\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period above \u001b[34m14\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mamod\u001b[0m-pobj-prep-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m\tLINEAR: \u001b[31mcalendar-year\u001b[0m timeframe \u001b[34mis\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mcompulsory\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-conj-parataxis-dobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mdevelop\u001b[0m.\u001b[1mROOT\u001b[0m-conj-parataxis-dobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mdisease\u001b[0m develops after an average of six days of incubation , and it takes an average of five days from morbidity to diagnosis ( according to NHCC ) , that is , 5 + 6 = \u001b[34m11\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34mdet\u001b[0m\tLINEAR: \u001b[34ma\u001b[0m 10-day \u001b[31mquarantine\u001b[0m period\tCOUNT: 2\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-\u001b[1mday\u001b[0m.\u001b[1mpobj\u001b[0m-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m22\u001b[0m days for \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mneed\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mprep\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m from symptom onset needs to be implemented \u001b[34mwithin\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mpobj\u001b[0m-prep-attr-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[34m14\u001b[0m days should be the period of \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-ccomp-conj-\u001b[1mvary\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nummod-\u001b[34mconj\u001b[0m\tLINEAR: varies between 7 and \u001b[34m14\u001b[0m days for moderate cases according to [ 3 ] , and this is why \u001b[31mquarantine\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubj\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of at least \u001b[34m15\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mexceed\u001b[0m.\u001b[1mROOT\u001b[0m-npadvmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mtime\u001b[0m for COVID-19 related medical waste in the hospital should not exceed \u001b[34m24\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mdepend\u001b[0m.\u001b[1mROOT\u001b[0m-conj-attr-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mQuarantine\u001b[0m duration depends on national regulations but should be a minimum of \u001b[34m30\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mperiod\u001b[0m.\u001b[1mnsubjpass\u001b[0m-prep-pobj-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period of 60 to \u001b[34m90\u001b[0m\tCOUNT: 1\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbe\u001b[0m.\u001b[1mROOT\u001b[0m-acomp-prep-pobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mquarantine\u001b[0m period , which starts when the most recently received animals are placed into a quarantine , should not be less than \u001b[34mseveral\u001b[0m\tCOUNT: 1\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 7:\n",
      "\targ1:[e]COVID-19 $infects arg2:cells\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2positive \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects endothelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m first predominantly infects lower \u001b[34mairways\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcell\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-COV-2\u001b[0m infects human \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly infects type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m primarily infects human lung epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects types I and II \u001b[34mpneumocytes\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects human host \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m infects lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m primarily infects \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m and SARS-CoV infect human primary T \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , infects the \u001b[34mhost\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the \u001b[34mhost\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m primarily infects epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects human lung alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may infect circulating immune \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects unciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , the virus responsible for the Covid-19 pandemic , infects \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m infects the \u001b[34mepithelium\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects mammalian \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mhumans\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mvirus\u001b[0m preferentially infects airway epithelial \u001b[34mcells\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSars-CoV-2\u001b[0m infects the respiratory \u001b[34mtract\u001b[0m\tCOUNT: 39\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the host \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters host \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m enters the \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters the pulmonary \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters target \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31m-II\u001b[0m enters the target \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m enters the host \u001b[34mcell\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mHCoV-229E\u001b[0m enters bone marrow \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human target \u001b[34mcells\u001b[0m\tCOUNT: 25\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a cell receptor to invade human \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the ACE2 receptor to invade human alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE-2 ) receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses a spike protein binding the angiotensin converting enzyme ( ACE2 ) to enter the \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses Angiotensin converting enzyme)-2 ( ACE2 ) as a viral receptor to enter host \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the ACE2 ( angiotensin-converting enzyme 2 ) receptor to enter human \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses the receptor dipeptidyl-peptidase-4 ( DPP-4 ) to enter its host \u001b[34mcell\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( ACE2 ) to enter 65 target \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m uses dipeptidyl peptidase 4 ( DPP4 ) receptor and the carcinoembryonic antigen  related cell-adhesion molecule 5 ( CEACAM5 ) cofactor ligand to infect unciliated bronchial \u001b[34mcells\u001b[0m\tCOUNT: 11\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARA-CoV-2\u001b[0m primarily invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades target \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m mainly invades alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minvade\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m invades host \u001b[34mcells\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects the GI \u001b[34mtract\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m preferentially infects respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-nCoV-2\u001b[0m infects the gastrointestinal ( GI ) \u001b[34mtract\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects immune \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects host \u001b[34mcells\u001b[0m\tCOUNT: 7\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) , the virus that causes COVID-19 , infects \u001b[34mhumans\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m ) infects ACE2 expressing epithelial \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mappos\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m ) infects host \u001b[34mcells\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects ACE2 + \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infects type I and type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m infects primary human bronchial epithelial Calu-3 \u001b[34mcells\u001b[0m and primary human kidney cells\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mconj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m also infects monocytes/macrophages [ 68 , 86 ] and dendritic \u001b[34mcells\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 receptor on ciliated bronchial epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m infect human respiratory epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31m(MERS)-CoV\u001b[0m infect intrapulmonary epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m predominantly infect lower \u001b[34mairways\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to access human \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to infect \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV\u001b[0m poorly infects \u001b[34mhuman\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect different \u001b[34mhuman\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( ACE2 ) receptor to enter its target \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m likely binds in the first instance to nasal epithelial \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enter and infect target host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m binds to the target \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-acl:relcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-acl:relcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-nsubjpass-\u001b[1mreport\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-acl:relcl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m is an enveloped virus and E proteins present in them are reported to form ion channels , which is mainly associated with \u001b[34mpathogenesis\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-conj-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters into and infects host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the ACE2 \u001b[34mreceptors\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-Cov-2\u001b[0m virus enters the \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m bind to their target \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to ACE2 with high affinity as a virus receptor to infect \u001b[34mhumans\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m virus enters the \u001b[34mbody\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[31mPIV3\u001b[0m infects ciliated \u001b[34mrespiratory\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mnmod\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus \u001b[31m2\u001b[0m , which invades \u001b[34mcells\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-acl:relcl-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-acl:relcl-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m recognizes the human Angiotensin Converting Enzyme 2 ( hACE2 ) as a cellular receptor that allows it to infect different host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnummod\u001b[0m-dobj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: use angiotensin-converting enzyme \u001b[31m2\u001b[0m as the cellular receptor to infect host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mROOT\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mappos\u001b[0m-\u001b[1mcoronavirus\u001b[0m.\u001b[1mROOT\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: coronavirus 2 ( \u001b[31mSARS-CoV-2\u001b[0m ) ( 6 ) , which infects the \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-acl-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to its target using the angiotensin-converting enzyme 2 ( ACE2 ) receptor on human \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-nmod-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( ACE2 ) as the receptor for entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-conj-attr-acl-advcl-conj-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-conj-attr-acl-advcl-conj-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreplicate\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mCoronavirus\u001b[0m replicates in epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-\u001b[1mentry\u001b[0m.\u001b[1mnsubjpass\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: entry of \u001b[31mSARS-CoV-2\u001b[0m into host \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-acl-dobj-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to angiotensin converting enzyme-II ( ACE-2 ) receptors on type II alveolar epithelial \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnummod\u001b[0m-dobj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-\u001b[34mdobj\u001b[0m\tLINEAR: uses the angiotensin-converting-enzyme \u001b[31m2\u001b[0m ( ACE2 ) receptor to bind the host \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1msars-cov-2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-acl:relcl-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which enters human target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( ACE2 ) as a viral receptor to enter the target \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mhave\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-acl-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has the potential to directly replicate within \u001b[34mcardiomyocytes\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( ACE2 ) to enter host target \u001b[34mcells\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1mQUERY 8:\n",
      "\targ1:[e]COVID-19 activates the arg2:ATP $receptor\u001b[0m\n",
      "\u001b[1m\n",
      "MOST FREQUENT PATTERNS:\n",
      "\u001b[0m\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV , uses the same receptor angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , like SARS-CoV ( Li et al. , 2003 ) , uses the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses human angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can further use transmembrane \u001b[34mprotease\u001b[0m serine 2 ( TMPRSS2 ) , a serine protease\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCoV-2\u001b[0m uses the ' Angiotensin Converting Enzyme-2 ' ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the receptor angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV use the same receptor , \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 17\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: Enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 16\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can use \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin converting \u001b[34menzyme\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the cell entry \u001b[34mreceptor\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses receptor \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same \u001b[34mreceptor\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m might also use \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses both \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARSCoV2\u001b[0m uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses \u001b[34mACE2\u001b[0m\tCOUNT: 10\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , much like the structurally similar and precedent SARS-CoV , uses the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m use the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV could use \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also uses the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m does not use other \u001b[34mCoV\u001b[0m\tCOUNT: 8\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the same cellular receptor , \u001b[34mhACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m uses the angiotensin converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mCOVID-19\u001b[0m ( like MERS and SARS ) uses the angiotensin-converting enzyme II ( \u001b[34mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 6\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m may use \u001b[34mhost\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mreceptor\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mTMPRSS2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the Angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the angiotensin I converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mappos\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the \u001b[34mACE2\u001b[0m\tCOUNT: 4\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to use the same \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , which is the virus causing coronavirus disease 2019 ( COVID-19 ) , uses the angiotensin-converting enzyme 2 ( ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , the pathogenic agent of COVID-19 , employs angiotensin converting enzyme-2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nmod-nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as one of the main receptors for both SARS-CoV ( 51 ) and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m has been shown to bind to the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , which also infects human respiratory tract epithelium , employs dipeptidyl \u001b[34mpeptidase\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mhACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mccomp\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the SARS-CoV receptor \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nmod-nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for 25 entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m ) receptor\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m employs the cellular transmembrane serine \u001b[34mprotease\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m binds to host \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds with the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses the membrane protein Angiotensin I converting enzyme 2(ACE2 ) as a \u001b[34mcell\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mconj\u001b[0m-nmod-nmod-nmod-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been identified as the main receptor for entry of both SARS-CoV and \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnummod\u001b[0m-\u001b[1menzyme\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mappos\u001b[0m\tLINEAR: enzyme \u001b[31m2\u001b[0m ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can bind to human angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mbind\u001b[0m.\u001b[1mccomp\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m binds to the \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mdep\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[34mreceptor\u001b[0m , angiotensin converting enzyme \u001b[31m(ACE)-2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1memploy\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m and SARS-CoV employ \u001b[34mACE2\u001b[0m\tCOUNT: 3\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-nmod-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m utilizes \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1menter\u001b[0m.\u001b[1mROOT\u001b[0m-advcl-nmod-nmod-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m enters human cells by binding to the extracellular domain of Angiotensin Converting Enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , as well as other corona viruses , requires the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mreceptor\u001b[0m.\u001b[1mnmod\u001b[0m-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[34mcell\u001b[0m \u001b[31mACE2\u001b[0m receptors\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mutilize\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m utilizes angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mshare\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , responsible for Coronavirus disease ( COVID-19 ) , shares the same \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interact directly with angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m glycoprotein spike binds to \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m can infect cells via the angiotensin-converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrequire\u001b[0m.\u001b[1mccomp\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m , just like SARS-CoV , requires the angiotensinconverting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mrecognize\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m also recognizes human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-advcl-\u001b[1msurprising\u001b[0m.\u001b[1mROOT\u001b[0m-ccomp-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-advcl-\u001b[1msurprising\u001b[0m.\u001b[1mROOT\u001b[0m-ccomp-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m was identified as the receptor for SARS-CoV , it is not surprising that SARS-CoV has adapted itself to bind human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-xcomp-\u001b[1mshow\u001b[0m.\u001b[1mROOT\u001b[0m-nsubjpass-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[34mACE2\u001b[0m ) has been shown to be a functional receptor for \u001b[31mSARS-CoV-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mconj\u001b[0m-nsubj-\u001b[1muse\u001b[0m.\u001b[1mROOT\u001b[0m-dobj-\u001b[34mappos\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m uses angiotensin converting enzyme 2 ( \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-\u001b[1mbelong\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-conj-\u001b[1mbelong\u001b[0m.\u001b[1mROOT\u001b[0m-nsubj-\u001b[34mcc:preconj\u001b[0m\tLINEAR: \u001b[34mBoth\u001b[0m COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through \u001b[31mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-nsubj-\u001b[1mbind\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m spike protein binds to angiotensin converting enzyme-2 ( Ace-2 ) on the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-acl:relcl-conj-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1marmed\u001b[0m.\u001b[1mROOT\u001b[0m-prep-pobj-acl:relcl-conj-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is armed with a large \" spike protein \" , which is used to interact with host cells and then gain entry through the \u001b[34mcell\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-nmod-\u001b[34mnummod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is known to enter the host cells via the angiotensin-converting enzyme \u001b[34m2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1minfect\u001b[0m.\u001b[1mROOT\u001b[0m-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mMERS-CoV\u001b[0m , but not SARS-CoV , can infect both CD4 and CD8 T cells from human blood and lymphoid organs via DPP4 \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubj-\u001b[1minteract\u001b[0m.\u001b[1mROOT\u001b[0m-\u001b[34mnmod\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m interacts with human \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-conj-attr-acl-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubj\u001b[0m-\u001b[1mvirus\u001b[0m.\u001b[1mROOT\u001b[0m-conj-attr-acl-advcl-nmod-\u001b[34mcompound\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m is an enveloped virus and there are ample evidences that its Spike protein ( S-protein ) is mainly associated with pathogenesis as it is surface-exposed and mediates entry into host cells by binding to angiotensin-converting \u001b[34menzyme-2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mcompound\u001b[0m-\u001b[1mprotein\u001b[0m.\u001b[1mdobj\u001b[0m\tLINEAR: \u001b[31mACE2\u001b[0m \u001b[34mprotein\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31m\u001b[1mace2\u001b[0m\u001b[0m.\u001b[31m\u001b[1mnmod\u001b[0m\u001b[0m-\u001b[34mamod\u001b[0m\tLINEAR: \u001b[34mhuman\u001b[0m \u001b[31mace2\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnmod\u001b[0m-nsubjpass-\u001b[1midentify\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV-2\u001b[0m into human host cells has been identified to use the same \u001b[34mreceptor\u001b[0m\tCOUNT: 2\n",
      "PATH: \u001b[31mnsubjpass\u001b[0m-\u001b[1mknow\u001b[0m.\u001b[1mROOT\u001b[0m-xcomp-\u001b[34mdobj\u001b[0m\tLINEAR: \u001b[31mSARS-CoV2\u001b[0m , SARS-CoV , and HCoV-NL63 , a virus that causes a mild respiratory infection , are all known to employ \u001b[34mACE2\u001b[0m\tCOUNT: 2\n",
      "\n",
      "\n",
      "\n",
      "=================================================================\n",
      "=================================================================\n"
     ]
    }
   ],
   "source": [
    "collect(500, \"lemmas-deps-root\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
